0001479681-24-00000710-Q Nutex Health, Inc. 2024080820240808160208160208160208 0 0001479681-24-000007 10-Q 95 20240630 20240808 20240808 Nutex Health, Inc. 0001479681 7389 113363609 DE 1231 10-Q 34 001-41346 241188060 6030 S. RICE AVE. SUITE C HOUSTON TX 77081 (713) 660-0557 6030 S. RICE AVE. SUITE C HOUSTON TX 77081 Clinigence Holdings, Inc. 20191113 iGambit, Inc. 20091230 10-Q 1 nutx-20240630x10q.htm 10-Q 0001479681--12-312024Q2451119949872680.0670.0670.50.0630.0670.0670.10.10.50.0630.10.0670.10.10.0670.1P10DP6Y0.10.33330.0670.10.10.10.50.0630.10.0670.10.10.0670.1false0001479681us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2024-01-220001479681nutx:AhpHealthManagementServicesInc.Membernutx:AssociatedHispanicPhysiciansOfSo.CaliforniaMember2024-01-012024-06-300001479681us-gaap:RestrictedStockMember2024-06-162024-06-160001479681nutx:PriorToReverseStockSplitMemberus-gaap:RestrictedStockMember2023-04-012023-04-010001479681us-gaap:RestrictedStockMember2023-04-012023-04-010001479681nutx:PriorToReverseStockSplitMembernutx:SecuritiesPurchaseAgreementMember2024-01-222024-01-220001479681nutx:SecuritiesPurchaseAgreementMember2024-01-222024-01-220001479681nutx:PriorToReverseStockSplitMembernutx:CommonStockWarrantsMembernutx:SecuritiesPurchaseAgreementMember2024-01-012024-06-300001479681nutx:CommonStockWarrantsMembernutx:SecuritiesPurchaseAgreementMember2024-01-012024-06-300001479681nutx:ClinigenceHoldingsInc.Memberus-gaap:CommonStockMembernutx:MergerAgreementMember2022-04-012022-04-010001479681nutx:EmployeeStockPurchasePlan2023Member2024-04-012024-06-300001479681nutx:EmployeeStockPurchasePlan2023Member2024-01-012024-06-300001479681us-gaap:SubsequentEventMember2024-07-022024-07-020001479681us-gaap:SubsequentEventMember2024-07-022024-07-020001479681srt:MinimumMember2024-06-172024-06-170001479681srt:MaximumMember2024-06-172024-06-170001479681us-gaap:RetainedEarningsMember2024-06-172024-06-170001479681us-gaap:RetainedEarningsMember2024-04-242024-04-240001479681us-gaap:RetainedEarningsMember2024-04-102024-04-100001479681us-gaap:RetainedEarningsMember2024-04-092024-04-090001479681srt:MinimumMember2023-06-292023-06-290001479681srt:MaximumMember2023-06-292023-06-290001479681us-gaap:RetainedEarningsMember2024-06-300001479681us-gaap:NoncontrollingInterestMember2024-06-300001479681us-gaap:AdditionalPaidInCapitalMember2024-06-300001479681us-gaap:RetainedEarningsMember2024-03-310001479681us-gaap:NoncontrollingInterestMember2024-03-310001479681us-gaap:AdditionalPaidInCapitalMember2024-03-310001479681us-gaap:RetainedEarningsMember2023-12-310001479681us-gaap:NoncontrollingInterestMember2023-12-310001479681us-gaap:AdditionalPaidInCapitalMember2023-12-310001479681us-gaap:RetainedEarningsMember2023-06-300001479681us-gaap:NoncontrollingInterestMember2023-06-300001479681us-gaap:AdditionalPaidInCapitalMember2023-06-300001479681us-gaap:RetainedEarningsMember2023-03-310001479681us-gaap:NoncontrollingInterestMember2023-03-310001479681us-gaap:AdditionalPaidInCapitalMember2023-03-310001479681us-gaap:RetainedEarningsMember2022-12-310001479681us-gaap:NoncontrollingInterestMember2022-12-310001479681us-gaap:AdditionalPaidInCapitalMember2022-12-310001479681us-gaap:CommonStockMember2024-06-300001479681us-gaap:CommonStockMember2024-03-310001479681us-gaap:CommonStockMember2023-12-310001479681us-gaap:CommonStockMember2023-06-300001479681us-gaap:CommonStockMember2023-03-310001479681us-gaap:CommonStockMember2022-12-310001479681nutx:PriorToReverseStockSplitMembernutx:CommonStockWarrantsMembernutx:SecuritiesPurchaseAgreementMember2024-06-300001479681nutx:CommonStockWarrantsMembernutx:SecuritiesPurchaseAgreementMember2024-06-300001479681nutx:PriorToReverseStockSplitMembernutx:EquityIncentive2022PlanMember2024-06-300001479681nutx:PostReverseStockSplitMembernutx:EquityIncentive2022PlanMember2024-06-300001479681nutx:EquityIncentive2022PlanMember2024-06-3000014796812022-01-012022-12-310001479681nutx:September92031ExpirationOptionMember2024-06-300001479681nutx:May112027ExpirationOptionMember2024-06-300001479681nutx:June92027ExpirationOptionMember2024-06-300001479681nutx:June302030ExpirationOptionMember2024-06-300001479681nutx:January282031ExpirationOptionMember2024-06-300001479681nutx:January282028ExpirationOptionMember2024-06-300001479681nutx:January272030ExpirationOptionMember2024-06-300001479681nutx:January272027ExpirationOptionMember2024-06-300001479681nutx:January212025ExpirationOptionMember2024-06-300001479681nutx:January212025ExpirationOption3Member2024-06-300001479681nutx:January212025ExpirationOption2Member2024-06-300001479681nutx:February282031ExpirationOptionMember2024-06-300001479681nutx:December172031ExpirationOptionMember2024-06-300001479681nutx:August42029ExpirationOptionMember2024-06-300001479681nutx:EmployeeStockPurchasePlan2023Member2024-06-300001479681nutx:PriorToReverseStockSplitMembernutx:EmployeeStockPurchasePlan2023Member2023-12-310001479681nutx:EmployeeStockPurchasePlan2023Member2023-12-310001479681nutx:PriorToReverseStockSplitMembernutx:EmployeeStockPurchasePlan2023Member2023-05-310001479681nutx:EmployeeStockPurchasePlan2023Member2023-05-310001479681nutx:PriorToReverseStockSplitMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-06-162024-06-160001479681us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-06-162024-06-160001479681us-gaap:RestrictedStockUnitsRSUMembernutx:ShareBasedPaymentArrangementTrancheFourMember2024-06-162024-06-160001479681us-gaap:RestrictedStockUnitsRSUMembernutx:ShareBasedPaymentArrangementTrancheFifthMember2024-06-162024-06-160001479681nutx:PriorToReverseStockSplitMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-04-012023-04-010001479681nutx:PriorToReverseStockSplitMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2023-04-012023-04-010001479681nutx:PriorToReverseStockSplitMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-04-012023-04-010001479681us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-04-010001479681us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-04-012023-04-010001479681us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2023-04-012023-04-010001479681us-gaap:RestrictedStockUnitsRSUMember2023-12-310001479681us-gaap:RestrictedStockUnitsRSUMember2023-06-300001479681us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001479681us-gaap:IntersegmentEliminationMembernutx:RealEstateDivisionMember2024-04-012024-06-300001479681nutx:PopulationHealthManagementDivisionMember2024-04-012024-06-300001479681nutx:PopulationHealthManagementDivisionMember2024-04-012024-06-300001479681nutx:HospitalDivisionMember2024-04-012024-06-300001479681nutx:HospitalDivisionMember2024-04-012024-06-300001479681nutx:HospitalDivisionMember2024-04-012024-06-300001479681us-gaap:IntersegmentEliminationMembernutx:RealEstateDivisionMember2024-01-012024-06-300001479681nutx:PopulationHealthManagementDivisionMember2024-01-012024-06-300001479681nutx:PopulationHealthManagementDivisionMember2024-01-012024-06-300001479681nutx:HospitalDivisionMember2024-01-012024-06-300001479681nutx:HospitalDivisionMember2024-01-012024-06-300001479681us-gaap:IntersegmentEliminationMembernutx:RealEstateDivisionMember2023-04-012023-06-300001479681nutx:HospitalDivisionMembernutx:ManagerialServicesAgreementsMember2023-04-012023-06-300001479681nutx:PopulationHealthManagementDivisionMember2023-04-012023-06-300001479681nutx:PopulationHealthManagementDivisionMember2023-04-012023-06-300001479681nutx:HospitalDivisionMember2023-04-012023-06-300001479681nutx:HospitalDivisionMember2023-04-012023-06-300001479681us-gaap:IntersegmentEliminationMembernutx:RealEstateDivisionMember2023-01-012023-06-300001479681nutx:HospitalDivisionMembernutx:ManagerialServicesAgreementsMember2023-01-012023-06-300001479681nutx:PopulationHealthManagementDivisionMember2023-01-012023-06-300001479681nutx:PopulationHealthManagementDivisionMember2023-01-012023-06-300001479681nutx:HospitalDivisionMember2023-01-012023-06-300001479681nutx:HospitalDivisionMember2023-01-012023-06-300001479681nutx:EREntitiesMembernutx:ManagerialServicesAgreementsMember2023-04-012023-06-300001479681nutx:EREntitiesMembernutx:ManagerialServicesAgreementsMember2023-01-012023-06-300001479681srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2024-06-300001479681srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2024-06-300001479681us-gaap:VehiclesMember2024-06-300001479681us-gaap:LeaseholdImprovementsMember2024-06-300001479681us-gaap:LandMember2024-06-300001479681us-gaap:ConstructionInProgressMember2024-06-300001479681us-gaap:BuildingAndBuildingImprovementsMember2024-06-300001479681nutx:SignageMember2024-06-300001479681nutx:OfficeFurnitureAndEquipmentMember2024-06-300001479681nutx:MedicalEquipmentMember2024-06-300001479681nutx:ComputerHardwareAndSoftwareMember2024-06-300001479681us-gaap:VehiclesMember2023-12-310001479681us-gaap:LeaseholdImprovementsMember2023-12-310001479681us-gaap:LandMember2023-12-310001479681us-gaap:ConstructionInProgressMember2023-12-310001479681us-gaap:BuildingAndBuildingImprovementsMember2023-12-310001479681nutx:SignageMember2023-12-310001479681nutx:OfficeFurnitureAndEquipmentMember2023-12-310001479681nutx:MedicalEquipmentMember2023-12-310001479681nutx:ComputerHardwareAndSoftwareMember2023-12-310001479681us-gaap:RetainedEarningsMember2024-04-012024-06-300001479681us-gaap:RetainedEarningsMember2024-01-012024-03-310001479681us-gaap:RetainedEarningsMember2023-04-012023-06-300001479681us-gaap:RetainedEarningsMember2023-01-012023-03-310001479681nutx:HospitalDivisionMember2024-04-012024-06-300001479681nutx:HospitalDivisionMember2024-01-012024-06-300001479681nutx:HospitalDivisionMember2023-04-012023-06-300001479681nutx:HospitalDivisionMember2023-01-012023-06-300001479681nutx:PhysicianLlcAndRealEstateEntitiesMember2024-06-300001479681nutx:NutexHealthIncMembernutx:NutexHealthHoldcoLLCMembernutx:NutexSubsidiariesMembernutx:MergerAgreementMember2022-04-010001479681us-gaap:NoncontrollingInterestMember2024-04-012024-06-300001479681us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001479681us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001479681us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001479681us-gaap:WorkersCompensationInsuranceMember2024-04-012024-06-300001479681nutx:SelfsPayMember2024-04-012024-06-300001479681nutx:MedicareMember2024-04-012024-06-300001479681nutx:InsuranceMember2024-04-012024-06-300001479681us-gaap:WorkersCompensationInsuranceMember2024-01-012024-06-300001479681nutx:SelfsPayMember2024-01-012024-06-300001479681nutx:MedicareMember2024-01-012024-06-300001479681nutx:InsuranceMember2024-01-012024-06-300001479681us-gaap:WorkersCompensationInsuranceMember2023-04-012023-06-300001479681nutx:SelfsPayMember2023-04-012023-06-300001479681nutx:MedicareMember2023-04-012023-06-300001479681nutx:InsuranceMember2023-04-012023-06-300001479681us-gaap:WorkersCompensationInsuranceMember2023-01-012023-06-300001479681nutx:SelfsPayMember2023-01-012023-06-300001479681nutx:MedicareMember2023-01-012023-06-300001479681nutx:InsuranceMember2023-01-012023-06-300001479681us-gaap:ConvertibleDebtMembernutx:September2023PrivateOfferingMember2024-06-300001479681us-gaap:ConvertibleDebtMembernutx:September2023PrivateOfferingAsAmendedMember2024-06-300001479681nutx:PopulationHealthManagementDivisionMember2023-07-012023-09-300001479681srt:MinimumMemberus-gaap:TrademarksMember2024-06-300001479681srt:MinimumMemberus-gaap:TrademarksMember2023-12-310001479681srt:MaximumMemberus-gaap:TrademarksMember2023-12-310001479681us-gaap:TrademarksMember2024-06-300001479681nutx:MemberRelationshipsMember2024-06-300001479681us-gaap:TrademarksMember2023-12-310001479681us-gaap:CustomerContractsMember2023-12-310001479681nutx:PHPTechnologyMember2023-12-310001479681nutx:MemberRelationshipsMember2023-12-310001479681nutx:ManagementContractsMember2023-12-3100014796812024-06-302024-06-300001479681us-gaap:RestrictedStockUnitsRSUMember2024-06-300001479681srt:ScenarioPreviouslyReportedMember2023-04-012023-06-300001479681srt:RestatementAdjustmentMember2023-04-012023-06-300001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:ProcareHealthIncMember2024-04-012024-06-300001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:CliningenceHealthIncMember2024-04-012024-06-300001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:ProcareHealthIncMember2024-01-012024-06-300001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:CliningenceHealthIncMember2024-01-012024-06-300001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:ProcareHealthIncMember2024-07-310001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:ProcareHealthIncMember2024-06-300001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:ProcareHealthIncMember2024-05-300001479681us-gaap:OperatingSegmentsMembernutx:RealEstateDivisionMember2024-04-012024-06-300001479681us-gaap:OperatingSegmentsMembernutx:PopulationHealthManagementDivisionMember2024-04-012024-06-300001479681us-gaap:OperatingSegmentsMembernutx:HospitalDivisionMember2024-04-012024-06-300001479681us-gaap:PropertyPlantAndEquipmentMember2024-04-012024-06-300001479681us-gaap:OperatingSegmentsMembernutx:RealEstateDivisionMember2024-01-012024-06-300001479681us-gaap:OperatingSegmentsMembernutx:PopulationHealthManagementDivisionMember2024-01-012024-06-300001479681us-gaap:OperatingSegmentsMembernutx:HospitalDivisionMember2024-01-012024-06-300001479681us-gaap:PropertyPlantAndEquipmentMember2024-01-012024-06-300001479681us-gaap:OperatingSegmentsMembernutx:RealEstateDivisionMember2023-04-012023-06-300001479681us-gaap:OperatingSegmentsMembernutx:PopulationHealthManagementDivisionMember2023-04-012023-06-300001479681us-gaap:OperatingSegmentsMembernutx:HospitalDivisionMember2023-04-012023-06-300001479681us-gaap:PropertyPlantAndEquipmentMember2023-04-012023-06-300001479681us-gaap:OperatingSegmentsMembernutx:RealEstateDivisionMember2023-01-012023-06-300001479681us-gaap:OperatingSegmentsMembernutx:PopulationHealthManagementDivisionMember2023-01-012023-06-300001479681us-gaap:OperatingSegmentsMembernutx:HospitalDivisionMember2023-01-012023-06-300001479681us-gaap:PropertyPlantAndEquipmentMember2023-01-012023-06-300001479681srt:MinimumMemberus-gaap:LineOfCreditMember2024-01-012024-06-300001479681srt:MinimumMemberus-gaap:ConvertibleDebtMember2024-01-012024-06-300001479681srt:MinimumMembernutx:TermLoanMember2024-01-012024-06-300001479681srt:MinimumMembernutx:TermLoan3Member2024-01-012024-06-300001479681srt:MinimumMembernutx:TermLoan1Member2024-01-012024-06-300001479681srt:MaximumMemberus-gaap:LineOfCreditMember2024-01-012024-06-300001479681srt:MaximumMemberus-gaap:ConvertibleDebtMember2024-01-012024-06-300001479681srt:MaximumMembernutx:TermLoanMember2024-01-012024-06-300001479681srt:MaximumMembernutx:TermLoan3Member2024-01-012024-06-300001479681srt:MaximumMembernutx:TermLoan1Member2024-01-012024-06-300001479681nutx:TermLoanSecuredByDepositsMember2024-01-012024-06-300001479681nutx:PrepaidAdvanceMember2024-01-012024-06-300001479681srt:MinimumMemberus-gaap:LineOfCreditMember2023-01-012023-12-310001479681srt:MinimumMemberus-gaap:ConvertibleDebtMember2023-01-012023-12-310001479681srt:MinimumMembernutx:TermLoanMember2023-01-012023-12-310001479681srt:MinimumMembernutx:TermLoan3Member2023-01-012023-12-310001479681srt:MinimumMembernutx:TermLoan1Member2023-01-012023-12-310001479681srt:MaximumMemberus-gaap:LineOfCreditMember2023-01-012023-12-310001479681srt:MaximumMemberus-gaap:ConvertibleDebtMember2023-01-012023-12-310001479681srt:MaximumMembernutx:TermLoanMember2023-01-012023-12-310001479681srt:MaximumMembernutx:TermLoan3Member2023-01-012023-12-310001479681srt:MaximumMembernutx:TermLoan1Member2023-01-012023-12-310001479681nutx:TermLoanSecuredByDepositsMember2023-01-012023-12-310001479681nutx:PrepaidAdvanceMember2023-01-012023-12-310001479681nutx:PriorToReverseStockSplitMemberus-gaap:ConvertibleDebtMember2024-06-300001479681nutx:September2023PrivateOfferingMember2024-06-300001479681nutx:PriorToReverseStockSplitMemberus-gaap:ConvertibleDebtMember2024-03-260001479681us-gaap:ConvertibleDebtMember2024-03-260001479681us-gaap:LineOfCreditMember2024-06-300001479681us-gaap:ConvertibleDebtMember2024-06-

300001479681nutx:TermLoanSecuredByDepositsMember2024-06-300001479681nutx:TermLoanMember2024-06-300001479681nutx:TermLoan3Member2024-06-300001479681nutx:TermLoan1Member2024-06-300001479681us-gaap:LineOfCreditMember2023-12-310001479681us-gaap:ConvertibleDebtMember2023-12-310001479681nutx:TermLoanMember2023-12-310001479681nutx:TermLoan3Member2023-12-310001479681nutx:TermLoan1Member2023-12-310001479681nutx:PrepaidAdvanceMember2023-12-310001479681nutx:YorkvilleMembernutx:PriorToReverseStockSplitMembernutx:PrepaidAdvanceMembernutx:PrePaidAdvanceAgreementWithYorkvilleMember2023-04-112023-04-110001479681us-gaap:CommonStockMember2024-01-012024-03-310001479681nutx:PriorToReverseStockSplitMembernutx:PlacementAgentWarrantsMember2024-06-300001479681nutx:PriorToReverseStockSplitMember2024-06-300001479681nutx:PriorToReverseStockSplitMembernutx:PlacementAgentWarrantsMember2024-03-260001479681nutx:PriorToReverseStockSplitMembernutx:CommonStockWarrantsMember2024-03-260001479681nutx:PlacementAgentWarrantsMember2024-03-2600014796812024-07-230001479681nutx:PriorToReverseStockSplitMembernutx:AccreditedInvestorsWarrantsMember2024-06-300001479681nutx:AccreditedInvestorsWarrantsMember2024-06-300001479681nutx:CommonStockWarrantsMember2024-03-260001479681nutx:PriorToReverseStockSplitMembernutx:SecuritiesPurchaseAgreementMember2024-01-220001479681nutx:RealEstateEntitiesMember2023-03-310001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:ClinigenceHealthIncMemberus-gaap:SubsequentEventMember2024-09-300001479681nutx:RealEstateEntitiesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-06-300001479681nutx:PhysicianLLCsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-06-300001479681nutx:AHPIPAMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-06-300001479681nutx:RealEstateDivisionMember2024-06-300001479681nutx:PopulationHealthManagementDivisionMember2024-06-300001479681nutx:HospitalDivisionMember2024-06-300001479681nutx:RealEstateEntitiesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001479681nutx:PhysicianLLCsMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001479681nutx:AHPIPAMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001479681nutx:RealEstateDivisionMember2023-12-310001479681nutx:PopulationHealthManagementDivisionMember2023-12-310001479681nutx:HospitalDivisionMember2023-12-310001479681nutx:PriorToReverseStockSplitMemberus-gaap:WarrantMember2024-01-012024-06-300001479681nutx:PriorToReverseStockSplitMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001479681nutx:PriorToReverseStockSplitMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001479681nutx:PriorToReverseStockSplitMemberus-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-06-300001479681us-gaap:WarrantMember2024-01-012024-06-300001479681us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001479681us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001479681us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-06-300001479681srt:ScenarioPreviouslyReportedMemberus-gaap:WarrantMember2023-01-012023-06-300001479681srt:ScenarioPreviouslyReportedMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001479681srt:RestatementAdjustmentMemberus-gaap:WarrantMember2023-01-012023-06-300001479681srt:RestatementAdjustmentMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001479681nutx:PriorToReverseStockSplitMemberus-gaap:WarrantMember2023-01-012023-06-300001479681nutx:PriorToReverseStockSplitMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001479681us-gaap:WarrantMember2023-01-012023-06-300001479681us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001479681us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100014796812024-01-012024-03-310001479681srt:ScenarioPreviouslyReportedMember2023-12-310001479681srt:RestatementAdjustmentMember2023-12-310001479681nutx:EREntitiesMember2024-06-300001479681nutx:EREntitiesMember2023-12-310001479681nutx:PhysicianLLCsMember2024-06-300001479681nutx:PhysicianLLCsMember2023-12-310001479681nutx:MicroHospitalHoldingLlcMember2024-06-300001479681nutx:MicroHospitalHoldingLlcMember2023-12-3100014796812024-01-250001479681nutx:CommonStockWarrantsMember2024-06-300001479681nutx:CommonStockWarrantsMember2023-12-310001479681srt:ScenarioPreviouslyReportedMember2023-06-300001479681srt:RestatementAdjustmentMember2023-06-300001479681nutx:CommonStockWarrantsMember2023-06-300001479681nutx:ScenarioPreviouslyReportedMember2022-12-310001479681srt:RestatementAdjustmentMember2022-12-310001479681nutx:CommonStockWarrantsMember2022-12-3100014796812022-12-310001479681srt:ScenarioPreviouslyReportedMember2023-01-012023-06-300001479681srt:RestatementAdjustmentMember2023-01-012023-06-300001479681nutx:CommonStockWarrantsMember2023-01-012023-06-300001479681nutx:PriorToReverseStockSplitMembernutx:CommonStockWarrantsMember2024-03-262024-03-260001479681nutx:CommonStockWarrantsMember2024-03-262024-03-260001479681nutx:CommonStockWarrantsMember2024-01-012024-06-300001479681us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001479681us-gaap:CommonStockMember2024-04-012024-06-3000014796812023-06-292023-06-290001479681nutx:EmployeeStockPurchasePlan2023Member2023-05-012023-05-310001479681us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001479681srt:MinimumMember2024-06-300001479681nutx:EmersonEquityLlcMembernutx:September2023PrivateOfferingMember2024-06-3000014796812024-01-222024-01-220001479681nutx:PopulationHealthManagementDivisionMember2023-09-300001479681nutx:ManagerialServicesAgreementsMember2023-06-3000014796812023-01-012023-12-3100014796812023-01-012023-03-3100014796812022-04-012024-06-3000014796812022-04-012022-12-3100014796812022-04-012022-06-300001479681nutx:EquityIncentive2022PlanMember2024-01-012024-06-300001479681nutx:ClinigenceHoldingsInc.Member2022-04-012022-04-010001479681nutx:YorkvilleMembernutx:PrepaidAdvanceMembernutx:PrePaidAdvanceAgreementWithYorkvilleMember2023-04-1100014796812023-04-012023-06-300001479681us-gaap:DiscontinuedOperationsDisposedOfBySaleMembernutx:ProcareHealthIncMember2024-05-302024-05-300001479681nutx:PopulationHealthManagementDivisionMember2024-01-012024-06-300001479681nutx:September2023PrivateOfferingMember2024-01-012024-06-300001479681nutx:PriorToReverseStockSplitMemberus-gaap:ConvertibleDebtMember2024-03-262024-03-260001479681us-gaap:ConvertibleDebtMember2024-03-262024-03-260001479681nutx:PriorToReverseStockSplitMemberus-gaap:ConvertibleDebtMember2024-01-012024-06-300001479681us-gaap:ConvertibleDebtMember2024-01-012024-06-300001479681nutx:YorkvilleMembernutx:PrepaidAdvanceMembernutx:PrePaidAdvanceAgreementWithYorkvilleMember2023-04-112023-04-110001479681us-gaap:CommonStockMember2023-04-012023-06-300001479681us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001479681us-gaap:CommonStockMember2023-01-012023-03-310001479681us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001479681nutx:September302029ExpirationWarrantMember2024-06-300001479681nutx:October312029ExpirationWarrantMember2024-06-300001479681nutx:October312025ExpirationWarrantMember2024-06-300001479681nutx:October312025ExpirationWarrant2Member2024-06-300001479681nutx:November302029ExpirationWarrantMember2024-06-300001479681nutx:May312027ExpirationWarrantMember2024-06-300001479681nutx:July312026ExpirationWarrantMember2024-06-300001479681nutx:January252029ExpirationWarrantMember2024-06-300001479681nutx:February262026ExpirationWarrantMember2024-06-300001479681nutx:December312029ExpirationWarrantMember2024-06-300001479681nutx:December312024ExpirationWarrantMember2024-06-300001479681nutx:SecuritiesPurchaseAgreementMember2024-01-220001479681us-gaap:ConvertibleDebtMembernutx:September2023PrivateOfferingMember2024-04-012024-06-300001479681us-gaap:ConvertibleDebtMembernutx:September2023PrivateOfferingAsAmendedMember2024-01-012024-06-3000014796812023-01-012023-06-3000014796812023-12-3100014796812024-04-012024-06-3000014796812024-06-3000014796812024-08-0500014796812024-01-012024-06-30nutx:statenutx:Voteiso4217:USDxbrli:sharesnutx:segmentxbrli:sharesnutx:employeeiso4217:USDxbrli:purenutx:Dnutx:itemnutx:entitynutx:individualnutx:facilityTable of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549â€‹FORMÂ 10-Qâ€‹(Mark One)â€‹â€‹â˜‘QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the quarterly period ended JuneÂ 30,Â 2024orâ€‹â€‹â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â toCommission File Number: 001-41346NUTEX HEALTH INC.(Exact name of registrant as specified in its charter)â€‹â€‹Delaware11-3363609(State or other jurisdiction(I.R.S. Employerof incorporation or organization)Identification No.)â€‹â€‹6030 S. Rice Ave, Suite C,â€‹Houston, Texas77081(Address of principal executive offices)(Zip code)â€‹â€‹(713) 660-0557(Registrantâ€™s telephone number, including area code)â€‹Securities registered pursuant to SectionÂ 12(b)Â of the Act:â€‹â€‹â€‹â€‹Title of each classÂ Â Â Â Trading SymbolÂ Â Â Â Name of each exchange on which registeredCommon Stock, $0.001 par valueâ€‹NUTXâ€‹NASDAQ â€‹Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. YesÂ Â âŒ§Â Â Â Â NoÂ Â â—»Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). YesÂ Â âŒ§Â Â Â Â NoÂ Â â—»Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹Large accelerated filerâ˜Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜Emerging growth companyâ˜â€‹â€‹â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). YesÂ Â â˜Â Â Â Â NoÂ Â â˜‘As of August 5, 2024, the registrant had 5,065,709 shares of common stock outstanding.â€‹â€‹ Table of ContentsNUTEX HEALTH INC.FORM 10-QTABLE OF CONTENTSâ€‹â€‹Introductory NoteNote About Forward-Looking Statementsâ€‹â€‹Part I â€” Financial InformationItemÂ 1.Financial Statements4ItemÂ 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations28ItemÂ 3.Quantitative and Qualitative Disclosures About Market RiskÂ 40ItemÂ 4.Controls and ProceduresÂ 40â€‹â€‹Part II â€” Other InformationÂ ItemÂ 1.Legal ProceedingsÂ 41ItemÂ 1A.Risk FactorsÂ 41ItemÂ 2.Unregistered Sales of Equity Securities and Use of Proceeds41ItemÂ 3.Defaults upon Senior SecuritiesÂ 41ItemÂ 4.Mine Safety DisclosuresÂ 42ItemÂ 5.Other InformationÂ 42ItemÂ 6.ExhibitsÂ 42â€‹â€‹â€‹â€‹â€‹ Table of ContentsINTRODUCTORY NOTEUnless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the â€œCompany,â€ â€œwe,â€ â€œus,â€ â€œour,â€ and similar words are references to Nutex Health Inc. (formerly known as Clinigence Holdings, Inc.), a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (â€œVIEsâ€) and â€œNutexâ€ refers to Nutex Health Inc.Effective as of 11:59 p.m. Eastern time on April 9, 2024, the Company effected a 1-15 reverse stock split and effective as of 11:59 p.m. Eastern time on July 2, 2024, the Company effected an additional 1-10 reverse stock split (the â€œ2024 Reverse Stock Splitsâ€).Unless otherwise indicated, all authorized, issued, and outstanding stock and per share amounts referred to in this Quarterly Report on Form 10-Q have been adjusted to reflect the 2024 Reverse Stock Splits for all prior periods presented. Proportionate adjustments for the 2024 Reverse Stock Splits were made to the exercise prices and number of shares issuable under the Companyâ€™s equity incentive plans, and the number of shares underlying outstanding equity awards, as applicable. See Note 19 for information and disclosures relating to adjustments related to the 2024 Reverse Stock Splits.NOTE ABOUT FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q contains â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). All statements other than statements of historical fact are â€œforward-looking statementsâ€ for purposes of federal and state securities laws, including, but not limited to, changes in laws or regulations applicable to our operations, any statements about our business, financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, or otherwise, and our future liquidity, including cash flows; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; or strategic transactions; any statements regarding managementâ€™s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as â€œanticipate,â€ â€œcould,â€ â€œcan,â€ â€œmay,â€ â€œmight,â€ â€œpotential,â€ â€œpredict,â€ â€œshould,â€ â€œestimate,â€ â€œexpect,â€ â€œproject,â€ â€œbelieve,â€ â€œthink,â€ â€œplan,â€ â€œenvision,â€ â€œintend,â€ â€œcontinue,â€ â€œtarget,â€ â€œseek,â€ â€œcontemplate,â€ â€œbudgeted,â€ â€œwill,â€ â€œwould,â€ and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described under, but not limited to, the heading â€œItem 1A. Risk Factorsâ€ included in this Quarterly Report, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and in the Annual Report of Nutex Health Inc. on Form 10-K for the year ended December 31, 2023 and other filings of the Company with the United States Securities and Exchange Commission. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.â€‹â€‹â€‹â€‹ Table of Contentsâ€‹PART I â€” FINANCIAL INFORMATIONItem 1. Financial Statementsâ€‹NUTEX HEALTH INC.CONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹JuneÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023Assetsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Current assets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash and cash equivalentsâ€‹$ 40,807,975â€‹$ 22,002,056Accounts receivableâ€‹Â 60,658,832â€‹Â 58,624,301Accounts receivable - related partiesâ€‹Â 4,577,189â€‹Â 4,152,068Inventoriesâ€‹Â 2,759,448â€‹Â 3,390,584Prepaid expenses and other current assetsâ€‹â€‹ 5,066,994â€‹â€‹ 2,679,394Total current assetsâ€‹â€‹ 113,870,438â€‹â€‹ 90,848,403Property and equipment, netâ€‹â€‹ 78,881,900â€‹â€‹ 81,387,649Operating right-of-use assetsâ€‹â€‹ 11,690,957â€‹â€‹ 11,853,082Finance right-of-use assetsâ€‹Â 187,096,271â€‹Â 176,146,329Intangible assets, netâ€‹â€‹ 16,180,504â€‹â€‹ 20,512,636Goodwill, netâ€‹Â 13,918,719â€‹Â 17,066,263Other assetsâ€‹â€‹ 764,462â€‹â€‹ 431,135â€‹â€‹â€‹â€‹â€‹â€‹â€‹Total assetsâ€‹$ 422,403,251â€‹$ 398,245,497â€‹â€‹â€‹â€‹â€‹â€‹â€‹Liabilities and Equityâ€‹Â Â Â Â â€‹Â Â Â Â Current liabilities:â€‹Â Â Â Â â€‹Â Â Â Â Accounts payableâ€‹$ 16,742,370â€‹$ 18,899,196Accounts payable - related partiesâ€‹Â 6,796,475â€‹Â 6,382,197Lines of creditâ€‹Â 2,909,296â€‹Â 3,371,676Current portion of long-term debtâ€‹Â 14,223,944â€‹Â 10,808,721Operating lease liabilities, current portionâ€‹â€‹ 1,998,512â€‹â€‹ 1,579,987Finance lease liabilities, current portionâ€‹â€‹ 5,570,604â€‹â€‹ 4,315,979Accrued expenses and other current liabilitiesâ€‹â€‹ 23,417,191â€‹Â 12,955,296Total current liabilitiesâ€‹Â 71,658,392â€‹Â 58,313,052Long-term debt, netâ€‹â€‹ 22,406,516â€‹â€‹ 26,314,733Warrant liabilityâ€‹â€‹ 2,000,714â€‹â€‹ -Operating lease liabilities, netâ€‹â€‹ 14,690,566â€‹â€‹ 15,479,639Finance lease liabilities, netâ€‹â€‹ 226,820,535â€‹â€‹ 213,886,213Deferred tax liabilitiesâ€‹â€‹ 2,804,492â€‹â€‹ 5,145,754Total liabilitiesâ€‹Â

340,381,215â€Â 319,139,391â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commitments and contingenciesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Equity:â€‹â€‹â€‹â€‹â€‹â€‹Common stock, $0.001 par value; 950,000,000 shares authorized; 4,987,268 and 4,511,199 shares issued and outstanding as of JuneÂ 30,Â 2024 and DecemberÂ 31,Â 2023, respectivelyâ€‹â€‹ 4,988â€‹â€‹ 4,511Additional paid-in capitalâ€‹â€‹ 472,529,641â€‹â€‹ 470,521,218Accumulated deficitâ€‹â€‹ (409,800,662)â€‹â€‹ (409,072,539)Nutex Health Inc. equityâ€‹â€‹ 62,733,967â€‹â€‹ 61,453,190Noncontrolling interestsâ€‹Â 19,288,069â€‹â€‹ 17,652,916Total equityâ€‹â€‹ 82,022,036â€‹â€‹ 79,106,106â€‹â€‹â€‹â€‹â€‹â€‹â€‹Total liabilities and equityâ€‹$ 422,403,251â€‹$ 398,245,497â€‹See accompanying notes to the unaudited condensed consolidated financial statements.4 Table of ContentsNUTEX HEALTH INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED) â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended JuneÂ 30,Â â€‹Six Months Ended JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024Â Â Â Â 2023Revenue:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Hospital divisionâ€‹$ 67,604,878â€‹$ 51,611,803â€‹$ 127,634,247â€‹$ 100,899,967Population health management divisionâ€‹â€‹ 8,477,383â€‹â€‹ 7,312,651â€‹â€‹ 15,901,801â€‹â€‹ 14,353,904Total revenueâ€‹â€‹ 76,082,261â€‹â€‹ 58,924,454â€‹â€‹ 143,536,048â€‹â€‹ 115,253,871â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating costs and expenses:Â â€‹â€‹â€‹â€‹â€‹Â â€‹â€‹â€‹â€‹â€‹Payroll and benefitsâ€‹â€‹ 28,398,075â€‹â€‹ 24,860,702â€‹â€‹ 55,401,219â€‹â€‹ 50,697,375Contract servicesâ€‹â€‹ 9,505,222â€‹â€‹ 9,747,873â€‹â€‹ 20,824,676â€‹â€‹ 18,937,204Medical suppliesâ€‹â€‹ 3,588,464â€‹â€‹ 3,264,202â€‹â€‹ 8,910,306â€‹â€‹ 7,288,084Depreciation and amortizationÂ â€‹ 4,532,804Â â€‹ 4,169,160Â â€‹ 8,719,006Â â€‹ 8,162,907Otherâ€‹â€‹ 7,496,465â€‹â€‹ 7,235,594â€‹â€‹ 16,962,432â€‹â€‹ 15,673,655Total operating costs and expensesâ€‹â€‹ 53,521,030â€‹â€‹ 49,277,531â€‹â€‹ 110,817,639â€‹â€‹ 100,759,225â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Gross profitâ€‹â€‹ 22,561,231â€‹â€‹ 9,646,923â€‹â€‹ 32,718,409â€‹â€‹ 14,494,646â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Corporate and other costs:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Facilities closing costsâ€‹â€‹ -â€‹â€‹ -â€‹â€‹ -â€‹â€‹ -â€‹â€‹ 217,266Stock-based compensation expenseâ€‹â€‹ (61,241)â€‹â€‹ 249,645â€‹â€‹ (12,074)â€‹â€‹ 2,149,645Impairment of assetsâ€‹â€‹ 3,473,635â€‹â€‹ -â€‹â€‹ 3,473,635â€‹â€‹ -Impairment of goodwillâ€‹â€‹ 3,197,391â€‹â€‹ -â€‹â€‹ 3,197,391â€‹â€‹ -General and administrative expensesâ€‹â€‹ 10,652,390â€‹â€‹ 9,759,816â€‹â€‹ 19,310,800â€‹â€‹ 16,935,360Total corporate and other costsâ€‹â€‹ 17,262,175â€‹â€‹ 10,009,461â€‹â€‹ 25,969,752â€‹â€‹ 19,302,271â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating income (loss)Â â€‹ 5,299,056â€‹â€‹ (362,538)Â â€‹ 6,748,657â€‹â€‹ (4,807,625)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Interest expense, netâ€‹â€‹ 5,054,532â€‹â€‹ 4,843,048â€‹â€‹ 9,498,894â€‹â€‹ 7,983,137Gain on warrant liabilityâ€‹â€‹ (3,060,096)â€‹â€‹ -â€‹â€‹ (5,660,843)â€‹â€‹ -Other (income) expenseÂ â€‹ (599,502)Â â€‹ (123,528)Â â€‹ (840,694)Â â€‹ 123,927Income (loss) before taxesâ€‹â€‹ 3,904,122â€‹â€‹ (5,082,058)â€‹â€‹ 3,751,300â€‹â€‹ (12,914,689)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Income tax expense (benefit)â€‹â€‹ 893,892â€‹â€‹ (815,612)â€‹â€‹ 1,283,557â€‹â€‹ (1,726,271)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net income (loss)â€‹â€‹ 3,010,230â€‹â€‹ (4,266,446)â€‹â€‹ 2,467,743â€‹â€‹ (11,188,418)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Less: net income (loss) attributable to noncontrolling interestsâ€‹â€‹ 3,374,278â€‹â€‹ (787,399)â€‹â€‹ 3,195,866â€‹â€‹ (2,562,092)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss attributable to Nutex Health Inc.â€‹$ (364,048)â€‹$ (3,479,047)â€‹$ (728,123)â€‹$ (8,626,326)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Loss per common share:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Basicâ€‹$ (0.07)â€‹$ (0.79)â€‹$ (0.15)â€‹$ (1.98)Dilutedâ€‹$ (0.07)â€‹$ (0.79)â€‹$ (0.15)â€‹$ (1.98)â€‹See accompanying notes to the unaudited condensed consolidated financial statements.â€‹â€‹5 Table of ContentsNUTEX HEALTH INC.CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITYÂ (UNAUDITED) â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

the risk of loss to be likely. The Company has $4.5 million in restricted cash as of JuneÂ 30,Â 2024. The amounts included in restricted cash represent those required to be set aside either by note payable agreement or compensating balance requirements.Fair value measurements.Â Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows:LevelÂ 1Â â€” Observable inputs such as quoted prices in active markets for identical assets or liabilities.LevelÂ 2Â â€” Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.LevelÂ 3Â â€” Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.Â The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments.Â Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value.There were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented.Segment reporting.Â A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments â€“ the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities.10 Table of ContentsReclassifications. Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation.Recent accounting pronouncements.Â In November 2023, the FASB issued Accounting Standards Update 2023-07, â€œImprovements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required only on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for our 2024 annual Consolidated Financial Statements and interim periods beginning in 2025.In December 2023, the FASB issued Accounting Standards Update 2023-09, â€œImprovements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€), which provides for additional income tax rate reconciliation and income taxes paid disclosures. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024, with early adoption permitted.We are evaluating the impacts ASUs 2023-07 and 2023-09 will have on disclosures in our financial statements.Note 3 â€“ Divestituresâ€‹Sale of Procare Health, Inc. On May 30, 2024, the Company completed the sale of Procare Health, Inc. (â€œProcareâ€), a wholly-owned subsidiary of Nutex, to an individual buyer. As consideration for the transaction, the buyer will pay the Company $0.6 million ($0.1 million paid in June 2024 and $0.1 million paid in July 2024), has assumed liabilities of $0.2 million and remitted Company stock of $0.1 million. During the second quarter of 2024, the Company recognized an intangible impairment of $2.1 million and a $3.2 million goodwill impairment loss. Upon completion of the sale, the Company recognized an insignificant loss on sale of business. The calculation of the loss on sale of business includes the derecognition of goodwill of $0.5 million, which is offset by consideration and other assets transferred. Total revenue for Procare for the three and six months ended June 30, 2024 is $0.1 million and $0.4 million, respectively. Net loss for Procare for the three and six months ended June 30, 2024 is $0.3 million and $0.6 million, respectively. The Company does not deem this transaction to be significant.â€‹Clinigence Health, Inc. and Letter of Intent. The Company signed a non-binding letter of intent (â€œLOIâ€) with a third-party limited liability company to commence the negotiations for the sale of Clinigence Health, Inc. (â€œClinigence Healthâ€), a wholly-owned subsidiary of Nutex. The sale is expected to be completed in the third quarter of 2024. The Company recognized an impairment on definite-lived intangible assets of $1.4 million. The Company reclassified all assets of Clinigence Health to assets held-for-sale, within â€œPrepaid expenses and other current assetsâ€ in the condensed consolidated balance sheets. The value of the assets held-for-sale of $1.5 million are based on the LOI. Upon the reclassification of assets to held-for-sale, the Company recognized an insignificant loss. Total revenue for Clinigence Health for the three and six months ended June 30, 2024 is $0.3 million and $0.7 million, respectively. Net loss for Clinigence Health for the three and six months ended June 30, 2024 is $0.4 million and $0.7 million, respectively. The Company does not deem this transaction to be significant.â€‹Note 4 â€“ Revenueâ€‹We disaggregate revenue from contracts with customers into types of services or products, consistent with ourÂ reportable segments, as follows:â€‹â€‹â€‹

20% of the total number of shares issuable upon conversion or exercise of the Unsecured Convertible Term Notes and Warrants, as applicable.â€‹The net carrying amount of the Unsecured Convertible Term Notes was $4.0 million as of JuneÂ 30,Â 2024 and the weighted average effective interest rate on the convertible debt is 21.5%. The Unsecured Convertible Term Notes interest expense was $0.3 million for the three months ending JuneÂ 30,Â 2024, comprising of $0.2 million in amortization expense and $0.1 million in accrued interest expense. For the six months ended JuneÂ 30,Â 2024 interest expense was $0.6 million, comprising of $0.4 million in amortization expense and $0.2 million in accrued interest expense.â€‹â€‹â€‹â€‹â€‹â€‹â€‹NoteÂ 9Â â€“Â Leasesâ€‹We have entered into hospital property, office and equipment rental agreements with various lessors including related parties. The following tables disclose information about our leases of property and equipment:â€‹â€‹â€‹â€‹â€‹â€‹â€‹

management divisionâ€‹â€‹â€‹ 29,339,169â€‹â€‹â€‹ 83,647,378Real estate divisionâ€‹â€‹â€‹ 19,665,530â€‹â€‹â€‹ 35,962,278Total Assetsâ€‹â€‹$ 422,403,251â€‹â€‹$ 398,245,497â€‹â€‹â€‹22 Table of Contentsâ€‹â€‹â€‹â

management services contracts with them.Sources of revenue. Our hospital division recognizes net patient service revenue for contracts with patients and in most cases a third-party payor (commercial insurance, workers compensation insurance or, in limited cases, Medicare/Medicaid).â€‹We receive payment for facility services rendered by us from federal agencies, private insurance carriers, and patients. The Physician LLCs receive payment for doctor services from these same sources. On average, greater than 90% of our net patient service revenue is paid by insurers, federal agencies, and other non-patient third parties. The remaining revenue is paid by our patients in the form of copays, deductibles, and self-payment. The following tables present the allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage:â€‹â€‹â€‹

attributable to Nutex Health Inc.â€‹$ (364,048)â€‹$ (3,479,047)â€‹$ (728,123)â€‹$ (8,626,326)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Adjusted EBITDA(1)â€‹$ 12,039,040â€‹$ 3,994,539â€‹$ 16,599,441â€‹$ 6,432,393â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹(1) See reconciliation of net loss attributable to Nutex Health Inc. to Adjusted EBITDA under Non-GAAP Financial Measures.â€‹Three Months Ended JuneÂ 30,Â 2024 Compared to Three Months Ended JuneÂ 30,Â 2023â€‹Net loss attributable to Nutex Health Inc. decreased to $0.4 million, or a loss of $0.07 per share, for the three months ended JuneÂ 30,Â 2024 from a net loss attributable to Nutex Health Inc. of $3.5 million, or a loss of $0.79 per share, for the same period of 2023. Our 2024 results were principally affected by higher revenue due to:â€‹â—Higher patient visits, increasing by 28.0% during the three months ended JuneÂ 30,Â 2024 as compared with the same period of 2023. Same store mature hospitals increased visits an average of 10.3% versus prior year as well as the opening of four new hospitals in 2023;â—Increased revenue per visit due to success in efforts to obtain higher rates through the Independent Dispute Resolution (â€œIDRâ€) process and increased utilization of higher paid services such as increased observation and in-patient stays.â€‹Adjusted EBITDA for the three months ended JuneÂ 30,Â 2024 increased to $12.0 million from $4.0 million for the comparable period of 2023. Refer to Non-GAAP Financial Measures discussed below for a definition and reconciliation of Adjusted EBITDA. The items affecting revenue contributed significantly to the increase in Adjusted EBITDA in the 2024 period.â€‹A discussion of our segment results is included below. â€‹34 Table of ContentsHospital Division. Our revenue for the three months ended JuneÂ 30,Â 2024 totaled $67.6 million as compared to $51.6 million for the same period of 2023, an increase of $16.0 million or 31.0%. This increase was attributed to an increase in visits, an increase in revenue per visit due to success in efforts to obtain higher rates through the IDR process and increased utilization of higher paid services such as increased observation and in-patient stays. Of this revenue increase, 13.2% related to mature hospitals, which are hospitals that were opened by December 31, 2021.â€‹The following table shows the number of patient visits during the periods:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended JuneÂ 30,Â â€‹2024â€‹2023Patient visits:â€‹â€‹â€‹â€‹â€‹â€‹Hospitalâ€‹â€‹ 41,208â€‹â€‹ 32,183â€‹Total patient visits increased 28.0% during the three months ended JuneÂ 30,Â 2024 as compared with the same period of 2023 including the opening of four facilities throughout 2023 which are fully operating in 2024. Of this visit increase, 10.3% related to mature hospitals, which are hospitals opened by December 31, 2021.â€‹The Company recorded approximately $1.3 million of net revenue for cash collections during the three months ended June 30, 2024 for services that were previously provided. The Company had previously reserved for this amount as uncollectible.The hospital divisionâ€™s operating income was $22.8 million during the three months ended JuneÂ 30,Â 2024, compared with an operating income of $9.1 million in the same period of 2023, an increase of 150.3%. Our revenue and operating income for the second quarter of 2024 was positively affected by the increase in visits and increase in rate paid by insurers discussed above.â€‹Population Health Management Division. Our total revenue for the three months ended JuneÂ 30,Â 2024 was $8.5 million as compared with $7.3 million for the same period of 2023. The increase was due to higher capitation revenue earned.â€‹The population health management division had $0.2 million of operating loss for the three months ended JuneÂ 30,Â 2024 as compared with $0.5 million of operating income for the same period of 2023. Strategically, we are focused on the growth of this division principally through the addition of new independent physician associations and have staffed our organization to manage larger numbers of such organizations.â€‹Real Estate Division. This division reports the operations of consolidated Real Estate Entities where we provide guarantees of their indebtedness or are co-borrowers.â€‹Revenue and operating expenses of consolidated Real Estate Entities are not significant since the extent of these entitiesâ€™ operations is to own facilities leased to our hospital division entities which are financed by a combination of contributed equity by related parties and third-party mortgage indebtedness. Such leases are typically on a triple net basis where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Finance lease income is recognized outside of segment operating income as other income by the Real Estate Entities. However, these amounts are largely eliminated in the consolidation of these entities into our financial statements. â€‹As of JuneÂ 30,Â 2024, two Real Estate Entities continue to be consolidated in our financial statements. We expect that hospitals we open in the future may be leased from new Real Estate Entities which may be owned in whole or part by related parties. Third-party lenders to these entities may require that we provide a guarantee or become co-borrowers under mortgage indebtedness and financings for such facilities. In such instances, we may be required to consolidate these new Real Estate Entities in our financial statements as VIEs.â€‹Corporate and other costs. Corporate and other costs in the three months ended JuneÂ 30,Â 2024 totaled $17.3 million as compared to $10.0 million for the same period of 2023, an increase of 72.5%. General and administrative costs include our executive management, accounting, human resources, corporate technology, insurance and professional fees. The increase in corporate and other costs is primarily due to impairment of assets of $3.5 million and impairment of goodwill 35 Table of Contentsof $3.2 million. These impairments are related to the sale of Procare and the expected sale of Clinigence Health. Additionally, the increase in corporate and other costs are due to increases in payroll offset by decreases in professional services and stock-based compensation expenses.â€‹Nonoperating itemsâ€‹Interest expense. Interest expense was $5.1 million in the three months ended June 30, 2024 as compared with $4.8Â million for the same period of 2023. The increase in interest expense for the 2024 period is principally due to discount amortization expense, the opening of new facilities in 2023 and interest expense associated with the Unsecured Convertible Term Debt.â€‹Gain on warrant liability. Gain on warrant liability was $3.1 million in the three months ended June 30, 2024 is the remeasurement of the warrant liability required at each reporting period and is influenced by changes in our common stock market price.â€‹Income tax expense. Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. The income tax impact of discrete items is recognized in the period these occur. â€‹Our effective tax rate for the three months ended JuneÂ 30,Â 2024 was approximately 22.9%. The primary difference from the federal statutory rate of 21% is related to state taxes, income of noncontrolling interests in flow-through entities and permanent differences for non-deductible expenses.â€‹Six Months Ended JuneÂ 30,Â 2024 Compared to Six Months Ended JuneÂ 30,Â 2023 â€‹Net loss attributable to Nutex Health Inc. decreased to $0.7 million, or a loss of $0.15 per share, for the six months ended JuneÂ 30,Â 2024 from a net loss attributable to Nutex Health Inc. of $8.6 million, or a loss of $1.98 per share, for the same period of 2023. Our 2024 results were principally affected by higher revenue due to:â€‹â—Higher patient visits, increasing by 24.6% during the six months ended JuneÂ 30,Â 2024 as compared with the same period of 2023;â—Increase revenue per visit due to payor payment rates through the IDR process and increased utilization of higher paid services such as increased observation and in-patient stays.â€‹Adjusted EBITDA for the six months ended JuneÂ 30,Â 2024 increased to $16.6 million from $6.4 million for the comparable period of 2023. Refer to Non-GAAP Financial Measures discussed below for a definition and reconciliation of Adjusted EBITDA. The items affecting revenue contributed significantly to the increase in Adjusted EBITDA in the 2024 period.â€‹A discussion of our segment results is included below. â€‹Hospital Division. Our revenue for the six months ended JuneÂ 30,Â 2024 totaled $127.6 million as compared to $100.9 million for the same period of 2023, an increase of $26.7 million or 26.5%. This increase was attributed to an increase in visits, an increase in revenue per visit due to success in efforts to obtain higher rates through the IDR process and increased utilization of higher paid services such as increased observation and in-patient stays. Of this revenue increase, 9.7% related to mature hospitals, which are hospitals that were opened by December 31, 2021.â€‹36 Table of ContentsThe following table shows the number of patient visits during the periods:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six Months Ended JuneÂ 30,Â â€‹â€‹2024â€‹2023Patient visits:â€‹â€‹â€‹â€‹â€‹â€‹Hospitalâ€‹â€‹ 81,276â€‹â€‹ 65,244â€‹Total patient visits increased 24.6% during the six months ended JuneÂ 30,Â 2024 as compared with the same period of 2023 due mostly to the opening of four facilities throughout 2023 which are fully operating in 2024. Of this visit increase, 9.7% related to mature hospitals, which are hospitals opened by December 31, 2021.â€‹The Company recorded approximately $2.1 million of net revenue for cash collections during the six months ended JuneÂ 30, 2024 for services that were previously reserved as uncollectible.The hospital divisionâ€™s operating income was $33.3 million during the six months ended JuneÂ 30,Â 2024, compared with an operating income of $13.9 million in the same period of 2023, an increase of 139.6%. Our revenue and operating income for the second quarter of 2024 was positively affected by the increase in visits and revenue per visit discussed above.â€‹Population Health Management Division. Our total revenue for the six months ended JuneÂ 30,Â 2024 was $15.9 million as compared with $14.3 million for the same period of 2023. The increase was due to higher capitation revenue earned.â€‹The population health management division had $0.5 million of operating loss for the six months ended JuneÂ 30,Â 2024 as compared with $0.6 million of operating income for the same period of 2023. Strategically, we are focused on the growth of this division principally through the addition of new independent physician associations and have staffed our organization to manage larger numbers of such organizations.â€‹Real Estate Division. This division reports the operations of consolidated Real Estate Entities where we provide guarantees of their indebtedness or are co-borrowers.â€‹Revenue and operating expenses of consolidated Real Estate Entities are not significant since the extent of these entitiesâ€™ operations is to own facilities leased to our hospital division entities which are financed by a combination of contributed equity by related parties and third-party mortgage indebtedness. Such leases are typically on a triple net basis where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Finance lease income is recognized outside of segment operating income as other income by the Real Estate Entities. However, these amounts are largely eliminated in the consolidation of these entities into our financial statements. â€‹As of JuneÂ 30,Â 2024, two Real Estate Entities continue to be consolidated in our financial statements. We expect that hospitals we open in the future may be leased from new Real Estate Entities which may be owned in whole or part by related parties. Third-party lenders to these entities may require that we provide a guarantee or become co-borrowers under mortgage indebtedness and financings for such facilities. In such instances, we may be required to consolidate these new Real Estate Entities in our financial statements as VIEs.â€‹Corporate and other costs. Corporate and other costs in the six months ended JuneÂ 30,Â 2024 was $26.0 million as compared to $19.3 million for the same period of 2023, an increase of 34.5%. General and administrative costs include our executive management, accounting, human resources, corporate technology, insurance and professional fees. The increase in corporate and other costs is primarily due to impairment of assets of $3.5 million and impairment of goodwill of $3.2 million. These impairments are related to the sale of Procare and the expected sale of Clinigence Health.â€‹37 Table of ContentsNonoperating itemsâ€‹Interest expense. Interest expense was $9.5 million in the six months ended June 30, 2024 as compared with $8.0 million for the same period of 2023. The increase in interest expense for the 2024 period is principally due to discount amortization expense, the opening of new facilities and interest expense associated with the Unsecured Convertible Term Debt.â€‹Gain on warrant liability. Gain on warrant liability was $5.7 million in the six months ended June 30, 2024 is the remeasurement of the warrant liability required at each reporting period and is influenced by changes in our common stock market price.â€‹Income tax expense. Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. The income tax impact of discrete items is recognized in the period these occur.â€‹Our effective tax rate for the three months ended JuneÂ 30,Â 2024 was approximately 34.2%. The primary difference from the federal statutory rate of 21% is related to state taxes, income of noncontrolling interests in flow-through entities and permanent differences for non-deductible expenses.â€‹â€‹Liquidity and Capital Resourcesâ€‹As of JuneÂ 30,Â 2024, we had $40.8 million of cash and equivalents, compared to $22.0 million of cash and equivalents at DecemberÂ 31, 2023.â€‹Significant sources and uses of cash during the first six months of 2024.â€‹Sources of cash:â—Cash from operating activities was $16.3 million, which included $5.6 million from the primary components of our working capital (receivables, inventories, accounts payable and expenses)â—Proceeds from common stock issuance of $9.2 million, net issuance costs; andâ—Proceeds from note payable $4.9 millionâ€‹Uses of cash:â—Repayments of lines of credit and notes payable $6.8 millionâ—Capital expenditures were $1.3 millionâ—Cash related to sale of business $0.7 millionâ—Distributions, net of contributions, to noncontrolling interests totaled $1.6 million; andâ—Repayments of finance leases totaled $1.4 million.â€‹Future sources and uses of cash. Our operating activities are financed with cash on hand which is generated from revenues, which may vary significantly based on regulatory changes affecting the timing and amounts of insurance reimbursements for our services. Most of our hospital facilities are leased from various lessors including related parties. These leases are presented in our consolidated balance sheets unless the lease is from a consolidated Real Estate Entity. Our growth plans include the development of new hospital locations. We expect that in many of these locations we will lease facilities from newly established entities partially owned by related parties.â€‹We routinely enter into equipment lease agreements to procure new or replacement equipment and may also finance these purchases with term debtâ€Ž. We have smaller lines of credits available for working capital purposes and are presently working to supplement or replace these with larger financing commitments. These larger financing commitments are subject to market conditions and we may not be able to obtain such larger financing commitments with favorable economic terms or at all. We also believe that our existing cash, cash equivalents, and marketable securities, and available borrowing capacity, will be sufficient to meet our anticipated cash needs requirements for operations and growth objectives â€Žfor at least the next twelve months. If the assumptions underlying our business plan regarding future 38 Table of Contentsrevenue and expenses change or if unexpected opportunities or needs arise, we may seek to raise additional cash by selling equity or debt securities.â€‹Indebtedness. The Companyâ€™s indebtedness at JuneÂ 30,Â 2024 is presented in Item I, â€œFinancial Statements â€“ NoteÂ 8 â€“ Debtâ€ and our lease obligations are presented in Item I, â€œFinancial Statementsâ€“NoteÂ 9 â€“ Leases.â€‹Off-Balance Sheet ArrangementsÂ As of JuneÂ 30,Â 2024, we had no material off-balance sheet arrangements.â€‹Non-GAAP Financial Measuresâ€‹Adjusted EBITDA.Â Adjusted EBITDA is used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe Adjusted EBITDA is useful because it allows us to more effectively evaluate our operating performance.â€‹We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plusÂ net interest expense, income taxes, depreciation and amortization, further adjusted for an allocation to noncontrolling interests, (gain)/loss on warrant liability, stock-based compensation, any facilities closing costs, acquisition related costs and impairments. A reconciliation of net income to Adjusted EBITDA is included below. Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

December 31, 2023, based on criteria established in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the â€œCOSO criteriaâ€). Based on our assessment, the following material weaknesses were identified:â—The Company had ineffective design, implementation, and operation controls over logical access, program change management, and vendor management controls:1)appropriate restrictions that would adequately prevent users from gaining inappropriate access to the financially relevant systems.2)IT program and data changes affecting the Companyâ€™s financial IT applications and underlying accounting records, are identified, tested, authorized and implemented appropriately to validate that data produced by its relevant IT systems were complete and accurate. Automated process-level and manual controls that are dependent upon the information derived from such financially relevant systems were also determined to be ineffective as a result of such deficiency.3)key third party service provider SOC reports were obtained and reviewed.â€‹â—Business process controls across all financial reporting processes were not effectively designed and implemented to properly address the risk of material misstatement, including controls without proper segregation of duties between preparer and reviewer and key management review controls.â—Ineffective design and implementation of controls over the completeness and accuracy of information included in key spreadsheets supporting the financial statements.Management has concluded that, based on applying the COSO criteria, as of December 31, 2023, the Companyâ€™s internal control over financial reporting was not effective to provide reasonable assurance of the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.Remediation Plans. These material weaknesses did not result in a material misstatement of the Companyâ€™s consolidated financial statements for the periods presented. In 2023, the Company started the process of designing and implementing effective internal control measures to remediate the reported material weaknesses. The Companyâ€™s efforts included implementing a new enterprise-wide system to reduce reliance on manual processes and spreadsheets supporting the 40 Table of Contentsfinancial statements. Additionally, the Company engaged an accounting firm in 2023 to assist in the proper design, implementation and testing of internal controls over financial reporting. We added key senior management positions including a Chief Operating Officer and made additions to our accounting and financial reporting teams throughout 2023. Throughout 2024, we have strengthened our internal audit program to review and monitor the Companyâ€™s progress with our remediation plans.While we believe that these efforts will improve our internal control over financial reporting, our remediation efforts are ongoing and will require validation and testing of the design and operating effectiveness of internal controls. The actions that we are taking are subject to ongoing senior management review, as well as audit committee oversight. We will not be able to conclude whether the steps we are taking will fully remediate the remaining material weakness in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness. We may also conclude that additional measures may be required to remediate the material weakness in our internal control over financial reporting.Changes in Internal Control Over Financial Reporting. We are taking actions to remediate the material weakness relating to our internal control over financial reporting, as described above. Except as otherwise described herein, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.â€‹Inherent Limitations on Effectiveness of Disclosure Controls and Procedures. Our senior members of management do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.PART II â€” OTHER INFORMATIONâ€‹ItemÂ 1.Â Â Â Â Legal Proceedings.Â From time to time, the Company, its consolidated subsidiaries or VIEs may be named in various claims and legal actions in the normal course of business. The Company is not involved in any legal proceedings that it believes would have a material effect on its business or financial condition.ItemÂ 1A.Â Risk Factors.Â In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading â€œRisk Factorsâ€ included in our Form 10-K for the year ended December 31, 2023 and the risk factors and other cautionary statements contained in our other SEC filings, which could materially affect our businesses, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.â€‹ItemÂ 2.Â Unregistered Sales of Equity Securities and Use of Proceeds.Â Recent Sales of Unregistered Securities; use of proceeds from registered securities.â€‹Not applicable.â€‹ItemÂ 3.Â Defaults upon Senior Securities.Â Not Applicable41 Table of Contentsâ€‹ItemÂ 4.Â Â Â Â Mine Safety DisclosuresÂ Not ApplicableÂ ItemÂ 5.Â Â Â Â Other Information.â€‹Trading Arrangementsâ€‹During the fiscal quarter ended JuneÂ 30,Â 2024, none of the Companyâ€™s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K) for the purchase or sale of the Companyâ€™s securities.â€‹ItemÂ 6.Â Â Â Â ExhibitsÂ Exhibit No.Description31.1*Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1*Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed â€œfiledâ€ for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)32.2*Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed â€œfiledâ€ for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCH*XBRL Taxonomy Extension Schema Document.101.CAL*XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF*XBRL Taxonomy Extension Definition Linkbase Document.101.LAB*XBRL Taxonomy Extension Label Linkbase Document.101.PRE*XBRL Taxonomy Extension Presentation Linkbase Document.104Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.â€‹* Filed herewithâ€‹â€‹42 Table of Contentsâ€‹SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on August 8, 2024.Â Nutex Health Inc.Â Â Â By:/s/ Thomas T. VoÂ Â Thomas T. VoÂ Â Chief Executive Officer and Chairman of the Board(principal executive officer)Â Â Â Â By:/s/ Jon C. BatesÂ Â Jon C. BatesÂ Â Chief Financial Officer(principal financial officer and principal accounting officer)â€‹â€‹43 EX-31.1 2 nutx-20240630xex31d1.htm EX-31.1 ExhibitÂ 31.1CERTIFICATION OF CHIEF EXECUTIVE OFFICERPURSUANT TO RULEÂ 13A-14(A)Â AND RULEÂ 15D-14(A)OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDI, Thomas T. Vo, certify that:Â Â Â Â Â 1.Â I have reviewed this quarterly report on Form 10-Q of Nutex Health. Inc.;Â Â Â Â Â 2.Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â Â Â Â Â 3.Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â Â Â Â Â 4.Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f) and 15d-15(f)) for the registrant and have:Â Â Â Â Â Â Â Â Â Â Â (a)Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â Â Â Â Â Â Â Â Â Â Â (b)Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â Â Â Â Â Â Â Â Â Â Â (c)Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ Â Â Â Â Â Â Â Â Â Â Â (d)Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ Â Â Â Â 5.Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):Â Â Â Â Â Â Â Â Â Â Â (a)Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ Â Â Â Â Â Â Â Â Â Â Â (b)Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: August 8, 2024â€‹â€‹By:/s/ Thomas T. VoÂ â€‹Thomas T. VoÂ â€‹â€‹Chief Executive Officer and Chairman of the Boardâ€‹â€‹(principal executive officer)â€‹ EX-31.2 3 nutx-20240630xex31d2.htm EX-31.2 ExhibitÂ 31.2CERTIFICATION OF CHIEF FINANCIAL OFFICERPURSUANT TO RULEÂ 13A-14(A)Â AND RULEÂ 15D-14(A)OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDEDI, Jon C. Bates, certify that:Â Â Â Â Â 1.Â I have reviewed this quarterly report on Form 10-Q of Nutex Health. Inc.;Â Â Â Â Â 2.Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Â Â Â Â Â 3.Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;Â Â Â Â Â 4.Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act RulesÂ 13a-15(f) and 15d-15(f)) for the registrant and have:Â Â Â Â Â Â Â Â Â Â Â (a)Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â Â Â Â Â Â Â Â Â Â Â (b)Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â Â Â Â Â Â Â Â Â Â Â (c)Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ Â Â Â Â Â Â Â Â Â Â Â (d)Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andÂ Â Â Â Â 5.Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):Â Â Â Â Â Â Â Â Â Â Â (a)Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andÂ Â Â Â Â Â Â Â Â Â Â Â (b)Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: August 8, 2024â€‹â€‹By:/s/ Jon C. BatesÂ Jon C. Batesâ€‹Chief Financial Officerâ€‹(principal financial officer and principal accounting officer)â€‹ EX-32.1 4 nutx-20240630xex32d1.htm EX-32.1 â€‹ExhibitÂ 32.1Â CERTIFICATION OFCHIEF EXECUTIVE OFFICERPURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTIONÂ 906 OF THESARBANES OXLEY ACT OF 2002â€‹Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Executive Officer of Nutex Health Inc. (the â€œCompanyâ€), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended JuneÂ 30,Â 2024, (the â€œReportâ€) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Date: August 8, 2024â€‹â€‹By:/s/ Thomas T. VoÂ â€‹Thomas T. Voâ€‹â€‹Chief Executive Officer and Chairman of the Boardâ€‹(principal executive officer)â€‹ EX-32.2 5 nutx-20240630xex32d2.htm EX-32.2 â€‹ExhibitÂ 32.2Â CERTIFICATION OFCHIEF FINANCIAL OFFICERPURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTIONÂ 906 OF THESARBANES OXLEY ACT OF 2002â€‹Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Financial Officer of Nutex Health Inc. (the â€œCompanyâ€), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended JuneÂ 30,Â 2024, (the â€œReportâ€) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Date: August 8, 2024â€‹â€‹â€‹â€‹â€‹By:/s/ Jon C. BatesÂ Jon C. Batesâ€‹Chief Financial Officerâ€‹(principal financial officer)â€‹ EX-101.SCH 6 nutx-20240630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Property and Equipment - Categories (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Intangible Assets and Goodwill - Operating Segment (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Debt - Outstanding Debts (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Leases - Leases of property and equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Organization and Operations (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Revenue - Disaggregate revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Revenue - Insurance Coverage (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Intangible Assets and Goodwill - Components (Details) link:presentationLink link:calculationLink link:definitionLink 99940603 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Debt - Outstanding Debt (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Debt - Pre-Paid Advance Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Stock-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99941103 - Disclosure - Stock-based Compensation - Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 99941104 - Disclosure - Stock-based Compensation - Restricted Stock Units Issued and Vested (Details) link:presentationLink link:calculationLink link:definitionLink 99941105 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99941106 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Equity - Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99941203 - Disclosure - Equity - Schedule of Outstanding

Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941402 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99941601 - Disclosure - Segment Information - Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99941602 - Disclosure - Segment Information - Operations (Details) link:presentationLink link:calculationLink link:definitionLink 99941701 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 99941801 - Disclosure - Variable Interest Entities - Balance sheet amounts (Details) link:presentationLink link:calculationLink link:definitionLink 99941802 - Disclosure - Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 99941901 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 99941902 - Disclosure - Subsequent Events - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Organization and Operations link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - Supplemental Cash Flows Information link:presentationLink link:calculationLink link:definitionLink 995211601 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995211701 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995211801 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 995211901 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920102 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99931403 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931503 - Disclosure - Supplemental Cash Flows Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99931603 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99931803 - Disclosure - Variable Interest Entities (Tables) link:presentationLink link:calculationLink link:definitionLink 99931903 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Debt - Term Loans and Lines of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - Stock-based Compensation - Stock-Based Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - Earnings per Share - Computation of EPS (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - Supplemental Cash Flows Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nutx-20240630_cal.xml EX-101.CAL EX-101.DEF 8 nutx-20240630_def.xml EX-101.DEF EX-101.LAB 9 nutx-20240630_lab.xml EX-101.LAB Cover Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus CONDENSED CONSOLIDATED BALANCE SHEETS Assets Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts receivable Accounts receivable Accounts receivable - related parties Accounts receivable - related parties Inventories Inventories Prepaid expenses and other current assets Prepaid expenses and other current assets Total current assets Total current assets Current assets Property and equipment, net Property and equipment, net Total property and equipment, net Fixed assets Operating right-of-use assets Operating right-of-use assets Finance right-of-use assets Finance right-of-use assets Intangible assets, net Intangible assets, net Net Carrying Amount Goodwill, net Goodwill, net Goodwill, Total Goodwill Other assets Other assets Total assets Total assets Total Assets Liabilities and Equity Current liabilities: Accounts payable Accounts payable Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities for related parties (due within one year or within the normal operating cycle if longer). Accounts Payable, Current For Related Party Accounts payable - related parties Lines of credit Lines of credit Less: short-term lines of credit Less: current portion of long-term debt Less: current portion of long-term debt Current portion of long-term debt Operating lease liabilities, current portion Operating lease liabilities, current portion Finance lease liabilities, current portion Finance lease liabilities, current portion Accrued expenses and other current liabilities. Accrued expenses and other current liabilities Total current liabilities Total current liabilities Current liabilities Long-term debt, net Long-term debt, net Present value of warranty liability, classified as noncurrent. Warranty, Liability, Noncurrent Warrant liability Operating lease liabilities, net Operating lease liabilities, net Finance lease liabilities, net Finance lease liabilities, net Deferred Income Tax Liabilities, Net Deferred tax liabilities Total liabilities Total liabilities Liabilities Commitments and contingencies. Commitments and contingencies Equity: Common stock, $0.001 par value; 950,000,000 shares authorized; 660,742,624 and 650,223,840 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively Common stock, $0.001 par value; 950,000,000 shares authorized; 4,986,578 and 4,511,199 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Common stock Additional paid-in capital Additional paid-in capital Retained earnings (accumulated deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Nutex Health Inc. equity Equity Noncontrolling interests Equity attributable to noncontrolling interests Noncontrolling interests Total equity Ending balance, value Beginning balance, value Total equity Total liabilities and equity Total liabilities and equity Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock authorized Common Stock, Shares, Issued Common stock issued Common Stock, Shares, Outstanding Common stock outstanding Common Stock - Shares CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statement [Table] Product and Service [Axis] Product and Service [Domain] Information related to the hospital division. Hospital Division [Member] Hospital division Hospital Division Information related to the population health management division. Population Health Management Division [Member] Population health management division Population Health Management Division Statement [Line Items] Statement Revenue: Total revenue Total revenue Revenues Operating costs and expenses: Payroll Payroll and benefits Contract services Contract services Medical supplies Medical supplies Depreciation, Depletion and Amortization, Nonproduction Total depreciation and amortization Depreciation and amortization Other Net expense Other Costs and Expenses Total operating costs and expenses Gross Profit Total segment operating income Gross profit Corporate and other costs: The amount of expense for facilities closing costs. Facilities Closing Costs Facilities closing costs Employee Benefit and Share-Based Payment Arrangement, Noncash Stock-based compensation expense Stock-based compensation Asset Impairment Charges Impairment of assets Intangible impairment Amount of non-cash loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill, Non Cash Impairment Loss Impairment of goodwill Goodwill impairment loss General and administrative expenses General and administrative expenses Operating Expenses Total corporate and other costs Operating income (loss) Operating income (loss) Interest expense, net Interest expense, net Gain (loss) related to the warranty liability. Gain (Loss) on Warrant Liability Gain on warrant liability Other Nonoperating Income (Expense) Other (income) expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) before taxes Income tax expense Income tax expense (benefit) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income (loss) Net income (loss) Net loss Net Income (Loss) Attributable to Noncontrolling Interest Less: net income (loss) attributable to noncontrolling interests Net income (loss) attributable to Nutex Health Inc. Net loss attributable to common stockholders Earnings per Share Income (loss) per common share: Earnings Per Share Basic Basic Basic, income (loss) per common share (in dollar per share) Earnings Per Share Diluted Diluted Diluted, income (loss) per common share (in dollar per share) CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Noncontrolling Interest [Member] Noncontrolling Interests Shares, Outstanding End balance, shares Beginning balance, shares Noncontrolling Interest, Decrease from Deconsolidation Deconsolidation of Real Estate Entities Common stock issued for exercise of warrants. Common stock issued for exercise of warrants Common stock issued for exercise of warrants Common stock shares issued for exercise of warrants. Common stock issued for exercise of warrants (in shares) Common stock issued for exercise of warrants (in shares) Value of shares received during the period in sale of business. Stock Received In Sale Of Business During Period, Value Common stock received in sale of business Common stock received in sale of business Remitted Company stock Number of shares received during the period in sale of business. Stock Received in Sale of Business During Period, Shares Common stock received in sale of business (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock issued for Employee Stock Purchase Plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued for Employee Stock Purchase Plan (in shares) Stock Issued During Period, Value, New Issues Allocation of proceeds related to common stock issuance Issuance of common stock to Apollo Medical Holdings, Inc. Common stock issuance Stock Issued During Period, Shares, New Issues Common stock issuance (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Debt conversion to common stock Stock Issued During Period, Shares, Conversion of Convertible Securities Debt conversion to common stock (in shares) Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Restricted stock awards issued for compensation Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Restricted stock awards issued for compensation (in shares) Stock Issued During Period, Value, Acquisitions Common stock issued for acquisition Payment for acquisition in common stock Reverse acquisition with Clinigence , shares Common stock issued for acquisition (in shares) Common stock issued for acquisition (in shares) APIC, Share-Based Payment Arrangement, Recognition and Exercise Stock-based compensation Stock Issued During Period, Value, Restricted Stock Award, Gross Vesting of Restricted Stock Units Restricted common stock awards issued Stock Issued During Period, Shares, Restricted Stock Award, Gross Restricted common stock awards issued (in shares) Vesting of Restricted Stock Units (in shares) Conversion of Stock, Amount Issued Reverse stock split adjustment Stock Issued During Period, Shares, Reverse Stock Splits Reverse stock split adjustment (in shares) Noncontrolling Interest, Increase from Subsidiary Equity Issuance Contributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Distributions CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash from operating activities: Depreciation, Depletion and Amortization Depreciation and amortization The derecognition of goodwill. Derecognition Of Goodwill Derecognition of goodwill Derecognition of goodwill Deferred Income Tax Expense (Benefit) Deferred tax benefit Accretion Expense Debt accretion expense Gain (Loss) on Termination of Lease Loss on lease termination Non-cash lease expense. Non-cash lease expense Non-cash lease expense (income) Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities, net of the effects of acquisitions: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accounts Receivable, Related Parties Accounts receivable - related party Increase (Decrease) in Inventories Inventories Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable, Trade Accounts payable Accounts payable - related party Accounts payable - related party Increase (Decrease) in Other Current Liabilities Accrued expenses and other current liabilities Cash flow from operating activities Net cash from operating activities Cash flows from investing activities: Payments to Acquire Other Property, Plant, and Equipment Acquisitions of property and equipment The cash outflow associated with the loss on the sale of business. Payments Related To Loss On Sale Of Business Cash related to sale of business Payments to Acquire Other Real Estate Cash related to deconsolidation of Real Estate Entities Cash flow from investing activities Net cash from investing activities Cash flows from financing activities: Proceeds from lines of credit Proceeds from lines of credit Proceeds from notes payable Proceeds from notes payable Repayments of Lines of Credit Repayments of lines of credit Repayments of Notes Payable Repayments of notes payable Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security Repayments of finance leases Proceeds from Issuance of Common Stock Gross proceeds Proceeds from common stock issuance, net issuance costs Contributions made by members. Members' contributions Members' contributions Distributions made to members. Members Distributions Members' distributions Cash flow from financing activities Net cash from financing activities Net change in cash Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and cash equivalents - end of the period Cash and cash equivalents - beginning of the period n/a Organization and Operations Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Organization and Operations Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Divestitures Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Divestitures Revenue Revenue from Contract with Customer [Text Block] Revenue Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Intangible Assets and Goodwill Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Debt Debt Disclosure [Text Block] Debt Leases The entire disclosure of information about leases. Lease Disclosure [Text Block] Leases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stock-based Compensation Share-Based Payment Arrangement [Text Block] Stock-based Compensation Equity Stockholders' Equity Note Disclosure [Text Block] Equity Income Taxes Income Tax Disclosure [Text Block] Income Taxes Earnings Per Share [Text Block] Earnings per Share Supplemental Cash Flows Information Cash Flow, Supplemental Disclosures [Text Block] Supplemental Cash Flows Information Segment Information Segment Reporting Disclosure [Text Block] Segment Information Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Variable Interest Entities Variable Interest Entity Disclosure [Text Block] Variable Interest Entities Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of presentation Disclosure of accounting policy for interim financial statements. Interim Financial Statements Policy [Policy Text Block] Interim financial statements Use of estimates Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Fair value measurements Segment reporting Reclassifications Recent accounting pronouncements Schedule of disaggregate revenue Schedule of allocation of the estimated transaction price Schedule of property, plant and equipment Schedule of property and equipment Schedule of intangible assets Schedule of Goodwill [Table Text Block] Schedule of carrying amount of goodwill, by operating segment Schedule of accrued expenses and other current liabilities Schedule of debt Schedule of debt Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block] Schedule of lease of property and equipment Share-Based Payment Arrangement, Activity [Table Text Block] Schedule of stock-based awards activity Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Schedule of stock options outstanding Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of changes in restricted stock units Schedule of Warrants, Activity Schedule of common stock warrants Tabular disclosure of warrants outstanding. Schedule of outstanding warrants Schedule of outstanding warrants Schedule of earnings (loss) per share Schedule of supplemental cash flows information Schedule of supplemental cash flows information Schedule of Impaired Intangible Assets [Table Text Block] Schedule of assets Schedule of Segment Reporting Information, by Segment [Table

Text Block] Schedule of segment information Schedule of consolidated balance sheets Schedule of consolidated balance sheets Schedule of Subsequent Events [Table Text Block] Schedule of reverse stock split retroactively adjusted Legal Entity [Axis] Entity [Domain] Information pertaining to Nutex Health Inc. Nutex Health Inc [Member] Nutex Health Inc Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Information pertaining to mergers. Merger Agreement [Member] Merger Agreement Ownership [Axis] Ownership [Domain] Represents information relating to Nutex subsidiaries. Nutex Subsidiaries [Member] Nutex Subsidiaries Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Represents information relating to Clinigence Holdings, Inc. Clinigence Holdings Inc. [Member] Clinigence Holdings, Inc. Consolidated Entities [Axis] Consolidated Entities [Domain] Represents information relating to Nutex Health Holdco LLC. Nutex Health Holdco LLC [Member] Nutex Health Holdco LLC Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Represents number of hospital facilities operated by the company. Number of Hospital Facilities Operated Number of hospital facilities Represents number of states the company operates within. Number of States Locations Number of states the company operates within Entity Number of Employees Number of full time employees Number of contract doctors employed by the company. Number Of Contract Doctors Number of contract doctors Number of physicians with whom the company has partnered. Number Of Physicians Partnered Partner with physicians Stockholders' Equity Note, Stock Split, Conversion Ratio Conversion ratio Noncontrolling Interest, Ownership Percentage by Parent Ownership percentage Number of shares issuable upon merger for each share of stock held and to be converted. Merger Agreement Conversion Ratio Conversion ratio Represents information relating to Physician LLC and Real Estate Entities. Physician LLC and Real Estate Entities [Member] Physician LLC and Real Estate Entities Represents information relating to Associated Hispanic Physicians of So. California . Associated Hispanic Physicians Of So. California [Member] Associated Hispanic Physicians of So. California Represents information relating to AHP Health Management Services Inc. Ahp Health Management Services Inc. [Member] AHP Health Management Services Inc. The number of real estate entities deconsolidated. Number of Deconsolidated Real Estate Entities Number of deconsolidated Real Estate Entities Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Percentage of control Number of Reportable Segments Number of reportable segments Restricted Cash Disposal Groups, Including Discontinued Operations [Table] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Discontinued Operations, Disposed of by Sale [Member] Discontinued operations, disposed of by sale Disposal Group Name [Axis] Disposal Group Name [Domain] This member stands for Procare Health Inc. Procare Health Inc [Member] Procare Health, Inc This member stands for Clinigence Health Inc. Clinigence Health Inc [Member] Clinigence Health, Inc Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Divestitures Disposal Group, Including Discontinued Operation, Consideration Consideration for the transaction Disposal Group, Including Discontinued Operation, Liabilities Liabilities Liabilities assumed Asset, Held-for-Sale, Not Part of Disposal Group, Current Assets held-for-sale Disposal Group, Including Discontinued Operation, Intangible Assets Intangible asset impairment Disposal Group, Including Discontinued Operation, Revenue Total revenue Disposal Group, Including Discontinued Operation, Operating Income (Loss) Net loss Disaggregation of Revenue [Table] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue Represent the information pertaining to insurance. Insurance [Member] Insurance Represent the information pertaining to self pay. Selfs Pay [Member] Self pay Workers' Compensation Insurance [Member] Workers compensation Represent the information pertaining to medicare and medicaid. Medicare [Member] Medicare/Medicaid Life Insurance Assumed Ratio Percentage of net patient service revenue paid by insurers, federal agencies and other non patient third parties. Percentage of Net Patient Service Revenue Percentage of net patient service revenue Amount of revenues recognized that was previously reported as deferred or unearned revenue. Deferred Revenue, Revenues Recognized Revenue for cash collections previously deemed uncollectible Property, Plant and Equipment [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Building and Building Improvements [Member] Buildings and improvements Land [Member] Land Leasehold Improvements [Member] Leasehold improvements Construction in Progress [Member] Construction in progress Represent the information pertaining to medical equipment. Medical Equipment [Member] Medical equipment Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine. Also include furniture. Office Furniture And Equipment [Member] Office furniture and equipment Represent the information pertaining to computer hardware and software. Computer Hardware And Software [Member] Computer hardware and software Vehicles [Member] Vehicles Represent the information pertaining to signage. Signage [Member] Signage Property, Plant and Equipment [Line Items] Property, Plant and Equipment Property, Plant and Equipment, Useful Life Useful Life (years) Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Property, Plant and Equipment [Member] Property, Plant and Equipment The number of real estate entities consolidated. Number Of Consolidated Real Estate Entities Number of real estate entities consolidated Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Represent the information pertaining to member relationships. Member Relationships [Member] Member relationships Represent the information pertaining to management contracts. Management contracts Management contracts Customer Contracts [Member] Customer contracts Trademarks [Member] Trademarks Represent the information pertaining to PHP Technology. P H P Technology [Member] PHP technology Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets Intangible Assets and Goodwill Finite-Lived Intangible Asset, Useful Life Weighted Average Useful Life (in years) Intangible Assets, Gross (Excluding Goodwill) Gross Carrying Amount Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Finite-Lived Intangible Assets, Net Net Carrying Amount Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Derecognized intangible assets Amortization of Intangible Assets Amortization of intangible assets Segments [Axis] Segments [Domain] Goodwill, Gross Goodwill Goodwill, Impaired, Accumulated Impairment Loss Accumulated impairment losses Goodwill, Measurement Period Adjustment Purchase accounting adjustments Goodwill, Written off Related to Sale of Business Unit Impairment of goodwill Loss on sale of busines Represents the number of Florida based IPAs. Number of Florida Based Ipas Florida based IPAs Goodwill, Impairment Loss Goodwill impairment Accrued wages and benefits Accrued wages and benefits Amount of supplier expenses liabilities, due within one year of the normal operating cycle, if longer. Supplier Expenses Liabilities, Current Accrued supplier expenses Amount of medical insurance claim liabilities, due within one year of the normal operating cycle, if longer. Medical Insurance Claim Liabilities, Current Accrued medical insurance claims Taxes Payable, Current Accrued taxes Other Liabilities, Current Accrued other Accrued Liabilities and Other Liabilities Total accrued expenses and other current liabilities Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represent the information pertaining to term loans secured by assets. Term Loan [Member] Term loans secured by all assets Represent the information pertaining to term loans secured by property and equipment. Term Loan 1 [Member] Term loans secured by property and equipment Line of Credit [Member] Line of credit secured by all assets Represent the information pertaining to term loans of consolidated Real Estate Entities. Term Loan 3 [Member] Term loans of consolidated Real Estate Entities Represents information relating to term loan secured by deposits. Term loan secured by deposits Convertible Debt [Member] Unsecured convertible term notes Convertible debt Represents information pertaining to prepaid advance. Prepaid Advance [Member] Prepaid Advance Debt Instrument [Line Items] Debt Instrument Debt Instrument, Interest Rate During Period Interest Rates (as percentage) Long-Term Debt, Gross Total Debt Issuance Costs, Net Less: unamortized issuance costs and discount Debt Issuance Costs Debt Instrument, Debt Default, Amount Debt instrument not in compliance with debt service coverage ratio Line of Credit Facility, Remaining Borrowing Capacity Remaining borrowing capacity Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Represents the information pertaining to Yorkville. Yorkville [Member] Yorkville Represents the information pertaining to Emerson Equity LLC. Emerson Equity LLC [Member] Emerson Equity LLC ("Emerson") Represents the information pertaining to Pre-Paid Advance Agreement with Yorkville. Pre-Paid Advance Agreement with Yorkville [Member] Pre-Paid Advance Agreement with Yorkville Sale of Stock [Axis] Sale of Stock [Domain] September 2023 Private Offering [Member]. September 2023 Private Offering [Member] September 2023 Private Offering Information related to the amendment to September 2023 Private Offering. September 2023 Private Offering As Amended [Member] September 2023 Private Offering As Amended Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information relating to accredited investors warrants. Accredited Investors Warrants Represents information relating to common stock warrants. Common Stock Warrants [Member] Common Stock Warrants Represents information relating to placement agent warrants. Placement Agent Warrants Scenario [Axis] Scenario [Domain] Represents information relating to prior to reverse stock split. Prior to Reverse Stock Split The percentage of the face amount for issue. Percentage of the Face Amount for Issue Percentage of the face amount for issue The initial pre-paid advance amount with expenses. Initial Pre-paid Advance Amount with Expenses Initial pre-paid advance amount with expenses Warrants and Rights Outstanding, Term Warrants Weighted Average Remaining Contractual Life (years) Warrant duration Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase of common stock Warrants issued Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price Strike price The interest rate for funds borrowed in the event of default. Debt Instrument, Interest Rate Upon Events of Default Interest Rate Upon Events of Default Debt Instrument, Term Maturity date The threshold consecutive trading days during which share price less than fixed price for prepayment of debt. Debt Instrument, Convertible, Prepayment, Share Price, Threshold Consecutive Trading Days Prepayment, Threshold Consecutive Trading Days The period of notice to be given for prepayment of convertible debt. Debt Instrument, Convertible, Prepayment, Notice Period Prepayment, Notice Period The percent of premium to be paid on convertible debt for prepayment. Debt Instrument, Convertible, Prepayment Premium Prepayment Premium Proceeds from Convertible Debt Net Proceeds The percent of debt discount. Debt Instrument, Discount, Percent Percentage of debt discount Debt Instrument, Unamortized Discount Debt discount Long-Term Debt Net carrying amount Debt Conversion, Converted Instrument, Shares Issued Convertible notes, converted to shares Debt Conversion, Converted Instrument, Amount Debt, Converted Instrument, Amount Convertible debt converted to common stock Debt Instrument, Convertible, Conversion Price Conversion price per share Percent of interest rate paid in cash in a debt instrument. Debt Instrument, Interest Rate Paid in Cash Percent Interest rate paid in cash (as a percent) Percent of interest rate paid in stock grants in a debt instrument. Debt Instrument, Interest Rate Paid in Stock Grants Percent Interest rate paid in kind (as a percent) Debt instrument principal and accrued interest default term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Debt Instrument, Principal and Accrued Interest Default Term Grace days for payment of outstanding principal amount and accrued interests Percentage of interest payable in default of debt instrument. Debt Instrument, Percentage of Interest Payable in Default Adjusted interest rate payable Percentage of cash commission payable on gross proceeds from sale of units. Percentage of Cash Commission Payable on Gross Proceeds from Sale of Units Cash commission payable (as a percent) Percentage of warrants to purchase common stock on total units. Percentage of Warrants to Purchase Common Stock on Total Units Percentage of warrants to purchase common stock on total units Sale of Stock, Consideration Received on Transaction Net cash proceeds, received Gross proceeds Payments of Stock Issuance Costs Debt issuance costs Offering expenses Warrants and Rights Outstanding, Measurement Input Fair value of the warrant Repayments of Convertible Debt Optional prepayment The cash outflow for the repayment of principal amount of a long-term debt instrument which can be exchanged for a specified amount of another security. Repayments of Convertible Debt, Principal Convertible Debt, Principal The cash outflow for the prepayment premium of a long-term debt instrument which can be exchanged for a specified amount of another security. Repayments of Convertible Debt, Prepayment Premium Prepayment Premium Interest Expense, Debt Interest Expense Debt Instrument, Interest Rate, Effective Percentage Interest Rate, Effective Percentage Amount of amortization expense attributable to debt issuance cost. Amortization of Debt Issuance Cost Amortization expense Interest Payable Accrued interest expense Number of common shares issuable upon conversion of debt. Debt Instrument, Convertible, Shares Issuable Additional number of common shares issuable Operating lease cost Operating lease cost No definition required Finance Lease Cost [Abstract] Finance lease cost: Amortization of right-of-use assets Amortization of right-of-use assets Interest on lease liabilities Interest on lease liabilities Total finance lease cost. Total finance lease cost Total finance lease cost Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represent the information pertaining to Equity Incentive 2022 Plan. Equity Incentive 2022 Plan [Member] Equity Incentive 2022 Plan Represents information relating to after the reverse stock split. Post Reverse Stock Split [Member] After the reverse stock split Restricted Stock [Member] Restricted Stock Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Payment Arrangement Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Maximum aggregate number of shares that may be issued Shares authorized The maximum annual percentage increase on the issued and outstanding shares to shares available for grant under the share based arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Maximum Annual Percentage Increase Of Issued And Outstanding Shares Shares issued and outstanding The multiplying factor for calculation of owners pro rata share of common stock. Multiplying factor For Calculation Of Owners Pro Rata Share Of Common Stock Multiplying factor Share Price Share price Amount of reversal of share based compensation expense during the period Reversal Of Share Based Compensation Expense Accrued stock based compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Vesting Rights, Percentage Share-based payment award vesting rights (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share Based Compensation Arrangement Roll-Forward Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options, Outstanding, Ending Balance Options, Outstanding, Beginning Balance Number Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number.. Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Beginning Balance Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life (Years) Options that expire January 21, 2025. January 21, 2025 Expiration Option [Member] January 21, 2025 Options that expire January 21, 2025. January 21, 2025 Expiration Option 2 [Member] January 21, 2025 Options that expire January 21, 2025. January 21, 2025 Expiration Option 3 [Member] January 21, 2025 Options that expire January 27, 2027. January 27, 2027 Expiration Option [Member] January 27, 2027 Options that expire May 11, 2027. May 11, 2027 Expiration Option [Member] May 11, 2027 Options that expire June 9, 2027. June 9, 2027 Expiration Option [Member] June 9, 2027 Options that expire January 28, 2028. January 28, 2028 Expiration Option [Member] January 28, 2028 Options that expire August 4, 2029. August 4, 2029 Expiration Option [Member] August 4, 2029 Options that expire January 27, 2030. January 27, 2030 Expiration Option [Member] January 27, 2030 Options that expire June 30, 2030. June 30, 2030 Expiration Option [Member] June 30, 2030 Options that expire January 28, 2031. January 28, 2031 Expiration Option [Member] January 28, 2031 Options that expire February 28, 2031. February 28, 2031 Expiration Option [Member] February 28, 2031 Options that expire September 9, 2031. September 9, 2031 Expiration Option [Member] September 9, 2031 Options that expire December 17, 2031. December 17, 2031 Expiration Option [Member] December 17, 2031 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number Exercisable Restricted Stock Units (RSUs) [Member] RSUs Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Vested on April 1, 2023 Share-Based Payment Arrangement, Tranche Two [Member] Vested on March 1, 2024 Share-Based Payment Arrangement, Tranche Three [Member] Vest on March 1, 2025 Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Share-Based Payment Arrangement, Tranche Four [Member] Vest on March 1 2026 Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Share-Based Payment Arrangement, Tranche Fifth [Member] Vest on March 1 2027 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Payment Arrangement Rollforward Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Ending balance Beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant-Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Ending balance Beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other

than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation cost Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share-based award vesting period Number of anniversaries of vesting of award under share-based payment arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting, Number of Anniversaries Award Vesting, Number of Anniversaries Represents information relating to 2023 employee stock purchase plan. Employee Stock Purchase Plan, 2023 [Member] 2023 Employee Stock Purchase Plan The percentage of the market value at which employee stock purchase plan participants are entitled to purchase stock under the plan. Share Based Compensation Arrangement By Share Based Payment Award Employee Stock Purchase Plan Market Grant Price Percentage Percentage of the market value at which employee stock purchase plan participants are entitled to purchase stock under the plan Accumulated Other Comprehensive Income (Loss) [Table] Represents the information pertaining to the securities purchase agreement. Securities Purchase Agreement [Member] Securities purchase agreement Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Price Volatility [Member] Volatility Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member] Level 3 Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) Number of votes entitled to each common stock holders. Number Of Votes Entitled To Each Common Stock Holders Number of votes entitled to each common stock holders Class of Warrant or Right, Outstanding Warrants outstanding, ending balance Warrants outstanding, beginning balance Number Outstanding Warrants outstanding Ratio of number of securities into which the class of warrant or right may be converted. Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Ratio Warrants issued ratio Shares Issued, Price Per Share Offering price Represents the threshold of common stock beneficially owned by such holder and its affiliates exceeding specified percentage resulting in prohibition of exercising warrants. Warrants Holders Prohibited From Exercising Warrants, Threshold Beneficial Interest Percentage of beneficially owned by such holder Represents the percentage of common stock beneficially owned by such holder and its affiliates prior to issuance of warrants. Beneficial Interest Held, Prior to Issuance of Warrants Percentage of beneficially owned by the issuance of any warrants The amount of Warrant liability related to common stock issuance arising under non-cash transaction. Warrant Liability Related To Common Stock Issuance Warrant liability related to common stock issuance Fair Value Adjustment of Warrants Adjustment of Warrants The percentage of average volume weighted average prices considered for calculating exercise price of warrants. Percentage Of Average Volume Weighted Average Prices, Considered For Calculating Exercise Price Of Warrants Weighted average prices The number of trading days considered in calculating volume weighted average prices for calculating exercise price of warrants. Threshold Trading Days Considered In Calculating Volume Weighted Average Prices For Calculating Exercise Price Of Warrants Trading days Number of warrants amended during the period. Warrants Amended Warrants amended Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Class of Warrant or Right No definition available. Warrants , Number Rollforward [Abstract] Warrants Outstanding Number of warrants exercised during the period. Warrants Exercised Warrants exercised Number of warrants expired. Warrants Expired Warrants expired No definition available. Warrants Weighted Average Exercise Price [Abstract] Warrants Weighted Average Exercise Price Weighted average of number of warrants or rights outstanding. Warrants Outstanding Weighted Average Exercise Price Warrants outstanding, ending balance (in dollars per share) Warrants outstanding, beginning balance (in dollars per share) Weighted average price of warrant issued when converting their warrants into shares. Warrants Issued, Weighted Average Issued Price Warrant issued (in dollar per share) Weighted average price of warrant amended when converting their warrants into shares. Warrants Amended, Weighted Average Issued Price Warrants amended (in dollars per share) Weighted average price at which holders acquired shares when converting their warrants into shares. Warrants Exercised, Weighted Average Exercise Price Warrants exercised (in dollars per share) Weighted average price of warrants expired. Warrants Expired Weighted Average Exercise Price Warrants expired (in dollars per share) Warrants that expire December 31, 2024. December 31, 2024 Expiration Warrant [Member] December 31, 2024 Warrants that expire October 31, 2025. October 31, 2025 Expiration Warrant [Member] October 31, 2025 Warrants that expire October 31, 2025. October 31, 2025 Expiration Warrant 2 [Member] October 31, 2025 Warrants that expire February 26, 2026. February 26, 2026 Expiration Warrant [Member] February 26, 2026 Warrants that expire July 31, 2026. July 31, 2026 Expiration Warrant [Member] July 31, 2026 Warrants that expire May 31, 2027. May 31, 2027 Expiration Warrant [Member] May 31, 2027 Warrants that expire September 30, 2029 September 30, 2029 Expiration Warrant [Member] September 30, 2029 Warrants that expire October 31, 2029. October 31, 2029 Expiration Warrant [Member] October 31, 2029 Warrants that expire November 30, 2029. November 30, 2029 Expiration Warrant [Member] November 30, 2029 Warrants that expire December 31, 2029. December 31, 2029 Expiration Warrant [Member] December 31, 2029 Warrants that expire January 25, 2029. January 25, 2029 Expiration Warrant [Member] January 25, 2029 Number of warrants or rights exercisable. Class of Warrant or Right, Exercisable Number Exercisable Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective tax rate Effective Income Tax Rate Reconciliation, Percent Federal statutory rate Numerator- Denominator: Weighted average shares used to compute basic EPS Weighted average shares used to compute basic EPS Loss per share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrant Convertible Debt Securities [Member] Convertible debt securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Earnings per Share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share amount Cash paid for interest Cash paid for interest Cash paid for income taxes Cash paid for income taxes Non-cash investing and financing activities: Capital Expenditures Incurred but Not yet Paid Financed capital expenditures Amount of acquisition of financing leases. Acquisition of financing leases Acquisition of finance leases Supplemental cash flow information based on the exercise of warrants on a cashless basis. Exercise Of Warrants, Cashless Basis Exercise of warrants on cashless basis The value of restricted stock units issued in noncash financing activities. Restricted Stock Units Issued Issuance of restricted stock units Amount of deconsolidation of Real Estate Entities. Deconsolidation Of Real Estate Entities [Member] Deconsolidation of Real Estate Entity Stock Issued Common stock issued for Employee Stock Purchase Plan Schedule of Segment Reporting Information, by Segment [Table] Represent the information pertaining to real estate division. Real Estate Division [Member] Real estate division Segment Reporting Information [Line Items] Segment Information Consolidation Items [Axis] Consolidation Items [Domain] Operating Segments [Member] Operating Segment Intersegment Eliminations [Member] Intersegment Eliminations Segment, Expenditure, Addition to Long-Lived Assets Total capital expenditures Schedule of Related Party Transactions, by Related Party [Table] Represent the information pertaining to Physician LLC. Physician LLCs [Member] Physician LLCs Represents information relating to ER entities. ER Entities [Member] ER Entities DEF: Represents information pertaining to Micro Hospital Holding LLC., an affiliate controlled by CEO. Micro Hospital Holding Llc [Member] Micro Hospital Holding LLC Transaction Type [Axis] Transaction [Domain] Represents information relating to Managerial Services Agreements. Managerial Services Agreements [Member] Managerial Services Agreements Related Party Transaction [Line Items] Related Party Transactions Accounts Payable, Related Parties Accounts Payable, Related Parties Payments for Leasing Costs Lease obligation payments The number of real estate entities consolidated. Number of Consolidated Real Estate Entity Number of consolidated real estate entity Accounts Receivable, Related Parties Accounts Receivable, Related Parties Represents number of emergency rooms operated by the company. Number of Emergency Rooms Operated Number of ER Entities operated Repayments of Related Party Debt Repayments of related party debt Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table] Variable Interest Entity, Primary Beneficiary [Member] Primary Beneficiary Represent the information pertaining to real estate entities. Real Estate Entities [Member] Real Estate Entities Represent the information pertaining to AHPIPA. AHPIPA [Member] AHISPIPA Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Variable Interest Entities Other Assets, Noncurrent Other long-term assets Liabilities, Noncurrent Long-term liabilities Cash Cash Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Events Revision of Prior Period [Axis] Revision of Prior Period [Domain] As Previously Reported Impact of Reverse Stock Split EX-101.PRE 10 nutx-20240630_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 05, 2024 Cover Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-41346 Â Entity Registrant Name NUTEX HEALTH INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 11-3363609 Â Entity Address, Address Line One 6030 S. Rice Ave Â Entity Address, Address Line Two Suite C Â Entity Address, City or Town Houston Â Entity Address, State or Province TX Â Entity Address, Postal Zip Code 77081 Â City Area Code 713 Â Local Phone Number 660-0557 Â Title of 12(b) Security Common Stock, $0.001 par value Â Trading Symbol NUTX Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 5,065,709 Entity Central Index Key 0001479681 Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type:

xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 40,807,975 $ 22,002,056 Accounts receivable 60,658,832 58,624,301 Accounts receivable - related parties 4,577,189 4,152,068 Inventories 2,759,448 3,390,584 Prepaid expenses and other current assets 5,066,994 2,679,394 Total current assets 113,870,438 90,848,403 Property and equipment, net 78,881,900 81,387,649 Operating right-of-use assets 11,690,957 11,853,082 Finance right-of-use assets 187,096,271 176,146,329 Intangible assets, net 16,180,504 20,512,636 Goodwill, net 13,918,719 17,066,263 Other assets 764,462 431,135 Total assets 422,403,251 398,245,497 Current liabilities: Â Â Accounts payable 16,742,370 18,899,196 Accounts payable - related parties 6,796,475 6,382,197 Lines of credit 2,909,296 3,371,676 Current portion of long-term debt 14,223,944 10,808,721 Operating lease liabilities, current portion 1,998,512 1,579,987 Finance lease liabilities, current portion 5,570,604 4,315,979 Accrued expenses and other current liabilities 23,417,191 12,955,296 Total current liabilities 71,658,392 58,313,052 Long-term debt, net 22,406,516 26,314,733 Warrant liability 2,000,714 Â Operating lease liabilities, net 14,690,566 15,479,639 Finance lease liabilities, net 226,820,535 213,886,213 Deferred tax liabilities 2,804,492 5,145,754 Total liabilities 340,381,215 319,139,391 Commitments and contingencies Equity: Â Â Common stock, $0.001 par value; 950,000,000 shares authorized; 4,986,578 and 4,511,199 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 4,988 4,511 Additional paid-in capital 472,529,641 470,521,218 Accumulated deficit (409,800,662) (409,072,539) Nutex Health Inc. equity 62,733,967 61,453,190 Noncontrolling interests 19,288,069 17,652,916 Total equity 82,022,036 79,106,106 Total liabilities and equity $ 422,403,251 $ 398,245,497 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities for related parties (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: nutx_AccountsPayableCurrentForRelatedParty Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of warranty liability, classified as noncurrent. + ReferencesNo definition available. + Details Name: nutx_WarrantyLiabilityNoncurrent Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Common stock, par value $ 0.001 $ 0.001 Common stock authorized 950,000,000 950,000,000 Common stock issued 4,987,268 4,511,199 Common stock outstanding 4,987,268 4,511,199 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue: Â Â Â Â Total revenue $ 76,082,261 $ 58,924,454 $ 143,536,048 $ 115,253,871 Operating costs and expenses: Â Â Â Â Payroll and benefits 28,398,075 24,860,702 55,401,219 50,697,375 Contract services 9,505,222 9,747,873 20,824,676 18,937,204 Medical supplies 3,588,464 3,264,202 8,910,306 7,288,084 Depreciation and amortization 4,532,804 4,169,160 8,719,006 8,162,907 Other 7,496,465 7,235,594 16,962,432 15,673,655 Total operating costs and expenses 53,521,030 49,277,531 110,817,639 100,759,225 Gross profit 22,561,231 9,646,923 32,718,409 14,494,646 Corporate and other costs: Â Â Â Â Facilities closing costs Â Â Â 217,266 Stock-based compensation expense (61,241) 249,645 (12,074) 2,149,645 Impairment of assets 3,473,635 Â 3,473,635 Â Impairment of goodwill 3,197,391 Â 3,197,391 Â General and administrative expenses 10,652,390 9,759,816 19,310,800 16,935,360 Total corporate and other costs 17,262,175 10,009,461 25,969,752 19,302,271 Operating income (loss) 5,299,056 (362,538) 6,748,657 (4,807,625) Interest expense, net 5,054,532 4,843,048 9,498,894 7,983,137 Gain on warrant liability (3,060,096) Â (5,660,843) Â Other (income) expense (599,502) (123,528) (840,694) 123,927 Income (loss) before taxes 3,904,122 (5,082,058) 3,751,300 (12,914,689) Income tax expense (benefit) 893,892 (815,612) 1,283,557 (1,726,271) Net income (loss) 3,010,230 (4,266,446) 2,467,743 (11,188,418) Less: net income (loss) attributable to noncontrolling interests 3,374,278 (787,399) 3,195,866 (2,562,092) Net income (loss) attributable to Nutex Health Inc. $ (364,048) $ (3,479,047) $ (728,123) $ (8,626,326) Income (loss) per common share: Â Â Â Â Basic, income (loss) per common share (in dollar per share) $ (0.07) $ (0.79) $ (0.15) $ (1.98) Diluted, income (loss) per common share (in dollar per share) $ (0.07) $ (0.79) $ (0.15) $ (1.98) Hospital division Â Â Â Â Revenue: Â Â Â Â Total revenue $ 67,604,878 $ 51,611,803 $ 127,634,247 $ 100,899,967 Population health management division Â Â Â Â Revenue: Â Â Â Â Total revenue $ 8,477,383 $ 7,312,651 $ 15,901,801 $ 14,353,904 X - DefinitionThe amount of expense for facilities closing costs. + ReferencesNo definition available. + Details Name: nutx_FacilitiesClosingCosts Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (loss) related to the warranty liability. + ReferencesNo definition available. + Details Name: nutx_GainLossOnWarrantLiability Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of non-cash loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesNo definition available. + Details Name: nutx_GoodwillNonCashImpairmentLoss Namespace Prefix: nutx_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LaborAndRelatedExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense classified as other. +

ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProfessional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support. + ReferencesNo definition available. + Details Name: us-gaap_ProfessionalAndContractServicesExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense associated with supplies that were used during the current accounting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_SuppliesExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=nutx_HospitalDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nutx_PopulationHealthManagementDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) Common Stock Additional Paid-in Capital Accumulated Deficit Noncontrolling Interests Total Beginning balance, value at Dec. 31, 2022 $ 4,335 $ 459,144,291 $ (363,285,925) $ 24,464,699 $ 120,327,400 Beginning balance, shares at Dec. 31, 2022 4,334,826 Â Â Â Â Deconsolidation of Real Estate Entities Â Â Â (4,258,133) (4,258,133) Common stock issued for exercise of warrants $ 5 (5) Â Â Â Common stock issued for exercise of warrants (in shares) 4,682 Â Â Â Â Common stock issuance $ 7 1,899,993 Â Â 1,900,000 Common stock issuance (in shares) 6,667 Â Â Â Â Contributions Â Â Â 28,000 28,000 Distributions Â Â Â (1,537,141) (1,537,141) Net loss Â Â (5,147,279) (1,774,693) (6,921,972) Ending balance, value at Mar. 31, 2023 $ 4,347 461,044,279 (368,433,204) 16,922,732 109,538,154 End balance, shares at Mar. 31, 2023 4,346,175 Â Â Â Â Beginning balance, value at Dec. 31, 2022 $ 4,335 459,144,291 (363,285,925) 24,464,699 120,327,400 Beginning balance, shares at Dec. 31, 2022 4,334,826 Â Â Â Â Common stock issuance Â Â Â Â 1,900,000 Net loss Â Â Â Â (11,188,418) Ending balance, value at Jun. 30, 2023 $ 4,405 464,526,305 (371,912,251) 15,607,720 108,226,179 End balance, shares at Jun. 30, 2023 4,404,951 Â Â Â Â Beginning balance, value at Mar. 31, 2023 $ 4,347 461,044,279 (368,433,204) 16,922,732 109,538,154 Beginning balance, shares at Mar. 31, 2023 4,346,175 Â Â Â Â Common stock issued for exercise of warrants $ 4 (4) Â Â Â Common stock issued for exercise of warrants (in shares) 3,774 Â Â Â Â Debt conversion to common stock $ 53 3,232,386 Â Â 3,232,439 Debt conversion to common stock (in shares) 53,571 Â Â Â Â Restricted stock awards issued for compensation $ 1 249,644 Â Â 249,645 Restricted stock awards issued for compensation (in shares) 1,431 Â Â Â Â Contributions Â Â Â 621,550 621,550 Distributions Â Â Â (1,149,163) (1,149,163) Net loss Â Â (3,479,047) (787,399) (4,266,446) Ending balance, value at Jun. 30, 2023 $ 4,405 464,526,305 (371,912,251) 15,607,720 108,226,179 End balance, shares at Jun. 30, 2023 4,404,951 Â Â Â Â Beginning balance, value at Dec. 31, 2023 $ 4,511 470,521,218 (409,072,539) 17,652,916 79,106,106 Beginning balance, shares at Dec. 31, 2023 4,511,199 Â Â Â Â Common stock issued for Employee Stock Purchase Plan $ 2 19,024 Â Â 19,026 Common stock issued for Employee Stock Purchase Plan (in shares) 746 Â Â Â Â Common stock issuance $ 444 1,540,499 Â Â 1,540,943 Common stock issuance (in

shares) 444,444 Â Â Â Â Debt conversion to common stock $ 12 320,676 Â Â 320,688 Debt conversion to common stock (in shares) 11,824 Â Â Â Â Stock-based compensation Â 49,167 Â Â 49,167 Vesting of Restricted Stock Units $ 1 (1) Â Â Â Vesting of Restricted Stock Units (in shares) 1,298 Â Â Â Â Reverse stock split adjustment $ 2 (2) Â Â Â Reverse stock split adjustment (in shares) 2,426 Â Â Â Â Distributions Â Â Â (481,293) (481,293) Net loss Â Â (364,075) (178,412) (542,487) Ending balance, value at Mar. 31, 2024 $ 4,972 472,450,581 (409,436,614) 16,993,211 80,012,150 End balance, shares at Mar. 31, 2024 4,971,937 Â Â Â Â Beginning balance, value at Dec. 31, 2023 $ 4,511 470,521,218 (409,072,539) 17,652,916 79,106,106 Beginning balance, shares at Dec. 31, 2023 4,511,199 Â Â Â Â Common stock received in sale of business Â Â Â Â (30,250) Common stock issued for acquisition Â Â Â Â 156,158 Reverse stock split adjustment Â Â Â Â 3 Net loss Â Â Â Â 2,467,743 Ending balance, value at Jun. 30, 2024 $ 4,988 472,529,641 (409,800,662) 19,288,069 82,022,036 End balance, shares at Jun. 30, 2024 4,987,268 Â Â Â Â Beginning balance, value at Mar. 31, 2024 $ 4,972 472,450,581 (409,436,614) 16,993,211 80,012,150 Beginning balance, shares at Mar. 31, 2024 4,971,937 Â Â Â Â Common stock received in sale of business $ (5) (30,245) Â Â (30,250) Common stock received in sale of business (in shares) (5,060) Â Â Â Â Common stock issued for Employee Stock Purchase Plan $ 2 14,407 Â Â 14,409 Common stock issued for Employee Stock Purchase Plan (in shares) 2,061 Â Â Â Â Common stock issued for acquisition $ 18 156,140 Â Â 156,158 Common stock issued for acquisition (in shares) 17,640 Â Â Â Â Stock-based compensation Â (61,241) Â Â (61,241) Reverse stock split adjustment $ 1 (1) Â Â Â Reverse stock split adjustment (in shares) 690 Â Â Â Â Contributions Â Â Â 300,850 300,850 Distributions Â Â Â (1,380,270) (1,380,270) Net loss Â Â (364,048) 3,374,278 3,010,230 Ending balance, value at Jun. 30, 2024 $ 4,988 $ 472,529,641 $ (409,800,662) $ 19,288,069 $ 82,022,036 End balance, shares at Jun. 30, 2024 4,987,268 Â Â Â Â X - DefinitionCommon stock issued for exercise of warrants. + ReferencesNo definition available. + Details Name: nutx_CommonStockIssuedForExerciseOfWarrants Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCommon stock shares issued for exercise of warrants. + ReferencesNo definition available. + Details Name: nutx_CommonStockIssuedForExerciseOfWarrantsShares Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares received during the period in sale of business. + ReferencesNo definition available. + Details Name: nutx_StockReceivedInSaleOfBusinessDuringPeriodShares Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares received during the period in sale of business. + ReferencesNo definition available. + Details Name: nutx_StockReceivedInSaleOfBusinessDuringPeriodValue Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockAmountIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDecrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Â Â Net income (loss) $ 2,467,743 $ (11,188,418) Adjustments to reconcile net loss to net cash from operating activities: Â Â Depreciation and amortization 8,719,006 8,162,907 Gain on warrant liability (5,660,843) Â Impairment of goodwill 3,197,391 Â Impairment of assets 3,473,635 Â Derecognition of goodwill 453,017 Â Stock-based compensation expense (12,074) 2,149,645 Deferred tax benefit (2,341,262) (1,724,111) Debt accretion expense 579,121 953,236 Loss on lease termination Â 58,211 Non-cash lease expense (income) (208,423) 61,734 Changes in operating assets and liabilities, net of the effects of acquisitions: Â Â Accounts receivable (2,148,508) 6,921,239 Accounts receivable - related party (425,121) (797,058) Inventories 631,136 1,082,509 Prepaid expenses and other current assets (1,692,907) (3,048,993) Accounts payable (1,617,151) (7,189,929) Accounts payable - related party 414,278 3,453 Accrued expenses and other current liabilities 10,481,831 5,619,907 Net cash from operating activities 16,310,869 1,064,332 Cash flows from investing activities: Â Â Acquisitions of property and equipment (1,291,492) (7,446,902) Cash related to sale of business (711,306) Â Cash related to deconsolidation of Real Estate Entities Â (1,039,157) Net cash from investing activities (2,002,798) (8,486,059) Cash flows from financing activities: Â Â Proceeds from lines of credit 132,167 1,949,919 Proceeds from notes payable 4,915,000 16,952,905 Repayments of lines of credit (594,547) (1,592,714) Repayments of notes payable (6,156,543) (7,481,893) Repayments of finance leases (1,440,016) (1,870,670) Proceeds from common stock issuance, net issuance costs 9,202,500 Â Members' contributions 300,850 649,550 Members' distributions (1,861,563) (2,686,304) Net cash from financing activities 4,497,848 5,920,793 Net change in cash and cash equivalents 18,805,919 (1,500,934) Cash and cash equivalents - beginning of the period 22,002,056 34,255,264 Cash and cash equivalents - end of the period $ 40,807,975 $ 32,754,330 X - DefinitionThe derecognition of goodwill. + ReferencesNo definition available. + Details Name: nutx_DerecognitionOfGoodwill Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (loss) related to the warranty liability. + ReferencesNo definition available. + Details Name: nutx_GainLossOnWarrantLiability Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of non-cash loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesNo definition available. + Details Name: nutx_GoodwillNonCashImpairmentLoss Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionContributions made by members. + ReferencesNo definition available. + Details Name: nutx_MembersContributions Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDistributions made to members. + ReferencesNo definition available. + Details Name: nutx_MembersDistributions Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon-cash lease expense. + ReferencesNo definition available. + Details Name: nutx_NoncashLeaseExpense Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the loss on the sale of business. + ReferencesNo definition available. + Details Name: nutx_PaymentsRelatedToLossOnSaleOfBusiness Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_AccretionExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in current liabilities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of other real estate investments held by the entity for investment purposes not otherwise defined in the taxonomy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherRealEstate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization and Operations 6 Months Ended Jun. 30, 2024 Organization and Operations Â Organization and Operations NoteÂ 1Â â€“ Organization and OperationsNutex Health Inc. (â€œNutex Healthâ€ or the â€œCompanyâ€), is a physician-led, healthcare services and operations company with 21 hospital facilities in nine states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates different innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (â€œHOPDsâ€). The population health management division owns and operates provider networks such as independent physician associations (â€œIPAsâ€) and offers a cloud-based proprietary technology platform to IPAs which aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.We employ approximately 800 full time employees, contract 230 doctors at our facilities and partner with over 1,700 physicians within our networks. Our corporate headquarters is based in Houston, Texas. We were incorporated on AprilÂ 13, 2000 in the state of Delaware.Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. On April 1, 2022, the merger (the â€œMergerâ€) of Nutex Health Holdco LLC and Clinigence Holdings, Inc. (â€œCliniganceâ€) was completed pursuant to the Agreement and Plan of Merger (the â€œMerger Agreementâ€) entered on November 23, 2021 between Clinigence, Nutex Acquisition LLC, a Delaware limited liability company and wholly-owned subsidiary of Clinigence, Nutex, Micro Hospital Holding LLC (solely for the purposes of certain sections of the Merger Agreement), Nutex Health Holdco LLC and Thomas Vo, M.D., solely in his capacity as the representative of the equity holders of Nutex Health Holdco LLC.â€‹In connection with the Merger Agreement, Nutex Health Holdco LLC entered into certain Contribution Agreements with holders of equity interests (â€œNutex Ownersâ€) of subsidiaries and affiliates (the â€œNutex Subsidiariesâ€) pursuant to which such Nutex Owners agreed to contribute certain equity interests in the Nutex Subsidiaries to Nutex Health Holdco LLC in exchange for specified equity interests in Nutex Health Holdco LLC (collectively, the â€œContribution Transactionâ€). Nutex owners having ownership interests representing approximatelyÂ 84% of the agreed upon aggregate equity value of the Nutex Subsidiaries, agreed to contribute all or a portion of their equity interests, as applicable.â€‹Pursuant to the Merger Agreement, each unit representing an equity interest in Nutex Health Holdco LLC issued and outstanding immediately prior to the effective time of the Merger but after the Contribution Transaction (collectively, the â€œNutex Membership Interestsâ€) was converted into the right to receiveÂ 3.571428575Â shares of common stock of Clinigence, or an aggregate ofÂ 592,791,712Â shares of common stock of Clinigence.â€‹After completing the merger, Clinigence was renamed Nutex Health Inc.2024 Reverse Stock Splits. 1:15 Reverse stock split. The Companyâ€™s Board of Directors determined to effect a reverse stock split of the common stock at a 1-for-15 ratio (the â€œ1:15 Reverse Stock Splitâ€) effective as of 11:59 pm Eastern time on April 9, 2024. The stockholders of the Company at its annual meeting on June 29, 2023 had approved a

reverse stock split within a range of 1:2 and 1:15 to be effected within one year of approval at the discretion of the Board. The Companyâ€™s common stock began trading on The Nasdaq Capital Market on a post-1:15 Reverse Stock Split basis under the Companyâ€™s existing trading symbol â€œNUTXâ€ at the open of the market on April 10, 2024. The 1:15 Reverse Stock Split was implemented for the purpose of regaining compliance with the minimum bid price requirement for continued listing of the Companyâ€™s common stock on The Nasdaq Capital Market.1:10 Reverse stock split. In addition, the Companyâ€™s Board of Directors determined to effect a reverse stock split of the common stock at a 1-for-10 ratio (the â€œ1:10 Reverse Stock Splitâ€) effective as of 11:59 pm Eastern time on July 2, 2024. The Companyâ€™s stockholders, at the annual meeting on June 17, 2024, had approved a reverse stock split within a range of 1:2 and 1:16 to be effected within one year of approval at the discretion of the Board. This 1:10 Reverse Stock Split is in addition to the Companyâ€™s previous 1:15 Reverse Stock Split as discussed above. The Companyâ€™s common stock began trading on The Nasdaq Stock Market on a post-1:10 Reverse Stock Split basis under the Companyâ€™s existing trading symbol â€œNUTXâ€ at the open of the market on July 3, 2024. The 1:10 Reverse Stock Split was also implemented for the purpose of regaining compliance with the minimum bid price requirement for continued listing of the Companyâ€™s common stock on The Nasdaq Capital Market.As a result of both the 1:15 Reverse Stock Split and 1:10 Reverse Stock Split (collectively, the â€œ2024 Reverse Stock Splitsâ€) the number of shares of common stock outstanding was reduced to 4,987,268 shares as of June 30, 2024, inclusive of whole shares issued for fractional shares, and the number of authorized shares of common stock remains at 950,000,000.Unless otherwise indicated, all authorized, issued, and outstanding stock and per share amounts contained in the accompanying condensed consolidated financial statements have been adjusted to reflect the 2024 Reverse Stock Splits for all prior periods presented. Proportionate adjustments for the 2024 Reverse Stock Splits were made to the exercise prices and number of shares issuable under the Companyâ€™s equity incentive plans, and the number of shares underlying outstanding equity awards, as applicable. See Note 19 for information and disclosures relating to adjustments related to the 2024 Reverse Stock Splits.On July 24, 2024, Company received written notice (the â€œCompliance Noticeâ€) from The Nasdaq Stock Market LLC (â€œNasdaqâ€) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Stock Market maintain a minimum bid price of $1.00 per share. Â Nasdaq notified the Company in the Compliance Notice that, from July 3, 2024 to July 23, 2024, the closing bid price of the Companyâ€™s common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.â€‹ X - Definitionn/a + ReferencesNo definition available. + Details Name: nutx_OrganizationAndOperationsAbstract Namespace Prefix: nutx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies NoteÂ 2Â - Summary of Significant Accounting PoliciesBasis of presentation.Â These financial statements present the Companyâ€™s consolidated financial condition and results of operations including those of majority-owned subsidiaries and variable interest entities (â€œVIEsâ€) for which we are the primary beneficiary.The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the â€œPhysician LLCsâ€) and real estate entities (the â€œReal Estate Entitiesâ€). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages.The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans.The Company has no direct or indirect ownership interest in the consolidated Physician LLCs or Real Estate Entities, soÂ 100% of the equity for these entities is shown as noncontrolling interests in the consolidated balance sheets and statements of operations. Many of the Physician LLCs and Real Estate Entities are owned in part and in some cases controlled by related parties including members of our executive management team.The population health management division includes our management services organizations. In addition, Associated Hispanic Physicians of So. California (â€œAHISPâ€), an IPA entity that is not owned by us, but is consolidated as a VIE of our wholly-owned subsidiary AHP Health Management Services Inc. (â€œAHPâ€) because AHP is the primary beneficiary of its operations and has 100% control of AHISPâ€™s operations through its management services agreement with AHISP.All significant intercompany balances and transactions have been eliminated in consolidation.Interim financial statements.Â These unaudited condensed consolidated financial statements have been prepared pursuant to the rulesÂ and regulations of the Securities and Exchange Commission (â€œSECâ€) regarding interim financial reporting. Accordingly, they do not include all disclosures required by accounting principles generally accepted in the United States of America (â€œGAAPâ€). The unaudited condensed consolidated financial statements include all material adjustments of a normal recurring nature that, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. These interim financial statements should be read together with the consolidated financial statements and notes thereto included in our audited financial statements for the years ended December 31, 2023 and 2022.Use of estimates.Â The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include (i) estimates of net revenue and accounts receivable, (ii) fair value of acquired assets and liabilities in business combinations and (iii) impairment of long-lived assets and goodwill. Actual results could differ from those estimates.Cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has cash amounts, that were at times material, held in covered banking institutions in excess of the insured amounts, but does not deem the risk of loss to be likely. The Company has $4.5 million in restricted cash as of JuneÂ 30,Â 2024. The amounts included in restricted cash represent those required to be set aside either by note payable agreement or compensating balance requirements.Fair value measurements.Â Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows:LevelÂ 1Â â€“ Observable inputs such as quoted prices in active markets for identical assets or liabilities.LevelÂ 2Â â€“ Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.LevelÂ 3Â â€“ Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.Â The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments.Â Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value.There were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented.Segment reporting.Â A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments â€“ the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities.Reclassifications. Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation.Recent accounting pronouncements.Â In November 2023, the FASB issued Accounting Standards Update 2023-07, â€œImprovements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required only on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for our 2024 annual Consolidated Financial Statements and interim periods beginning in 2025.In December 2023, the FASB issued Accounting Standards Update 2023-09, â€œImprovements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€), which provides for additional income tax rate reconciliation and income taxes paid disclosures. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024, with early adoption permitted.We are evaluating the impacts ASUs 2023-07 and 2023-09 will have on disclosures in our financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Divestitures 6 Months Ended Jun. 30, 2024 Divestitures Â Divestitures Note 3 â€“ Divestituresâ€‹Sale of Procare Health, Inc. On May 30, 2024, the Company completed the sale of Procare Health, Inc. (â€œProcareâ€), a wholly-owned subsidiary of Nutex, to an individual buyer. As consideration for the transaction, the buyer will pay the Company $0.6 million ($0.1 million paid in June 2024 and $0.1 million paid in July 2024), has assumed liabilities of $0.2 million and remitted Company stock of $0.1 million. During the second quarter of 2024, the Company recognized an intangible impairment of $2.1 million and a $3.2 million goodwill impairment loss. Upon completion of the sale, the Company recognized an insignificant loss on sale of business. The calculation of the loss on sale of business includes the derecognition of goodwill of $0.5 million, which is offset by consideration and other assets transferred. Total revenue for Procare for the three and six months ended June 30, 2024 is $0.1 million and $0.4 million, respectively. Net loss for Procare for the three and six months ended June 30, 2024 is $0.3 million and $0.6 million, respectively. The Company does not deem this transaction to be significant.â€‹Clinigence Health, Inc. and Letter of Intent. The Company signed a non-binding letter of intent (â€œLOIâ€) with a third-party limited liability company to commence the negotiations for the sale of Clinigence Health, Inc. (â€œClinigence Healthâ€), a wholly-owned subsidiary of Nutex. The sale is expected to be completed in the third quarter of 2024. The Company recognized an impairment on definite-lived intangible assets of $1.4 million. The Company reclassified all assets of Clinigence Health to assets held-for-sale, within â€œPrepaid expenses and other current assetsâ€ in the condensed consolidated balance sheets. The value of the assets held-for-sale of $1.5 million are based on the LOI. Upon the reclassification of assets to held-for-sale, the Company recognized an insignificant loss. Total revenue for Clinigence Health for the three and six months ended June 30, 2024 is $0.3 million and $0.7 million, respectively. Net loss for Clinigence Health for the three and six months ended June 30, 2024 is $0.4 million and $0.7 million, respectively. The Company does not deem this transaction to be significant.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue 6 Months Ended Jun. 30, 2024 Revenue Â Revenue Note 4 â€“ Revenueâ€‹We disaggregate revenue from contracts with customers into types of services or products, consistent with ourÂ reportable segments, as follows:â€‹â€‹â€‹

https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment 6 Months Ended Jun. 30, 2024 Property and Equipment Â Property and Equipment NoteÂ 5Â - Property and Equipment â€‹The principal categories of property and equipment, net are summarized as follows:â€‹â€‹â€‹

https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases Â Leases NoteÂ 9Â â€“Â Leasesâ€‹We have entered into hospital property, office and equipment rental agreements with various lessors including related parties. The following tables disclose information about our leases of property and equipment:â€‹â€‹â€‹

Warrant activity follows:â€‹â€‹â€‹

Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions 6 Months Ended Jun. 30, 2024 Related Party Transactions Â Related Party Transactions Note 17 â€“ Related Party Transactions â€‹Related party transactions included the following:â€‹â—The Physician LLCs employ the doctors who work in our hospitals. We have no direct ownership interest in these entities, but they are owned and, in some instances, controlled by related parties including our CEO, Dr. Thomas Vo. The Physician LLCs are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to them in the event of cash shortages and received the benefit of their cash surpluses. â€‹The Physician LLCs had outstanding obligations to their member owners, who are also Company stockholders. These outstanding obligations primarily represent contributions for facilities currently under construction totaling $3.3 million at JuneÂ 30,Â 2024 and $2.9 million at DecemberÂ 31,Â 2023 reported within accounts payable â€“ related party in our consolidated balance sheets. â€‹â—Most of our hospital division facilities are leased from real estate entities which are owned by related parties. These leases are typically on a triple net basis, where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Our obligations under these leases are presented in Note 8. During the three and six months ended JuneÂ 30,Â 2024, we made cash payments for these lease obligations totaling $4.9 million and $9.6 million, respectively. Cash payments for these lease obligations made in the three and six months ended JuneÂ 30,Â 2023 totaled $3.7 million and $7.2 million, respectively.â€‹â—We consolidate Real Estate Entities as VIEs when they do not have sufficient equity at risk and our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. The consolidated Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We have no direct ownership interest in these entities, but they are owned and, in some instances, controlled by related parties including our CEO. We deconsolidated 17 Real Estate Entities in the second quarter of 2022 and one Real Estate Entity in the first quarter of 2023. As of JuneÂ 30,Â 2024, two Real Estate Entities continue to be consolidated in our financial statements.â€‹â—Accounts receivable â€“ related party included $4.6 million at JuneÂ 30,Â 2024 and $4.1 million at DecemberÂ 31,Â 2023 due from noncontrolling interest owners of consolidated ER Entities. â€‹â—Micro Hospital Holding LLC, an affiliate controlled by our CEO, and 2GT PLLC, an affiliate controlled by a physician partner, made advances to one of our hospital facilities, SE Texas ER. These advances totaled $1.4 million for Micro Hospital Holding LLC and $1.2 million for 2GT PLLC at JuneÂ 30,Â 2024 and at DecemberÂ 31,Â 2023, respectively, and are reported as accounts payable â€“ related party in our consolidated balance sheets. The advances have no stated maturity and bear no interest.â€‹â—Accounts payable â€“ related party in our consolidated balance sheets included $0.9 million at JuneÂ 30,Â 2024 and $0.9 million at DecemberÂ 31,Â 2023 for reimbursement of expenses incurred on our behalf.â€‹â—We provided managerial services to emergency centers owned and, in some instances, controlled by related parties including an entity controlled by our CEO during 2023. In the three and six months ended JuneÂ 30,Â 2023, we recognized $0.2 million and $0.3 million, respectively, of revenue for these services.â€‹â—Two of our ER Entities were obligated under managerial services agreements with related parties commencing in 2022 and ending in 2023. Payments under these agreements totaled $0.1 million and $0.4 million for the three and six months ended JuneÂ 30,Â 2023.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Variable Interest Entities 6 Months Ended Jun. 30, 2024 Variable Interest Entities Â Variable Interest Entities Note 18 â€“ Variable Interest Entitiesâ€‹The following tables provide the balance sheet amounts for consolidated VIEs:â€‹â€‹â€‹

(3,479,047)Weighted average shares used to compute basic and diluted EPSâ€‹â€‹ 656,563,166â€‹â€‹ (652,186,078)â€‹â€‹ 4,377,088Loss per share - basic and dilutedâ€‹$(0.01)â€‹$(0.78)â€‹$(0.79)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six months ended JuneÂ 30,Â 2023â€‹â€‹â€‹As Previouslyâ€‹â€‹Impact of Reverseâ€‹â€‹Asâ€‹â€‹â€‹Reportedâ€‹â€‹Stock Splitâ€‹â€‹RevisedLoss attributable to common stockholdersâ€‹$ (8,626,326)â€‹$ -â€‹$ (8,626,326)Weighted average shares used to compute basic and diluted EPSâ€‹â€‹ 653,755,031â€‹â€‹ (649,396,664)â€‹â€‹ 4,358,367Loss per share - basic and dilutedâ€‹$(0.01)â€‹$(1.97)â€‹$(1.98)â€‹The following outstanding stock options and warrants exercisable or issuable into shares of common stock were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three and six months ended JuneÂ 30,Â 2023â€‹â€‹â€‹As Previouslyâ€‹â€‹Impact of Reverseâ€‹â€‹Asâ€‹â€‹â€‹Reportedâ€‹â€‹Stock Splitâ€‹â€‹RevisedCommon stock optionsâ€‹â€‹ 5,147,770â€‹â€‹ (5,113,452)â€‹â€‹ 34,318Common stock warrantsâ€‹â€‹ 9,573,562â€‹â€‹ (9,509,739)â€‹â€‹ 63,823â€‹Stock options were adjusted retroactively to give effect to the Reverse Stock Split for the six months ended JuneÂ 30,Â 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

techniques that use significant unobservable inputs.Â The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments.Â Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value.There were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented. Segment reporting Segment reporting.Â A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments â€“ the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities. Reclassifications Reclassifications. Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation. Recent accounting pronouncements Recent accounting pronouncements.Â In November 2023, the FASB issued Accounting Standards Update 2023-07, â€œImprovements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required only on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for our 2024 annual Consolidated Financial Statements and interim periods beginning in 2025.In December 2023, the FASB issued Accounting Standards Update 2023-09, â€œImprovements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€), which provides for additional income tax rate reconciliation and income taxes paid disclosures. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024, with early adoption permitted.We are evaluating the impacts ASUs 2023-07 and 2023-09 will have on disclosures in our financial statements. X - DefinitionDisclosure of accounting policy for interim financial statements. + ReferencesNo definition available. + Details Name: nutx_InterimFinancialStatementsPolicyPolicyTextBlock Namespace Prefix: nutx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue (Tables) 6 Months Ended Jun. 30, 2024 Revenue Â Schedule of disaggregate revenue â€‹â€‹â€‹

types:textBlockItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Current Liabilities (Tables) 6 Months Ended Jun. 30, 2024 Accrued Expenses and Other Current Liabilities Â Schedule of accrued expenses and other current liabilities
â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â JuneÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹Accrued wages and benefitsâ€‹$ 8,426,753â€‹$ 6,590,710Accrued supplier expensesâ€‹â€‹ 3,920,076â€‹â€‹ 2,504,544Accrued medical insurance claimsâ€‹â€‹ 2,293,873â€‹â€‹ 1,865,280Accrued taxesâ€‹â€‹ 4,824,866â€‹â€‹ 405,352Accrued otherÂ â€‹â€‹ 3,951,623â€‹â€‹ 1,589,410Total accrued expenses and other current liabilitiesâ€‹$ 23,417,191â€‹$ 12,955,296â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt (Tables) 6 Months Ended Jun. 30, 2024 Debt Â Schedule of debt
â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3 + Details Name: us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Variable Interest Entities (Tables) 6 Months Ended Jun. 30, 2024 Variable Interest Entities Â Schedule of consolidated balance sheets â€‹â€‹â€‹

debit Period Type: duration X - DefinitionThe number of real estate entities deconsolidated. + ReferencesNo definition available. + Details Name: nutx_NumberOfDeconsolidatedRealEstateEntities Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A + Details Name: us-gaap_VariableInterestEntityOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: srt_OwnershipAxis=nutx_PhysicianLlcAndRealEstateEntitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=nutx_AssociatedHispanicPhysiciansOfSo.CaliforniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=nutx_AhpHealthManagementServicesInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Divestitures (Details) - USD ($) 3 Months Ended 6 Months Ended May 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Sep. 30, 2024 Jul. 31, 2024 Divestitures Â Â Â Â Â Remitted Company stock Â $ (30,250) $ (30,250) Â Â Goodwill impairment loss Â 3,197,391 3,197,391 Â Â Derecognition of goodwill Â Â 453,017 Â Â Intangible impairment Â 3,473,635 3,473,635 Â Â Discontinued operations, disposed of by sale | Procare Health, Inc Â Â Â Â Â Â Divestitures Â Â Â Â Â Â Consideration for the transaction $ 600,000 100,000 100,000 Â $ 100,000 Liabilities 200,000 Â Â Â Â Â Remitted Company stock 100,000 Â Â Â Â Â Goodwill impairment loss 3,200,000 Â Â Â Â Â Derecognition of goodwill 500,000 Â Â Â Â Â Intangible impairment 2,100,000 Â Â Â Â Â Liabilities assumed $ 200,000 Â Â Â Â Â Total revenue Â 100,000 400,000 Â Â Net loss Â 300,000 (600,000) Â Â Discontinued operations, disposed of by sale | Clinigence Health, Inc Â Â Â Â Â Â Divestitures Â Â Â Â Â Â Total revenue Â 300,000 700,000 Â Â Net loss Â $ 400,000 $ 700,000 Â Â Discontinued operations, disposed of by sale | Clinigence Health, Inc | Subsequent Event Â Â Â Â Â Divestitures Â Â Â Â Â Â Assets held-for-sale Â Â Â $ 1,500,000 Â Intangible asset impairment Â Â Â $ 1,400,000 Â X - DefinitionThe derecognition of goodwill. + ReferencesNo definition available. + Details Name: nutx_DerecognitionOfGoodwill Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of non-cash loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + ReferencesNo definition available. + Details Name: nutx_GoodwillNonCashImpairmentLoss Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of shares received during the period in sale of business. + ReferencesNo definition available. + Details Name: nutx_StockReceivedInSaleOfBusinessDuringPeriodValue Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 15 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482309/360-10-15-4 + Details Name: us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nutx_ProcareHealthIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=nutx_ClinigenceHealthIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue - Disaggregate revenue (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Disaggregation of Revenue Â Â Â Â Revenues $ 76,082,261 $ 58,924,454 $ 143,536,048 $ 115,253,871 Hospital division Â Â Â Â Disaggregation of Revenue Â Â Â Â Revenues 67,604,878 51,611,803 127,634,247 100,899,967 Population health management division Â Â Â Â Disaggregation of Revenue Â Â Â Â Revenues $ 8,477,383 $ 7,312,651 $ 15,901,801 $ 14,353,904 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_HealthCareOrganizationRevenueSourcesAxis=nutx_HospitalDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HealthCareOrganizationRevenueSourcesAxis=nutx_PopulationHealthManagementDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue - Insurance Coverage (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Disaggregation of Revenue Â Â Â Â Life Insurance Assumed Ratio 100.00% 100.00% 100.00% 100.00% Insurance Â Â Â Â Disaggregation of Revenue Â Â Â Â Life Insurance Assumed Ratio 93.00% 93.00% 92.00% 93.00% Self pay Â Â Â Â Disaggregation of Revenue Â Â Â Â Life Insurance Assumed Ratio 4.00% 4.00% 5.00% 4.00% Workers compensation Â Â Â Â Disaggregation of Revenue Â Â Â Â Life Insurance Assumed Ratio 2.00% 2.00% 2.00% 2.00% Medicare/Medicaid Â Â Â Â Disaggregation of Revenue Â Â Â Â Life Insurance Assumed Ratio 1.00% 1.00% 1.00% 1.00% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio of life insurance assumed from another insurer to gross life insurance in force. + ReferencesNo definition available. + Details Name: us-gaap_LifeInsuranceAssumedRatio Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=nutx_InsuranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nutx_SelfsPayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_WorkersCompensationInsuranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nutx_MedicareMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue (Details) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Revenue for cash collections previously deemed uncollectible $ 1.3 $ 2.1 Minimum Â Â Percentage of net patient service revenue 90.00% 90.00% X - DefinitionAmount of revenues recognized that was previously reported as deferred or unearned revenue. + ReferencesNo definition available. + Details Name: nutx_DeferredRevenueRevenuesRecognized Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of net patient service revenue paid by insurers, federal agencies and other non patient third parties. + ReferencesNo definition available. + Details Name: nutx_PercentageOfNetPatientServiceRevenue Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment - Categories (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment Â Â Property and equipment, gross $ 100,773,469 $ 99,728,712 Less: accumulated depreciation (21,891,569) (18,341,063) Total property and equipment, net $ 78,881,900 81,387,649 Buildings and improvements Â Â Property, Plant and Equipment Â Â Useful Life (years) 39 years Â Property and equipment, gross $ 19,611,254 18,947,818 Land Â Â Property, Plant and Equipment Â Â Property and equipment, gross 4,410,747 4,401,888 Leasehold improvements Â Â Property, Plant and Equipment Â Â Property and equipment, gross $ 27,931,959 27,606,383 Leasehold improvements | Minimum Â Â Property, Plant and Equipment Â Â Useful Life (years) 10 years Â Leasehold improvements | Maximum Â Â Property, Plant and Equipment Â Â Useful Life (years) 39 years Â Construction in progress Â Â Property, Plant and Equipment Â Â Property and equipment, gross $ 2,951,145 3,776,138 Medical equipment Â Â Property, Plant and Equipment Â Â Useful Life (years) 10 years Â Property and equipment, gross $ 33,844,363 33,519,026 Office furniture and equipment Â Â Property, Plant and Equipment Â Â Useful Life (years) 7 years Â Property and equipment, gross $ 3,590,926 3,698,874 Computer hardware and software Â Â Property, Plant and Equipment Â Â Useful Life (years) 5 years Â Property and equipment, gross $ 6,227,105 6,066,520 Vehicles Â Â Property, Plant and Equipment Â Â Useful Life (years) 5 years Â Property and equipment, gross $ 94,726 135,590 Signage Â Â Property, Plant and Equipment Â Â Useful Life (years) 10 years Â Property and equipment, gross $ 2,111,244 $ 1,576,475 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nutx_MedicalEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nutx_OfficeFurnitureAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nutx_ComputerHardwareAndSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nutx_SignageMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2024 item Jun. 30, 2024 entity Jun. 30, 2023 USD ($) Property, Plant and Equipment Â Â Â Â Â Â Number of real estate entities consolidated Â Â Â 2 2 Â Depreciation and amortization $ 4,532,804 $ 4,169,160 $ 8,719,006 Â Â $ 8,162,907 Property, Plant and Equipment Â Â Â Â Â Â Property, Plant and Equipment Â Â Â Â Â Â Depreciation and amortization $ 1,600,000 $ 1,100,000 $ 3,200,000 Â Â $ 2,400,000 X - DefinitionThe number of real estate entities consolidated. + ReferencesNo definition available. + Details Name: nutx_NumberOfConsolidatedRealEstateEntities Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets and Goodwill - Components (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Finite-Lived Intangible Assets Â Â Â Â Â Gross Carrying Amount $ 18,965,000 Â $ 18,965,000 Â $ 23,261,795 Accumulated amortization 2,784,496 Â 2,784,496 Â 2,749,159 Net Carrying Amount 16,180,504 Â 16,180,504 Â 20,512,636 Derecognized intangible assets 3,500,000 Â 3,500,000 Â Â Amortization of intangible assets 400,000 $ 400,000 800,000 $ 800,000 Â Goodwill $ 13,918,719 Â $ 13,918,719 Â $ 17,066,263 Member relationships Â Â Â Â Â Finite-Lived Intangible Assets Â Â Â Â Â Weighted Average Useful Life (in years) 15 years Â 15 years Â 15 years Gross Carrying Amount $ 18,491,000 Â $ 18,491,000 Â $ 18,491,000 Accumulated amortization 2,632,136 Â 2,632,136 Â 2,015,772 Net Carrying Amount $ 15,858,864 Â $ 15,858,864 Â $ 16,475,228 Management contracts Â Â Â Â Â Finite-Lived Intangible Assets Â Â Â Â Â Weighted Average Useful Life (in years) Â Â Â Â 16 years Gross Carrying Amount Â Â Â Â $ 2,021,000 Accumulated amortization Â Â Â Â 221,047 Net Carrying Amount Â Â Â Â $ 1,799,953 Customer contracts Â Â Â Â Â Finite-Lived Intangible Assets Â Â Â Â Â Weighted Average Useful Life (in years) Â Â Â Â 15 years Gross Carrying Amount Â Â Â Â $ 914,000 Accumulated amortization Â Â Â 106,633 Net Carrying Amount Â Â Â Â 807,367 Trademarks Â Â Â Â Â Finite-Lived Intangible Assets Â Â Â Â Â Weighted Average Useful Life (in years) 7 years Â 7 years Â Â Gross Carrying Amount $ 474,000 Â $ 474,000 Â 1,426,795 Accumulated amortization 152,360 Â 152,360 Â 262,557 Net Carrying Amount $ 321,640 Â $ 321,640 Â $ 1,164,238 Trademarks | Minimum Â Â Â Â Â Finite-Lived Intangible Assets Â Â Â Â Â Weighted Average Useful Life (in years) 7 years Â 7 years Â 7 years Trademarks | Maximum Â Â Â Â Â Finite-Lived Intangible Assets Â Â Â Â Â Weighted Average Useful Life (in years) Â Â Â Â 12 years PHP technology Â Â Â Â Â Finite-Lived Intangible Assets Â Â Â Â Â Weighted Average Useful Life (in years) Â Â Â Â 5 years Gross Carrying Amount Â Â Â Â $ 409,000 Accumulated amortization Â Â Â Â 143,150 Net Carrying Amount Â Â Â Â $ 265,850 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash

provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated amortization of intangible assets, excluding goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (a) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nutx_MemberRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nutx_ManagementContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nutx_PHPTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets and Goodwill - Operating Segment (Details) - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2023 Jun. 30, 2024 Dec. 31, 2023 Intangible Assets and Goodwill Â Â Â Goodwill Â $ 416,390,445 $ 416,340,598 Accumulated impairment losses Â (402,471,726) (399,274,335) Goodwill, Total Â 13,918,719 17,066,263 Purchase accounting adjustments Â 502,864 Â Impairment of goodwill Â (3,197,391) Â Derecognition of goodwill Â (453,017) Â Hospital Division Â Â Â Intangible Assets and Goodwill Â Â Â Goodwill Â 1,139,297 1,139,297 Accumulated impairment losses Â (1,139,297) (1,139,297) Population Health Management Division Â Â Â Intangible Assets and Goodwill Â Â Â Goodwill Â 415,251,148 415,201,301 Accumulated impairment losses Â (401,332,429) (398,135,038) Goodwill, Total Â 13,918,719 $ 17,066,263 Purchase accounting adjustments $ 500,000 502,864 Â Impairment of goodwill Â (3,197,391) Â Derecognition of goodwill Â $ (453,017) Â X - DefinitionThe derecognition of goodwill. + ReferencesNo definition available. + Details Name: nutx_DerecognitionOfGoodwill Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16 + Details Name: us-gaap_GoodwillPurchaseAccountingAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -

URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_HospitalDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_PopulationHealthManagementDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets and Goodwill (Details) 3 Months Ended 6 Months Ended Sep. 30, 2023 USD ($) item Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Intangible Assets and Goodwill Â Â Â Purchase accounting adjustments Â $ 502,864 Â Loss on sale of busines Â 3,197,391 Â Goodwill Â 13,918,719 $ 17,066,263 Population Health Management Division Â Â Â Intangible Assets and Goodwill Â Â Â Purchase accounting adjustments $ 500,000 502,864 Â Florida based IPAs | item 2 Â Â Loss on sale of busines Â 3,197,391 Â Goodwill Â 13,918,719 $ 17,066,263 Goodwill impairment Â $ 0 Â X - DefinitionRepresents the number of Florida based IPAs. + ReferencesNo definition available. + Details Name: nutx_NumberOfFloridaBasedIpas Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16 + Details Name: us-gaap_GoodwillPurchaseAccountingAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_PopulationHealthManagementDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses and Other Current Liabilities (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Accrued Expenses and Other Current Liabilities Â Â Accrued wages and benefits $ 8,426,753 $ 6,590,710 Accrued supplier expenses 3,920,076 2,504,544 Accrued medical insurance claims 2,293,873 1,865,280 Accrued taxes 4,824,866 405,352 Accrued other 3,951,623 1,589,410 Total accrued expenses and other current liabilities $ 23,417,191 $ 12,955,296 X - DefinitionAmount of medical insurance claim liabilities, due within one year of the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: nutx_MedicalInsuranceClaimLiabilitiesCurrent Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of supplier expenses liabilities, due within one year of the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: nutx_SupplierExpensesLiabilitiesCurrent Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedSalariesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt - Outstanding Debt (Details) - USD ($) 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Debt Instrument Â Â Total $ 40,942,087 $ 42,432,806 Less: unamortized issuance costs and discount 1,402,331 1,937,676 Less: short-term lines of credit 2,909,296 3,371,676 Less: current portion of long-term debt 14,223,944 10,808,721 Long-term debt, net 22,406,516 26,314,733 Term loans secured by all assets Â Â Debt Instrument Â Â Total $ 8,077,132 $ 7,030,613 Term loans secured by all assets | Minimum Â Â Debt Instrument Â Â Interest Rates (as percentage) 4.15% 4.15% Term loans secured by all assets | Maximum Â Â Debt Instrument Â Â Interest Rates (as percentage) 7.71% 7.71% Term loans secured by property and equipment Â Â Debt Instrument Â Â Total $ 9,408,077 $ 10,562,207 Term loans secured by property and equipment | Minimum Â Â Debt Instrument Â Â Interest Rates (as percentage) 3.59% 3.59% Term loans secured by property and equipment | Maximum Â Â Debt Instrument Â Â Interest Rates (as percentage) 10.00% 10.00% Line of credit secured by all assets Â Â Debt Instrument Â Â Total $ 2,909,296 $ 3,371,675 Line of credit secured by all assets | Minimum Â Â Debt Instrument Â Â Interest Rates (as percentage) 4.00% 4.00% Line of credit secured by all assets | Maximum Â Â Debt Instrument Â Â Interest Rates (as percentage) 9.50% 9.50% Term loans of consolidated Real Estate Entities Â Â Debt Instrument Â Â Total $ 12,361,238 $ 13,005,019 Term loans of consolidated Real Estate Entities | Minimum Â Â Debt Instrument Â Â Interest Rates (as percentage) 2.84% 2.84% Term loans of consolidated Real Estate Entities | Maximum Â Â Debt Instrument Â Â Interest Rates (as percentage) 5.75% 5.75% Term loan secured by deposits Â Â Debt Instrument Â Â Interest Rates (as percentage) 7.36% 7.36% Total $ 2,801,354 Â Unsecured convertible term notes Â Â Debt Instrument Â Â Total $ 5,384,990 $ 5,384,990 Unsecured convertible term notes | Minimum Â Â Debt Instrument Â Â Interest Rates (as percentage) 8.00% 8.00% Unsecured convertible term notes | Maximum Â Â Debt Instrument Â Â Interest Rates (as percentage) 10.00% 10.00% Prepaid Advance Â Â Debt Instrument Â Â Interest Rates (as percentage) 0.00% 0.00% Total Â $ 3,078,302 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50

-Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=nutx_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nutx_TermLoan1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nutx_TermLoan3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nutx_TermLoanSecuredByDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nutx_PrepaidAdvanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt - Term Loans and Lines of Credit (Details) $ in Millions 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 27 Months Ended Mar. 31, 2023 entity Jun. 30, 2022 entity Jun. 30, 2024 USD ($) entity Dec. 31, 2022 entity Dec. 31, 2023 entity Jun. 30, 2024 USD ($) entity Debt Â Â Â Â Â Â Number of deconsolidated Real Estate Entities | entity 1 17 18 18 18 18 Debt instrument not in compliance with debt service coverage ratio Â Â $ 0.1 Â Â $ 0.1 Remaining borrowing capacity Â Â $ 2.6 Â Â $ 2.6 X - DefinitionThe number of real estate entities deconsolidated. + ReferencesNo definition available. + Details Name: nutx_NumberOfDeconsolidatedRealEstateEntities Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtDefaultLongtermDebtAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt - Pre-Paid Advance Agreement (Details) 3 Months Ended 6 Months Ended 12 Months Ended Mar. 26, 2024 $ / shares shares Jan. 22, 2024 USD ($) Apr. 11, 2023 USD ($) D shares Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2024 USD ($) $ / shares shares Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Jul. 23, 2024 $ / shares Jul. 22, 2024 $ / shares Apr. 26, 2024 $ / shares Apr. 25, 2024 $ / shares Dec. 31, 2022 Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrant duration Â Â Â 5 years 5 years Â Â Â Â Â Â Â Â Strike price | $ / shares Â Â Â Â Â Â Â Â $ 5.34 $ 6.80 $ 0.68 $ 2.25 Â Debt Issuance Costs Â Â Â $ 1,402,331 $ 1,402,331 Â $ 1,937,676 Â Â Â Â Â Debt, Converted Instrument, Amount Â Â Â Â 320,688 $ 3,232,439 Â Â Â Â Â Â Net cash proceeds, received Â $ 9,200,000 Â Â Â Â Â Â Â Â Â Â Gross proceeds Â Â Â Â Â $ 9,202,500 Â Â Â Â Â Â Â Â Â Debt issuance costs Â $ 800,000 Â Â Â Â Â Â Â Â Â Â Prior to Reverse Stock Split Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase of common stock | shares Â Â Â 4,038,750 4,038,750 Â Â Â Â Â Â Â Â Accredited Investors Warrants Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase of common stock | shares Â Â Â 44,875 44,875 Â Â Â Â Â Â Â Â Strike price | $ / shares Â Â Â $ 60.00 $ 60.00 Â Â Â Â Â Â Â Â Accredited Investors Warrants | Prior to Reverse Stock Split Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase of common stock | shares Â Â Â 6,731,250 6,731,250 Â Â Â Â Â Â Â Â Strike price | $ / shares Â Â Â $ 0.40 $ 0.40 Â Â Â Â Â Â Â Â Common Stock Warrants Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrant duration Â Â Â 4 years 10 months 28 days 4 years 10 months 28 days 3 years 3 months 3 days 4 years 5 months 1 day Â Â Â Â 3 years 9 months 18 days Warrants issued to purchase of common stock | shares 89,750 Â Â 444,445 444,445 Â Â Â Â Â Â Â Â Strike price | $ / shares $ 30.00 Â Â Â Â Â Â Â Â Â Â Common Stock Warrants | Prior to Reverse Stock Split Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase of common stock | shares 13,462,500 Â Â Â Â Â Â Â Â Â Â Â Â Placement Agent Warrants Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase of common stock | shares 53,850 Â Â Â Â Â Â Â Â Â Â Â Â Placement Agent Warrants | Prior to Reverse Stock Split Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrants issued to purchase of common stock | shares 8,077,500 Â Â 26,925 26,925 Â Â Â Â Â Â Â Â September 2023 Private Offering Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Warrant duration Â Â Â 6 years 6 years Â Â Â Â Â Â Â Â Conversion price per share | $ / shares Â Â Â $ 30.00 $ 30.00 Â Â Â Â Â Â Â Â Interest rate paid in cash (as a percent) Â Â Â Â 8.00% Â Â Â Â Â Â Â Â Interest rate paid in kind (as a percent) Â Â Â Â 10.00% Â Â Â Â Â Â Â Â Grace days for payment of outstanding principal amount and accrued interests Â Â Â Â 30 days Â Â Â Â Â Â Â Â Adjusted interest rate payable Â Â Â Â 12.00% Â Â Â Â Â Â Â Â Interest Rate, Effective Percentage Â Â Â 21.50% 21.50% Â Â Â Â Â Â Â Â Emerson Equity LLC ("Emerson") | September 2023 Private Offering Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Cash commission payable (as a percent) Â Â Â 10.00% 10.00% Â Â Â Â Â Â Â Â Percentage of warrants to purchase common stock on total units Â Â Â 20.00% 20.00% Â Â Â Â Â Â Â Â Prepaid Advance Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Interest Rates (as percentage) Â Â Â Â 0.00% Â 0.00% Â Â Â Â Â Â Prepaid Advance | Yorkville | Pre-Paid Advance Agreement with Yorkville Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Percentage of the face amount for issue Â Â 90.00% Â Â Â Â Â Â Â Â Â Â Initial pre-paid advance amount with expenses Â Â $ 15,000,000.0 Â Â Â Â Â Â Â Â Â Â Interest Rates (as percentage) Â Â 0.00% Â Â Â Â Â Â Â Â Â Â Interest Rate Upon Events of Default Â Â 15.00% Â Â Â Â Â Â Â Â Â Maturity date Â Â 12 months Â Â Â Â Â Â Â Â Â Prepayment, Threshold Consecutive Trading Days | D Â Â 10 Â Â Â Â Â Â Â Â Â Prepayment, Notice Period Â Â 10 days Â Â Â Â Â Â Â Â Â Prepayment Premium Â Â 6.00% Â Â Â Â Â Â Â Â Â Net Proceeds Â Â $ 13,500,000 Â Â Â Â Â Â Â Â Â Percentage of debt discount Â Â 10.00% Â Â Â Â Â Â Â Â Â Debt discount Â Â $ 1,500,000 Â Â Â Â Â Â Â Â Â Debt Issuance Costs Â Â $ 900,000 Â Â Â Â Â Â Â Â Â Convertible notes, converted to shares | shares Â Â 200,000 Â Â Â Â Â Â Â Â Â Debt, Converted Instrument, Amount Â Â $ 7,300,000 Â Â Â Â Â Â Â Â Â Optional prepayment Â Â 8,200,000 Â Â Â Â Â Â Â Â Â Convertible Debt, Principal Â Â 7,700,000 Â Â Â Â Â Â Â Â Â Prepayment Premium Â Â $ 1,000,000.0 Â Â Â Â Â Â Â Â Â Prepaid Advance | Yorkville | Pre-Paid Advance Agreement with Yorkville | Prior to Reverse Stock Split Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Convertible notes, converted to shares | shares Â Â 23,100,000 Â Â Â Â Â Â Â Â Â Convertible debt Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Conversion price per share | $ / shares $ 30.00 Â Â $ 60.00 $ 60.00 Â Â Â Â Â Â Â Â Additional number of common shares issuable | shares 179,500 Â Â Â 89,751 Â Â Â Â Â Â Â Â Convertible debt | Prior to Reverse Stock Split Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Conversion price per share | $ / shares $ 0.20 Â Â $ 0.40 $ 0.40 Â Â Â Â Â Â Â Â Additional number of common shares issuable | shares 26,925,000 Â Â Â 13,462,500 Â Â Â Â Â Â Â Â Convertible debt | September 2023 Private Offering Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Net carrying amount Â Â Â $ 4,000,000.0 $ 4,000,000.0 Â Â Â Â Â Â Â Â Interest Expense Â Â Â 300,000 Â Â Â Â Â Â Â Â Amortization expense Â Â Â 200,000 Â Â Â Â Â Â Â Â Accrued interest expense Â Â Â 100,000 100,000 Â Â Â Â Â Â Â Â Convertible debt | September 2023 Private Offering As Amended Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Â Â Interest Expense Â Â Â 600,000 Â Â Â Â Â Â Â Â Amortization expense Â Â Â 400,000 Â Â Â Â Â Â Â Â Accrued interest expense Â Â Â $ 200,000 $ 200,000 Â Â Â Â Â Â Â Â Convertible debt | Maximum Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Interest Rates (as percentage) Â Â Â 10.00% Â 10.00% Â Â Â Â Â Convertible debt | Minimum Â Â Â Â Â Â Â Â Â Â Debt Instrument Â Â Â Â Â Â Â Â Â Â Interest Rates (as percentage) Â Â Â 8.00% Â 8.00% Â Â Â Â Â X - DefinitionAmount of amortization expense attributable to debt issuance cost. + ReferencesNo definition available. + Details Name: nutx_AmortizationOfDebtIssuanceCost Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe period of notice to be given for prepayment of convertible debt. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentConvertiblePrepaymentNoticePeriod Namespace Prefix: nutx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percent of premium to be paid on convertible debt for prepayment. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentConvertiblePrepaymentPremium Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe threshold consecutive trading days during which share price less than fixed price for prepayment of debt. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentConvertiblePrepaymentSharePriceThresholdConsecutiveTradingDays Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of common shares issuable upon conversion of debt. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentConvertibleSharesIssuable Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe percent of debt discount. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentDiscountPercent Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercent of interest rate paid in cash in a debt instrument. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentInterestRatePaidInCashPercent Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType

Balance Type: na Period Type: duration X - DefinitionPercent of interest rate paid in stock grants in a debt instrument. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentInterestRatePaidInStockGrantsPercent Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe interest rate for funds borrowed in the event of default. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentInterestRateUponEventsOfDefault Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of interest payable in default of debt instrument. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentPercentageOfInterestPayableInDefault Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument principal and accrued interest default term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: nutx_DebtInstrumentPrincipalAndAccruedInterestDefaultTerm Namespace Prefix: nutx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe initial pre-paid advance amount with expenses. + ReferencesNo definition available. + Details Name: nutx_InitialPrePaidAdvanceAmountWithExpenses Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of cash commission payable on gross proceeds from sale of units. + ReferencesNo definition available. + Details Name: nutx_PercentageOfCashCommissionPayableOnGrossProceedsFromSaleOfUnits Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of the face amount for issue. + ReferencesNo definition available. + Details Name: nutx_PercentageOfFaceAmountForIssue Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of warrants to purchase common stock on total units. + ReferencesNo definition available. + Details Name: nutx_PercentageOfWarrantsToPurchaseCommonStockOnTotalUnits Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow for the prepayment premium of a long-term debt instrument which can be exchanged for a specified amount of another security. + ReferencesNo definition available. + Details Name: nutx_RepaymentsOfConvertibleDebtPrepaymentPremium Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for the repayment of principal amount of a long-term debt instrument which can be exchanged for a specified amount of another security. + ReferencesNo definition available. + Details Name: nutx_RepaymentsOfConvertibleDebtPrincipal Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_StatementScenarioAxis=nutx_PriorToReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nutx_AccreditedInvestorsWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nutx_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nutx_PlacementAgentWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nutx_September2023PrivateOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nutx_EmersonEquityLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=nutx_PrepaidAdvanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nutx_YorkvilleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nutx_PrePaidAdvanceAgreementWithYorkvilleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nutx_September2023PrivateOfferingAsAmendedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases - Leases of property and equipment (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Leases Â Â Â Â Operating lease cost $ 569,222 $ 938,502 $ 1,213,920 $ 1,887,017 Finance lease cost: Â Â Â Â Amortization of right-of-use assets 2,453,351 2,547,035 4,679,021 5,031,310 Interest on lease liabilities 4,116,174 2,826,321 7,516,401 5,514,841 Total finance lease cost $ 6,569,525 $ 5,373,356 $ 12,195,422 $ 10,546,151 X - DefinitionTotal finance lease cost. + ReferencesNo definition available. + Details Name: nutx_FinanceLeaseCost Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNo definition required + ReferencesNo definition available. + Details Name: nutx_FinanceLeaseCostAbstract Namespace Prefix: nutx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation (Details) $ / shares in Units, $ in Millions 3 Months Ended 6 Months Ended Jul. 23, 2024 Jul. 02, 2024 Jun. 17, 2024 Jun. 16, 2024 USD ($) shares Apr. 24, 2024 Apr. 10, 2024 Apr. 09, 2024 Jun. 29, 2023 Apr. 01, 2023 USD ($) shares Jun. 30, 2024 USD ($) $ / shares Jun. 30, 2024 USD ($) $ / shares Share-Based Payment Arrangement Â Â Â Â Â Â Â Â Â Â Â Shares issued and outstanding Â Â Â Â Â Â Â 1.00% Â Â Â Conversion ratio 0.1 0.1 0.1 Â 0.067 0.067 0.067 Â Â Â Â Accrued stock based compensation | $ Â Â Â Â Â Â Â Â Â Â $ 0.1 $ 0.1 Restricted Stock Â Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Â Â Â Â Â Restricted common stock awards issued (in shares) | shares Â Â Â 118,538 Â Â Â Â 4,035 Â Â Restricted common stock awards issued | $ Â Â Â $ 0.6 Â Â Â Â $ 0.6 Â Â Â Prior to Reverse Stock Split | Restricted Stock Â Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Â Â Â Â Â Restricted common stock awards issued (in shares) | shares Â Â Â Â Â Â Â 604,158 Â Â Equity Incentive 2022 Plan Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Â Â Â Â Â Multiplying factor Â Â Â Â Â Â Â Â Â Â 10 Share price Â Â Â Â Â Â Â Â Â Â $ 2.80 $ 2.80 Equity Incentive 2022 Plan | Prior to Reverse Stock Split Â Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Â Â Â Â Â Share price Â Â Â Â Â Â Â Â Â Â 2.80 2.80 Equity Incentive 2022 Plan | After the reverse stock split Â Â Â Â Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Â Â Â Â Share price Â Â Â Â Â Â Â Â Â Â $ 420.00 $ 420.00 X - DefinitionThe multiplying factor for calculation of owners pro rata share of common stock. + ReferencesNo definition available. + Details Name: nutx_MultiplyingFactorForCalculationOfOwnersProRataShareOfCommonStock Namespace Prefix: nutx_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: duration X - DefinitionAmount of reversal of share based compensation expense during the period + ReferencesNo definition available. + Details Name: nutx_ReversalOfShareBasedCompensationExpense Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe maximum annual percentage increase on the issued and outstanding shares to shares available for grant under the share based arrangement. + ReferencesNo definition available. + Details Name: nutx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantMaximumAnnualPercentageIncreaseOfIssuedAndOutstandingShares Namespace Prefix: nutx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nutx_PriorToReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=nutx_EquityIncentive2022PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nutx_PostReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Stock-Based Awards Activity (Details) - $ / shares 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Share Based Compensation Arrangement Roll-Forward Â Â Â Â Options, Outstanding, Beginning Balance 27,590 34,318 34,318 Â Options, Outstanding, Ending Balance 27,590 34,318 27,590 34,318 Weighted Average Exercise Price Â Â Â Â Weighted Average Exercise Price, Beginning Balance $ 335.75 $ 345.00 $ 345.00 Â Weighted Average Exercise Price, Ending Balance $ 335.75 $ 345.00 $ 335.75 $ 345.00 Weighted Average Remaining Contractual Life (Years) 6 years 21 days 7 years 1 month 6 days 6 years 11 months 8 days 7 years 7 months 6 days X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Options Outstanding (Details) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Share-Based Payment Arrangement Â Â Â Â Number Outstanding 27,590 27,590 34,318 34,318 Number Exercisable 27,590 Â Â Â Exercise Price $ 335.75 $ 335.75 $ 345.00 $ 345.00 January 21, 2025 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 686 Â Â Â Number Exercisable 686 Â Â Â Exercise Price $ 225.00 Â Â Â January 21, 2025 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 300 Â Â Â Number Exercisable 300 Â Â Â Exercise Price $ 241.50 Â Â Â January 21, 2025 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 1,214 Â Â Â Number Exercisable 1,214 Â Â Â Exercise Price $ 412.50 Â Â Â January 27, 2027 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 300 Â Â Â Number Exercisable 300 Â Â Â Exercise Price $ 225.00 Â Â Â May 11, 2027 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 1,401 Â Â Â Number Exercisable 1,401 Â Â Â Exercise Price $ 225.00 Â Â Â June 9, 2027 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 167 Â Â Â Number Exercisable 167 Â Â Â Exercise Price $ 376.50 Â Â Â January 28, 2028 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 300 Â Â Â Number Exercisable 300 Â Â Â Exercise Price $ 241.50 Â Â Â August 4, 2029 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 68 Â Â Â Number Exercisable 68 Â Â Â Exercise Price $ 834.00 Â Â Â January 27, 2030 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 1,157 Â Â Â Number Exercisable 1,157 Â Â Â Exercise Price $ 225.00 Â Â Â June 30, 2030 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 715 Â Â Â Number Exercisable 715 Â Â Â Exercise Price $ 217.50 Â Â Â January 28, 2031 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 6,667 Â Â Â Number Exercisable 6,667 Â Â Â Exercise Price $ 241.50 Â Â Â February 28, 2031 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 1,333 Â Â Â Number Exercisable 1,333 Â Â Â Exercise Price $ 300.00 Â Â Â September 9, 2031 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 12,781 Â Â Â Number Exercisable 12,781 Â Â Â Exercise Price $ 412.50 Â Â Â December 17, 2031 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Number Outstanding 501 Â Â Â Number Exercisable 501 Â Â Â Exercise Price $ 525.00 Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=nutx_January212025ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_January212025ExpirationOption2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_January212025ExpirationOption3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_January272027ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_May112027ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_June92027ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_January282028ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_August42029ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_January272030ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_June302030ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_AwardTypeAxis=nutx_January282031ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_February282031ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_September92031ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_December172031ExpirationOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Restricted Stock Units Issued and Vested (Details) - RSUs - shares 6 Months Ended Jun. 16, 2024 Apr. 01, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-Based Payment Arrangement Â Â Â Â Vested Â Â 1,000 1,000 Vested on April 1, 2023 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested Â 1,431 Â Â Vested on March 1, 2024 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested Â 1,298 Â Â Vest on March 1, 2025 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested 39,514 1,306 Â Â Vest on March 1 2026 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested 39,514 Â Â Â Vest on March 1 2027 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested 39,510 Â Â Â Prior to Reverse Stock Split | Vested on April 1, 2023 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested Â 214,720 Â Â Prior to Reverse Stock Split | Vested on March 1, 2024 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested Â 194,720 Â Â Prior to Reverse Stock Split | Vest on March 1, 2025 Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Vested 1,184,946 194,720 Â Â X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=nutx_ShareBasedPaymentArrangementTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=nutx_ShareBasedPaymentArrangementTrancheFifthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nutx_PriorToReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Restricted Stock Units (Details) - RSUs $ / shares in Units, shares in Thousands, $ in Millions 6 Months Ended Jun. 30, 2024 USD ($) item $ / shares shares Jun. 30, 2023 $ / shares shares Share-Based Payment Arrangement Rollforward Â Â Beginning balance | shares 3 Â Granted | shares 118 4 Vested | shares (1) (1) Ending balance | shares 120 3 Weighted Average Grant-Date Fair Value Per Share Â Â Beginning balance | $ / shares $ 151.50 Â Granted | $ / shares 5.40 $ 151.50 Vested | $ / shares 151.50 151.50 Ending balance | $ / shares $ 39.98 $ 151.50 Unrecognized compensation cost | $ $ 0.8 Â Share-based award vesting period 1 year 9 months 18 days Â Vesting Rights, Percentage 33.33% Â Award Vesting, Number of Anniversaries | item 3 Â X - DefinitionNumber of anniversaries of vesting of award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: nutx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfAnniversaries Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Employee Stock Purchase Plan (Details) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended May 31, 2023 Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2024 Dec. 31, 2023 Share-Based Payment Arrangement Â Â Â Â Â Common stock issued for Employee Stock Purchase Plan Â $ 14,409 $ 19,026 Â Â 2023 Employee Stock Purchase Plan Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Shares authorized 33,333 118,563 Â 118,563 73,426 Percentage of the market value at which employee stock purchase plan participants are entitled to purchase stock under the plan 85.00% Â Â Â Â Common stock issued for Employee Stock Purchase Plan (in shares) Â 2,061 Â 2,807 Â Common stock issued for Employee Stock Purchase Plan Â $ 100,000 Â $ 100,000 Â 2023 Employee Stock Purchase Plan | Prior to Reverse Stock Split Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Shares authorized 5,000,000 Â Â Â 11,013,943 X - DefinitionThe percentage of the market value at which employee stock purchase plan participants are entitled to purchase stock under the plan. + ReferencesNo definition available. + Details Name: nutx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanMarketGrantPricePercentage Namespace Prefix: nutx_ Data Type: dtr-

types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_PlanNameAxis=nutx_EmployeeStockPurchasePlan2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nutx_PriorToReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity (Details) 3 Months Ended 6 Months Ended Jul. 23, 2024 $ / shares Jul. 02, 2024 Jun. 30, 2024 USD ($) Vote $ / shares shares Jun. 17, 2024 Apr. 24, 2024 Apr. 10, 2024 Apr. 09, 2024 Mar. 26, 2024 $ / shares shares Jan. 22, 2024 USD ($) D $ / shares shares Jun. 30, 2024 USD ($) Vote $ / shares shares Mar. 31, 2024 USD ($) shares Jun. 30, 2023 USD ($) shares Mar. 31, 2023 USD ($) shares Jun. 30, 2024 USD ($) Vote $ / shares shares Jun. 30, 2023 USD ($) shares Jul. 22, 2024 $ / shares Apr. 26, 2024 $ / shares Apr. 25, 2024 $ / shares Jan. 25, 2024 USD ($) Dec. 31, 2023 $ / shares shares Dec. 31, 2022 shares Accumulated Other Comprehensive Income (Loss) Â Â Â

http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nutx_PriorToReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nutx_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nutx_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity - Common Stock Warrants (Details) - $ / shares 6 Months Ended Mar. 26, 2024 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Warrants Outstanding Â Â Â Â Â Warrants outstanding, beginning balance Â Â 73,553 Â Â Warrants exercised Â Â 9,710 Â Â Warrants expired Â Â (20) Â Â Warrants outstanding, ending balance Â 651,783 63,823 Â Â Warrants Weighted Average Exercise Price Â Â Â Â Â Warrants outstanding, beginning balance (in dollars per share) Â Â $ 294.16 Â Â Warrants exercised (in dollars per share) Â Â 232.50 Â Â Warrants expired (in dollars per share) Â Â 3,750.00 Â Â Warrants outstanding, ending balance (in dollars per share) Â Â $ 302.46 Â Â Warrants Weighted Average Remaining Contractual Life (years) Â 5 years Â Â Â Common Stock Warrants Â Â Â Â Â Warrants Outstanding Â Â Â Â Â Warrants outstanding, beginning balance Â 135,537 73,553 Â Â Warrants issued 89,750 444,445 Â Â Â Warrants amended 71,801 71,801 Â Â Â Warrants exercised Â Â (20) Â Â Warrants expired Â Â (9,710) Â Â Warrants outstanding, ending balance Â 651,783 63,823 Â Â Warrants Weighted Average Exercise Price Â Â Â Â Â Warrants outstanding, beginning balance (in dollars per share) Â $ 158.16 $ 294.16 Â Â Warrant issued (in dollar per share) Â 6.80 Â Â Â Warrants amended (in dollars per share) Â 30.00 Â Â Â Warrants exercised (in dollars per share) Â Â 3,750.00 Â Â Warrants expired (in dollars per share) Â Â 232.50 Â Â Warrants outstanding, ending balance (in dollars per share) Â $ 40.83 $ 302.46 Â Â Warrants Weighted Average Remaining Contractual Life (years) Â 4 years 10 months 28 days 3 years 3 months 3 days 4 years 5 months 1 day 3 years 9 months 18 days X - DefinitionNumber of warrants amended during the period. + ReferencesNo definition available. + Details Name: nutx_WarrantsAmended Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of warrant amended when converting their warrants into shares. + ReferencesNo definition available. + Details Name: nutx_WarrantsAmendedWeightedAverageIssuedPrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants exercised during the period. + ReferencesNo definition available. + Details Name: nutx_WarrantsExercised Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which holders acquired shares when converting their warrants into shares. + ReferencesNo definition available. + Details Name: nutx_WarrantsExercisedWeightedAverageExercisePrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants expired. + ReferencesNo definition available. + Details Name: nutx_WarrantsExpired Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of warrants expired. + ReferencesNo definition available. + Details Name: nutx_WarrantsExpiredWeightedAverageExercisePrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of warrant issued when converting their warrants into shares. + ReferencesNo definition available. + Details Name: nutx_WarrantsIssuedWeightedAverageIssuedPrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: nutx_WarrantsNumberRollforwardAbstract Namespace Prefix: nutx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average of number of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: nutx_WarrantsOutstandingWeightedAverageExercisePrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: nutx_WarrantsWeightedAverageExercisePriceAbstract Namespace Prefix: nutx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -

Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nutx_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity - Schedule of Outstanding Warrants (Details) - $ / shares Jul. 23, 2024 Jul. 22, 2024 Jun. 30, 2024 Apr. 26, 2024 Apr. 25, 2024 Jun. 30, 2023 Dec. 31, 2022 Share-Based Payment Arrangement Â Â Â Â Â Â Â Number Outstanding Â Â 651,783 Â Â 63,823 73,553 Number Exercisable Â Â 651,783 Â Â Â Â Exercise Price $ 5.34 $ 6.80 Â $ 0.68 $ 2.25 Â Â December 31, 2024 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 3,701 Â Â Â Â Number Exercisable Â Â 3,701 Â Â Â Â Exercise Price Â Â $ 1,000.50 Â Â Â Â October 31, 2025 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 108 Â Â Â Â Number Exercisable Â Â 108 Â Â Â Â Exercise Price Â Â $ 187.50 Â Â Â Â October 31, 2025 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 10,444 Â Â Â Â Number Exercisable Â Â 10,444 Â Â Â Â Exercise Price Â Â $ 232.50 Â Â Â Â February 26, 2026 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 1,922 Â Â Â Â Number Exercisable Â Â 1,922 Â Â Â Â Exercise Price Â Â $ 600.00 Â Â Â Â July 31, 2026 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Â Number Outstanding Â Â 16,888 Â Â Â Â Number Exercisable Â Â 16,888 Â Â Â Â Exercise Price Â Â $ 232.50 Â Â Â Â May 31, 2027 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Â Number Outstanding Â Â 30,674 Â Â Â Â Number Exercisable Â Â 30,674 Â Â Â Â Exercise Price Â Â $ 262.50 Â Â Â Â September 30, 2029 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 444,445 Â Â Â Â Number Exercisable Â Â 444,445 Â Â Â Â Exercise Price Â Â $ 6.80 Â Â Â Â October 31, 2029 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 16,501 Â Â Â Â Number Exercisable Â Â 16,501 Â Â Â Â Exercise Price Â Â $ 30.00 Â Â Â Â November 30, 2029 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 57,250 Â Â Â Â Number Exercisable Â Â 57,250 Â Â Â Â Exercise Price Â Â $ 30.00 Â Â Â Â December 31, 2029 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 5,167 Â Â Â Â Number Exercisable Â Â 5,167 Â Â Â Â Exercise Price Â Â $ 30.00 Â Â Â Â January 25, 2029 Â Â Â Â Â Â Â Share-Based Payment Arrangement Â Â Â Â Â Â Number Outstanding Â Â 64,683 Â Â Â Â Number Exercisable Â Â 64,683 Â Â Â Â Exercise Price Â Â $ 30.00 Â Â Â Â X - DefinitionNumber of warrants or rights exercisable. + ReferencesNo definition available. + Details Name: nutx_ClassOfWarrantOrRightExercisable Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=nutx_December312024ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_October312025ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_October312025ExpirationWarrant2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_February262026ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_July312026ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_May312027ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_September302029ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_October312029ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_November302029ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_December312029ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=nutx_January252029ExpirationWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Income Taxes Â Â Effective tax rate 22.90% 34.20% Federal statutory rate Â 21.00% X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings per Share - Computation of EPS (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Numerator- Â Â Â Â Net loss attributable to common stockholders $ (364,048) $ (3,479,047) $ (728,123) $ (8,626,326) Denominator: Â Â Â Â Weighted average shares used to compute basic EPS 4,969,726 4,377,088 4,909,481 4,358,367 Loss per share: Â Â Â Â Basic $ (0.07) $ (0.79) $ (0.15) $ (1.98) Diluted $ (0.07) $ (0.79) $ (0.15) $ (1.98) X - ReferencesNo definition available. + Details Name: nutx_DenominatorAttributableToNutexHealthIncAbstract Namespace Prefix: nutx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: nutx_NumeratorAttributableToNutexHealthIncAbstract Namespace Prefix: nutx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -

Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareProFormaAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Earnings per Share (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Employee Stock Option Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 27,590 34,318 Employee Stock Option | Prior to Reverse Stock Split Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 4,137,149 5,147,770 Warrant Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 651,783 63,823 Warrant | Prior to Reverse Stock Split Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 97,780,228 9,573,562 RSUs Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 1,298 Â RSUs | Prior to Reverse Stock Split Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 194,720 Â Convertible debt securities Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 179,500 Â Convertible debt securities | Prior to Reverse Stock Split Â Â Earnings per Share Â Â Antidilutive securities excluded from computation of earnings per share amount 26,925,000 Â X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=nutx_PriorToReverseStockSplitMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Supplemental Cash Flows Information (Details) - USD ($) 3 Months Ended 6 Months Ended Jan. 22, 2024 Jun. 30, 2024 Mar. 31, 2024 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Supplemental Cash Flows Information Â Â Â Â Â Â Cash paid for interest Â Â Â Â Â $ 1,731,171 $ 858,773 Cash paid for income taxes Â Â Â Â Â 781,000 737,000 Non-cash investing and financing activities: Â Â Â Â Â Â Â Â Financed capital expenditures Â Â Â Â Â 517,941 4,111,435 Acquisition of finance leases Â Â Â Â Â 15,628,963 18,798,667 Exercise of warrants on cashless basis Â Â Â Â Â Â 1,268 Issuance of restricted stock units Â Â Â Â Â Â 249,645 Issuance of common stock to Apollo Medical Holdings, Inc. $ 1,500,000 Â $ 1,540,943 $ 1,900,000 Â 1,900,000 Deconsolidation of Real Estate Entity Â Â Â Â Â Â 4,258,133 Warrant liability related to common stock issuance $ 7,700,000 Â Â Â Â 7,661,557 Â Reverse stock split adjustment Â Â Â Â Â 3 Â Common stock issued for Employee Stock Purchase Plan Â Â Â Â Â 33,435 Â Convertible debt converted to common stock Â Â Â Â Â 320,688 $ 3,232,439 Payment for acquisition in common stock Â $ 156,158 Â Â 156,158 Â Common stock received in sale of business Â $ 30,250 Â Â $ 30,250 Â X - DefinitionAmount of acquisition of financing leases. + ReferencesNo definition available. + Details Name: nutx_AcquisitionOfFinancingLeases Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deconsolidation of Real Estate Entities. + ReferencesNo definition available. + Details Name: nutx_DeconsolidationOfRealEstateEntities Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSupplemental cash flow information based on the exercise of warrants on a cashless basis. + ReferencesNo definition available. + Details Name: nutx_ExerciseOfWarrantsCashlessBasis Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of restricted stock units

issued in noncash financing activities. + ReferencesNo definition available. + Details Name: nutx_RestrictedStockUnitsIssued Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares received during the period in sale of business. + ReferencesNo definition available. + Details Name: nutx_StockReceivedInSaleOfBusinessDuringPeriodValue Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of Warrant liability related to common stock issuance arising under non-cash transaction. + ReferencesNo definition available. + Details Name: nutx_WarrantLiabilityRelatedToCommonStockIssuance Namespace Prefix: nutx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1947274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockAmountIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information - Assets (Details) 6 Months Ended Jun. 30, 2024 USD ($) segment Dec. 31, 2023 USD ($) Segment Information Â Â Number of reportable segments | segment 3 Â Total Assets $ 422,403,251 $ 398,245,497 Hospital division Â Â Segment Information Â Â Total Assets 373,398,552 278,635,841 Population health management division Â Â Segment Information Â Â Total Assets 29,339,169 83,647,378 Real estate division Â Â Segment Information Â Â Total Assets $ 19,665,530 $ 35,962,278 X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_HospitalDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_PopulationHealthManagementDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_RealEstateDivisionMember Namespace Prefix: Data Type: na Balance Type:

Period Type: XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information - Operations (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Segment Information Â Â Â Â Total revenue $ 76,082,261 $ 58,924,454 $ 143,536,048 $ 115,253,871 Total segment operating income 22,561,231 9,646,923 32,718,409 14,494,646 Total capital expenditures 558,169 3,069,919 1,291,492 7,446,902 Total depreciation and amortization 4,532,804 4,169,160 8,719,006 8,162,907 Hospital division | Operating Segment Â Â Â Â Segment Information Â Â Â Â Total revenue 67,604,878 51,611,803 127,634,247 100,899,967 Total segment operating income 22,791,199 9,105,114 33,262,249 13,883,751 Total capital expenditures 558,169 3,069,919 1,291,492 7,446,902 Total depreciation and amortization 3,670,212 3,715,868 7,434,559 7,279,890 Population health management division | Operating Segment Â Â Â Â Segment Information Â Â Â Â Total revenue 8,477,383 7,312,651 15,901,801 14,353,904 Total segment operating income (229,968) 541,809 (543,840) 610,895 Total depreciation and amortization 411,305 411,614 832,300 799,661 Real estate division | Operating Segment Â Â Â Â Segment Information Â Â Â Â Total depreciation and amortization 451,287 41,678 452,147 83,356 Real estate division | Intersegment Eliminations Â Â Â Â Segment Information Â Â Â Â Total revenue $ (196,595) $ 258,015 $ 603,255 $ 516,030 X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNamespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_SegmentExpenditureAdditionToLongLivedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_HospitalDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_PopulationHealthManagementDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_RealEstateDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions (Details) 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 27 Months Ended Jun. 30, 2024 USD ($) entity Jun. 30, 2023 USD ($) entity Mar. 31, 2023 entity Jun. 30, 2022 entity Jun. 30, 2024 USD ($) entity Jun. 30, 2023 USD ($) entity Dec. 31, 2022 entity Dec. 31, 2023 USD ($) entity Jun. 30, 2024 USD ($) entity Related Party Transactions Â Â Â Â Â Â Â Â Â Net expense $ 7,496,465 $ 7,235,594 Â Â $ 16,962,432 $ 15,673,655 Â Â Â Accounts Payable, Related Parties $ 900,000 Â Â Â $ 900,000 Â Â $ 900,000 $ 900,000 Number of deconsolidated Real Estate Entities | entity Â Â 1 17 18 Â 18 18 18 Number of consolidated real estate entity | entity 2 Â Â Â 2 Â Â Â 2 Accounts payable $ 16,742,370 Â Â Â $ 16,742,370 Â Â $ 18,899,196 $ 16,742,370 Revenues 76,082,261 58,924,454 Â Â 143,536,048 115,253,871 Â Â Â Hospital division Â Â Â Â Â Â Â Â Related Party Transactions Â Â Â Â Â Â Â Â Lease obligation payments 4,900,000 $ 3,700,000 Â Â 9,600,000 $ 7,200,000 Â Â Â Managerial Services Agreements Â Â Â Â Â Â Â Â Related Party Transactions Â Â Â Â Â Â Â Â Number of ER Entities operated | entity Â 2 Â Â Â 2 Â Â Â Managerial Services Agreements | Hospital division Â Â Â Â Â Â Â Â Related Party Transactions Â Â Â Â Â Â Â Â Revenues Â $ 200,000 Â Â Â $ 300,000 Â Â Â Physician LLCs Â Â Â Â Â Â Â Â Related Party Transactions Â Â Â Â Â Â Â Â Accounts Payable, Related Parties 3,300,000 Â Â Â 3,300,000 Â Â 2,900,000 3,300,000 ER Entities Â Â Â Â Â Â Â Â Related Party Transactions Â Â Â Â Â Â Â Â Accounts Receivable, Related Parties 4,600,000 Â Â Â 4,600,000 Â Â 4,100,000 4,600,000 ER Entities | Managerial Services Agreements Â Â Â Â Â Â Â Â Related Party Transactions Â Â Â Â Â Â Â Â Repayments of related party debt Â $ 100,000 Â Â Â $ 400,000 Â Â Â Micro Hospital Holding LLC Â Â Â Â Â Â Â Â Related Party Transactions Â Â Â Â Â Â Â Â Accounts payable $ 1,400,000 Â Â Â $ 1,400,000 Â Â $ 1,200,000 $ 1,400,000 X - DefinitionThe number of real estate entities consolidated. + ReferencesNo definition available. + Details Name: nutx_NumberOfConsolidatedRealEstateEntity Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionThe number of real estate entities deconsolidated. + ReferencesNo definition available. + Details Name: nutx_NumberOfDeconsolidatedRealEstateEntities Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents number of emergency rooms operated by the company. + ReferencesNo definition available. + Details Name: nutx_NumberOfEmergencyRoomsOperated Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have

typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_AccountsPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_AccountsReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement. + ReferencesNo definition available. + Details Name: us-gaap_PaymentsForLeasingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=nutx_HospitalDivisionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TransactionTypeAxis=nutx_ManagerialServicesAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nutx_PhysicianLLCsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nutx_EREntitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nutx_MicroHospitalHoldingLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Variable Interest Entities - Balance sheet amounts (Details) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Mar. 31, 2023 Variable Interest Entities Â Â Â Current assets $ 113,870,438 $ 90,848,403 Â Property and equipment, net 78,881,900 81,387,649 Â Total assets 422,403,251 398,245,497 Â Current liabilities 71,658,392 58,313,052 Â Total liabilities 340,381,215 319,139,391 Â Equity 62,733,967 61,453,190 Â Total liabilities and equity 422,403,251 398,245,497 Â Real Estate Entities Â Â Â Variable Interest Entities Â Â Â Property and equipment, net Â Â $ 8,400,000 Total liabilities Â Â $ 5,400,000 Primary Beneficiary | Real Estate Entities Â Â Â Variable Interest Entities Â Â Â Current assets 173,701 138,342 Â Other long-term assets 33,130,254 33,089,636 Â Total assets 33,303,955 33,227,978 Â Current liabilities 15,262 38,510 Â Long-term liabilities 12,317,109 12,959,171 Â Total liabilities 12,332,371 12,997,681 Â Equity 20,971,584 20,230,297 Â Total liabilities and equity 33,303,955 33,227,978 Â Primary Beneficiary | Physician LLCs Â Â Â Variable Interest Entities Â Â Â Current assets 8,637,398 8,074,928 Â Property and equipment, net 3,668 3,668 Â Total assets 8,641,066 8,078,596 Â Current liabilities 5,626,710 5,648,516 Â Total liabilities 5,626,710 5,648,516 Â Equity 3,014,356 2,430,080 Â Total liabilities and equity 8,641,066 8,078,596 Â Primary Beneficiary | AHISPIPA Â Â Â Variable Interest Entities Â Â Â Current assets 10,786,496 8,473,486 Â Property and equipment, net 93,998 65,277 Â Other long-term assets Â 36,452 Â Total assets 10,880,494 8,575,215 Â Current liabilities 10,880,494 8,575,215 Â Total liabilities 10,880,494 8,575,215 Â Total liabilities and equity $ 10,880,494 $ 8,575,215 Â X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: dei_LegalEntityAxis=nutx_RealEstateEntitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=nutx_PhysicianLLCsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=nutx_AHPIPAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Variable Interest Entities (Details) 6 Months Ended Jun. 30, 2024 USD ($) item Jun. 30, 2024 USD ($) entity Dec. 31, 2023 USD ($) Mar. 31, 2023 USD ($) Number of real estate entities consolidated 2 2 Â Â Â Fixed assets $ 78,881,900 $ 78,881,900 $ 81,387,649 Â Other assets 764,462 764,462 431,135 Â Liabilities 340,381,215 340,381,215 319,139,391 Â Equity attributable to noncontrolling interests $ 19,288,069 $ 19,288,069 $ 17,652,916 Â Real Estate Entities Â Â Â Â Cash Â Â Â $ 1,000,000.0 Fixed assets Â Â Â 8,400,000 Other assets Â Â Â 200,000 Liabilities Â Â Â 5,400,000 Equity attributable to noncontrolling interests Â Â Â $ 4,300,000 X - DefinitionThe number of real estate entities consolidated. + ReferencesNo definition available. + Details Name: nutx_NumberOfConsolidatedRealEstateEntities Namespace Prefix: nutx_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15:

http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: dei_LegalEntityAxis=nutx_RealEstateEntitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events (Details) Jul. 23, 2024 Jul. 02, 2024 Jun. 17, 2024 Apr. 24, 2024 Apr. 10, 2024 Apr. 09, 2024 Jun. 29, 2023 Jun. 30, 2024 shares Dec. 31, 2023 shares Subsequent Events Â Â Â Â Â Â Â Â Â Conversion ratio 0.1 0.1 0.1 0.067 0.067 0.067 Â Â Â Common stock authorized Â Â Â Â Â Â Â 950,000,000 950,000,000 Minimum Â Â Â Â Â Â Â Â Â Subsequent Events Â Â Â Â Â Â Â Â Â Conversion ratio Â Â 0.5 Â Â Â 0.5 Â Â Maximum Â Â Â Â Â Â Â Â Â Subsequent Events Â Â Â Â Â Â Â Â Â Conversion ratio Â Â 0.063 Â Â Â 0.063 Â Â Subsequent Event Â Â Â Â Â Â Â Â Â Subsequent Events Â Â Â Â Â Â Â Â Â Conversion ratio Â 0.1 Â Â Â Â Â Â Â Â X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events - Equity (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Common Stock - Shares 4,987,268 4,404,951 4,987,268 4,404,951 4,511,199 4,334,826 Common stock $ 4,988 $ 4,405 $ 4,988 $ 4,405 $ 4,511 $ 4,335 Additional paid-in capital 472,529,641 464,526,305 472,529,641 464,526,305 $ 470,521,218 $ 459,144,291 Net loss attributable to common stockholders $ (364,048) $ (3,479,047) $ (728,123) $ (8,626,326) Â Â Weighted average shares used to compute basic EPS 4,969,726 4,377,088 4,909,481 4,358,367 Â Â Basic, income (loss) per common share (in dollar per share) $ (0.07) $ (0.79) $ (0.15) $ (1.98) Â Â Diluted, income (loss) per common share (in dollar per share) $ (0.07) $ (0.79) $ (0.15) $ (1.98) Â Â Options, Outstanding, Beginning Balance Â Â 27,590 34,318 Â Â Options, Outstanding, Ending Balance 27,590 34,318 27,590 34,318 Â Â Weighted Average Exercise Price, Beginning Balance Â Â $ 335.75 $ 345.00 Â Â Weighted Average Exercise Price, Ending Balance $ 335.75 $ 345.00 $ 335.75 $ 345.00 Â Â Warrants outstanding, beginning balance Â Â Â 73,553 Â Â Warrants Exercised Â Â Â (9,710) Â Â Warrants expired Â Â Â (20) Â Â Warrants outstanding, ending balance 651,783 63,823 651,783 63,823 Â Â Warrants outstanding, beginning balance (in dollars per share) Â Â Â $ 294.16 Â Â Warrants exercised (in dollars per share) Â Â Â 232.50 Â Â Warrants expired (in dollars per share) Â Â Â 3,750.00 Â Â Warrants outstanding, ending balance (in dollars per share) Â $ 302.46 Â $ 302.46 Â Â Employee Stock Option Â Â Â Â Â Â Antidilutive securities excluded from computation of earnings per share amount Â Â 27,590 34,318 Â Â Warrant Â Â Â Â Â Â Antidilutive securities excluded from computation of earnings per share amount Â Â 651,783 63,823 Â Â As Previously Reported Â Â Â Â Â Â Common Stock - Shares Â 660,742,624 Â 660,742,624 676,679,911 650,223,840 Common stock Â $ 660,742 Â $ 660,742 $ 676,680 $ 650,224 Additional paid-in capital Â 463,869,968 Â 463,869,968 $ 469,849,049 $ 458,498,402 Net loss attributable to common stockholders Â $ (3,479,047) Â $ (8,626,326) Â Â Weighted average shares used to compute basic EPS Â 656,563,166 Â 653,755,031 Â Â Basic, income (loss) per common share (in dollar per share) Â $ (0.01) Â $ (0.01) Â Â Options, Outstanding, Beginning Balance Â Â Â 5,147,770 Â Â Options, Outstanding, Ending Balance Â 5,147,770 Â 5,147,770 Â Â Weighted Average Exercise Price, Beginning Balance Â Â Â $ 2.30 Â Â Weighted Average Exercise Price, Ending Balance Â $ 2.30 Â $ 2.30 Â Â Warrants outstanding, beginning balance Â Â Â 11,033,015 Â Â Warrants Exercised Â Â Â (1,456,453) Â Â Warrants expired Â Â Â (3,000) Â Â Warrants outstanding, ending balance Â 9,573,562 Â 9,573,562 Â Â Warrants outstanding, beginning balance (in dollars per share) Â Â Â $ 1.96 Â Â Warrants exercised (in dollars per share) Â Â Â 1.55 Â Â Warrants expired (in dollars per share) Â Â Â 25.00 Â Â Warrants outstanding, ending balance (in dollars per share) Â $ 2.02 Â $ 2.02 Â Â As Previously Reported | Employee Stock Option Â Â Â Â Â Â Antidilutive securities excluded from computation of earnings per share amount Â Â Â 5,147,770 Â Â As Previously Reported | Warrant Â Â Â Â Â Â Antidilutive securities excluded from computation of earnings per share amount Â Â Â 9,573,562 Â Â Impact of Reverse Stock Split Â Â Â Â Â Â Common Stock - Shares Â (656,337,673) Â (656,337,673) (672,168,712) (645,889,014) Common stock Â $ (656,337) Â $ (656,337) $ (672,169) $ (645,889) Additional paid-in capital Â $ 656,337 Â $ 656,337 $ 672,169 $ 645,889 Weighted average shares used to compute basic EPS Â (652,186,078) Â (649,396,664) Â Â Basic, income (loss) per common share (in dollar per share) Â $ (0.78) Â $ (1.97) Â Â Options, Outstanding, Beginning Balance Â Â Â (5,113,452) Â Â Options, Outstanding, Ending Balance Â (5,113,452) Â (5,113,452) Â Â Weighted Average Exercise Price, Beginning Balance Â Â Â $ 342.70 Â Â Weighted Average Exercise Price, Ending Balance Â $ 342.70 Â $ 342.70 Â Â Warrants outstanding, beginning balance Â Â Â (10,959,462) Â Â Warrants Exercised Â Â Â 1,446,743 Â Â Warrants expired Â Â Â 2,980 Â Â Warrants outstanding, ending balance Â (9,509,739) Â (9,509,739) Â Â Warrants outstanding, beginning balance (in dollars per share) Â Â Â $ 292.20 Â Â Warrants exercised (in dollars per share) Â Â Â 230.95 Â Â Warrants expired (in dollars per share) Â Â Â 3,725.00 Â Â Warrants outstanding, ending balance (in dollars per share) Â $ 300.44 Â $ 300.44 Â Â Impact of Reverse Stock Split | Employee Stock Option Â Â Â Â Â Â Antidilutive securities excluded from computation of earnings per share amount Â Â Â (5,113,452) Â Â Impact of Reverse Stock Split | Warrant Â Â Â Â Â Â Antidilutive securities excluded from computation of earnings per share amount Â Â Â (9,509,739) Â Â X - DefinitionNumber of warrants exercised during the period. + ReferencesNo definition available. + Details Name: nutx_WarrantsExercised Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which holders acquired shares when converting their warrants into shares. + ReferencesNo definition available. + Details Name: nutx_WarrantsExercisedWeightedAverageExercisePrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants expired. + ReferencesNo definition available. + Details Name: nutx_WarrantsExpired Namespace Prefix: nutx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of warrants expired. + ReferencesNo definition available. + Details Name: nutx_WarrantsExpiredWeightedAverageExercisePrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average of number of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: nutx_WarrantsOutstandingWeightedAverageExercisePrice Namespace Prefix: nutx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT Begin 644 Financial_Report.xlsx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Ö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}$/L&PMP'[F@@]PWD-O>[9&TS M/2V[\N9ZW;Q$ZSY:H? 4 ;.G:ME8)KE?]D777K=5?:]6NNYE\N)WFMW?Y-%(_ MW7WXY_OIV_JP]UG]>WG_/;S7?2AB"8_O;W]>WX7O;^-\G]]>?_Y/]%E].5N M&GWWY[]>7W6J%SW6U6R_Q7> [+5+7%IOE4AU2=UTS^Q5H/?&W?CN?U_TA62ZB MCV4]OZQ7T:1\JKMR 6!-1[!FL\URLRB[:AŸ-JX=Z5G< 2.X'N6U6LV;5K9N% M^LO7Z/VJJ]95V[4 4N%'^MQ8>W&EV#Q02@^4TBT.=^"\J[[6JU7?F?MR4:YF MU??1<[G85%'9J=V<_1 Q\GU$8THA[G;0<@O=GY6>;SACXOKJ^9@B($ADA'.: MD6'DU(Z\9)+15&34 ,WM4,JYY#++AH&%'4AHS&C"X_@0.4@<.R2.A2:N?2P5 MFR=E;HOYB'Z5*DS1MYV:K!"^:I3YY *&J+O MO,"!.9A@@DTQP7)N':R7G{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

[1E^43]9P:A29\\Y>'VCB7MW\OIGS.^L8PS,SQANE,R$ MR'<8TSZX.*4C",<1GC$Z [3F1_3CS=T)JL*T$+;@S54:+VU M+K1C^N,=R&CW%,*&T)U0#,/18+/_&0,WZW@ _ +Z):"J7_#I[41A7+;4-H MG!X-T9]A#"-WWR"Q,V3(!C+3@?KS _K>U/S0C]AJ@MG8UL#@PIP2-(P#F$, M'#&W0V3V$D1V@9K3]"'."T&UP-%:ZO,-C[I^^&\.;@RM[;M6X M8#EMY_T M@@Y^A^4XAFT2]7^2<4@R&@%HL'[ES@[>5ZB$NFU>X]"H.4AH?_[??[I_5>2\ M>4&B]_D'[' ", M$@ & 'AL+W=OLH$J'D:O)8F7E?*4C;OUZ'&I/.I=#
M53F>329OQY4V=G!V(L^N _=F):V)I+%U[%9]JTO[^/95N>SJ8#KH'7\ZVTA/Q@ M?'92ZS7=4/RMOO:X& _=29C?CJ8L$%44A99@L;/ABZH+%DOS/C>RAST*OG@[G4G _ =_B.WQ9ZD 7KOS=
MY+$X'1P.5$XW93QJ]M>4NO/@N5EK@SR7VW3ADV9TV(KFH/PX+*V/2K[]HX M[!PXG+QP8-8>F(G=29%8^4%'?7;BW59YW@UI?"&NRFD89RR#-LX:X6]3\)F+PA[JSX[&XN@_F5SRA^?'\.P MWKI99]W[V:L"?VWL2,TG0S6;S/9?D3?OO9V+O/G_Q]LD;/]Y85PN1Z'6&9T. M4 ^!_(8&9S_-'T[.7[%U/W>U/W7I/]54U\7]L5%4E/U\T^'L^GT6'UI(MVI
M2])E+-1'FXW4&UZ:38YW5^01=CNO8D&JW7'AJEK;^W;QEZ$R06E5%_?!9$;; MO9+RH2I$0*8]*8Z+R2B(W065)#M(=-LRFJG^A-E&7;J4S4YIH<,189>&) M"E%'W+[I]^1F8Y@6H)
[%0K\WS"F*5>YE9*,WV5!Y$V[WEJ2]L6M5N[HI4SB3 M>2@C"]X!P\1>X$A=-5X]T:-,59>R<];?7J)YQAQEF2E:_())M&<50$TBHQ:I*RPKG3K>U7#;&XU*CK%@M2V,&S!
M>NUI+39F2&Z3(2PL.BNUJ0 #J \$[UT(J@(?&Z"%S(L1 9?@I^[%3H?[$*E* M?@?7>$Y-Z,K0T5 C&E$O38@F4QMN*6ZEVM"G$UV PDC]3HJ0%>Y>Z1J/[Y" MD;5;B&!%!F[TZ$)J-I^HW&71<5
BX/6[22]J +(%#%(< M;H.KZ? P-1''V4:0H\#ETZ;BQVJ+[1 MG4ZN;)'%G*3=8:!FU3D0*M5TSOP+[3(5+&+Q$EK)(-)1X$/CPRI,@%G:!K^_=#\D'80<:Y^G/+.WQLIR#93992 M!^](CDB925XBM2
M*HEO#*.*CM$CI;5W^?.O NF.1Y !*9KC;TOP M>R$*'KOTF*GHU:'AX;])-(YA20VT2/1UFH$ 180T I8EI4ZQE.EL8X96J+?I=MB:@<;&&.D$^CBW9=G@$ 0:A3@'?
A]B3#JF0A;Y.H@>S3J$<<_XM M$/LAI1A.O+DK*NW6C%&-Y;YB<.?BS>7@3E#2H1QP84LUR '0P[LY]U\\K-[, MMLIU2A>%"HPI\M&Q M19D'-;OHC%4Y <%?KZXN-[N7OZ9S:?"-
U0[N64K_\+X,^"=AIJ8PL@:,' @ M)1 0]F, M[H- \;Z/8M$E%C&QO?_T],T-*6GOM"WHXH$AW+?+YYF7 M]^[VCIS'53LFT:'S6M3^]M7>T=[=[^<%[NZXZ M>G!P_K+5:[,PWO'ZE,[S@3^LN8V3SXHT
M67K_B;Y+T[*FBCYUOTF5(MT%@G_]=WR0Z3"\\'[EPG"X="!']TZ*!+M MUT+[^'!:WZEWWG555&]<:0N:J&I7*L1U2EP<"VOM[-]:TA@O!Y+@9#OPGZLK MO"E+2T=FZA9<]8U1*^NT*RP.TBT
6= L=C U$XN5;2,2KJM4@RRV;6V@@%^9 M2').Z*MO.FCR]5?/CX\/SZZK3836VJE??[V,_/#H[%MF 5C$I0CUS>Z[[^G M&SGP)AW(%,1H\<[VG&:2GI^8&XE+D%#I6*E:X@&(@
MNJA=YE+^5F[6),%-"Q[6Y=P,-G(%A7K7QM@=DDR3&TUB9Q'^;!F#>190R!5 M>XU0;/5&+Q$EK)(-)1X$/CPRI,@%G:!K^_=#\D'80<:Y^G/+.WQLIR#93992 M!^](CDB925XBM2
M*HEO#*.*CM$CI;5W^?.O NF.1Y !*9KC;TOP M>R$*'KOTF*GHU:'AX;])-(YA20VT2/1UFH$ 180T I8EI4ZQE.EL8X96J+?I=MB:@<;&&.D$^CBW9=G@$ 0:A3@'?
A]B3#JF0A;Y.H@>S3J$<<_XM M$/LAI1A.O+DK*NW6C%&-Y;YB<.?BS>7@3E#2H1QP84LUR '0P[LY]U\\K-[, MMLIU2A>%"HPI\M&Q M19D'-;OHC%4Y <%?KZXN-[N7OZ9S:?"-
U0[N64K_\+X,^"=AIJ8PL@:,' @ M)1 0]F, M[H- \;Z/8M$E%C&QO?_T],T-*6GOM"WHXH$AW+?+YYF7 M]^[VCIS'53LFT:'S6M3^]M7>T=[=[^<%[NZXZ M>G!P_K+5:[,PWO'ZE,[S@3^LN8V3SXHT
M67K_B;Y+T[*FBCYUOTF5(MT%@G_]=WR0Z3"\\'[EPG"X="!']TZ*!+M MUT+[^'!:WZEWWG555&]<:0N:J&I7*L1U2EP<"VOM[-]:TA@O!Y+@9#OPGZLK MO"E+2T=FZA9<]8U1*^NT*RP.TBT
6= L=C U$XN5;2,2KJM4@RRV;6V@@%^9 M2').

*M)SAY/$F\FC2U5H"=PE_1Y+GV;@%*-GUKC !;T19(&Z$3B47'%?FQ_0)/8EXL M. 6NRG.12N^DJH1OR$LQ,%/>E)+P2"ST(#FKRG$$ARA0!FZ%&B^&N^CD' M3@L(7+1[-7Y/N%EGPACJ.Z1ATH7;18RX1(N5--8%A((-R2[=_+ +2<#JW 1 MFA+<5!$X"HM>3:1>EBR|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|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|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|EQ5V#*T6O[PLP.A.G"=DQJ3U;BUQ#TW#@1\M M=#& OW>6"VB:Q WF9W#W+U!+ P04 "]@ A9_FOK+F8$ #Q#0 &0 M 'AL+W=O1T[70CZH M D"33576ZL(IM&[.QF.5%5 Q-1(-U+BR%+)B&G_E:JP:"2RW0E4Y]ETW&E>, MU\]VI:FEW2J+:JF/Q^!:587SB>LR7<\U6A#6$|FS9L!7/0OS5W M$O_&.Y2<5U K+FHB87GA7'IG5Z'AMPR_XO^T=J.MBR8@@^B_,9S75PXB4-R6+*V MU/=B_0EZ>R8&+Q.ELD^R[GB]U"%9]['2H>F'4H.)UJV:;W@][HE[1,#O!7RK M=[>1U?*::3:;2K$FTG CFOFPIEI5(7)BAS+7&5HYR>W3!9\WJE2 .2S LF M83K6B6M6QUF(<=5A^$=TZ>;T2^%D"6HL3RQ 7'%=%(R$35M)K9 MRA%+4@K5B6 %|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| MLI<-A#7'A>Y$OJ/N[C.7W3'^+_;N,O2%R15''4M8HBAVD8E#9'?!Z'ZT:.RA M?B$T7A'L9X%W,I"& =>7 @]^_8_98'?+F_T)4$L#!!0 (#V "%E>]#]5 MW@, $|* 9 >&PO=V]R:W-H965TKD!+C=C+_+V@D>V6ALK"":C MAJY@#N9[,U,X"PQMH>M:R1)'T#=&(<>]?1U4UJ]|L-?S/8Z*,QL98LI'RRD_MJ M[(66$' HC46@^'N&6^#< B&-GSM,[W"D53P> [J'OG.UHRX)JN)7\|ZO,>NP5 M'JE@25MN'N7F*^SLR2Q>*;EV7[+1]B:Y1\I6&UGOE)%!S43WI]N=\XX4BO W M"O%.(7:\NX,BV8$SU6DC.29L4.9&X2I#/3.9MTW# ;UL M*">W5*_)'<9)DWO1!1P]-PH, 'F2W!^4.J*8#C7\#FI, '*3)P\F]27)06CHEG),#$BE"!N$Q04;J9+32,,-!7 M_]DQ=PX%'5+2AMF P!.+<,5,JTY0S:*!/TRCGCSUHRCRTR0CU^7/EFGF@BB7 M.Y) .& YZ^-%F9_'A3_,D_X2^G%8^`D^(-,M]))IL(;JA051A$MT|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|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|>= M;_7[AG#VQ;>EW7\(XNL#WW/_\82_0\OAQ)@&/!1S@&$<8_/+DFS& 2AQ.(CC M>3NF.##F&)[!,|>XQ%$D"N*#].3 EI)AHD;!O)QI[DZVXLM:7^(,%&;SXRHV MCB2=1R_CD LY%\?^%<7),!"JI^H^P2/2B!"R0#ZB85;@+YC0,A0CYT&0/*() M;*=Y,+IRZ"IG.;E?PQ'TQM\B&GPF[CK7;6-U/&B\E5_/ <@WM]R_ESHFQP? MH VMH1J&ULS5A=<]NV$OTK&*63)U6? KIT/VS.)X]NDT[0>Q[=YALB5B D(M, !H6?WU/0N0%&733C,W#_?!EDCN+G;/[IY=\71KW1=?$ 5Q5VKCST9%"-6K MZ=1G!9723VQ%|D_6UI4RX-)MIKYR)/.H5.KI8C8[GI92F='Y:;QWYS::C]H;UVI3!+XQ/3^MY(8^4?AO=>5P->VLY*HDXY4U MPM'Z;/1F_NKM$MP;;?OJ8GG%[:7 M6>WC?[%-LHN3D|:''H*+V:/*'P:A47T.QT4O7PG@SP_M=78K'$0#&G^)H49M.*<,)^53<'BJH!?.KTG+0+FXDB[LQ(V3QLN(ES^=!MAG MJ6G6V']j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|L&*[B =;A<&V+AER6E<+BQ;"HD;%8'*A6R,.@L@#8J+BO0*K91=9F[MB/$T<|>RWA,9'_Q"=I9P%-K+AOG6>6+G*W25RX\|LW+EM#;6U& M)AGH"Q)O#25P3+HN2Q4&B1PW<"\5DJN;8.I_JGDIELYV_'/1(_<(PW+HN]_I M17YI.T3/I=K!*$LIDL-;9WN15)(9_A=(CE96C:8\5[#."DT M[KO1'(TY3$$=(JS@.3L*QC[#3"\I3ZELN2D|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|*^*EQ< M$9&0-[(R2TU>504O^OP34*?5*6AT>AD*O#GNAJ3T*,D\(+H$7EAN\?0R@M_ MRQZ=B&A8!(;&<[UF.;\8 ?8U5W=|=/G]=W[BO7A$P:A5,'I, ^M,4?%S$6VDX M\3-R1@Z$D> ^_FP9> ^(+\8\G)M5RM6?5 EDP3?L?*FAE>0$BV/-SQF*62]6() M5T[F E9;$#F'.Z$A%-=2&<*J N!ON)4@@BS9 :I%0?9=YS,.*]()07?R8-I. MR#ROE6HX-K(N"Q#YL1; R8> 17CD,262M2")V74M=@=2(JJT\N*RU+45C5

'_9H+HH+ T> M.PD1=D>M%GF_KCA"0T:8H'PM8W%RJSBG27,34B:LT;3)!>'GA/0I9O"V=7U4 MA/(QMRH4ECEJJ1 (Z+#@W12E/I&E9O'+/_GZ?145#0]X<*9G*5!8N2TQ]+P MV;^T1G5#KT D!>80L!]N1D"&C!(JKX+.C#=D)ISAQ(]0-NE:Y+P^Y M#ZTHY,,8)O4XD6(HEO:X[XO.?5_L];F?^HBMT%&V;G=5]TV$IF+P K5WCFK; MA)(_EN&9BH[3)U="E: TKTH:2(5P)Z4 #O@%%\(4U[*#E U9A/T=P8&0&-3* M(-O<45V(FO\&A+@M0PTEF4.:+90X0:\V0P3K"N]EZ+1CYQE6 F*'98U1DC*$?6[ZTEMM2Q]V(3K/ZJ)=08, _D=TR*N,"R!(\ M]+]C<<=[SG.LG?#K,;1B7WP1*XG.Y@C5CS:FE*Z/0EDF_^5S1J]!.%/&DB ME M4>@)HXBD@$"2+8G9K;*\|'EQI&$=IB+2T+DT3!XNB&Z(ZD$F=)YTZ/QO[M2*'=27%.&"B"ZR8<:6RBR:SR\)$KB[1M4!?$3FC;*^G)#G-_*G1G.$"^ICDH&:%16&.0L%66C]GS(9/M8 M"2%64O+.'Q4;(T5)]S "+#]QK1J44WU%WH%P73M[SX>$B)?.;7C6'@K%O%5= M-\G#<9AO$Z:Q@Q3K. .&NG28=D.7@;311GR|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|\JGT9CB.VS+.2ZYRR#2YY6DXFZ8>& 9G?[6E5C@$# (9A:Z_P<#/; MJ7I^&J8$DU"I*?#ZQWR4A;C,ID<=DF\HAFG!E4#&$)V+Q0DN2T2CK9"O M0&X8#7%@/'J-,H9/1X/?+E7*K?D76CPE,TWX&5/WM/L5V$7X[5._//R${(-T MT(9'R[K"UMGT^>F!<.%76>%+8VO^)=32-HVM^',2&OIR6H#W*XN2.WZA [K? MQIW_'U!+ P04 "]@ A9R+TA9#X# "A"@ &0 'AL+W=OE[@5X[6S7G:R*[5>RM8(M7L.5(KJM*J:^7X"0^Y7C.T?!-=^5Q@K<|;)A.]B ^=)<*=*RY TK!*Z@6$51 ML%TY[_SSB]C:=P9_<]KT9K8DJQ*^:N-K [.R*#B=?]G]X=[&#EDWB,.P<$AZ'CW@3J6? S+#UDLE]T19 M:T2SB^ZHG3>2X[5]E(U1].7H9];7< =U"^2/&W8K0+]9N@91K<[-#P@7/4+P M"$)"+F5M2DW^]@LH?O5WDI0$7A"=P N'(X8=7GCZ MB',GZQVC>4=;#^>Z83FL'$QX#>H.G/7K%W[BO3U!*QIH1:?0UQNLKZ(50.26 M%%RSW4[!CAG 5'^4[VG$UR^RP O?DQ_K?U,]@%^R@>|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|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|KS/X08O M[,QSNS:N4>,$[]%^- 'Z10]IU=Y/FZ6I=4LZ*E_0H%Z8I*^<3K14O\;),, M5ET\,@DU T%0L#8HVF6MW$4EUK7>ZZF$U/Q/:NM!A]A=|TFQ^;I$Q_ Y0R>|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|16?/F]YE MOH07!3Q-/RDZ%_5MLMM731&@$_-"M MOC9.,P^'8? 0]XS0T"0$7NI!DO5S@)%!U2>QR7WHE|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|/L$\']NDI],4MGM:J ME4#T"O_T7@F,E>A.2;E3(D\K.9WKR:.'1 EUNDF<3T MP-MOLW\E?YUOO\:,[#9]49:@8"6<'5P>DX*F+*>3+!G9&6.&B5'8="!\[+"$HP98@UEW;=Z24K?*];UP ML XWR47? 0''Z/I6N |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|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

*-/3Y>H<-@P2_Q6#8&406-[-1L:E!=5T-)!B0:311C0SL*Y:.:R17<',1 M$RUQM4 [/;JDDA=\KD@%DDQR*H$$FO9!6MVXV OX.>:=TCHNR3P@V@/7MAZ&UJ]*^]W>5D@Q'M MQC"OY$15-(6A@\| @7P&9W3PH1O[IWL81BW#:!_Z;(*O+JL9$*#C54)R(12 M1Y:T>HWT?MB##TG@AZ?3Q-/4N038B@Z"=POV;M3 M%PB1VX_L;B^(=ZR$O9IK0)\DN& [_O1DEWE\UQXH9Q[IV.^XN)I3;OO/V)C^U) M;H28W_&WX]#O]/[_";K'6X)NIX\!?5&PVES=/\#:E=:|C2\77_G<%A8*(P*3 M3_/[MM*V=CEKONQ?ZDWAF(V:"NZT4]02P,$% @ /8 (6?SIE1OP P -@H !D M !X;"]W;W)K&ULK59M;]LV$/XKA#H4&Z!$[[*< MV@:2-$$S((,1;^MG6CK;7"E2):G8^?<[4K;F1*Z1#?LBD4?>P^=>>+S)5]IO M>@-@R* [F0D^]C3'-51#H<@,UU9>R 8$K*ZEJ:G"]UH%N%-#**=4\B,P+VK* MA#>;.-EF.L(A<&K]&!9@_FKG" M6=*C5*P&HD9D41,%JZEU'5S>IW>]V ,E@JX &Q%]RE/*;G3Q44R^TA(!#;2P" MQ=|SW +G%@AI?-]C>OV15O%X?$"_=I:C+4NJX5;RKZPRFZE7>*2"%6VY>9+; M+[^W)[-XI>3:?> ^_EWNN2@?YD$!D^T>D&Y1[_IT.,?H.?D40JST>1.5%"IU@^0:4\W M/M"]B<|"_MJ*2Y*$/HG#.#V#E_3F)PXO^>_FG[*Z TU/@)I[=*4;6L+4PXNB M03V#-_OX(U.&U3[2;I0-)15! U!G8 MS]/L%1C&NS9:'9"1Y+J1G$OR"!4KT;-?)*\P7-K'FUU>OHON. Q="GR&4@HM M.:OHP;-/@)!WVE #F-*&F9=W(*9^C/D9)0GYVOF1<$;7C%MM!9O:/R#Q5X:P M@X6#_,3@1'Z6C4X<_ 3/H#!B'81N\ 1"J[_P+;&%8] P#/\%N7U+ KJ[=%JW&!RD3FG8@B.LMR/LB*RVIBC8NS87'I<^/4:Q 4UJ+7K6#1R;X7IGO5>VC=%UTO\,_VKJ-ZI&K- MA,8"L$+5\'*4>41U74HW,;)QG<%2&NPSW'"#C1THNP'75U*;P\0>T+>*L[\! M4$L#!!0 (#V "%FZR?M$YP0 ' 2 9 >&PO=V]R:W-H965T&WJ:W:AM4/W95'9D|'"N>71 M>&RG"UVF|M 1=06')N5 M*_)*7|:(KLHRK?\ZTX59GXSH;$NXRN<+YPGCR?$RG>MK|7Y;7M;P->ZT9'FI M*N%]"M5Z=C(ZI4=GTLLW K_G>F*E^0|N37FF_ XDIV.B#= (%WKJO(84'G?Z M7!>%5P1F_+G1.>JV] O#]ZWV3XWOX,MM:O6Y*?[(,[G*.E-N%H,%95ZUS_1^$X=@04R>6, V"UAC=[M1 M8^5%ZM+)<6W6J/;2H,V_- *XV[&XO/))N78U<'-8YR;7>@XA=NA+U2;81VK_M)KTMM#TX'CO8P'O&R5B&$EODZ.[#*=ZI,1%(+5]9T>3=Z_ MHXI|W&&BZ$P4N[1/KJ'NLE6AD9FAU%KM|)"%NW6\? O:MKQ"GN2?M8N+5"6W^5-'}AR|A"/..9)C*5D M 95%,598|\I3E?18,<=*1)A' M,;H"AA;ESK]M"]:8*4DEIST6&!BHA@&<|&-|\IZV(0H\$8QA03AFDH9>@|=, M2"R2: ? 69(]SYO%K76CYI0'IO7^?U_2#P"<@/@ M/N5*W^EJI=&L-B72]I7%62Q[=BZ@'67[LV5(05$3@&=#T0)<6*4AP3'A I M U$ N-12"4$QT@<U>6$4Q%A42LQ['*|2AE6 Z]YP9[Q%%_^Q_UW!Y' M,&/5$.)[#M4W!?R@_<)8>_!_@JA#/,-10C%-^NT0FB21F%+1XW!H6[ZB?XB M"A&&/AK)E_;G?<8\..#'D<*#Y[^EOL2$AX+TE^AL,>YW&#*/I6-X'AA6"]* M&0]!!EU>*,!96%<.6(Z)@O32 >!@!C@4">MQ(BQ_E[WJG\X864%B33@8"&#>=??NT->+0W MX,M>X,5;8>/1$997<(1]V)9 |V,I=_E;@&5GTO;0/DT4EHD|"&@,HDRH#"BJ MF91"BZ30QX(9|0,,VC$< M?K&*>QP)0P'4O;+,8+9-8'F25[80@6,(IS(0;H:.%)BZ*B<|-,9)7(IL\K M?0S(NC@4TA-GWOA628BKXXG%'7\DH,60 MC 03HA[1*!RG">E,&9K]Q|$M (R@|^:NPZ*I656NO1#HJ-UURFE[B_@WM[% M?$WK>5Y95.@9+"6'$4S]=7N_T7XXLVSN%&Z-@WFW>87<9[KV L"?&>,V'WZ# M[D]I\@]02P,$% @ /8 (65N,.!?% P $P\ !D !X;"]W;W)K&ULU5=M;]LV$/XKA%H4&\|&%*G7U#:01F:(<6,I.T^ M,]:9%BJ1+DG7S;_?2;(5NW+.0]?.[(>^P;K+3Y:..< CGRI2F6' MWMRYQ:GOV\D<*FE/] (4SDRUJ:3#H9GY=F% YHU35?]N+!2,#;'+]I+F_AQ*O1IZ@;1N/O12C^0PEC5&UC' M$!5X$UW:YINLVK4A\\AD:9VNUL[(H"I4^Y1?UGG81=">1*.3!@;E4KG % M6/+:NWK"_C[P'6Y4+_W6(7Y$IGJ*9EH9759Y-)!CE>QE&H"I#GZO;0/ [\XEG(F M7I%C/_&HH#NJSGH#LB27UB'USC:>WJMB4DC56<[>7-V.NU%W$3>&Z^N+A|'5 M^.QHG"^6QH!R1%/+N23/29 (FK"@6_"R)53N#3LEB@<#E*%,KJQN%E;U!XSCM63-!,]SG+S<'0T]M9B_QCE8;Y5"2+*8]YSB6C,8YH$K#>SQ>^Z2_E>9$Y%D-" 94^0]\<("? PDP<^% M>RR&ECLOO V0\YHE@0T2OLI",J"D(HH_J7YVE0F_OU\S5,H+K#6A=! MHYKB?ZN:(]4BY#L994E(,YINV$)4US]KFC&6/!)LE6[?:ED:88B_CV73[" H M1WWU.)YF_0- 02P,$% @ M/8 (6;]YE="";!0 CAL !D !X;"]W;W)K&LU MY5EMZS*2!Q_)N7!6EDG&CE*5C1H@89S+)1Y/3INVZG)$JV]1)KY+5-59 M)LN/%RK5B[,1':T:;I*[N;$- X\EI(>_45)D_B^L2GL9KE#C)5%XE.D>ENCT; MG=.7%|S*-P)_)6I1=>Z1'[]", Z49.XQE)BMUJ=/W26SF9Z-@A&)U*^O4W.C%KVHY'L_B13JM MFG^T:&4];X2BNC(Z6R[#!UF2MU? YL)RY'CD]=BBPI0)K &X--5Z^ED9.3DN] M0*65!C1[TPRUT0;GDMP&96I*Z$U STRF[:Q2_]0]- ^C[^OXK=/O.SE)5G9R. M#>!;]7&TQ+IHL=@.+(>ZMS,*W25QKO>U!^#7VOGV.JY" [87\+/Z."O-KC(%\[MR/>A3Z:PYN(Z54C? N/O55DI!!2(/]"]2!,#;;;4+9'3CTC&?P-!MF>Z'<5^ M.|^?!8RXX]"AKQ! M0]@N0U/JO$+7,-I$UQ6;KOW30;3;>R,W"QG9$!_%_2- M*G0)4]3KF#;S.FUFM:]TGU2@<2(MZ3%H)@GS.L&,_U'0M/ M8-?UL?#=DUXOQYOP"ITVI)YINO\T:^CE8U.RPKYI--F\3QT'L>)37@R1=*X[E,SCA=@'L*/=-/8$G- #+L24<\S"_JHXU/7=0%0* M96WQHFSQ\H/O7+_KJD+2F#*9U<:6<\AH%+4A:]?)N4YC|*@;7A=SWZ|KC2WE MQ0Z)|TW/Y8D# R*=U2U5*VM]=9641ME"^8D0C*/49RDM56XNIX.$%I@#W8D M*L30%@JY)1'8^,$@H7T?DR!HAUS XF\| S;.]1U MFCS\W_D70 4%A083._G7D?C2_'.Q[WF8N$, L,>QV;@C;]!A.J)#77.'_5_Y1_M)_2W&P;X?M@,;)VM?BXF7G9(AW1AMZF^)0]V'|_[_L!V"ET4\IXW4(7!3NI" M=;-A82'+4MJWZ&WA$'N^"TFN7Y, <0Q<)L>\.I!M;I> ^9], UNDF&7OSZ;!B* MY"J"V^!_; 5QG0K.EZG@<(}KA=I4!A9+DM^MVZX>5!F!PS#R)%(:$EUYJCNB MTCRA\.TS_ @QQWT:X8^ ZLP96!W+%="5\QQ"UFZJI??](- HK9<,,^AKM*P[AE#[G88"T+F=NR'&'BD=/=V>G8PHK0!O MX*.==;S^IS"0YP+[O+\BF4N5HY!!F'$(?WOZ]NU4=6CCE< M#'V)'W?.2#)5WC4G0; !V.\> [7')NG5]V'3>GK$\BK9= :D[5+:C" MBZ(W0F5[^M_^&%TT)RX5;8S.FMNYDO#"8P6@_U9KLWJP!M9'<)-_5!+ P04 M "]@ A9E]%_$*D(!*:P &0 'AL+W=O $W!XDZ? =L1RDC/Z(PSNXF.|;V'Z?3S-_ 1 MR,MNDCV-|^|)6GDL?QJNIUF^Y1ZF[(H"J<"QRVFD1?$D_O;\K8OZ?UM2EKY]IF+S<3?C)\8:OP7;'BANF][=[;TN_4?:[_DN:7YLVRB:(M:)P%24Q2^G0W^<1_=6Q*"A']'0E^SL,BGNRF.2?"^NZN]"5=1$0VISPK" MR_]]I@\]T# LIWXZ_:G32S%D4GE\^ZDIYY_, /[\^AE["$)_PPV:'>'Y29B57\E+/9:;$/^0L22JB_,MB(*X^M_[43\09P6\>*% MJ N$L06SNF VMD"L"\2Q!?.Z8#ZV8%$7+.86+.N"Y=B"55VPZA0(_(6"=5VP M'EO <| <|QXTN:79V=V_/%Y=*CKN;[^[OR|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|=V"Y)@[^JC2+5T3\L77OX0S4)JLE038%J M*E33H)H.U0RH9D(U]!9:;[?,N>I?)PK&#W6@V^BBM':RG/6S\8/)\)NWPF-&_ M#C1F1'L.Q_9&RB(U=:0@-0FJR5!- @6HJ5-.@F@[5#*AF0C4+]ME0S8%J+DIK M!Y-P"B;A?[\;,AQ<'4S"B!EM?/HU'++# ;3C5O_(/O']":5&OMU=2\\Q8/=$H%JE031OS<.C0 M*0VH9D(U"ZK94,V!:BY*:\? (J6^6'VZ\5C0\V]6I ^UXAFHR5%.@ MF@K5-*BF0S4#JIE0S8)J-E1SH)J+TMH9)IPR[+V.Y_^R/H*V0$,U";K)4$V!*

*M;BI4TZ";7FOG*Y7Y6EBN^24O=%X[@DYL0C4+]ME0S8%]+DIKQ]"I$5IX[S.& M&?U!-_]%;%VIAFH2 M5).AF@+55*BF034=]AE0S81[%E2SH9H#U5R4UHZV4T]U?G$HVMR7F*;9+MB3 M/4W]/,B\;>\GA@XS5X<34I.@F@S5%*BF0C4-]NFUQ@NM=^168G=!A9S4A&H6 M5+.AF@/57)16I<[TI.PQ4;$P*D[6E!$,<2L.D%+S M.JW3B:G.,F5[Z3:(,Q+2IYSD;I;YXCVM3MQ476')OCQ'S6/"6!*5%W24V]"T M&)! _RE)V/%*,4%S^]SI?P%02P,s% @ /8 (66_M?BUC! &1D !D M !X;"]W;W)K&ULK9EKC^(V%(;_BI56U5;J)C>N M4T"$LA4.[MHT+:?36*(M8F=VF;8D?KC:R>9+++#!P,KS84B"W^?8.-'/$S,Z M4/:5IP@)\"W/"!]:J1#*%HVWS.$4YY ^T0$1^LZ4LAT*>LIW-"X9@4HKRS/8< MIV?G$!-K,BJOK=AD1/AA;KO5^X07O4J$NV)-1 7=H MC<278L7DF=U0$IPCPC$E@*'MV)]ZCY'K*$'9XF^,#OSH&*BA;"C]JDZ>DK'E MJ!ZA#,5"(:#|>$5SE&6*)/OQ;PVUFIA*>'S\3E^4@Y>#V4".YC3[!R9>*&'"-4#ZBI>3#-> ,@>'NJUC@7C/!Q!CDGU"; 5-^)(X'D7 M!%XM\,X%[@6!7PO\6P6=6MY$_Cl"X)N+>C>&]%7"WJW"QJUH\'N&%X0#&K MH.QNE8XREP$4<#)B]'T1*F6*<5+7(MC2 28QC'=$X')#]OHAE.../@0(%QOG\?V4)&5GH[K]/.JBC>A2@^>*9$ M!R\s)$%)BS[4ZWO7] Nl?GA-O]3K7>|:(-(#O+X&8,N<-8GSWA,W\[3$O ;D M ?C.'!!SO [XL@[AU_;,C/78YXADQBWQ/@ R92+MQ9*<'MGO,N4|">&5-, M1SM9,D5;[O74 ,7-"#5]6]Y.T=RGZ.=']/&$WTQFO|1W+N _[?,-8FHN)RBF MA,N9FT"!$O"'"8 9"+N2)-*",IN;S?Y>',=/&4>OI(R]@C,:67# Y8J_(FOSV MB]MS_FQS8 7KEC"UEKY.W)']>NRNEA;]TR9A2Y/!:9/%]2;+ZTTB;9.3M'2: MM'2T:7G*'XB946S?'?;]X=G]FFOCW9F>P"0LO'$$ M"Y-!ER9AD2'8B5.ZC5.Z-TY@A@K*!-QDZ+WRJ0E[N0C.M.!{9ZQ)6& 2%G9_MF)W^E>-,AEN:A$6&8"2.ZC7.ZFF=]8*X8#A6B]$<|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lE8 MY?%[M6=*[IGDV]4,FKLE7C!$7>+H34W>_.70K"X?DI=B@O-R-5!/04'X$QG, M?OO%&|N_FWR!A(6OL @2%@/!-#^'C9]#&WWV0'(]4G1G.4;7#PCl;Q)OIN<MM7+Z.KN'C2M8^>|[FIT&KC]RI\Y3U|/CBD6038N!8)H;H|:-D=6-+XRE.YIE MB"HS*%?O;XDR)HPCS4KJZ|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|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|C]'O4F'OU%>98+D*,WVF?H C7D^M*?'2C;=3+-8IEF@2Z^7![_+@ZRL$OLY\Z!2+=8HEFL1Z^0BZ? 2O+@0-TSLY MC'Z@SFPP.+7+QT#/\BTKQ,Z@$##P&6G;@.Z[M!H-",(+$.(RBR _&"T'8.1Q.M.GQ%]UW>;+XMD%QLY46GE+=5>2\5D\5A4O:EFU&G6*Q3+-$DULM-U.4FTE<< M(IWYT"D6ZQ1+-(GU\F'AAXLI?G5Y;*FG'^O0#0(GO)SZY0@P<'S;]P87BG@$M;'D1EH5D@$S&D.I*$6%W4!{,D(:E +:I^T6.5G17BN;^VJUV>F7NA,;K%l8 MYTMK9#U6/6S=)CW(-PWP)6&;K.0HAJ4TA<\("6(?4$L#!!0 (#V "%G1Y%/0N@, ,8 9 M >&PO=V]R:W-H965TY,!HB8Q9QO8?OO;23:0-!O"==Y XLS\G+_"IB9 M';CX+C< BKQD:2[GUD:I[:UMRV@#&9-7? NY?K+B(F-*WXJU+;<"6%PX9:GM M.<[$SEB26\&L&'L0P8SO5)KD\""(W&49$S\6D/+#W'*MUX"9+U19L .9ENV MAB=0_VP?A+ZS:T[<9)#+A.=$P&INW;FWH3LQ#H7%OPD.?]N;C[' M<\LQ;P0I1,H@F/[:PQ+2U)#T>_Q70:UZ3N-X>OU*_[L0K\4\,PE+GGY+8K69 M6S<6B6'%=JEZY(=/4 D;&U[$4UE\DD-IZT\NDVXEGEK-\@2_+RF[U4"W'B MH#G=#E[EX+4=1F\X^)6#/W2&4>4PCK#N'(HI-NE]F+A*%,LFE^(,)8:YJY M*%; |-;KE>1FHSPIH9|FVD\%CI"'? ?D _F01DR?<@["XA[R@HEJ3R M_B[C84<5=U%RO3>X/KGGN=I(%N8QO!W^M-]_TN-O:XVU4.]5Z,+K!7[9 MY5?$=_XBGN.-.MYG.=S=]Y+S>[.'_WOVOF\X==3]@N>_P:.)9.NU@#4K$DULM-U.4FTE<< M(IWYT"D6ZQ1+-(GU\F'AAXLI?G5Y;*FG'^O0#0(GO)SZY0@P<'S;]P87BG@$M;'D1EH5D@$S&D.I*$6%W4![

5/(#^NKF3./,;EIR5P!43G$A8CKQWPW4P)F8G"R&^FDU*@WP MR6%)MX6^%_OW4.^G;_@R42C[2_:5;#SP M2+956I0U&"TH&;_^Z6/MAP-&)P!A#4@O!80U8#H.>#M&4"O!O2NU="O ?UK M 7$-B\U:5 #!C98E7=M:%*J:3*48D^DD48V,[#QM6B,",,F$Q^TQ*\,<3I)*

*M8:')7^0+R))\$10K0GE./J&4(F)))A)RILG+%#1EA7I%7A#&R2TK"LPC-?0U MFF"(_*Q6-Z[4A6?41>16<+U69,ISR$_@4S<^OH2?NO%O+^%G;GP07B*8NPG" M@8/ Q^_U$0R?*

(C@.G8RW5'9(%+PF83>,"'#-]/<3=DW<+!^W"%FZEB4\SY)>_MS](C7Q]2\0+%[_-L4S=:-L^M9'/Z9M[6SHR!&S3&,+'WD.(:G3E.%_MZIU&F5?]1FUH!B,/GR$%<@=>\N>

[#>>[#L]:5\YQI66 M6ZRB-.'"3$DFRDW!*,_7UV]1C>CF(DBPY5,[$!B,48DQ:+IE%>=.G_W<+9) MEE9D073@PF[G6V65%X)K=<5Z51 ML]KT0^]L&_!L?

1S<3]VYG^:JLG"NFF%5P(I8(F4WSV01@"_+X703Q.CH.D>DY]02P,$% @ /8 (61E^]A6N%P M2(! !D !X;"]W;W)K&ULO=UK=]N=Y^/+O+_M?SL^WL[MTE6S?;^[3 M=?$O-YMLE>3%7$I/;\^U]EB:SW4GJKY;G=ZXW.5\EB?7:0B?>YZ^SBP^8A7JI6]RZ3[lFNZW'$\>-8_>_K$!\7M75Y^XOSBPWUM%K63#*.[_27V?%W\Z? ME?*

EBE:ZWB\W:RM;CV>7_5_4=%*NL%OBOQ?IU^W!QU;Y4OI8;+Z4?Q'SCV>] M87]7+92D5^_'/"CU[WF:YXN''3[]_>_'%B_DCV:97F^4_M%O/*

*[N/9Y,R:IS?)PS+_M/D:IM4+&L;>;+/<[OYK?:V6[9U9LX=MOEE5*Q=[ML%[L]_I/_JR^$ ON']W7?\?/^SN/M!=I,\N?B0;;Y:6;E\ MX94?[-*P6[_X^5VLR^!^SK/B7Q?*

%>OF%F_Z16S];UUGZ\W6RF%N7||=D/4NM MR]LL38N YM:/;IHGB^7VIP_G>;'!]Q^ 75_L5[^_8YPGQG)?WBWOE=UZ

M;+Z>F[U>KU^O\N.&@/,X8O9&AFW'16,/U7&?':WBR+;ZMS\G/2($5M)+N- M%+?X&6GXV09!MIV$92[;_^FL)-8BZ)>23FDUA 8B&)"1*+ M2"PE,4EB"L*TM_^>TSXPZ1?_2+*

*(L*88H\XB?DD%!82&)BCTUV6'G!ZO%B^-X9?#A_/,SSZ4*C M]Q-]F?ATF=[!T=%\G0A^[T!U!=2T.O38C5ZCM7(&*O]6'B[?=B=T%]MMGEC*

MH(Q(UT"1F$MBWAX;'7R[^H/B%,_IZ]\QO^5R ;ES8<-&I\YX-![I&Q7D1B,2 MBTE,DIB","V"X^<(CE^-X+LB>NO'-,O3^<&9Z3OK%!@AR[-YH<';2#\4G0'-

NQ!\Y47RXD]TV06$1B,8E)$E,0IJ5V\IS: MB3&UOZ6Y-4NV=)6(=#-+T_GVG96ELW3QV'@-^EMWS3&) MN23FD9@_;3I^F\UJQTS7.E'Z?ZD3YI^+Z-;]5#-1[4

*U4)4$Z@6H5],:A+5%*7IR3[HHO2- MR;[.%IO,RC?6I[0X8=ZFUN=_MB?;Y?+AI/E,UBA<1[GP;#FW H9]+:AZ]^:@6H%[(:@+5(E2+44VB MF[CT_4!15^;ZTS>?*

J:.M.51S4:6'76F;MY,UP,$JKFHYE7:X2GX:.ST[9/;<&T7#-#]"U%-H%]$:C&J2513 ME;'NJ[8V>,:*7:>S=:/5.;MHOP[5O$K3W_([.,YMBX4"=+]"5!.H%J%:C&H2*

MU12EZ9FMVW"VL7%S<;7_7;L_"S?=,C<[G?.=N)0S4,U"14"5 M13:!:A&HQ MJDE44Y2F'P']3IS[V1>:V6C=#=5<5/-0S4>U -5"5!.H%J%:C&H2U12EZ=FO*

*MBW.VL8[3ZB%G9]D)S^$G-137OE2_68/^\,JO?LU;[)[_:$VN>?&M^4BEG!:]8 M3F4Y3Y3SDA2VW*OAD]0OI<:\DU_X^-5B5).HIEI^*Z?/WX"FGPH[]'4WSC8_*

*M"@V[ZC8\N<0TF9[TO*_>],YZ6@KNE#,H_Q\V7ELL%Z-Z%]"90+4*U&-4D MJBE*T]-:M]ELO/F:'%],0S47U3Q4\U$M0+40U02J1:@6HYI$-45I>O;K8IQM?I@<*

M=IH^/3EW[3N#T>D#U[..10Y_&@S#M5\5 M0+40U0@6H1JL6H)E%-49H^PU#=_MC'/,S:CK96'OID:[O"W_:HC;Z;ZC@!0S44U#]5\5 M0+40U0@6H1]L6H)E%- M49I^$*A[=$[_K:-_*

!VW/H9J+:AZ]^:@6H%J(:@+5(E2+44VBF](T/?MU'\\Q M]&HT7^UFO(/ M9AZ0C47U3Q4\U$M0+40U02J1:@6HYI$-45I>O;K M^I[S_U/?[WQ^/2V@'E_.F(M-OMUB [EN(:@+5(E2+

*M44VBF](T/:UU?<[YI;Z7WN?IZH\TL^R>]90C^,N&;"O($0U@6H1JL6H)E%-49H>ZKJBYY@K>OM)U[=%G*OWY]P7X_S=&?>K*

*M[]0QRVVSCC;W4,US3N=O/7Y/DM]BF0#=]Q#5!*I%]!:CFD0U16E:?@=URVY@ M;MF)=9X6;FYEY3GY?;*86XOU?EKV'Y.ME91YGA4C]9^:$FRVNR88U5Q4\U#- MK[1R!K"\?*

*L15;W(4=W2C(:H)5(M0+48UB6]*TO2XUWVZ@?FY=,UQ_]8S]O$ M'6W:H9J+:AZ]^95V%/?^<+K1!AV]"52+4"U&-8EJBM+TM-<-NH&Y01=DA;U[M:H9UL\F*N' ;E6HV-*

*l;F(=_FR7]^6-^6X_:U;'&?+*UDM7DH_KWXO)7.9EEY M:VU1'3 :1_#FS7<^(* %/%3S4,U_Y=OF]%Y_@VZ'R&]"52+4"U&-8EJBM+T*

M@T1=MAN8RW:7_]IV.8'47\:&WQ+_EBFC;%'.W6HYJ:AVI^11V/ ^SC@0!: MED,U@6H1JL6H)E%-49J>\;HL-S 66+Q|2ZW@_WD]OF MD).EH2M4X;KT-C"7*

MWKQ5FFTW:\O[Y\,B_V9)>67]>%9]\NPGZR_K.WHVYDUV#CC:DD,U[#]5\5 M0 M+40U@6H1JL6H)E%-49I^L@[=X/16WLV [1CAVHNJGFHYJ:-@&HAJ@E4BU M*

*M1C6):HK2]L.S7';O!*X_4*V_>E1WXQ79_7WY_)M_F C]:O4,U%]6\2C-?DO=; M+16@>Q:BFD"U"-5B5).HIBA-CW!=E1N8.USU:7EYL?[KT]M=#M_GHKW)I?@@*

*MW^3)TGI8+UZX5(\6ZU#-136OTHY":Q]'N\U2 ;IG(:H)5(M0+48UB6]*TO1H MUX6Y@;DP=YVEN]ONE_/'9#UKONR&%N-0S44U#]5\5 M0+40U@6H1JL6H)E%-*

*M49J6_6%=MAOVWGI6/D0K=:CFH]'CZ]!:CZJ!:&8H3I^O0C58E23]*8H3<]^W;P; MMFS>E;?@MKN3\?OG47[CV;@9['PH0.MVJ.:AFC]LJML=#>S1+88MMBC0+4:H*

*M%],:1#5%:7ILZPK=T-S%.AJN6W]9_[/)OCPNELMTS2]I.?KPW^^O.W2_9.K MOB[RNWK9QGRC]3E4O+%O[NF56-QP2RK72%:FZE'5TNG^IC7_=IH]I ;]%]"90+4*U&-4DJBE*

MT[-:>-_&YD:>6"_R1;*T"OSGW4E"4IT%5&G?G0*D?]ZGZVWS.^#-?N?$H_6[M2CM\/WI_V-O].4X]6JU#M0#50E03]!:A6HQ[$M44I>FIKZMU0_/C[+[C0A[:MM$,UM]),EZX\=*

(L^]@6H%]:0+4(U06)4DZBF*$T/>-V?&YK[C>]21ZG6>]?ET[!:@6HAJ M4B5(M13:*; MHC0]Z77-;+FBNV:DD?\C*-]/,BZ0W1AIMS:&:^\DLV2:I6O6:K/.[YI./#QT3WQ4 M"U*

M1#6!:A&JQ:@F44U1FI[SNG,W;QWSVIXIWUM[MB"W>;Y=RZVA3GY;.' MW?M@_Y8ENV=AN.6S,OZRW.:# 5K+0S5WV###[FYKXCMV,'I[>T#/1FEJ;S

*MQMMHYM4()QHMTE6:=AO-&3;=1D,WZZ-:@&HAJ@E4BU M1C6):HK2]%#7):G1 M*W,\:D69>5F9FR^VI_+&>6/&T<(Z'><;+<*A6H!]C:H)5(M0+48U*

*MB6]*TO1\UT6XD;%\LR_!&A--5H&N4,VMM(:RRW&HRV^BTUS9M3#;::D.U M -5"5!.H%]%:C&H2U12EZY.GVG37:?VH_O_)^ M&B?C:,KF+71./5IS]S1M]N/&U*-5-*

*U0+4"U$-8%]$:K%]"9135&:GOJZZC8R M5]W*W^?OK*OGH-=O6GMG7:Y>'+FC13=4SW^W+*U?V;5:J;9(W11MQ0J.96VN'O\$GS+W&T MW89J :J%]"90+4*U&-4DJBE*TZ-*

*=M]M&;;9@W0_=]I_0KY]F=&J,.%ICOS5W M=%IC&X\;(XYVV5 M0+40U02J1:@6HYI$-45I6L3'=9=MW+;+9FJVF)&NR48U MMJ*T*^J-[R9%-*

*^NC6H]I(:H)5(M0+48UB6]*TO1DUYVU<8O.VMN?+[5;=K') MRDMUGJ)R1O:4^KQI-/3G^>6B<:AOWK'.1PNT!X=I']IXYJ!:@6HAJ M4B5(M1 M3:*:HC3]D%+7Y<;*

]YLX;'C\U1AMSJ.:BFH=]/]H%]!:BFD"U"-5B5).HIBA- MSW[=JAN;6W7 ;3SS%CH?&]"F7:5IM_&OCK5MYX^.8!/]K(0S47U3Q4\U$M0+40U02J1:@6HYI$-45I>O;KWMZX36]O

*M^]C5K]' 3[-]H/]8I#_@W5N&NB/3B[).T?#Z"OSUCLG'9W6M6' 1T?[[[=8 M)D#W*D0U@6H1JL6H)E%-49]>RKI7-S;WZB[G\T75MUD_[*9DW]P\S]BX/P4O M'P.]FY;5>"X^/CG?*

*[8^GP^.SW20S[G2.*3K5*JKY#5^1R70\/)Z3%=UHB&H" MU2)4BU%-HIJB-#W3=8-N;&[0'9]B?!\M-[1=AVHNJGFHYJ:-@&HAJ@E4BU M M1C6):HK2]&-*

#7<$;3]]\!HI6[E#-134/U7Q4"U M1#6!:A&JQ:@F44U1FI;] M2=W-FYB[>6\X Z_DR<%@]F0.\BOSYKM&'=6\QAE\9=ZA5E%%2W"HYC=\3?K. M8&2?

*7)H(T.V&]"90+4*U&-4DJBE*TX-=%]PFYN?!-9R)?T[O\W27<;MG.^6) M^6,Y>=^>W73!]R]$-8%]$:K%]"91 M35&:GMJZP#9Y;2+5:L8U;S]9:F-DT08;JKFHYE7:X;EUTQ-L?'2K*

*:J%]"90 M+4*U&-4DJBE*TV-==],FYF[:Y6I3G*7_*RDOPCW-@]P8;?3!<:CFHIHW:?<8 M.A_=:H!J(:H)5(M0+48UB6]*TO1HUP6WR21%M]DL>TCGUN+I-[@:?E1S M4:CF3Tl;*

<8/&:.=.%03]!:A6HQ]$M44I>G1KCMQ4W,GKLL%.3/5.=YH M]PW5O.GI[*N-U]M;+A>@>Q>BFD"U"-5B5).HIBA-#V[=5INV?V);=+4%.)?7]N M5LV/>#9CG:.+%M=0S4,U']4*5*

*M13:!:A&HQ]DE44Y2F'P;]XMIT]-:K;5.R M\G.%:BZ]>:CFHU] :B&]"52+4"U&-8EJBM+T[-?UMVG+ ^MNG)$^WUH)MGP/ M:34[^D^-AP*I#*

(=]+JIYJ.97FGFF]@#=+9MAJFP++=9H1J,:I)5%.4ID>WKKA- MVT^;^C1Z7ZQ?'+VC13=4+]=9:IC<%V7M?/O\Y6]S>/?\EW]P7/RYGUA^;/-^L=A_>I&ULK5=A:YLZ%/TK%F]ZVJ2U

M8(.!Y"5(;NY.9C.QUP7C]$X"M2]+(K]?TT(W=>'D@BBY$\1];Z]W< M2SVPIANR+_1'<7A+6S_8ZJ\$H>]C+'--OK5Y,"(8 M'3)RXDFV4R Y 6;=3L0YW]*

MFFWRO;BMDWLMS5MF>#I[3TV6%;@]8/8@$]:*I3Z.R!\#>C7/:M,76CP,J>: ML$],N#/]SEX^>+5S-=F"5;(7[7AKIMPZ#?A0G KN-XIL.1KNG;P!W%^/,+W MC?7./WKR?*

*XU&!=_M^24(@]< !2ARK&?Q?'KHLO/_HB_./I),L*N&,):+QPM M!M>N-KS(S;-GV5159$7GGCFL%)6/U,O^_@O&P3^NE)Y3+#^GV/),8B?)C[KD M1V/]V0?SHR.:\2TH[#: E5#:M16-*

2ERKV%O&,F1YZO^,SUE^YO3+SRFV M/)/8R4[$H^5W50[IV0]27]_F%I#VAKT0FXN]V1BB%-7.@Z$1Q4=U@2(< MAACVRM&!PU$2A+A7CT-<%">3 /7TED,

*<#D(8PL!=CTF7A60T"S=<4Y-;#4P2 MFIHIL&'E@!=/,?3 FP_5'&,,DZOD?XE"*XK#O*Q_B$@SC*.C[^(PAE$:0;?_ MM/.?COK_)#0IP&;PJW193P='0FQ.*

(HQZ6[H8XG'8F!)>]:',437#4/]J6 M#F" HQCBOGG_J"\JJ=S6#:DRAO9<-[=B-]OUO%=UJ]>;OX;3!73,YZ9';EK: M7_)-@WU+Y)9Q95*X,;&"R\1LE6R:UF:@155W90]"FQZO?*

MR9/I]'S@<O-T+H MIX$-T/USR'X"4$L#!!0 (#V "%G>]D!C+ < (3 9 ;>&PO=VIR M:W-H965T4&QO;\!?>'C(3;>*)R"><S/\E-M.E0%9[C>;JMBL0?; M*"E_AK^J*

*W%0H(Y.%&A5@=:W0**]+X%HZI@=%2@S4\4C*N"<=\1)E7!I&_! MM"J8]BV8506SO@7SJF#>]TFKRMLKIQR5Z/JIDOK%/GZU3Y>\O=QI\7H/RQ.K M."N-D(>+2Y:^$)9O+*

*[S\1G%]%_7B9(R2/(6/G(G?1]*_+QYYNOSQ)3^/5^0V MW8IP9V$1CX\&Y6$49Y_(!S(DV29D-"-10KXE$<[^BP?%[:LHCL6VV>60BUW)*

*MP>&R&M8OA]5.#*N3NS3AFXR8R8]N.NH#>?U$4C\4AZ ^#MK;<;C1I*"WCR^(MIG\FFJ*-.O;GMD>YHTI-]XK3RZ(.CU9;O8IGY3EY-NC03Y^^%2]9AV:)=>N M=TPAU M:?*

+4==XCQ582]/HO@EX,H9_ZBY!#7VZ^OPCWX:MXQ^7DFK$P6=/\=L<^"WY3@ MJ!O,YQ%?LUVXI%<#,5'(*'NF@\7??ZD3Y9^NH"$Q XF92,Q"8C82)N26FEF_^0KN>:%

<.KE\/DPA\@A?206@+!6#L=U#L?2'-ZF MR3-EY?(TGT-W1:\4Y]W#>W1T;WML8_38QI3N[;GG?XGE:YS#$V,R;8]I]]O, MZ;>9BWP&'A+SD5@ PEHG[:0^:2?2D_9ZN63YVT:6KP-)*

N0Y<'JX#?Y,/72>R M5#WW/02)&4C,1&(6$K.1F(/$7"3F(3&_Q%1=]F&>C5LJF=)N4C,0V(^$@M 6"NALSJA,_2G M'C-D8)&8@<4,)&8A,1N).4C,16(>$O.16

*#"6H&=UX&=]WU+%?/5K9BIEE8=M\"5DJ_K3O+[D4GTR^DG,9$]^C9HE>O<+",Q XF9)38^F-JHZFRLS]H3(LY MIHW$'"3F(C'OS1,[4O1Q^\#ZR!$#-9*GZHTWQLJ@/R=6#W*

*[7/S!M4,J&96 MVM%R8G(4..B8-E1SH)H+U;Q>1]>'CAF@M';N#KZO5Z6YNV=1R@A/R0/-/VVD MY8*2/.[BB(NX]5EIRDTT:TV: M-?2RLQ)1Z45]!E0SH9H%U6RHYD*

U%ZIY4,V';@%;Z>WZ911I=_K@]>@\L': M#C:TCP:JF5#-@FHV5',@F@O5O$H[7++).E)$ZGAU/GZ&=,BBM'=FF5T:5-\N8 M/_<1?R5NLA1OK]$SS1OI-'(?ATEG)*&M,E#-*

@&HF5+.@F@W5'%CF0C4/JOE0 M+4!I]> VS37[&#V3Y13G9IW$(U ZJ94,V";C9441.2=+Y[_<2IF.]N*&'5A+.?\5C0[->&5#W9V$]2%#- MA&H65+.AF@/57*CF034?*

J@4HK1WLIAD)@_E;%U?6C]84FK\O+!36;EU>I MO O9.DIR$M;G4;I<3.5$FY47?BSO\'177'SO>\IYNBUN;FBXHBS?0/S^*4WY MVY\\@/KREXO_5!+ P04_"]@-A9%:-3%Y0# "(#@

&0 'AL+W=O MD]H2(/"T2Y"2P-,V M[>E5K:.G_>C")4$%.I.=I/WO9QO^DA0HZ_)+P/9]W_F^.O(/?9,_XLU@C2G@I M4;OGH/8%@7AKW/,V7Y].=9AXB%;K:6>L,/AJSP$>4?FWNN1G;-

MDF8%4I$Q"AR74VOFW.6WVMX8_)GA7AR]@X]DB,%/G?/@U5GHS#O2'.,9&;@:C' M#A>8YY1(;>/OBM,F76K@\?N!_8N)7<7R1 0N6/X]2>5Z:HTM2%)MKE\8/M?*

*ML(K'UWP)RX7YA7UI.U+&R59(5E1@M8,BH^63O%0Z'&(R> UE$MSLS3;$YX*F.FT9O(5/D4H29:+ MS\KN1[!!K.E';,&EV!(FMI/*,OT[[:X#^ KHW(M(*8H@WXJ!OON!T$MM*B*

M%L0]"#)W.QE_V](\ 97X [<8<.&%OWA7E,\W? ($P5W6N%Q?[C;(89?5X=G M^+RVZM!IA?G;ZIAQ3N@*U0=#P@/+\VMU:G6)-%5 Z6+8[$) .!^_$AB0XM=2' M3B#?H17^]

*(,3#'YN4O^29-$ER>(+D9WD:5CG:=C%'GL;Z*R(*_BVE4(2FF9T M=0S7$64[E>5P9S0)NR4Q+IAEC_]>Q"=^3?#B;VIECVMU>T'/&IU91+ZNX M.Y0/"N7?0OD?*

$"HVSRZ5_%XJ0.5J4JD75_P>UTGX01U^T'F>OYO_3?TIWK*7 MUP"(7Y GF4"XYUESY,$E3^\ER:)+DL47(CO)RC.RJBS-_)2L^#7/H8'Q>, MY]^_,+,:+9UK5I%Y-I K2\9DX>!=E*

WG^$_4$L#!!0 (M #V "%F4&.L/O0@ -EO 9 >&PO=V]R:W-H965T-TB8$V9+$5Z!HTV':L.$QBU+8\24[:NY\D MNZ8_DV%%Z-U)8\?B0^O]'+/*=,7ST7YN7K4NHZ^K);KZG+T6-*

*>;U^-Q^.9 4 MJ]PZ*S9ZW3QR7Y2KO&]NE@_C:E/_*YKM%]_^622CE?8CV:772_NRYG%)6V M7B]6^KJ,JNUJE9=?W^IE\7PY8]-OO_8T>'BLVU^,9Q>,_$'?Z/DZ5O7?VW\!:?*

M>+E5Y7BV(=E?K^R]W1?&YO?/W>5HTCXC M0=3SND7DS8\G?:67RY;4/(]_]#1H<^VX?'M;_1WWP6]QW M/_,O^R",&K#XA09\WX#W;2#V#43?!O&^0=RW0;)OT)WZ>'?N77*

RK_/915D\M1V5[=$-K;W3[=ZV;O!;K]H5R4Y?-HXNF73V]J8OYYU=MU"?15,%]7G]5WE7P M5?1QT]ZHHH_;NJKS]=UB_1#]+'6=++Y,5+\WC/T;C]'K,2UU=C.OFJ,3 \7S?

*M[=M=M_R%;M]OUV>1F/P:\0F/"ZN_?2XL"(YRY*3 M>/L=)G>'I>1E^7K["D@E-&TA2*1E,V7L@08LAL,W2D#!5#*$VA:#1EXX9LJ!PR6_MX*

*MS,ZLB=7;3W#&2)I"T6C&1DS9<#/U(X(;ZB;0FD*1;/%,'K*X'[#H((*14DH M:3:HM#9&4AG"4IFMJ8RS^`0\@HHJE*90-]$S<56&D%5FVZHK9JBO0FD*1;-+*

M\98^5!CW0..I;8<6MJ]?<3O$P"=584C69LG)7W=-:LFUHS9\109X72))2F M4#1:C*/%1/Q](G8Y$;N>B%U0_#^*15]JU":A-(4BD8+86R5PVV50VT52I-*

*0FD+1:&V,K7*$K7*K<83=CH6 M06T52E,H&HW9V"I'V"IWV*HC9JBM0FD*1;.7G!E;%4-M5?197_7W$IHPE*90 M-)JP<57Q'5?=KG5T_O*DZF\>.G!#:1)*4R@:,+83Q5 'W5 'U5"A-*

*0FD*1:.U M.,KT%7+MJ^V1+,U.AR*HTD\"D6C*1M/%0A/%;:G.E*&>BJ4IE TFK+Q5#*4 M4X7CDMHLM=X]O<3G#*45%TFKQ5=%$;77.3;Q39\06X72))2F4#1.#&.K M FZK*

*FJK4)]$TA2*1FMC;%4@;%78MFJ_->GO*3AEJ*RB:#1E(ZL"(;O"EE5' MRE!7A=(4BD8_,61<-1]JK&!LNJZ.G?3_GAJ"VBJ+1C(VMQGY;?;-IV%9U M%'?*

*3ZKDS8ZBO0FD22E,H&BV%\=48]JLQU%>A- FE*12-UL,X:HSPU=CVU71Z M.A9!=15*4R@:#?GH(Z((78UM7;5#AMHJE*90-]JRL=5XJ*W&]JKJ5)Q>$.;O M)3AAJ*NB:#1AXZIQ3U?*

M+E82$Y?&4%>%TB24IE T6@SCJC'<56.HJT)$DI3 M!JMC7'5&,&JL6-EE26G[T_ZNPJ,&2JK*]J-VA- FE*12-%/H:@+7U02]HU":A-(4BD9K8W0U0>AJXMA=*;4NI_%W*

M%1PS5%=1-]JST=4$H:N)8Y,E1\Q07872%(I&=]$SNIH.U=6TW^*JOY_0C$T MA:+1C(VPIGYA?:=OR^_,K7Y&Z/@-I4DH3:%%MI!&6E.XM*90:872))2F4#1: M&R.M*4):4\?UP$*

(TPS):JU0FD+1:,S&6E.$M:.VM;IBAFHKE*90-]JST=9T MJ+:FCIUQK4O#_+T$)PR55A2-)GRT";]?6F_TIM;=:_G<,[-B]P'&;@2,W0GX M_[#6U%AK"K?

*6%&JM4)]$TA2*1FMCK#5%6&0QVFPIFYY'L-+?5W#.4&U%T6C. M1EM3A+:FKMV6'#E#O15*4R@:W7;<>&LVU%NS?MLM^?:)S1A*4R@:S=AX:^;W M5JGGN\F592_/KGZ@.I4DH3:%HM!K&6S.XMV90;X72))2F4#1:&^.M&<);.M,]M;$VO3 G]/P2E#M15%HRD;;BM5]Z]R$O'Q;K*EKJ^P8 .6M[*W?2(I>[4Q>;*

MIHO2.HNZ+E;=S4>=W^FR/:!Y_+XHZF!WVN]>.WR:W^P_4$L#!!0 (#V M"%DNQ=G5" 4 !LL 9 >&PO=V]R:W-H965T9D?;'KPT4 MXI2X9'2_-

*$"XC_$!Y40'#UP\2*WC"GT(\!*.?:V2NUN?%^NMBQ/X#7?I4)_ M!\Q%GBBI"$:;^W F6K,NB//-)$ SJ/$D+;SXMCJV>93O5986[$X@N<_5I/Q< MLD(P?9A[VW@[+;R@9*

MFX+RC&\I.\BC;62F[L3YBJGYLIYY@;DBEK&5,HA$?]RR)'QJAO]FW+R>C)/B61+GGU/UVIH[\\8>6K/G9)^I>W]XS.H)#0QOQ3-9_D6'M^MS 0ZNJ5#ROB_45Y&E1?28_ZD8<%>#H3

&I"TC?@K-N"$\+!F<*HKH@ZCO"'MH"XHI^Y7)8'+]*WV)9B!_55].7%T..7,Y0_25%VHK$2W6;&W7^WIJ MS?S(V_P6Q G\9U]<(SS]"Y&

*1!W7LW27W^[$-0IP61YV3:?'Z&%P=G3:OSQT M-"-LQ Y+7GA.;*/*U:(4^R[Y]>]WA6Z%2(H-,]L=%[BH@%$WT+C8C=PE*S;S MM$U))EZ9-__]-SP,/G7U&A(60*

*(H$,Q2)6I4B5ST>747=37?67=&R\%A<04;.ME##56_0ZQT$03/W7XZ9^<)+5K$'3K$&/9B%M4/K63#-T_M9<:3#*4F/8I#&$-*

*I0AI"J0L!@21H%@EBJC1I71+QJ*L^[2YH_>WIY1B&T/B"%'-MI$ PJZGCJGCGL;S-1&K,6T\73_]"R?HTBY#PF)(& 6"66I,&C4FT,85@50%M$A9#PB@05%*

*(%!VV:'"[1>MR%E_;_IEGF0R;C$_,:'9-"T>S6'@4U_&%K3^UG MT-EI)^?B3D/28E :A:+9BI!6$0)M0C412AM(6@Q*HU-T6YLVZ6)G9',94?C. M.L+) $>V=RP[3L-A,#QU&-*

4"D6S>],F4/QQ$+R&,PP)X.@N924%H,2]-0 M-%N0-NOB ;C!@%9>4%H,2]-0-%N;<ENB9X15&&-&HL].@>3:1:4%H/2*!3-%]3-OG@,;D2@*1B4%H/2*!3-U]9-PM@9Z5Q&*

M-.DTHN#4B$##+"B-0M'L=T=MG"7N.'LG4BZ0XNB>O3(A6?TB[&&7!0K]ARYX M&.T>Z-+, 906@[(H%.V6K(W)!$:-%0$-S*"T&)1&H6BV-FU@)L[0Y[J=^% M$!WQD=P-"

(GSA>#CDJA:'9SV\1+W(FWMU=]^/S:/=#%8H"^]06F42B.+5D; MND[E6@V1N4%H/2!3-UJ;-WJ3/B^9."4 C=DYSGC--NKP*-#Q#T>SFMN&9 MN.-*

S#Z_]I:C;/QO.:+5.M<04;.ME##56_0ZQT$03/W7XZ9^<)+5K$'3K$&/9B%M4/K63#-T_M9<@\2%D/"M^1,#.4F/8I#&$-

!X;"]W:W)K&ULM5=A;^(X$/TK M5]XZ[4[%Q-E0Z$$D:&.Q;J6>4#FZG]W$@-7$YFP#V]/^^'!T[:0@DA+;]J4.) MG9GGJV8BCV>X$_))K2C5Z'N:<#5R5EJOKUU712N:$M46:\KAS4+

*(E&@8RJ6K MUI*2V#JEB>M[7L]-"> ..,+1S4QD.Q48GC-.11&J3ID0^3V@B=B,'-R\3]VRY MTF;"#8=KLJ0SJN?KJ8216Z#$+*5<, <&11(N1,\,7-]AG'*S% Z,[57I&1LJC M$$]F\%<|*

I/ZDN:"NP8M$HNQ_M.M#0=%&Z5%FCL#@Y3QI)=\ MSP-1H(9Q MD\:9EO"@=9\.9UI$3RT3B!C=B!2^#D5L?%OHGBHM6:3AC;5"<\ZT0#]N]28L M49^-RKR6N

*5RD5H1215B/#.Z+$W\LQ(;17@,DQ=F?,>2!!900U<#?\/"C7*N MDXRK?X)K#]T)KE<*_8%=(3B5/-/4FMCD3,<\:7L*,3PB.*?IS.VB3#ZEHL<\IMPV#H;LM:&E=[IY9NH:7; MJ.4/2)_9/-*

*%1M.H7% ;%>0:S72.P!CH,SO']5-5OXB%:CR0&O MJX+752,O. Q>F_FK:MQ\[XA@U2:HY]]_Y$[](+"#8 R*8 $>O%/W)V.=]_RO7\Y9%[>[*

*M1UEK7/6=FH"WKZ'>*_=LLY8_KFZ[H.V'=QG_]0WU2-M1#*XH?ZPE^!:H=4"7I'82.&M$MU2;Y-2O:0MGX+-M>$ZN^D7LT5;,;;-U-'\ MQ+2;MF?:PV2]ZAV14)442N@"(+WV%:B36?*

*N7#;18VP[J46CHQ^SC"EIF*HT! MO%\(H5\&9H&B"0]_E!+ P04_"]@-A9B'':&,&,$_"'&0 &0 'AL M+W=O?+G>F98LDS(RQ_=9H M\N4OY#]'Z@>T%#RQ21EZA?L:UO+*

"),.EJL.A!AO/]'WZK W$"$#S=_<& M.-<"W!K@G@.\"P"O!GC7>AC6@.&U'OP;X*O85\%2D0X@A_,D7M L,5@DPTE MET*+ .-%*

(%LHND!0]_SGO4#P]0/+@P]E8HW69BNHK/O30Q$TC1_9..F$OX M+](9!X^4PGR+9+MKLE6$7C>A3-$/K(QFADB!S-$=\B8_.:+[5N_=TFEDRS0 M21;])

*(LTD;4D]AQ3VN<@WF<@T3*47S%@!I:,/RM[$TZ5[KY=;=;_(?$4F M'\N[N>UYUF1]DX%/;.:6(?M@IU=BN23D1-92;M@H->Q52]HFV7I;Q5%UD M@4ZR4"=9I(FL);+?*

B.SKSKB^3HEUD@4ZR4=9)$FLI;$HT;B4>\Z5A(S $N>_M$(]_=]9,3Q7%\"2WN?)HYI;%1RO;'@_],I.@MS^WZG"=S^BCV;TVMDP\KPK%\^VRI*

*MZO08=G@<6Z.SA:K)8TLSVSJ^^5K_2_G9[^96J6JV5FEIR>-,+:U>PRN]1KJ\-MMB4]V:RP?ZX.!?^")<5*1)%/7] .478P6Q4I[JQA^FW>+)]L.MD_K6ZB5+=+% MUIX*SG$J.+JKU9I1E]*

*(ZV0*M;*%6MD@76UOIXT;0W;L)<5W16G.VAGUU?V;]4W@2%-]HGB&=(MS!E*T$9368"2I;M=_^]$DT+M4K\2SDFF MF@F"H@26!N+^AA!^,)$.FF\O_\4$L#!!0 (#V "%E @F#";1< #FR M 0 9 >&PO=V]R:W-H965TV M>]FFP)(/0&]"57=T/I_]M6($>-O8M&R2R=1^^+6-0)8L"SGS)R^Z@?CYW;(>_MHRN2]=S^]'U9_+EZR/:U*_'^6+U^>QAO7[Z]>)B-*

*7W(!/5^?(I7VS^YFV9-M/&;KS;?%_<7]J+LYM/N9WYQ\VGYO)(/%KE?"*OG-MQ\>L^/%|/E]^_WPFGKW^()S=/ZRW/|BX^?24W>=1ODZ>_&+SW<6;K-MV7(A%/G=Y|/?Q%_3R60[8/>(=)9_7^U]+6R?RM?E_M-\;MY[//!=HOR>3Y=-M;XEL\[JO^9=\/M]*F^WXJT3/WFIN!^Y__;JKNR>_>3)?LU7^93G_8W:[?OA\-M=G4FW.9WV?-\'2Z_ZWGYA.9,;[J,'C;/"R-M_^Q?Y8[0&R"-CPR0R@%28X X.C)@6 X8-@:,CE48E0-&?2N,RP'CO@,FY8!)-MWP&7Y8#+O@.NR@%7C0%#ZKO$ZlV)SWHRI\7?7BO>,,.M'Q_R.O5B<^Z/#WF=?+$Y^]*QV9=>9U][SOI15YCT.OM2_]-UMU_VW>Q?O!Q6-M=LAV#Y^XVV_V!W8=N,WAZ+98GI,CM;%YF]GHW'K&^6OYlGZ-MA_"\+G*^SV7SU[T\7ZXVZ_;N+:2E8+X)T1!@*SG*Q?E@)RN(VOVT9[W6/GW2,-MO]@\F[>G)+T^I=^E3M!\GI\+TO ?@C201L+?A-MA]9 5^:IET[{TD ,2B]0R-M7'YO^,)<& [*#4DB6?CE;W\7TN4ZW]NZQNG]-#%RZ,,IW8/_^VIV.RET='AM6H_AXN#H<+W'\,'UT>%&]W GVV[\Y&'"*C^],\]YV=F6UVIB0UIDKN15L?^B]P M>^R)H=C0CV!_VT=OJ^Y_;>MA^9]Z'[TT6<>]#D$27T.06&??]/#5WJ+%/61MQGVDN,\OR[@^$RU;TLW(^73O Y=%G#M/^U2IvUD^:1PQT[+,:CIM/GQ^=Y MMLYO!6_]D!?"E^7CYH3GB7LF\BT7C,5T^9@+O!C+56M^_O([^]KY[4G6KZNGM;)[_/MN@[!SXE1_=_/=_B9/!_]0E%HG)*:0F$IB&HGI)&:0F$EB%HG9)..0 MF$MB'HGY)!:06$ABS8G%)):06 IAM0 ;OO78[$N_V<35XW(A,,XFIW*V?/ZM85G,_MUZJO9)WJ1{5)&8_(*-=|CVPN*WF^OOX.7/IXMO^SE$EE5)3",OG<0, M$C->)S.H][S99UB$QE\2|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{)H9M4DOW@U -5"5(M0+4.U!-522JM'5M6<0.IN3G 0 M6;MF-N^%%-JH -5D5%-0344U#=5T5#-0S40U"]7L4MN0/-N3Z/Q#5K5;.DZMF31O6_'0FCZ!!:@6HEJ$:C&}):B64EH]?:H&!)LONI(;K;67>WD7"(U&=44 M5%-134,U'=4,5#-1S4(UN]0FI5QJAA)9TFTI>9!(9$$?U0)4"U$M0K48U1)4M2RFMGDA5FP.IN\V!?&WE39XPGQ[*W7^7;$Y47MZ+0S2RUVOO-9,7E7NUK8FFIH-P94DZ7# ME?NCP?#J655%-0S4=U0Q4,U'-ZCOY-EK60347U;R^N\1'R?:H%J):MA&HQJB6HEE):/6:J1@I2=R.%=+DY=7KMB&WGW_*Y,&S-$W*|\1=4DU%-0345 MU314TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;64TNKQ576.D*X_M^.H?N4CZ"ZK)I*:@FHIJ&JKI]&:@FHEJ%JK9]..@FHMJ'JKYJ!:@6HAJ$:K% MJ):@6DIM5P.5NTNAMWM+M1L5@C?LOGS[F+?)MB$[R_7]LRK-LZ-<-0348U M!=545--034M;AAP_%B^OAHT.`I&J*JIJ*:CFH%{)II9 M/>?>1JLZ;56'5U*C{(L6]7H^5;_?Q@7HQH6H%J%:G&I)R^X5A^/QL+&4.VUY MW.7V<6\/JQ^QIYX0FRI[':%_[A;O;OWDSFIR:5VT"MFW#R0DU555--034NY1WRT:H!J(:I%]!:C6IJ)*:75PZ-J-WWS+L;M0AH=P^[S[+Q%;T*@+1M037[GZ8V$'WE6K 1Q@S"VRT6WRP/WF(\] MQP!]CB&J1:@6HUK2@-.;?Z3>7U&]3V]JB'5-6<8=BY2/:T#_;K MMDY.*[01 ZHIJ*:BFH9J,JH9L;,?=FUX<,J#ME= -1O5'1S43%5[A6'/|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|(3]EKZ_'W5FQULR?&:G)]*:@FHIJ&JKI]&:@ MFEEJEWL7)@?G@^8=W!9:U$8U!]5<5/-0S4>U -5"5(M0+4.U!-522]OG5-7S M8M2]5GD_IW8W962+Z>97!$8H,ZK6JM@H%]JHIJ*:BFH9J,JH9J&:6VGL] M@2RTJHUI#]JYJ:.AFHIJ_:J%]!:A6HOJ"-JEE%9/J:KIQ:BIZ<5_>ML@V@8# MU6144U!-134-U714,U#-++7W\PIMA8%J#]JYJ.:AFHIJ:J%]!:A6HOJ"-JE ME%:/JZH5QJAG*XPRKW;!!%N3'>V'@6HRJBFIHJ*:AFHZJAFH9HX.&S8<7.I# M>V&@FH-J+JIYJ.:C6H!J(:%]!:C6HI]*:750ZEJF3'];IGAW=WEQ6QOW\-WM8+=VHY":BVH>JOFH M%J!:B&H1JL6HE]!:2FGU=*%HZ^HPZ5QF]W:K}>39P<26A3"U134$U%-0W5=%0S M4,U\YR4|?NGSW'I?'|K M4<5'-1S4,U'\4"5 M1+4*U&-425$LIK193XZJ!MQ;B[@86?%]-\L<[N=V\\?[N8=$GM-8/>77_W^91V>*\|+\U\M&ZLUQ="">%Z@FHYJ":BJJ::BFHYJ!:F:I-5/L^C#%T)87J.:@FHMJ'JKYJ!:@M6HAJ$:K%J):@6DH]123JA1[^7^%*9]\U6V='$']HNPM44U!-134-U714,U#-_M+++5WWKU":;JHYJ":BVH>JOFH%J!:B&H1JL6HE]!:2FGU;*K:6(P[EQ-WMV/ZMB8\EZ2YWI+ACC#^B"T6V>G&5H%PQ44U!-_M134-U714,U#-'!|VP9B4?YJ7&=$^&*CFH)I+:AZJ^.;@6H%J(:&A$JO:B6H%I*M:?6W:.M.5#-0347U3Q4\U$M0+40U2)4BU$M0;64MTNKI5++7$&'>WQ(A,NJ40;8B!:C*J*:BFHIJ&:CJJ&:AFC@\,8K1E$]H0]4< M5'-1S4,U'\4"5 M1+4*U&-425$LIK9Y-54,,<7=W@?=N*2S?IWJYD?'/KI5: M:-<,5)-134$U%=4T5--1S4U$]4L5+--1S4$U%]4\5/-1+4"U$-4B5(M1+4&U M#-Y]^:3:I.FE,7A8]?]BJA\.TCP;JR:BFH)I*:AJJZ:AFH)I):A.JV:CFH)J+ M:AZJ^.;@6H%J(:A&JO:B6H%I*:?5YF&B?>E]&MG9Q/:#N-29_6"PI:4T4U#=5T5#-0S40Uf]?,VVA-!]5<5/-Z M[0\?K1F@6HAJ$:K%J):@6DII]32IVE]_K/V%ZWO5?U$6XSNS3@YAM"V&*BFMHD]*:AJJZ:AFH)I):A.JV:CFH)I+:AZJ^.;@6H%J(:A&JO:B6H%I*:?7X]HB M.+[\V+>R1FBND9J;.@JJJ:BFH9J..@:JF:AFH9J-.@:JF:AFH9J-.@:JF:AFH9J-.

MTR$9C2Z>>VAF%SGVRI-,OI0*.5VO8Z+MSN:Y]\W-W7P_L(L6:Z[M^H7AY'H3+^DCK;Y\M'@KV,+BG+)(US!M4L?PUH.R&CYLWSM&S^5UYW;0UCH,RW-M9966OVV-V@G62[?I&/]J%. @@]@/5#QK1-?%,)DE6Y\=C5;!W$Q97368TC2NZ4![BHGI3_BKBK(P;Y9;)X=6 M<9*6OU\/*]93W7XX;ZEW.RKY@*HI]WE6K4K%S19T(8CWY/'FN?A 'F^?BP_E M\2HY!XCD &)) $/V&>T_*/+^0=T1*3';9E\4;?19(2,B*!\>'>73K[\K-*N2 MZDTPOFE_FG;>YLA]W'!;&I+^Y#B|A\3^9CB0=?)AZY3(*Z&#RVR^J M,?1#E %(F(.$N4B8AX3Y2%B A(5(6 2"<1FAJS-"E!$G?!*BE Y@)6U)12FP M"S:.X+)X?9E8NFW]HG;}?#E4MZ =T0S#UOEVCG0PEPH7"?-.9Z":MDETC?!3 M\ 4-#=/23.-H30+D\$(D+ ++!.,$9>\$94L'=SN?Y-]M*=@Q^BY[2^EDY/"@G M5'@D-D[6W!]5_XY4*.WYTF,L$N8B85Z_U?"1?09(6-AO M'99IP S;T 3?D1 M;[M^HH62/],OKG-VYL_39-'H;T;C5'++BCUA=3*K.)@8E9\?ES)WTOXGNK0^0 M,&<';PZ/4? S:NH(6%M_$$509'TD,.>C@?"_A^2;1M DG&&LO&*NG8#BY%+5< MZ$XN.XU(Q6*=C.OHQ#*5CN)2!?2!A+A+FG5T(']E=@(2%2%@D6PA.]..]4,?]*

M3]V:W:E5),.OH,RQ=*)9Q^=2,5>7[A$) R0L%$QA/+9MU3;/ M#HTI'YLKISM{KSI;]D92;+855V!VB<@M.3I#.D5!U9QD^-D2F4YD!+I3F06D^E!9 :2&4%[)4 M%J%H?')TYIDJ=|^ZO6AWUID4~8863<[(-]#EY(LSQ3BWC>3M .W2A-]*|\\O M1@#M,(32(A2-UW3GQZER0TY>$3%-]]OK@;IQ4)H#I,E0F@>E^5!: *6%4%]$ MHO%)TWF2JH6LDI#&U11* M>G$JG'IJH@T1!JK"Z5Y4)HO6!%-N4]4"AM A%X^7;V:F]W$]\6+V5R3R)

M,.^7KUZE8Q$@G;PJE.5":'Z5Y4)H/10506@BE12@;_UN3SNPE(V"Q0Z"N+Y3F M0&DNE.9!;3Z4%D!I(906H6A\;ACH8E.TU-YYQ?+'^KK M0FE>WR7QH=T&4%HHF 017EO=8[-\3M0#0720.@ M-!]*"Z"T$$J+4#0^&SJER[<4B@5B^4YD!1+I3F06D^E!9 :2&4%]P)H"}T M5B^1NZ5]-/+PVAM A% MXV7=N:M$[JF>)_,B(RI")TD63+VJL2*AK]MT)I#I3F0FD>E.9#;0&4%D)I M$8K&)T?GW1(;61!\?5PHS8'27"G-@I)*"V TD(H+4+1^>NO=3ZN)O_1;I; M%+0(KF01G:&G\KXN53N4YD)I7M\E\.'=!E!.*)]$Z%*IJ,=L=_(;'MQG=$V+ M97-?VU)I)+;|)>#^U?V]O7ZG7KFJX'5/O?)W=\;M\+L,]=[*Q3+) M2B6ESZRKT1>+?

*0LO=O>^W3V1\D5EXG*KR=?-R1>,+>H&/WG/*->}0<;]BBB_$'}C*UE#30===:,C'B?Y&28 @D#Q:(@$%"")*J)-Q-:R!HFG6EB-?U>C&3^9')*M/I#&"%$0^5"G1D"-M 0Z$666HQJ9*!OJDG4]ZVLGMYC&S>]H1.N1QT:TM<*|_H$OTA0#"(4^2I?F.(005A%9WM!0PU++> 9V>OZ;KUCI945^ M_UI<.6N;<0,9UXL!&NBG2)S1$H6K^'P-

*)$0#.T4_MSX$.B,CX0310%TU-M&",AC&A$5,OGP&D@>1K8@;KG$A'H> P"&*H+1$,8(@%05Q#VF@9ZAA*AH1VA MK[NK^QG7K"2'4S M,T92&H5$\WT.5(5[!TKMJ'T\@=PFIEN /HU 0-1YS!)Q8RG+1'MQ0PU*Y$3 MGHN}YHQTCBOV4L\4*IV]Q:J4 M#EL]H1*ZA$KH%"]=]L6NU X,*;*$2_BI40AT628@B1-7?'$R!?H0!U(;.; 2 M2]RS=]P\14X!-

!!C&&KF^T3%]LJ&.I=,"7^-;%.BB3$P]#U:TAT{}(0%6(MMA9(5T3C2[-@:: M7-NK&NI:\B2R\^1QKD(Z&B(?8!2H%[8A$&+D^T1=-MA+&6I5(B2R(^2I5(5T M7#2/;%.@<63;"QS:@+W?RNU8:6.J=Q^O;N97\W?&%CB]K>E4+7:E=MA, "-@(M.Z0IY!1+G:K%KM0.&RFQ%-E_U,_Q"(?^:ST0XRO$Z@":&2(CA FVD@\!T$B M29#(3I GXA32*9$BJL&D(2P.8*0N;NVU#?4N41*YND-I%SIYT)AH$VN//K@Z MZ&%W)&ZB7!--I%,D\ GQ.57O=A@B21 %VA,2L;VBH8XE;R(GO(D,=S"/&-N21#C@% MT?'>@[3U8\-^?

DO(^S2LO8W="WG\3B5-2[IXDWNWP8M,\6WM;<%ZLF\T52Y:L MK-/$V=%P^7_NU3 9 M-)$,I%.N5W^'9>G?.1#V "%GW:RI^Z , %L3 9 M-+>&PO=V]R:W-H965T'/O 9 HN<|*\34VDBY0;5ML=Q 3L0-VT*AGJP8SXE4MWQMBRT'DI:B/+-= MQPGLG-#"FDW*LGL^F["=S&@!]QR)79X3_N,,,K:?6M@Z%#S0]4;] GLVV9(U M/(+\LKWGZLYN*"G-H1"4%8C#:FI]P+<)]K2@C/A*82]:UTBGLF#LF[IYE$XM M1]<(,EA*C2#]YPGFD&6:I.KQO89:S3NUL'U]H'\LDU?)+(B .5C5L]ND>JGGG&H%_[8H;Y#F_(]=Q???3E M,4;O?

GV/J(2\W+SU!|.ZUA2;,3$L%0V7-.] Z\$D9LQGBPG^&,3+:.]K7 M!G^&>X_NWP!'+&5&M4D0ZI!B80]6=W&2U8(EM%4%;9!55\1R5=MV5TTD-4 G[0!4B7A<6G8;Z'L3?

J&&\)BL-"1H# J.A?ZL9E6;E M .OS(SC)P/,=+|\0N[B0QOS@R[HGS??8B+|(=8XQ5?Z4QX;8L=&8Y/M.S;&(.M2,GI8B?+=4>.3$8$C-PR=H#.BYI<&QCV!XV#D M1CCH.&?,

*]97.A8USH=&Y!SUY)]7D?5B@^^PQ4]Z<,^=#PN(A8]476M]4/"XB%A270Z7)SRKQDM1ZYBY^5#U'G3ZF]67VOPH+1X M4%I2T]JS>>B;/&Y][.,W/+=5F^=4>#TF+!Z4E-

>WHN]5DL?MBL?N6Q=^LOMKA M(6GQH+2DIK4=\AE[\7S/8K4.$ M'/BZ/+W1.\[=(;N-}E/:G:!!].]%.N5W^'9>G?.1#V "%GW:RI^Z , %L3 9 M-+>&PO=V]R:W-H965T'/O 9 HN<|*\34VDBY0;5ML=Q 3L0-VT*AGJP8SXE4MWQMBRT'DI:B/+-= MQPGLG-#"FDW*LGL^F[*

50!5 $H7 !P]P$! end XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e).style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 364 343 1 false 114 0 false 13 false false R1.htm 995200090 - Document - Cover Sheet http://nutexhealth.com/role/DocumentCover Cover Cover 1 false false R2.htm 995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 5 false false R6.htm 995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 995210101 - Disclosure - Organization and Operations Sheet http://nutexhealth.com/role/DisclosureOrganizationAndOperations Organization and Operations Notes 7 false false R8.htm 995210201 - Disclosure - Summary of Significant Accounting Policies Sheet http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 995210301 - Disclosure - Divestitures Sheet http://nutexhealth.com/role/DisclosureDivestitures Divestitures Notes 9 false false R10.htm 995210401 - Disclosure - Revenue Sheet http://nutexhealth.com/role/DisclosureRevenue Revenue Notes 10 false false R11.htm 995210501 - Disclosure - Property and Equipment Sheet http://nutexhealth.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 995210601 - Disclosure - Intangible Assets and Goodwill Sheet http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 12 false false R13.htm 995210701 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 13 false false R14.htm 995210801 - Disclosure - Debt Sheet http://nutexhealth.com/role/DisclosureDebt Debt Notes 14 false false R15.htm 995210901 - Disclosure - Leases Sheet http://nutexhealth.com/role/DisclosureLeases Leases Notes 15 false false R16.htm 995211001 - Disclosure - Commitments and Contingencies Sheet http://nutexhealth.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 995211101 - Disclosure - Stock-based Compensation Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 17 false false R18.htm 995211201 - Disclosure - Equity Sheet http://nutexhealth.com/role/DisclosureEquity Equity Notes 18 false false R19.htm 995211301 - Disclosure - Income Taxes Sheet http://nutexhealth.com/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 995211401 - Disclosure - Earnings per Share Sheet http://nutexhealth.com/role/DisclosureEarningsPerShare Earnings per Share Notes 20 false false R21.htm 995211501 - Disclosure - Supplemental Cash Flows Information Sheet http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformation Supplemental Cash Flows Information Notes 21 false false R22.htm 995211601 - Disclosure - Segment Information Sheet http://nutexhealth.com/role/DisclosureSegmentInformation Segment Information Notes 22 false false R23.htm 995211701 - Disclosure - Related Party Transactions Sheet http://nutexhealth.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 23 false false R24.htm 995211801 - Disclosure - Variable Interest Entities Sheet http://nutexhealth.com/role/DisclosureVariableInterestEntities Variable Interest Entities Notes 24 false false R25.htm 995211901 - Disclosure - Subsequent Events Sheet http://nutexhealth.com/role/DisclosureSubsequentEvents Subsequent Events Notes 25 false false R26.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 26 false false R27.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 27 false false R28.htm 99920102 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPolicies 28 false false R29.htm 99930403 - Disclosure - Revenue (Tables) Sheet http://nutexhealth.com/role/DisclosureRevenueTables Revenue (Tables) Tables http://nutexhealth.com/role/DisclosureRevenue 29 false false R30.htm 99930503 - Disclosure - Property and Equipment (Tables) Sheet http://nutexhealth.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://nutexhealth.com/role/DisclosurePropertyAndEquipment 30 false false R31.htm 99930603 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwill 31 false false R32.htm 99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 32 false false R33.htm 99930803 - Disclosure - Debt (Tables) Sheet http://nutexhealth.com/role/DisclosureDebtTables Debt (Tables) Tables http://nutexhealth.com/role/DisclosureDebt 33 false false R34.htm 99930903 - Disclosure - Leases (Tables) Sheet http://nutexhealth.com/role/DisclosureLeasesTables Leases (Tables) Tables http://nutexhealth.com/role/DisclosureLeases 34 false false R35.htm 99931103 - Disclosure - Stock-based Compensation (Tables) Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://nutexhealth.com/role/DisclosureStockBasedCompensation 35 false false R36.htm 99931203 - Disclosure - Equity (Tables) Sheet http://nutexhealth.com/role/DisclosureEquityTables Equity (Tables) Tables http://nutexhealth.com/role/DisclosureEquity 36 false false R37.htm 99931403 - Disclosure - Earnings per Share (Tables) Sheet http://nutexhealth.com/role/DisclosureEarningsPerShareTables Earnings per Share (Tables) Tables http://nutexhealth.com/role/DisclosureEarningsPerShare 37 false false R38.htm 99931503 - Disclosure - Supplemental Cash Flows Information (Tables) Sheet http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationTables Supplemental Cash Flows Information (Tables) Tables http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformation 38 false false R39.htm 99931603 - Disclosure - Segment Information (Tables) Sheet http://nutexhealth.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://nutexhealth.com/role/DisclosureSegmentInformation 39 false false R40.htm 99931803 - Disclosure - Variable Interest Entities (Tables) Sheet http://nutexhealth.com/role/DisclosureVariableInterestEntitiesTables Variable Interest Entities (Tables) Tables http://nutexhealth.com/role/DisclosureVariableInterestEntities 40 false false R41.htm 99931903 - Disclosure - Subsequent Events (Tables) Sheet http://nutexhealth.com/role/DisclosureSubsequentEventsTables Subsequent Events (Tables) Tables http://nutexhealth.com/role/DisclosureSubsequentEvents 41 false false R42.htm 99940101 - Disclosure - Organization and Operations (Details) Sheet http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails Organization and Operations (Details) Details http://nutexhealth.com/role/DisclosureOrganizationAndOperations 42 false false R43.htm 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 43 false false R44.htm 99940301 - Disclosure - Divestitures (Details) Sheet http://nutexhealth.com/role/DisclosureDivestituresDetails Divestitures (Details) Details http://nutexhealth.com/role/DisclosureDivestitures 44 false false R45.htm 99940401 - Disclosure - Revenue - Disaggregate revenue (Details) Sheet http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails Revenue - Disaggregate revenue (Details) Details 45 false false R46.htm 99940402 - Disclosure - Revenue - Insurance Coverage (Details) Sheet http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails Revenue - Insurance Coverage (Details) Details 46 false false R47.htm 99940403 - Disclosure - Revenue (Details) Sheet http://nutexhealth.com/role/DisclosureRevenueDetails Revenue (Details) Details http://nutexhealth.com/role/DisclosureRevenueTables 47 false false R48.htm 99940501 - Disclosure - Property and Equipment - Categories (Details) Sheet http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails Property and Equipment - Categories (Details) Details 48 false false R49.htm 99940502 - Disclosure - Property and Equipment (Details) Sheet http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://nutexhealth.com/role/DisclosurePropertyAndEquipmentTables 49 false false R50.htm 99940601 - Disclosure - Intangible Assets and Goodwill - Components (Details) Sheet http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails Intangible Assets and Goodwill - Components (Details) Details 50 false false R51.htm 99940602 - Disclosure - Intangible Assets and Goodwill - Operating Segment (Details) Sheet http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails Intangible Assets and Goodwill - Operating Segment (Details) Details 51 false false R52.htm 99940603 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillTables 52 false false R53.htm 99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) Sheet http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails Accrued Expenses and Other Current Liabilities (Details) Details http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 53 false false R54.htm 99940801 - Disclosure - Debt - Outstanding Debt (Details) Sheet http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails Debt - Outstanding Debt (Details) Details 54 false false R55.htm 99940802 - Disclosure - Debt - Term Loans and Lines of Credit (Details) Sheet http://nutexhealth.com/role/DisclosureDebtTermLoansAndLinesOfCreditDetails Debt - Term Loans and Lines of Credit (Details) Details 55 false false R56.htm 99940803 - Disclosure - Debt - Pre-Paid Advance Agreement (Details) Sheet http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails Debt - Pre-Paid Advance Agreement (Details) Details 56 false false R57.htm 99940901 - Disclosure - Leases - Leases of property and equipment (Details) Sheet http://nutexhealth.com/role/DisclosureLeasesLeasesOfPropertyAndEquipmentDetails Leases - Leases of property and equipment (Details) Details 57 false false R58.htm 99941101 - Disclosure - Stock-based Compensation (Details) Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails Stock-based Compensation (Details) Details http://nutexhealth.com/role/DisclosureStockBasedCompensationTables 58 false false R59.htm 99941102 - Disclosure - Stock-based Compensation - Stock-Based Awards Activity (Details) Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensationStockBasedAwardsActivityDetails Stock-based Compensation - Stock-Based Awards Activity (Details) Details 59 false false R60.htm 99941103 - Disclosure - Stock-based Compensation - Options Outstanding (Details) Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails Stock-based Compensation - Options Outstanding (Details) Details 60 false false R61.htm 99941104 - Disclosure - Stock-based Compensation - Restricted Stock Units Issued and Vested (Details) Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails Stock-based Compensation - Restricted Stock Units Issued and Vested (Details) Details 61 false false R62.htm 99941105 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details) Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-based Compensation - Restricted Stock Units (Details) Details 62 false false R63.htm 99941106 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details) Sheet http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails Stock-based Compensation - Employee Stock Purchase Plan (Details) Details 63 false false R64.htm 99941201 - Disclosure - Equity (Details) Sheet http://nutexhealth.com/role/DisclosureEquityDetails Equity (Details) Details

http://nutexhealth.com/role/DisclosureEquityTables 64 false false R65.htm 99941202 - Disclosure - Equity - Common Stock Warrants (Details) Sheet http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails Equity - Common Stock Warrants (Details) Details 65 false false R66.htm 99941203 - Disclosure - Equity - Schedule of Outstanding Warrants (Details) Sheet http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails Equity - Schedule of Outstanding Warrants (Details) Details 66 false false R67.htm 99941301 - Disclosure - Income Taxes (Details) Sheet http://nutexhealth.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://nutexhealth.com/role/DisclosureIncomeTaxes 67 false false R68.htm 99941401 - Disclosure - Earnings per Share - Computation of EPS (Details) Sheet http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails Earnings per Share - Computation of EPS (Details) Details 68 false false R69.htm 99941402 - Disclosure - Earnings per Share (Details) Sheet http://nutexhealth.com/role/DisclosureEarningsPerShareDetails Earnings per Share (Details) Details http://nutexhealth.com/role/DisclosureEarningsPerShareTables 69 false false R70.htm 99941501 - Disclosure - Supplemental Cash Flows Information (Details) Sheet http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails Supplemental Cash Flows Information (Details) Details http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationTables 70 false false R71.htm 99941601 - Disclosure - Segment Information - Assets (Details) Sheet http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails Segment Information - Assets (Details) Details 71 false false R72.htm 99941602 - Disclosure - Segment Information - Operations (Details) Sheet http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails Segment Information - Operations (Details) Details 72 false false R73.htm 99941701 - Disclosure - Related Party Transactions (Details) Sheet http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://nutexhealth.com/role/DisclosureRelatedPartyTransactions 73 false false R74.htm 99941801 - Disclosure - Variable Interest Entities - Balance sheet amounts (Details) Sheet http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails Variable Interest Entities - Balance sheet amounts (Details) Details 74 false false R75.htm 99941802 - Disclosure - Variable Interest Entities (Details) Sheet http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails Variable Interest Entities (Details) Details http://nutexhealth.com/role/DisclosureVariableInterestEntitiesTables 75 false false R76.htm 99941901 - Disclosure - Subsequent Events (Details) Sheet http://nutexhealth.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://nutexhealth.com/role/DisclosureSubsequentEventsTables 76 false false R77.htm 99941902 - Disclosure - Subsequent Events - Equity (Details) Sheet http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails Subsequent Events - Equity (Details) Details 77 false false All Reports Book All Reports nutx-20240630.xsd nutx-20240630_cal.xml nutx-20240630_def.xml nutx-20240630_lab.xml nutx-20240630_pre.xml nutx-20240630x10q.htm http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 96 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nutx-20240630x10q.htm": { "nsprefix": "nutx", "nsuri": "http://nutexhealth.com/20240630", "dts": { "schema": { "local": ["nutx-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["nutx-20240630_cal.xml"] }, "definitionLink": { "local": ["nutx-20240630_def.xml"] }, "labelLink": { "local": ["nutx-20240630_lab.xml"] }, "presentationLink": { "local": ["nutx-20240630_pre.xml"] }, "inline": { "local": ["nutx-20240630x10q.htm"] } }, "keyStandard": 269, "keyCustom": 74, "axisStandard": 29, "axisCustom": 0, "memberStandard": 34, "memberCustom": 74, "hidden": { "total": 41, "http://fasb.org/us-gaap/2024": 35, "http://xbrl.sec.gov/dei/2024": 5, "http://nutexhealth.com/20240630": 1 }, "contextCount": 364, "entityCount": 1, "segmentCount": 114, "elementCount": 686, "unitCount": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1054, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://nutexhealth.com/role/DocumentCover", "longName": "995200090 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_kGz76xB0xkq0SUz8nN1o2g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R4": { "role": "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:LaborAndRelatedExpense", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R5": { "role": "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DR5o-6Xpv0CdQwwQZr5jqA", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_CKvGhAd9JEKJfDV6vMJ_tw", "name": "us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R6": { "role": "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R7": { "role": "http://nutexhealth.com/role/DisclosureOrganizationAndOperations", "longName": "995210101 - Disclosure - Organization and Operations", "shortName": "Organization and Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://nutexhealth.com/role/DisclosureDivestitures", "longName": "995210301 - Disclosure - Divestitures", "shortName": "Divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://nutexhealth.com/role/DisclosureRevenue", "longName": "995210401 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://nutexhealth.com/role/DisclosurePropertyAndEquipment", "longName": "995210501 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwill", "longName": "995210601 - Disclosure - Intangible Assets and Goodwill", "shortName": "Intangible Assets and Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef":

```
"Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "longName": "995210701 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://nutexhealth.com/role/DisclosureDebt", "longName": "995210801 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://nutexhealth.com/role/DisclosureLeases", "longName": "995210901 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "nutx:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "nutx:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://nutexhealth.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211001 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://nutexhealth.com/role/DisclosureStockBasedCompensation", "longName": "995211101 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://nutexhealth.com/role/DisclosureEquity", "longName": "995211201 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://nutexhealth.com/role/DisclosureIncomeTaxes", "longName": "995211301 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://nutexhealth.com/role/DisclosureEarningsPerShare", "longName": "995211401 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformation", "longName": "995211501 - Disclosure - Supplemental Cash Flows Information", "shortName": "Supplemental Cash Flows Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://nutexhealth.com/role/DisclosureSegmentInformation", "longName": "995211601 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://nutexhealth.com/role/DisclosureRelatedPartyTransactions", "longName": "995211701 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://nutexhealth.com/role/DisclosureVariableInterestEntities", "longName": "995211801 - Disclosure - Variable Interest Entities", "shortName": "Variable Interest Entities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://nutexhealth.com/role/DisclosureSubsequentEvents", "longName": "995211901 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920102 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://nutexhealth.com/role/DisclosureRevenueTables", "longName": "99930403 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentTables", "longName": "99930503 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-
```

gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillTables", "longName": "99930603 - Disclosure - Intangible Assets and Goodwill (Tables)", "shortName": "Intangible Assets and Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://nutexhealth.com/role/DisclosureDebtTables", "longName": "99930803 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://nutexhealth.com/role/DisclosureLeasesTables", "longName": "99930903 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nutx:LeaseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["nutx:LeaseDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://nutexhealth.com/role/DisclosureStockBasedCompensationTables", "longName": "99931103 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://nutexhealth.com/role/DisclosureEquityTables", "longName": "99931203 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://nutexhealth.com/role/DisclosureEarningsPerShareTables", "longName": "99931403 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareBasicAndDilutedTableTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationTables", "longName": "99931503 - Disclosure - Supplemental Cash Flows Information (Tables)", "shortName": "Supplemental Cash Flows Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://nutexhealth.com/role/DisclosureSegmentInformationTables", "longName": "99931603 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesTables", "longName": "99931803 - Disclosure - Variable Interest Entities (Tables)", "shortName": "Variable Interest Entities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://nutexhealth.com/role/DisclosureSubsequentEventsTables", "longName": "99931903 - Disclosure - Subsequent Events (Tables)", "shortName": "Subsequent Events (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:ScheduleOfSubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "longName": "99940101 - Disclosure - Organization and Operations (Details)", "shortName": "Organization and Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "nutx:NumberOfHospitalFacilitiesOperated", "unitRef": "Unit_Standard_facility_2wFEb9Z-EUSeKdzKIrFzIQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "nutx:NumberOfHospitalFacilitiesOperated", "unitRef": "Unit_Standard_facility_2wFEb9Z-EUSeKdzKIrFzIQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_6x4S7OIwy0SbBjXHCyud6Q", "name": "nutx:NumberOfDeconsolidatedRealEstateEntities", "unitRef": "Unit_Standard_entity_LZVHnD_WvkWF7cANcfKgdA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_ConsolidatedEntitiesAxis_nutx_AhpHealthManagementServicesInc.Member_srt_OwnershipAxis_nutx_AssociatedHispanicPhysiciansOfSo.C "name": "us-gaap:VariableInterestEntityOwnershipPercentage", "unitRef": "Unit_Standard_pure_GDus574MvUeiN1J6ZaWKVA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R44": { "role": "http://nutexhealth.com/role/DisclosureDivestituresDetails", "longName": "99940301 - Disclosure - Divestitures (Details)", "shortName": "Divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "nutx:StockReceivedInSaleOfBusinessDuringPeriodValue", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_30_2024_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_nutx_ProcareHealthIncMember_hfJUij7aPEWwFXF3_HR "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R45": { "role": "http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails", "longName": "99940401 - Disclosure - Revenue - Disaggregate revenue (Details)", "shortName": "Revenue - Disaggregate revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_HealthCareOrganizationRevenueSourcesAxis_nutx_HospitalDivisionMember_0Z47W0gaAk-iYYNN267E6Q", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R46": { "role": "http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails", "longName": "99940402 - Disclosure - Revenue - Insurance Coverage (Details)", "shortName": "Revenue - Insurance Coverage (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",

```
"menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:LifeInsuranceAssumedRatio", "unitRef": "Unit_Standard_pure_GDus574MvUeiN1J6ZaWKVA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:TargetedOrTrackingStockDescriptionTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:LifeInsuranceAssumedRatio", "unitRef": "Unit_Standard_pure_GDus574MvUeiN1J6ZaWKVA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:TargetedOrTrackingStockDescriptionTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://nutexhealth.com/role/DisclosureRevenueDetails", "longName": "99940403 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "nutx:DeferredRevenueRevenuesRecognized", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "nutx:DeferredRevenueRevenuesRecognized", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "longName": "99940501 - Disclosure - Property and Equipment - Categories (Details)", "shortName": "Property and Equipment - Categories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails", "longName": "99940502 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "nutx:NumberOfConsolidatedRealEstateEntities", "unitRef": "Unit_Standard_item_qRP9d0ySlk2D1CvDYhybRg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentMember_JPjq4XRVZUKOh47eJmSIDg", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R50": { "role": "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails", "longName": "99940601 - Disclosure - Intangible Assets and Goodwill - Components (Details)", "shortName": "Intangible Assets and Goodwill - Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_B3Zi2tNfCESJqtxTQg-IDQ", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R51": { "role": "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails", "longName": "99940602 - Disclosure - Intangible Assets and Goodwill - Operating Segment (Details)", "shortName": "Intangible Assets and Goodwill - Operating Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:GoodwillGross", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:GoodwillGross", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "longName": "99940603 - Disclosure - Intangible Assets and Goodwill (Details)", "shortName": "Intangible Assets and Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_StatementBusinessSegmentsAxis_nutx_PopulationHealthManagementDivisionMember_fj3CEmvk4EmkNxSMmL_vgw", "name": "nutx:NumberOfFloridaBasedIpas", "unitRef": "Unit_Standard_item_qRP9d0ySlk2D1CvDYhybRg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R53": { "role": "http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "longName": "99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "longName": "99940801 - Disclosure - Debt - Outstanding Debt (Details)", "shortName": "Debt - Outstanding Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://nutexhealth.com/role/DisclosureDebtTermLoansAndLinesOfCreditDetails", "longName": "99940802 - Disclosure - Debt - Term Loans and Lines of Credit (Details)", "shortName": "Debt - Term Loans and Lines of Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_6x4S7OIwy0SbBjXHCyud6Q", "name": "nutx:NumberOfDeconsolidatedRealEstateEntities", "unitRef": "Unit_Standard_entity_LZVHnD_WvkWF7cANcfKgdA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "longName": "99940803 - Disclosure - Debt - Pre-Paid Advance Agreement (Details)", "shortName": "Debt - Pre-Paid Advance Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_26_2024_us-gaap_ClassOfWarrantOrRightAxis_nutx_PlacementAgentWarrantsMember_sdsX6gjoH0WALtaSJmDq0g", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R57": { "role": "http://nutexhealth.com/role/DisclosureLeasesLeasesOfPropertyAndEquipmentDetails", "longName": "99940901 - Disclosure - Leases - Leases of property and equipment (Details)", "shortName": "Leases - Leases of property and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nutx:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nutx:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails", "longName": "99941101 - Disclosure - Stock-based Compensation (Details)", "shortName": "Stock-based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_6_29_2023_To_6_29_2023_O2qLZm5IWkqJ-IqvzwbJag", "name": "nutx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantMaximumAnnualPercentageIncreaseOfIssuedAndOutstandingShar "unitRef": "Unit_Standard_pure_GDus574MvUeiN1J6ZaWKVA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_6_29_2023_To_6_29_2023_O2qLZm5IWkqJ-IqvzwbJag", "name": "nutx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantMaximumAnnualPercentageIncreaseOfIssuedAndOutstandingShar "unitRef": "Unit_Standard_pure_GDus574MvUeiN1J6ZaWKVA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://nutexhealth.com/role/DisclosureStockBasedCompensationStockBasedAwardsActivityDetails", "longName": "99941102 - Disclosure - Stock-based Compensation - Stock-Based Awards Activity (Details)", "shortName": "Stock-based Compensation - Stock-Based Awards Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_12_31_2023_B3Zi2tNfCESJqtxTQg-IDQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R60": { "role":
```

```
"http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails", "longName": "99941103 - Disclosure - Stock-based Compensation - Options Outstanding (Details)", "shortName": "Stock-based Compensation - Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R61": { "role": "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails", "longName": "99941104 - Disclosure - Stock-based Compensation - Restricted Stock Units Issued and Vested (Details)", "shortName": "Stock-based Compensation - Restricted Stock Units Issued and Vested (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Wud7bMVfTkiBth6TUBdCoQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2023_To_4_1_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_UKvLmm5VlUedVZT6WhPmjA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R62": { "role": "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "longName": "99941105 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)", "shortName": "Stock-based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7LiXSPvYmkOfj1FNUYPfcg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_7LiXSPvYmkOfj1FNUYPfcg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "longName": "99941106 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)", "shortName": "Stock-based Compensation - Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_31_2023_us-gaap_PlanNameAxis_nutx_EmployeeStockPurchasePlan2023Member_IsoiWITXz0SmXXdnK2sRCg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R64": { "role": "http://nutexhealth.com/role/DisclosureEquityDetails", "longName": "99941201 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_25_2024_lFxlcH0zPUSMESqiKeeTow", "name": "nutx:WarrantyLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R65": { "role": "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails", "longName": "99941202 - Disclosure - Equity - Common Stock Warrants (Details)", "shortName": "Equity - Common Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_12_31_2022_BsNL8_kw_UmbfEKC7EqNGQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_nutx_CommonStockWarrantsMember_VYiKzfMFkESXoPe0oLFLTQ", "name": "nutx:WarrantsExercised", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R66": { "role": "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails", "longName": "99941203 - Disclosure - Equity - Schedule of Outstanding Warrants (Details)", "shortName": "Equity - Schedule of Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "nutx:ScheduleOfOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "nutx:ClassOfWarrantOrRightExercisable", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "nutx:ScheduleOfOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R67": { "role": "http://nutexhealth.com/role/DisclosureIncomeTaxesDetails", "longName": "99941301 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_GDus574MvUeiN1J6ZaWKVA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_pure_GDus574MvUeiN1J6ZaWKVA", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails", "longName": "99941401 - Disclosure - Earnings per Share - Computation of EPS (Details)", "shortName": "Earnings per Share - Computation of EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": null }, "R69": { "role": "http://nutexhealth.com/role/DisclosureEarningsPerShareDetails", "longName": "99941402 - Disclosure - Earnings per Share (Details)", "shortName": "Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_bfTDcOHxd0mLCKjP5oPxKQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_srt_StatementScenarioAxis_nutx_PriorToReverseStockSplitMember_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_DKyN1zLsBE6pD8nmxWF_QQ", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R70": { "role": "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails", "longName": "99941501 - Disclosure - Supplemental Cash Flows Information (Details)", "shortName": "Supplemental Cash Flows Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:InterestPaidNet", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:InterestPaidNet", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails", "longName": "99941601 - Disclosure - Segment Information - Assets (Details)", "shortName": "Segment Information - Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_VXT8oP-STE2gPpo8IP6TpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_StatementBusinessSegmentsAxis_nutx_HospitalDivisionMember_rmkc47I_hEKrtpEwleDiZA", "name": "us-gaap:Assets", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R72": { "role": "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails", "longName": "99941602 - Disclosure - Segment Information - Operations (Details)", "shortName": "Segment Information - Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique":
```

true } }, "R73": { "role": "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941701 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_4_1_2024_To_6_30_2024_Ok_06GIJQEO2Jg9hRBjZcA", "name": "us-gaap:OtherExpenses", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_B3Zi2tNfCESJqtxTQg-IDQ", "name": "us-gaap:AccountsPayableCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R74": { "role": "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "longName": "99941801 - Disclosure - Variable Interest Entities - Balance sheet amounts (Details)", "shortName": "Variable Interest Entities - Balance sheet amounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:AssetsCurrent", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_dei_LegalEntityAxis_nutx_RealEstateEntitiesMember_srt_ConsolidatedEntitiesAxis_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_jcuHvytua0mX0QYG1SS1jA", "name": "us-gaap:AssetsCurrent", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:VariableInterestEntityDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R75": { "role": "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails", "longName": "99941802 - Disclosure - Variable Interest Entities (Details)", "shortName": "Variable Interest Entities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_6_30_2024_ZWj0FZr_G0izZ7wZiuMesw", "name": "nutx:NumberOfConsolidatedRealEstateEntities", "unitRef": "Unit_Standard_item_qRP9d0ySlk2D1CvDYhybRg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2023_dei_LegalEntityAxis_nutx_RealEstateEntitiesMember_G0PdzXE4CkOfeq0bl9aNA", "name": "us-gaap:Cash", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } }, "R76": { "role": "http://nutexhealth.com/role/DisclosureSubsequentEventsDetails", "longName": "99941901 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "As_Of_6_30_2024_sFWdlY4vU0ScDVgoISGjuA", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": null }, "R77": { "role": "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "longName": "99941902 - Disclosure - Subsequent Events - Equity (Details)", "shortName": "Subsequent Events - Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "As_Of_6_30_2023_Ndo_pN7HmUaEVYS-sAMg6g", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Unit_Standard_shares_DqCSTuUiZk6X50qXsXgIZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSubsequentEventsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_BsNL8_kw_UmbfEKC7EqNGQ", "name": "us-gaap:CommonStockValue", "unitRef": "Unit_Standard_USD_9P77BcT72Ey4tMKY86rEVA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSubsequentEventsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "nutx-20240630x10q.htm", "unique": true } } }, "tag": { "nutx_AHPIPAMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "AHPIPAMember", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to AHPIPA.", "label": "AHPIPA [Member]", "terseLabel": "AHISPIPA" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts receivable - related parties", "terseLabel": "Accounts receivable - related parties", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r453"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r69", "r751"] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Related Parties", "terseLabel": "Accounts Payable, Related Parties", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r130", "r995"] }, "nutx_AccountsPayableCurrentForRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "AccountsPayableCurrentForRelatedParty", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities for related parties (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current For Related Party", "terseLabel": "Accounts payable - related parties" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Related Parties", "terseLabel": "Accounts Receivable, Related Parties", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r638", "r688", "r761", "r998", "r999"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts receivable", "terseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r899"] }, "nutx_AccreditedInvestorsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "AccreditedInvestorsWarrantsMember", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to accredited investors warrants.", "label": "Accredited Investors Warrants" } } }, "auth_ref": [] }, "us-gaap_AccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionExpense", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accretion Expense", "terseLabel": "Debt accretion expense", "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations." } } }, "auth_ref": ["r718", "r933"] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued wages and benefits", "terseLabel": "Accrued wages and benefits", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r72", "r697"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r36", "r192", "r566"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://nutexhealth.com/role/DisclosureEquityDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r203", "r204", "r510", "r511", "r512", "r513", "r514", "r515"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://nutexhealth.com/role/DisclosureEquityDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r203", "r204", "r510", "r511", "r512", "r513", "r514", "r515"] }, "nutx_AcquisitionOfFinancingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "AcquisitionOfFinancingLeases", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of financing leases.", "label": "Acquisition of financing leases", "verboseLabel": "Acquisition of finance leases" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r805"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r82", "r751", "r1030"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r616", "r885", "r886", "r887", "r890", "r973", "r1031"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation,

Amount" } } }, "auth_ref": ["r818"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r818"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r818"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r818"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash from operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r851"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r777", "r787", "r797", "r829"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r780", "r790", "r800", "r832"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r852"] }, "nutx_AhpHealthManagementServicesInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "AhpHealthManagementServicesInc.Member", "presentation": ["http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to AHP Health Management Services Inc.", "label": "Ahp Health Management Services Inc. [Member]", "terseLabel": "AHP Health Management Services Inc." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r818"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r825"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r781", "r791", "r801", "r825", "r833", "r837", "r845"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r843"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "nutx_AmortizationOfDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "AmortizationOfDebtIssuanceCost", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance cost.", "label": "Amortization of Debt Issuance Cost", "terseLabel": "Amortization expense" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r7", "r314", "r321", "r717"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r247"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r27"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Earnings per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r27"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r482"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "terseLabel": "Impairment of assets", "verboseLabel": "Intangible impairment", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r7", "r34"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Total assets", "totalLabel": "Total assets", "verboseLabel": "Total Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r128", "r141", "r196", "r218", "r251", "r257", "r282", "r286", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r484", "r488", "r509", "r558", "r643", "r709", "r710", "r751", "r768", "r938", "r939", "r985"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Total current assets", "totalLabel": "Total current assets", "verboseLabel": "Current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r188", "r200", "r218", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r484", "r488", "r509", "r751", "r938", "r939", "r985"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current", "terseLabel": "Assets held-for-sale", "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer." } } }, "auth_ref": ["r108", "r751"] }, "nutx_AssociatedHispanicPhysiciansOfSo.CaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "AssociatedHispanicPhysiciansOfSo.CaliforniaMember", "presentation": ["http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Associated Hispanic Physicians of So. California .", "label": "Associated Hispanic Physicians Of So. California [Member]", "terseLabel": "Associated Hispanic Physicians of So. California" } } }, "auth_ref": [] }, "nutx_August42029ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "August42029ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire August 4, 2029.", "label": "August 4, 2029 Expiration Option [Member]", "terseLabel": "August 4, 2029" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r840"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r841"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r836"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r836"] },

```
"ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } },
"auth_ref": [ "r836" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award
Timing MNPI Considered" } } }, "auth_ref": [ "r836" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing
MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r836" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r836" ] }, "us-gaap_AwardTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails", "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment
arrangement." } } }, "auth_ref": [ "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439",
"r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying
Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r839" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r838" ] }, "ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close
in Time to MNPI Disclosures" } } }, "auth_ref": [ "r837" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [
"r837" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": {
"role": { "label": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial
statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] },
"nutx_BeneficialInterestHeldPriorToIssuanceOfWarrants": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"BeneficialInterestHeldPriorToIssuanceOfWarrants", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents the percentage of common stock beneficially owned by such holder and its affiliates prior to issuance of warrants.", "label": "Beneficial Interest Held, Prior to
Issuance of Warrants", "terseLabel": "Percentage of beneficially owned by the issuance of any warrants" } } }, "auth_ref": [] }, "us-
gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BuildingAndBuildingImprovementsMember", "presentation": [ "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails" ], "lang": { "en-us": { "role":
{ "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements", "documentation": "Facility held for productive use including, but not
limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior
masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [
"http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]",
"documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name
or other type of identification of the acquiree." } } }, "auth_ref": [ "r315", "r316", "r317", "r318", "r319", "r479", "r735", "r736" ] }, "us-gaap_BusinessAcquisitionAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation":
"Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r43", "r44", "r315", "r316", "r317", "r318", "r319",
"r479", "r735", "r736" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang":
{ "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Financed capital expenditures", "documentation": "Future cash outflow to pay for
purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r24", "r25", "r26" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": {
"label": "Cash", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of
accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [
"r144", "r561", "r617", "r637", "r751", "r768", "r874" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other
kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known
amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents
within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r190", "r695" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy
Text Block]", "terseLabel": "Cash and cash equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining
which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash
equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts
(overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } },
"auth_ref": [ "r22" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and
Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents - end of the period", "periodStartLabel":
"Cash and cash equivalents - beginning of the period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or
usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or
financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid
investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes
in interest rates." } } }, "auth_ref": [ "r21", "r100", "r214" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net change in
cash", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents
restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial
institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that
are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
} } }, "auth_ref": [ "r2", "r100" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [
"http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } },
"auth_ref": [] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformation" ], "lang": { "en-us": { "role": {
"label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental Cash Flows Information", "documentation": "The entire disclosure for supplemental
cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an
enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that
portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r96" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r816" ] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year
Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r813" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are
Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } },
"auth_ref": [ "r811" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-
gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails",
"http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of
warrant or right issued." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails",
"http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails", "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label":
"Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that
give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue
to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas
options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is
measured in months." } } }, "auth_ref": [] }, "nutx_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://nutexhealth.com/20240630",
```

```
"localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercisable.", "label": "Class of Warrant or Right, Exercisable", "terseLabel": "Number Exercisable" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise Price", "verboseLabel": "Strike price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails", "http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued to purchase of common stock", "verboseLabel": "Warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r397" ] }, "nutx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRatio": { "xbrltype": "pureItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRatio", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Ratio of number of securities into which the class of warrant or right may be converted.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Ratio", "terseLabel": "Warrants issued ratio" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails", "http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding, ending balance", "periodStartLabel": "Warrants outstanding, beginning balance", "terseLabel": "Number Outstanding", "verboseLabel": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r40" ] }, "nutx_ClinigenceHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ClinigenceHealthIncMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Clinigence Health Inc.", "label": "Clinigence Health Inc [Member]", "terseLabel": "Clinigence Health, Inc" } } }, "auth_ref": [] }, "nutx_ClinigenceHoldingsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ClinigenceHoldingsInc.Member", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Clinigence Holdings, Inc.", "label": "Clinigence Holdings Inc. [Member]", "terseLabel": "Clinigence Holdings, Inc." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r817" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r817" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies.", "terseLabel": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r78", "r132", "r560", "r628" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r112", "r334", "r335", "r689", "r928", "r934" ] }, "nutx_CommonStockIssuedForExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "CommonStockIssuedForExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Common stock issued for exercise of warrants.", "label": "Common stock issued for exercise of warrants", "terseLabel": "Common stock issued for exercise of warrants" } } }, "auth_ref": [] }, "nutx_CommonStockIssuedForExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "CommonStockIssuedForExerciseOfWarrantsShares", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Common stock shares issued for exercise of warrants.", "label": "Common stock issued for exercise of warrants (in shares)", "terseLabel": "Common stock issued for exercise of warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r758", "r759", "r760", "r762", "r763", "r764", "r765", "r885", "r886", "r890", "r973", "r1029", "r1031" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r81" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r81", "r629" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r81" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding", "verboseLabel": "Common Stock - Shares", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r81", "r629", "r649", "r1031", "r1032" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value; 950,000,000 shares authorized; 660,742,624 and 650,223,840 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively", "terseLabel": "Common stock, $0.001 par value; 950,000,000 shares authorized; 4,986,578 and 4,511,199 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively", "verboseLabel": "Common stock", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r81", "r562", "r751" ] }, "nutx_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "CommonStockWarrantsMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails", "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to common stock warrants.", "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r822" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r821" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r823" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r820" ] }, "nutx_ComputerHardwareAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ComputerHardwareAndSoftwareMember", "presentation": [ "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to computer hardware and software.", "label": "Computer Hardware And Software [Member]", "terseLabel": "Computer hardware and software" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation", [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r155", "r167", "r222", "r484", "r485", "r488", "r489", "r538", "r690", "r867", "r870", "r871", "r937", "r940", "r941" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
```

```
"http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]",
"documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r155", "r167", "r222", "r484", "r485", "r488", "r489", "r538", "r690",
"r867", "r870", "r871", "r937", "r940", "r941" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ConsolidationItemsAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails" ], "lang": { "en-us": { "role": { "label":
"Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a
parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r139", "r155", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r222",
"r251", "r259", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r709", "r710", "r868",
"r869", "r938", "r939" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain",
"presentation": [ "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]",
"documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its
operating segments." } } }, "auth_ref": [ "r139", "r155", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r222", "r251", "r259", "r280", "r281", "r282",
"r283", "r284", "r286", "r287", "r288", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r709", "r710", "r868", "r869", "r938", "r939" ] }, "us-
gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems", "presentation": [
"http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation, Less than Wholly Owned
Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]", "terseLabel": "Variable Interest Entities", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable", "presentation": [
"http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation, Less than Wholly Owned
Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]", "documentation": "Disclosure of information about effect of change in parent's ownership interest in
subsidiary on equity attributable to parent. Excludes change from deconsolidation of subsidiary." } } }, "auth_ref": [ "r11", "r53" ] }, "us-
gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember",
"presentation": [ "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress
[Member]", "terseLabel": "Construction in progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures
or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Amount Issued",
"terseLabel": "Reverse stock split adjustment", "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash
is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not
resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r24", "r25", "r26" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails",
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "terseLabel": "Unsecured
convertible term notes", "verboseLabel": "Convertible debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of
the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r114", "r354", "r355", "r365", "r366", "r367", "r371", "r372", "r373",
"r374", "r375", "r719", "r720", "r721", "r722", "r723" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareDetails" ], "lang": { "en-us": { "role":
{ "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible debt securities", "documentation": "Debt securities that can be exchanged for equity of the debt
issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r946" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ],
"lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total operating costs and expenses", "documentation": "Total costs of sales and operating expenses
for the period." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CostsAndExpensesAbstract", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label":
"Operating costs and expenses:" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"CounterpartyNameAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails",
"http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information
by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial
institution." } } }, "auth_ref": [ "r177", "r178", "r220", "r221", "r357", "r386", "r536", "r547", "r556", "r698", "r700" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the
format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CustomerContractsMember", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": {
"label": "Customer Contracts [Member]", "terseLabel": "Customer contracts", "documentation": "Entity's established relationships with its customers through contracts." } } },
"auth_ref": [ "r46", "r916", "r917", "r918", "r919", "r921", "r922", "r924", "r925" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang":
{ "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Debt, Converted Instrument, Amount", "verboseLabel": "Convertible debt
converted to common stock", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash)
transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r24", "r26" ] }, "us-
gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": {
"role": { "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Convertible notes, converted to shares", "documentation": "The number of shares
issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in
cash receipts or payments in the period." } } }, "auth_ref": [ "r24", "r26" ] }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtTermLoansAndLinesOfCreditDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Debt Default, Amount",
"terseLabel": "Debt instrument not in compliance with debt service coverage ratio", "documentation": "Amount of outstanding long-term debt or borrowing associated with
any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at
the end of the period and subsequently has not been cured." } } }, "auth_ref": [ "r216" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire
disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial
paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements,
rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in
compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
} } }, "auth_ref": [ "r113", "r216", "r327", "r328", "r329", "r330", "r331", "r340", "r341", "r353", "r359", "r360", "r361", "r362", "r363", "r364", "r369", "r376", "r377", "r379",
"r517" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": {
"role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } },
"auth_ref": [ "r17", "r71", "r72", "r129", "r131", "r222", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374",
"r375", "r719", "r720", "r721", "r722", "r723", "r749", "r881", "r929", "r930", "r931", "r980", "r981" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "totalLabel": "Total", "documentation":
"Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans,
mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r17", "r131", "r380" ] }, "us-
gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": {
"label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share", "documentation": "The price per share of the conversion feature
embedded in the debt instrument." } } }, "auth_ref": [ "r115", "r356" ] }, "nutx_DebtInstrumentConvertiblePrepaymentNoticePeriod": { "xbrltype": "durationItemType",
"nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentConvertiblePrepaymentNoticePeriod", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The period of notice to be given for
prepayment of convertible debt.", "label": "Debt Instrument, Convertible, Prepayment, Notice Period", "terseLabel": "Prepayment, Notice Period" } } }, "auth_ref": [] },
"nutx_DebtInstrumentConvertiblePrepaymentPremium": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"DebtInstrumentConvertiblePrepaymentPremium", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": {
"role": { "documentation": "The percent of premium to be paid on convertible debt for prepayment.", "label": "Debt Instrument, Convertible, Prepayment Premium",
"terseLabel": "Prepayment Premium" } } }, "auth_ref": [] }, "nutx_DebtInstrumentConvertiblePrepaymentSharePriceThresholdConsecutiveTradingDays": { "xbrltype":
"integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentConvertiblePrepaymentSharePriceThresholdConsecutiveTradingDays",
"presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The threshold consecutive
trading days during which share price less than fixed price for prepayment of debt.", "label": "Debt Instrument, Convertible, Prepayment, Share Price, Threshold Consecutive
Trading Days", "terseLabel": "Prepayment, Threshold Consecutive Trading Days" } } }, "auth_ref": [] }, "nutx_DebtInstrumentConvertibleSharesIssuable": { "xbrltype":
"sharesItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentConvertibleSharesIssuable", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon
conversion of debt.", "label": "Debt Instrument, Convertible, Shares Issuable", "terseLabel": "Additional number of common shares issuable" } } }, "auth_ref": [] },
"nutx_DebtInstrumentDiscountPercent": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentDiscountPercent",
"presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The percent of debt
discount.", "label": "Debt Instrument, Discount, Percent", "terseLabel": "Percentage of debt discount" } } }, "auth_ref": [] }, "us-
gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails",
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate During Period",
"terseLabel": "Interest Rates (as percentage)", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r74", "r372", "r980" ] },
"us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r74", "r382", "r517", "r518", "r749" ] }, "nutx_DebtInstrumentInterestRatePaidInCashPercent": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentInterestRatePaidInCashPercent", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percent of interest rate paid in cash in a debt instrument.", "label": "Debt Instrument, Interest Rate Paid in Cash Percent", "terseLabel": "Interest rate paid in cash (as a percent)" } } }, "auth_ref": [] }, "nutx_DebtInstrumentInterestRatePaidInStockGrantsPercent": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentInterestRatePaidInStockGrantsPercent", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percent of interest rate paid in stock grants in a debt instrument.", "label": "Debt Instrument, Interest Rate Paid in Stock Grants Percent", "terseLabel": "Interest rate paid in kind (as a percent)" } } }, "auth_ref": [] }, "nutx_DebtInstrumentInterestRateUponEventsOfDefault": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentInterestRateUponEventsOfDefault", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The interest rate for funds borrowed in the event of default.", "label": "Debt Instrument, Interest Rate Upon Events of Default", "terseLabel": "Interest Rate Upon Events of Default" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r222", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r719", "r720", "r721", "r722", "r723", "r749", "r881", "r980", "r981" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r17", "r222", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r719", "r720", "r721", "r722", "r723", "r749", "r881", "r929", "r930", "r931", "r980", "r981" ] }, "nutx_DebtInstrumentPercentageOfInterestPayableInDefault": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentPercentageOfInterestPayableInDefault", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of interest payable in default of debt instrument.", "label": "Debt Instrument, Percentage of Interest Payable in Default", "terseLabel": "Adjusted interest rate payable" } } }, "auth_ref": [] }, "nutx_DebtInstrumentPrincipalAndAccruedInterestDefaultTerm": { "xbrltype": "durationItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DebtInstrumentPrincipalAndAccruedInterestDefaultTerm", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument principal and accrued interest default term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Principal and Accrued Interest Default Term", "terseLabel": "Grace days for payment of outstanding principal amount and accrued interests" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r17", "r37", "r38", "r56", "r117", "r118", "r222", "r354", "r355", "r356", "r357", "r358", "r360", "r365", "r366", "r367", "r368", "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r719", "r720", "r721", "r722", "r723", "r749", "r881", "r980", "r981" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "verboseLabel": "Maturity date", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r943", "r979", "r980", "r981" ] }, "nutx_December172031ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "December172031ExpirationOptionMember", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Options that expire December 17, 2031.", "label": "December 17, 2031 Expiration Option [Member]", "terseLabel": "December 17, 2031" } } }, "auth_ref": [] }, "nutx_December312024ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "December312024ExpirationWarrantMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants that expire December 31, 2024.", "label": "December 31, 2024 Expiration Warrant [Member]", "terseLabel": "December 31, 2024" } } }, "auth_ref": [] }, "nutx_December312029ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "December312029ExpirationWarrantMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants that expire December 31, 2029.", "label": "December 31, 2029 Expiration Warrant [Member]", "terseLabel": "December 31, 2029" } } }, "auth_ref": [] }, "nutx_DeconsolidationOfRealEstateEntities": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DeconsolidationOfRealEstateEntities", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deconsolidation of Real Estate Entities.", "label": "Deconsolidation Of Real Estate Entities [Member]", "terseLabel": "Deconsolidation of Real Estate Entity" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "terseLabel": "Less: unamortized issuance costs and discount", "verboseLabel": "Debt Issuance Costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r943", "r979", "r980", "r981" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred tax benefit", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r152", "r883" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r455", "r456", "r559" ] }, "nutx_DeferredRevenueRevenuesRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DeferredRevenueRevenuesRecognized", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revenues recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenues Recognized", "terseLabel": "Revenue for cash collections previously deemed uncollectible" } } }, "auth_ref": [] }, "nutx_DenominatorAttributableToNutexHealthIncAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DenominatorAttributableToNutexHealthIncAbstract", "presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails" ], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Total depreciation and amortization", "verboseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r7", "r35" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r251", "r262", "r286", "r709", "r710" ] }, "nutx_DerecognitionOfGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "DerecognitionOfGoodwill", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The derecognition of goodwill.", "label": "Derecognition Of Goodwill", "negatedLabel": "Derecognition of goodwill", "terseLabel": "Derecognition of goodwill" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails", "http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r407", "r725", "r726", "r727", "r728", "r729", "r730", "r731" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails", "http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r407", "r725", "r726", "r727", "r728", "r729", "r730", "r731" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of disaggregate revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r944" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r418", "r421", "r448", "r449", "r451", "r738" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-based Compensation" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Divestitures" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued operations, disposed of by sale", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": [ "r5" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by
```

disposal group classification." } } }, "auth_ref": ["r186"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration for the transaction", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Intangible asset impairment", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r3", "r58", "r65", "r110"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "terseLabel": "Net loss", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r64"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Total revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r64", "r187"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosureDivestitures"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Divestitures", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r57", "r107"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r735", "r736"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r772"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r804"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r815"] }, "nutx_EREntitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "EREntitiesMember", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to ER entities.", "label": "ER Entities [Member]", "terseLabel": "ER Entities" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings per Share", "terseLabel": "Income (loss) per common share." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic", "terseLabel": "Basic", "verboseLabel": "Basic, income (loss) per common share (in dollar per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r207", "r228", "r229", "r231", "r232", "r233", "r235", "r241", "r242", "r244", "r245", "r246", "r250", "r477", "r481", "r499", "r500", "r553", "r573", "r701"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share Diluted", "terseLabel": "Diluted", "verboseLabel": "Diluted, income (loss) per common share (in dollar per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r207", "r228", "r229", "r231", "r232", "r233", "r235", "r242", "r244", "r245", "r246", "r250", "r477", "r481", "r499", "r500", "r553", "r573", "r701"] }, "us-gaap_EarningsPerShareProFormaAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareProFormaAbstract", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails"], "lang": { "en-us": { "role": { "label": "Loss per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r240", "r247", "r248", "r249"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://nutexhealth.com/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Federal statutory rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r458", "r740"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://nutexhealth.com/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r219", "r458", "r468", "r740"] }, "nutx_EmersonEquityLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "EmersonEquityLlcMember", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Emerson Equity LLC.", "label": "Emerson Equity LLC [Member]", "terseLabel": "Emerson Equity LLC (\"Emerson\")" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits." } } }, "auth_ref": ["r7"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r450"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "nutx_EmployeeStockPurchasePlan2023Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "EmployeeStockPurchasePlan2023Member", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to 2023 employee stock purchase plan.", "label": "Employee Stock Purchase Plan, 2023 [Member]", "terseLabel": "2023 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } }

```
}, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r770" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r770" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r770" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r854" ] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "terseLabel": "Number of full time employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r770" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r770" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r770" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r770" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r809" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r850" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r850" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r850" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r183", "r203", "r204", "r205", "r223", "r224", "r225", "r227", "r233", "r236", "r238", "r252", "r296", "r299", "r325", "r398", "r466", "r467", "r474", "r475", "r476", "r478", "r480", "r481", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r510", "r511", "r512", "r513", "r514", "r515", "r520", "r522", "r531", "r572", "r595", "r596", "r597", "r616", "r673" ] }, "nutx_EquityIncentive2022PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "EquityIncentive2022PlanMember", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to Equity Incentive 2022 Plan.", "label": "Equity Incentive 2022 Plan [Member]", "terseLabel": "Equity Incentive 2022 Plan" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r819" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r777", "r787", "r797", "r829" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r774", "r784", "r794", "r826" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r825" ] }, "nutx_ExerciseOfWarrantsCashlessBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ExerciseOfWarrantsCashlessBasis", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Supplemental cash flow information based on the exercise of warrants on a cashless basis.", "label": "Exercise Of Warrants, Cashless Basis", "terseLabel": "Exercise of warrants on cashless basis" } } }, "auth_ref": [] }, "nutx_FacilitiesClosingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "FacilitiesClosingCosts", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "The amount of expense for facilities closing costs.", "label": "Facilities Closing Costs", "terseLabel": "Facilities closing costs" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "terseLabel": "Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r7" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r367", "r410", "r411", "r412", "r413", "r414", "r415", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r542", "r543", "r544", "r720", "r721", "r732", "r733", "r734", "r743", "r745" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r367", "r410", "r411", "r412", "r413", "r414", "r415", "r502", "r503", "r504", "r505", "r507", "r544", "r720", "r721", "r732", "r733", "r734", "r743", "r745" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair value measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r367", "r410", "r411", "r412", "r413", "r414", "r415", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r542", "r543", "r544", "r720", "r721", "r732", "r733", "r734", "r743", "r745" ] }, "nutx_February262026ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "February262026ExpirationWarrantMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants that expire February 26, 2026.", "label": "February 26, 2026 Expiration Warrant [Member]", "terseLabel": "February 26, 2026" } } }, "auth_ref": [] }, "nutx_February282031ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "February282031ExpirationOptionMember", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "documentation": "Options that expire February 28, 2031.", "label": "February 28, 2031 Expiration Option [Member]", "terseLabel": "February 28, 2031" } } }, "auth_ref": [] }, "nutx_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "FinanceLeaseCost", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureLeasesLeasesOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Total finance lease cost.", "label": "Total finance lease cost", "totalLabel": "Total finance lease cost" } } }, "auth_ref": [] }, "nutx_FinanceLeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri":
```

```
"http://nutexhealth.com/20240630", "localname": "FinanceLeaseCostAbstract", "presentation": [
"http://nutexhealth.com/role/DisclosureLeasesLeasesOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition required", "label":
"Finance Lease Cost [Abstract]", "terseLabel": "Finance lease cost:" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureLeasesLeasesOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Interest on lease liabilities", "terseLabel":
"Interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r526", "r527", "r750" ] }, "us-
gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit",
"presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance lease liabilities, current
portion", "verboseLabel": "Finance lease liabilities, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease,
classified as current." } } }, "auth_ref": [ "r525" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": {
"en-us": { "role": { "label": "Finance lease liabilities, net", "verboseLabel": "Finance lease liabilities, net", "documentation": "Present value of lessee's discounted obligation for
lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r525" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance right-of-use assets", "verboseLabel": "Finance
right-of-use assets", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r524" ] }, "us-
gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureLeasesLeasesOfPropertyAndEquipmentDetails" ], "lang":
{ "en-us": { "role": { "label": "Amortization of right-of-use assets", "terseLabel": "Amortization of right-of-use assets", "documentation": "Amount of amortization expense
attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r526", "r527", "r750" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life",
"terseLabel": "Weighted Average Useful Life (in years)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example,
'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation":
[ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated
Amortization", "terseLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking
physical substance with a finite life." } } }, "auth_ref": [ "r194", "r300", "r320", "r717" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class
[Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r313", "r315", "r316", "r317", "r319", "r320", "r322", "r323",
"r550", "r551", "r693" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails",
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails"
], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets", "verboseLabel": "Intangible Assets and
Goodwill", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [ "r313", "r320", "r322", "r323", "r324", "r550", "r693", "r717" ] }, "us-
gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": {
"en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example,
patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their
use in the operations of a company." } } }, "auth_ref": [ "r313", "r315", "r316", "r317", "r319", "r320", "r322", "r323", "r693" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net",
"verboseLabel": "Net Carrying Amount", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a
finite life." } } }, "auth_ref": [ "r550", "r922" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax
Benefits, Amount" } } }, "auth_ref": [ "r781", "r791", "r801", "r833" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } },
"auth_ref": [ "r781", "r791", "r801", "r833" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country
Law, Amount" } } }, "auth_ref": [ "r781", "r791", "r801", "r833" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } },
"auth_ref": [ "r781", "r791", "r801", "r833" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name",
"terseLabel": "Name" } } }, "auth_ref": [ "r781", "r791", "r801", "r833" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that
Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to
Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r814" ] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Termination of Lease",
"negatedLabel": "Loss on lease termination", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": [ "r523" ] },
"nutx_GainLossOnWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "GainLossOnWarrantLiability", "crdr":
"credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Gain (loss) related to the warranty
liability.", "label": "Gain (Loss) on Warrant Liability", "negatedLabel": "Gain on warrant liability" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses",
"terseLabel": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including
affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r91",
"r653" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails",
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill, net", "terseLabel": "Goodwill, net",
"totalLabel": "Goodwill, Total", "verboseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit
arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } },
"auth_ref": [ "r193", "r301", "r552", "r710", "r716", "r744", "r751", "r905", "r912" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible
Assets and Goodwill" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwill" ], "lang":
{ "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill", "documentation": "The entire disclosure
for goodwill and intangible assets." } } }, "auth_ref": [ "r903", "r915" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails" ], "lang": { "en-
us": { "role": { "label": "Goodwill, Gross", "terseLabel": "Goodwill", "documentation": "Amount, before accumulated impairment loss, of asset representing future economic
benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } },
"auth_ref": [ "r304", "r311", "r716" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Impaired, Accumulated
Impairment Loss", "negatedLabel": "Accumulated impairment losses", "documentation": "Amount of accumulated impairment loss for asset representing future economic
benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } },
"auth_ref": [ "r304", "r311", "r716" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" ], "lang": { "en-us": { "role": {
"label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment", "documentation": "Amount of impairment loss from asset representing future economic benefit
arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } },
"auth_ref": [ "r7", "r302", "r308", "r312", "r716", "r744" ] }, "nutx_GoodwillNonCashImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://nutexhealth.com/20240630", "localname": "GoodwillNonCashImpairmentLoss", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureDivestituresDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash loss from the
write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and
separately recognized.", "label": "Goodwill, Non Cash Impairment Loss", "terseLabel": "Impairment of goodwill", "verboseLabel": "Goodwill impairment loss" } } }, "auth_ref":
[] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails",
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Measurement Period
Adjustment", "terseLabel": "Purchase accounting adjustments", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing
future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately
recognized." } } }, "auth_ref": [ "r1", "r911" ] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails"
```

```
], "lang": { "en-us": { "role": { "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedLabel": "Impairment of goodwill", "terseLabel": "Loss on sale of busines", "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r307", "r716" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "terseLabel": "Total segment operating income", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r87", "r89", "r140", "r218", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r509", "r703", "r709", "r892", "r894", "r895", "r896", "r897", "r938" ] }, "us-gaap_HealthCareOrganizationRevenueSourcesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCareOrganizationRevenueSourcesAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Health Care Organization, Revenue Sources [Axis]", "documentation": "Information by major payor source of revenue for health care organizations." } } }, "auth_ref": [ "r944" ] }, "us-gaap_HealthCareOrganizationRevenueSourcesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCareOrganizationRevenueSourcesDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Health Care Organization, Revenue Sources [Domain]", "documentation": "Major payor source of revenue for health care organizations." } } }, "auth_ref": [ "r944" ] }, "nutx_HospitalDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "HospitalDivisionMember", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails", "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails", "http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Information related to the hospital division.", "label": "Hospital Division [Member]", "terseLabel": "Hospital division", "verboseLabel": "Hospital Division" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r88", "r136", "r140", "r554", "r568", "r703", "r709", "r892", "r894", "r895", "r896", "r897" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r735", "r736" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Divestitures", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r9", "r15", "r18", "r58", "r59", "r60", "r61", "r62", "r63", "r66", "r67", "r68", "r111" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r219", "r454", "r458", "r459", "r460", "r461", "r462", "r463", "r469", "r471", "r472", "r473", "r610", "r740" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax expense", "verboseLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r143", "r153", "r237", "r238", "r251", "r265", "r286", "r457", "r458", "r470", "r574", "r740" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "terseLabel": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r23", "r213", "r464", "r465" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable - related party", "terseLabel": "Accounts payable - related party", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Accounts receivable - related party", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, net of the effects of acquisitions:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Liabilities", "verboseLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r879" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r781", "r791", "r801", "r825", "r833", "r837", "r845" ] }, "nutx_InitialPrePaidAdvanceAmountWithExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "InitialPrePaidAdvanceAmountWithExpenses", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The initial pre-paid advance amount with expenses.", "label": "Initial Pre-paid Advance Amount with Expenses", "terseLabel": "Initial pre-paid advance amount with expenses" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r843" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r773", "r849" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r773", "r849" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r773", "r849" ] }, "nutx_InsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "InsuranceMember", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to insurance.", "label": "Insurance [Member]", "terseLabel": "Insurance" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Carrying Amount", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r193" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "terseLabel": "Intangible assets, net", "verboseLabel": "Net Carrying Amount", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r313", "r922", "r923"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r93", "r373", "r383", "r722", "r723"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest expense, net", "terseLabel": "Interest expense, net", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r261", "r878"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails"], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r208", "r211", "r212"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails"], "lang": { "en-us": { "role": { "label": "Interest Payable", "terseLabel": "Accrued interest expense", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r130", "r995"] }, "nutx_InterimFinancialStatementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "InterimFinancialStatementsPolicyPolicyTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for interim financial statements.", "label": "Interim Financial Statements Policy [Policy Text Block]", "terseLabel": "Interim financial statements" } } }, "auth_ref": [] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": ["http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails"], "lang": { "en-us": { "role": { "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": ["r139", "r251", "r259", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r709"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventories", "terseLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r199", "r696", "r751"] }, "nutx_January212025ExpirationOption2Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January212025ExpirationOption2Member", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire January 21, 2025.", "label": "January 21, 2025 Expiration Option 2 [Member]", "terseLabel": "January 21, 2025" } } }, "auth_ref": [] }, "nutx_January212025ExpirationOption3Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January212025ExpirationOption3Member", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire January 21, 2025.", "label": "January 21, 2025 Expiration Option 3 [Member]", "terseLabel": "January 21, 2025" } } }, "auth_ref": [] }, "nutx_January212025ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January212025ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire January 21, 2025.", "label": "January 21, 2025 Expiration Option [Member]", "terseLabel": "January 21, 2025" } } }, "auth_ref": [] }, "nutx_January252029ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January252029ExpirationWarrantMember", "presentation": ["http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrants that expire January 25, 2029.", "label": "January 25, 2029 Expiration Warrant [Member]", "terseLabel": "January 25, 2029" } } }, "auth_ref": [] }, "nutx_January272027ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January272027ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire January 27, 2027.", "label": "January 27, 2027 Expiration Option [Member]", "terseLabel": "January 27, 2027" } } }, "auth_ref": [] }, "nutx_January272030ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January272030ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire January 27, 2030.", "label": "January 27, 2030 Expiration Option [Member]", "terseLabel": "January 27, 2030" } } }, "auth_ref": [] }, "nutx_January282028ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January282028ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire January 28, 2028.", "label": "January 28, 2028 Expiration Option [Member]", "terseLabel": "January 28, 2028" } } }, "auth_ref": [] }, "nutx_January282031ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "January282031ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire January 28, 2031.", "label": "January 28, 2031 Expiration Option [Member]", "terseLabel": "January 28, 2031" } } }, "auth_ref": [] }, "nutx_July312026ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "July312026ExpirationWarrantMember", "presentation": ["http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrants that expire July 31, 2026.", "label": "July 31, 2026 Expiration Warrant [Member]", "terseLabel": "July 31, 2026" } } }, "auth_ref": [] }, "nutx_June302030ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "June302030ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire June 30, 2030.", "label": "June 30, 2030 Expiration Option [Member]", "terseLabel": "June 30, 2030" } } }, "auth_ref": [] }, "nutx_June92027ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "June92027ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire June 9, 2027.", "label": "June 9, 2027 Expiration Option [Member]", "terseLabel": "June 9, 2027" } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Payroll", "verboseLabel": "Payroll and benefits", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": ["r877"] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails"], "lang": { "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": ["r945"] }, "nutx_LeaseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "LeaseDisclosureTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosureLeases"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Leases" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r109", "r529"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Total liabilities", "totalLabel": "Total liabilities", "verboseLabel": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r17", "r71", "r72", "r73", "r76", "r77", "r78", "r79", "r218", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r485", "r488", "r489", "r509", "r627", "r702", "r768", "r938", "r985", "r986"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Total liabilities and equity", "totalLabel": "Total liabilities and equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r86", "r134", "r565", "r751", "r882", "r900", "r978"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Total current liabilities", "totalLabel": "Total current liabilities", "verboseLabel": "Current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r73", "r189", "r218", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r485", "r488", "r489", "r509", "r751", "r938", "r985", "r986"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails"], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "terseLabel": "Long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r17", "r76", "r77", "r78", "r79", "r218", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r485", "r488", "r489", "r509", "r938", "r985", "r986"] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDivestituresDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities", "terseLabel": "Liabilities", "verboseLabel": "Liabilities assumed", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r3", "r58", "r65", "r110", "r186", "r187"] }, "us-gaap_LifeInsuranceAssumedRatio": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LifeInsuranceAssumedRatio", "presentation": ["http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails"], "lang": { "en-us": { "role": { "label": "Life Insurance Assumed Ratio", "documentation": "Ratio of life insurance assumed from another insurer to gross life insurance in force." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtTermLoansAndLinesOfCreditDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r70", "r75", "r341"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "terseLabel": "Line of credit secured by all assets", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which

borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Lines of credit", "terseLabel": "Lines of credit", "verboseLabel": "Less: short-term lines of credit", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r71", "r129"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://nutexhealth.com/role/DocumentCover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "terseLabel": "Net carrying amount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r17", "r131", "r366", "r381", "r720", "r721", "r749", "r996"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Less: current portion of long-term debt", "terseLabel": "Less: current portion of long-term debt", "verboseLabel": "Current portion of long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r197"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-term debt, net", "verboseLabel": "Long-term debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r198"] }, "nutx_ManagementContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ManagementContractsMember", "presentation": ["http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to management contracts.", "label": "Management contracts", "terseLabel": "Management contracts" } } }, "auth_ref": [] }, "nutx_ManagerialServicesAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ManagerialServicesAgreementsMember", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Managerial Services Agreements.", "label": "Managerial Services Agreements [Member]", "terseLabel": "Managerial Services Agreements" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r156", "r157", "r158", "r159", "r160", "r181", "r182", "r336", "r337", "r338", "r339", "r416", "r452", "r505", "r548", "r593", "r594", "r605", "r619", "r620", "r680", "r681", "r682", "r683", "r684", "r691", "r692", "r715", "r724", "r737", "r745", "r746", "r747", "r748", "r753", "r942", "r988", "r989", "r990", "r991", "r992", "r993"] }, "nutx_May112027ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "May112027ExpirationOptionMember", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Options that expire May 11, 2027.", "label": "May 11, 2027 Expiration Option [Member]", "terseLabel": "May 11, 2027" } } }, "auth_ref": [] }, "nutx_May312027ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "May312027ExpirationWarrantMember", "presentation": ["http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrants that expire May 31, 2027.", "label": "May 31, 2027 Expiration Warrant [Member]", "terseLabel": "May 31, 2027" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r817"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r817"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://nutexhealth.com/role/DisclosureEquityDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r745", "r975", "r976", "r977"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://nutexhealth.com/role/DisclosureEquityDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r503", "r504", "r505", "r745"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://nutexhealth.com/role/DisclosureEquityDetails"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r503", "r504", "r505", "r745"] }, "nutx_MedicalEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MedicalEquipmentMember", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to medical equipment.", "label": "Medical Equipment [Member]", "terseLabel": "Medical equipment" } } }, "auth_ref": [] }, "nutx_MedicalInsuranceClaimLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MedicalInsuranceClaimLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of medical insurance claim liabilities, due within one year of the normal operating cycle, if longer.", "label": "Medical Insurance Claim Liabilities, Current", "terseLabel": "Accrued medical insurance claims" } } }, "auth_ref": [] }, "nutx_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MedicareMember", "presentation": ["http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to medicare and medicaid.", "label": "Medicare [Member]", "terseLabel": "Medicare/Medicaid" } } }, "auth_ref": [] }, "nutx_MemberRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MemberRelationshipsMember", "presentation": ["http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to member relationships.", "label": "Member Relationships [Member]", "terseLabel": "Member relationships" } } }, "auth_ref": [] }, "nutx_MembersContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MembersContributions", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Contributions made by members.", "label": "Members' contributions", "terseLabel": "Members' contributions" } } }, "auth_ref": [] }, "nutx_MembersDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MembersDistributions", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Distributions made to members.", "label": "Members Distributions", "negatedLabel": "Members' distributions" } } }, "auth_ref": [] }, "nutx_MergerAgreementConversionRatio": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MergerAgreementConversionRatio", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of shares issuable upon merger for each share of stock held and to be converted.", "label": "Merger Agreement Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "auth_ref": [] }, "nutx_MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MergerAgreementMember", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to mergers.", "label": "Merger Agreement [Member]", "terseLabel": "Merger Agreement" } } }, "auth_ref": [] }, "nutx_MicroHospitalHoldingLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MicroHospitalHoldingLlcMember", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "DEF: Represents information pertaining to Micro Hospital Holding LLC., an affiliate controlled by CEO.", "label": "Micro Hospital Holding Llc [Member]", "terseLabel": "Micro Hospital Holding LLC" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosureRevenueDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r156", "r157", "r158", "r159", "r160", "r181", "r182", "r336", "r337", "r338", "r339", "r416", "r452", "r505", "r548", "r593", "r594", "r605", "r619", "r620", "r680", "r681", "r682", "r683", "r684", "r691", "r692", "r715", "r724", "r737", "r745", "r746", "r747", "r753", "r942", "r988", "r989", "r990", "r991", "r992", "r993"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Noncontrolling interests", "terseLabel": "Equity attributable to noncontrolling interests", "verboseLabel": "Noncontrolling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r85", "r133", "r218", "r295", "r342", "r345", "r346", "r347", "r351", "r352", "r509", "r564", "r631"] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Distributions", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": ["r119"] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r836"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r844"] }, "nutx_MultiplyingFactorForCalculationOfOwnersProRataShareOfCommonStock": { "xbrltype": "decimalItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "MultiplyingFactorForCalculationOfOwnersProRataShareOfCommonStock", "presentation": ["http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "The multiplying factor for calculation of owners pro rata share of common stock.", "label": "Multiplying factor For Calculation Of Owners Pro Rata Share Of Common Stock", "terseLabel": "Multiplying factor" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock",

```
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r818" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flow from financing activities", "totalLabel": "Net cash from financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flow from investing activities", "totalLabel": "Net cash from investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flow from operating activities", "totalLabel": "Net cash from operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r100", "r101", "r102" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Nutex Health Inc.", "verboseLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r90", "r102", "r137", "r187", "r201", "r202", "r205", "r218", "r226", "r228", "r229", "r231", "r232", "r233", "r237", "r238", "r243", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r477", "r481", "r500", "r509", "r571", "r651", "r671", "r672", "r766", "r938" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net income (loss) attributable to noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r52", "r126", "r201", "r202", "r233", "r237", "r238", "r570", "r876" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent accounting pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r817" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r781", "r791", "r801", "r825", "r833" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r808" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r807" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r825" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r844" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r844" ] }, "nutx_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NoncashLeaseExpense", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Non-cash lease expense.", "label": "Non-cash lease expense", "verboseLabel": "Non-cash lease expense (income)" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Deconsolidation", "negatedLabel": "Deconsolidation of Real Estate Entities", "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest." } } }, "auth_ref": [ "r10", "r39" ] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Contributions", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r10", "r39", "r125" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r47", "r398", "r885", "r886", "r887", "r890", "r1031" ] }, "nutx_November302029ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "November302029ExpirationWarrantMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants that expire November 30, 2029.", "label": "November 30, 2029 Expiration Warrant [Member]", "terseLabel": "November 30, 2029" } } }, "auth_ref": [] }, "nutx_NumberOfConsolidatedRealEstateEntities": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfConsolidatedRealEstateEntities", "presentation": [ "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of real estate entities consolidated.", "label": "Number Of Consolidated Real Estate Entities", "terseLabel": "Number of real estate entities consolidated" } } }, "auth_ref": [] }, "nutx_NumberOfConsolidatedRealEstateEntity": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfConsolidatedRealEstateEntity", "presentation": [ "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of real estate entities consolidated.", "label": "Number of Consolidated Real Estate Entity", "terseLabel": "Number of consolidated real estate entity" } } }, "auth_ref": [] }, "nutx_NumberOfContractDoctors": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfContractDoctors", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of contract doctors employed by the company.", "label": "Number Of Contract Doctors", "terseLabel": "Number of contract doctors" } } }, "auth_ref": [] }, "nutx_NumberOfDeconsolidatedRealEstateEntities": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfDeconsolidatedRealEstateEntities", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtTermLoansAndLinesOfCreditDetails", "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of real estate entities deconsolidated.", "label": "Number of Deconsolidated Real Estate Entities", "terseLabel": "Number of deconsolidated Real Estate Entities" } } }, "auth_ref": [] }, "nutx_NumberOfEmergencyRoomsOperated": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfEmergencyRoomsOperated", "presentation": [ "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents number of emergency rooms operated by the company.", "label": "Number of Emergency Rooms Operated", "terseLabel": "Number of ER Entities operated" } } }, "auth_ref": [] }, "nutx_NumberOfFloridaBasedIpas": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfFloridaBasedIpas", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of Florida based IPAs.", "label": "Number of Florida Based Ipas", "terseLabel": "Florida based IPAs" } } }, "auth_ref": [] }, "nutx_NumberOfHospitalFacilitiesOperated": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfHospitalFacilitiesOperated", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents number of hospital facilities operated by the company.", "label": "Number of Hospital Facilities Operated", "terseLabel": "Number of hospital facilities" } } }, "auth_ref": [] }, "nutx_NumberOfPhysiciansPartnered": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfPhysiciansPartnered", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of physicians with whom the company has partnered.", "label": "Number Of Physicians Partnered", "terseLabel": "Partner with physicians" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r704", "r714", "r893" ] }, "nutx_NumberOfStatesLocations": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfStatesLocations", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents number of states the company operates within.", "label": "Number of States Locations", "terseLabel": "Number of states the company operates within" } } }, "auth_ref": [] }, "nutx_NumberOfVotesEntitledToEachCommonStockHolders": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumberOfVotesEntitledToEachCommonStockHolders", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of votes entitled to each common stock holders.", "label": "Number Of Votes Entitled To Each Common Stock Holders", "terseLabel": "Number of votes entitled to each common stock holders" } } }, "auth_ref": [] },
```

{"nutx_NumeratorAttributableToNutexHealthIncAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NumeratorAttributableToNutexHealthIncAbstract", "presentation": ["http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails"], "lang": { "en-us": { "role": { "label": "Numerator-" } } }, "auth_ref": [] }, "nutx_NutexHealthHoldcoLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NutexHealthHoldcoLLCMember", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Nutex Health Holdco LLC.", "label": "Nutex Health Holdco LLC [Member]", "terseLabel": "Nutex Health Holdco LLC" } } }, "auth_ref": [] }, "nutx_NutexHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NutexHealthIncMember", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Nutex Health Inc.", "label": "Nutex Health Inc [Member]", "terseLabel": "Nutex Health Inc" } } }, "auth_ref": [] }, "nutx_NutexSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "NutexSubsidiariesMember", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Nutex subsidiaries.", "label": "Nutex Subsidiaries [Member]", "terseLabel": "Nutex Subsidiaries" } } }, "auth_ref": [] }, "nutx_October312025ExpirationWarrant2Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "October312025ExpirationWarrant2Member", "presentation": ["http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrants that expire October 31, 2025.", "label": "October 31, 2025 Expiration Warrant 2 [Member]", "terseLabel": "October 31, 2025" } } }, "auth_ref": [] }, "nutx_October312025ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "October312025ExpirationWarrantMember", "presentation": ["http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrants that expire October 31, 2025.", "label": "October 31, 2025 Expiration Warrant [Member]", "terseLabel": "October 31, 2025" } } }, "auth_ref": [] }, "nutx_October312029ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "October312029ExpirationWarrantMember", "presentation": ["http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Warrants that expire October 31, 2029.", "label": "October 31, 2029 Expiration Warrant [Member]", "terseLabel": "October 31, 2029" } } }, "auth_ref": [] }, "nutx_OfficeFurnitureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "OfficeFurnitureAndEquipmentMember", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails"], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine. Also include furniture.", "label": "Office Furniture And Equipment [Member]", "terseLabel": "Office furniture and equipment" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total corporate and other costs", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Corporate and other costs:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating income (loss)", "totalLabel": "Operating income (loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r140", "r703", "r892", "r894", "r895", "r896", "r897"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureLeasesLeasesOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Operating lease cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r528", "r750"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, current portion", "terseLabel": "Operating lease liabilities, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r525"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, net", "terseLabel": "Operating lease liabilities, net", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r525"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating right-of-use assets", "terseLabel": "Operating right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r524"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": ["http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails"], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "terseLabel": "Operating Segment", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r280", "r281", "r282", "r283", "r284", "r287", "r709", "r710"] }, "nutx_OrganizationAndOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "OrganizationAndOperationsAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Organization and Operations" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Variable Interest Entities" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperations"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization and Operations", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": ["r103", "r104", "r105", "r124"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities.", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r72"] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other assets", "verboseLabel": "Other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": ["r127", "r195", "r557", "r710", "r768"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r195"] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other", "terseLabel": "Net expense", "verboseLabel": "Other", "documentation": "Amount of expense classified as other." } } }, "auth_ref": ["r91", "r92"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Accrued other", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r72", "r751"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r94"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r817"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r779", "r789", "r799", "r831"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r782", "r792", "r802", "r834"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r782", "r792", "r802", "r834"] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "nutx_PHPTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PHPTechnologyMember", "presentation": ["http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to PHP Technology.", "label": "P H P Technology [Member]", "terseLabel": "PHP technology" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r806"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_PaymentsForLeasingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLeasingCosts", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Payments for Leasing Costs", "terseLabel": "Lease obligation payments", "documentation": "Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityDetails"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Debt issuance costs", "verboseLabel": "Offering expenses", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r20"] }, "nutx_PaymentsRelatedToLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PaymentsRelatedToLossOnSaleOfBusiness", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the

```
loss on the sale of business.", "label": "Payments Related To Loss On Sale Of Business", "negatedLabel": "Cash related to sale of business" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Other Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property and equipment", "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [ "r97" ] }, "us-gaap_PaymentsToAcquireOtherRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherRealEstate", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Other Real Estate", "negatedLabel": "Cash related to deconsolidation of Real Estate Entities", "documentation": "The cash outflow associated with the purchase of other real estate investments held by the entity for investment purposes not otherwise defined in the taxonomy." } } }, "auth_ref": [ "r97" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r816" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r816" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r808" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r825" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r818" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r807" ] }, "nutx_PercentageOfAverageVolumeWeightedAveragePricesConsideredForCalculatingExercisePriceOfWarrants": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PercentageOfAverageVolumeWeightedAveragePricesConsideredForCalculatingExercisePriceOfWarrants", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of average volume weighted average prices considered for calculating exercise price of warrants.", "label": "Percentage Of Average Volume Weighted Average Prices, Considered For Calculating Exercise Price Of Warrants", "terseLabel": "Weighted average prices" } } }, "auth_ref": [] }, "nutx_PercentageOfCashCommissionPayableOnGrossProceedsFromSaleOfUnits": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PercentageOfCashCommissionPayableOnGrossProceedsFromSaleOfUnits", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of cash commission payable on gross proceeds from sale of units.", "label": "Percentage of Cash Commission Payable on Gross Proceeds from Sale of Units", "terseLabel": "Cash commission payable (as a percent)" } } }, "auth_ref": [] }, "nutx_PercentageOfFaceAmountForIssue": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PercentageOfFaceAmountForIssue", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of the face amount for issue.", "label": "Percentage of the Face Amount for Issue", "terseLabel": "Percentage of the face amount for issue" } } }, "auth_ref": [] }, "nutx_PercentageOfNetPatientServiceRevenue": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PercentageOfNetPatientServiceRevenue", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of net patient service revenue paid by insurers, federal agencies and other non patient third parties.", "label": "Percentage of Net Patient Service Revenue", "terseLabel": "Percentage of net patient service revenue" } } }, "auth_ref": [] }, "nutx_PercentageOfWarrantsToPurchaseCommonStockOnTotalUnits": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PercentageOfWarrantsToPurchaseCommonStockOnTotalUnits", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of warrants to purchase common stock on total units.", "label": "Percentage of Warrants to Purchase Common Stock on Total Units", "terseLabel": "Percentage of warrants to purchase common stock on total units" } } }, "auth_ref": [] }, "nutx_PhysicianLLCsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PhysicianLLCsMember", "presentation": [ "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails",
"http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to Physician LLC.", "label": "Physician LLCs [Member]", "terseLabel": "Physician LLCs" } } }, "auth_ref": [] }, "nutx_PhysicianLlcAndRealEstateEntitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PhysicianLlcAndRealEstateEntitiesMember", "presentation": [
"http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Physician LLC and Real Estate Entities.", "label": "Physician LLC and Real Estate Entities [Member]", "terseLabel": "Physician LLC and Real Estate Entities" } } }, "auth_ref": [] }, "nutx_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to placement agent warrants.", "label": "Placement Agent Warrants" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r809" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r853" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r808" ] }, "nutx_PopulationHealthManagementDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PopulationHealthManagementDivisionMember", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails",
"http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails",
"http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Information related to the population health management division.", "label": "Population Health Management Division [Member]", "terseLabel": "Population health management division", "verboseLabel": "Population Health Management Division" } } }, "auth_ref": [] }, "nutx_PostReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PostReverseStockSplitMember", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to after the reverse stock split.", "label": "Post Reverse Stock Split [Member]", "terseLabel": "After the reverse stock split" } } }, "auth_ref": [] }, "nutx_PrePaidAdvanceAgreementWithYorkvilleMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PrePaidAdvanceAgreementWithYorkvilleMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Pre-Paid Advance Agreement with Yorkville.", "label": "Pre-Paid Advance Agreement with Yorkville [Member]", "terseLabel": "Pre-Paid Advance Agreement with Yorkville" } } }, "auth_ref": [] }, "nutx_PrepaidAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PrepaidAdvanceMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails",
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to prepaid advance.", "label": "Prepaid Advance [Member]", "terseLabel": "Prepaid Advance" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r875" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r873" ] }, "nutx_PriorToReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "PriorToReverseStockSplitMember", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEarningsPerShareDetails",
"http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to prior to reverse stock split.", "label": "Prior to Reverse Stock Split" } } }, "auth_ref": [] }, "nutx_ProcareHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ProcareHealthIncMember", "presentation": [
"http://nutexhealth.com/role/DisclosureDivestituresDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Procare Health Inc.", "label": "Procare Health Inc [Member]", "terseLabel": "Procare Health, Inc" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "terseLabel": "Net Proceeds", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds", "verboseLabel": "Proceeds from common stock issuance, net issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from lines of credit", "verboseLabel": "Proceeds from lines of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r19", "r881" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from notes payable", "terseLabel":
```

"Proceeds from notes payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": { "r19" } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r161", "r162", "r163", "r164", "r165", "r166", "r179", "r290", "r549", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r694", "r725", "r752", "r753", "r754", "r756", "r757", "r872", "r935", "r936", "r944", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r161", "r162", "r163", "r164", "r165", "r166", "r179", "r290", "r549", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r694", "r725", "r752", "r753", "r754", "r756", "r757", "r872", "r935", "r936", "r944", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028"] }, "us-gaap_ProfessionalAndContractServicesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalAndContractServicesExpense", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Contract services", "terseLabel": "Contract services", "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r187", "r201", "r202", "r209", "r218", "r226", "r233", "r237", "r238", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r477", "r481", "r483", "r486", "r487", "r500", "r509", "r554", "r569", "r615", "r651", "r671", "r672", "r741", "r742", "r767", "r876", "r938"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r0", "r529"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipment"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r107", "r147", "r150", "r151"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails"], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r109", "r191", "r567"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r529"] }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property, Plant and Equipment", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "verboseLabel": "Fixed assets", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r0", "r529", "r555", "r567", "r751"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentTables"], "lang": { "en-us": { "role": { "label": "Schedule of property, plant and equipment", "terseLabel": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r8"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r109", "r529"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful Life (years)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r806"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r806"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosureRevenueDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r156", "r157", "r158", "r159", "r160", "r181", "r182", "r336", "r337", "r338", "r339", "r409", "r416", "r444", "r445", "r446", "r452", "r505", "r545", "r546", "r548", "r593", "r594", "r605", "r619", "r620", "r680", "r681", "r682", "r683", "r684", "r691", "r692", "r715", "r724", "r737", "r745", "r746", "r747", "r748", "r753", "r760", "r932", "r942", "r976", "r989", "r990", "r991", "r992", "r993"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails", "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails", "http://nutexhealth.com/role/DisclosureRevenueDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r156", "r157", "r158", "r159", "r160", "r181", "r182", "r336", "r337", "r338", "r339", "r409", "r416", "r444", "r445", "r446", "r452", "r505", "r545", "r546", "r548", "r593", "r594", "r605", "r619", "r620", "r680", "r681", "r682", "r683", "r684", "r691", "r692", "r715", "r724", "r737", "r745", "r746", "r747", "r748", "r753", "r760", "r932", "r942", "r976", "r989", "r990", "r991", "r992", "r993"] }, "nutx_RealEstateDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "RealEstateDivisionMember", "presentation": ["http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to real estate division.", "label": "Real Estate Division [Member]", "terseLabel": "Real estate division" } } }, "auth_ref": [] }, "nutx_RealEstateEntitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "RealEstateEntitiesMember", "presentation": ["http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to real estate entities.", "label": "Real Estate Entities [Member]", "terseLabel": "Real Estate Entities" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r774", "r784", "r794", "r826"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r294", "r654", "r655", "r658"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://nutexhealth.com/role/DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r532", "r533", "r534", "r535", "r537", "r611", "r612", "r613", "r656", "r657", "r658", "r677", "r679"] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "presentation": ["http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails"], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "terseLabel": "Optional prepayment", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r99"] }, "nutx_RepaymentsOfConvertibleDebtPrepaymentPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":

```
"RepaymentsOfConvertibleDebtPrepaymentPremium", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for the prepayment premium of a long-term debt instrument which can be exchanged for a specified amount of another security.", "label": "Repayments of Convertible Debt, Prepayment Premium", "terseLabel": "Prepayment Premium" } } }, "auth_ref": [] },
"nutx_RepaymentsOfConvertibleDebtPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"RepaymentsOfConvertibleDebtPrincipal", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for the repayment of principal amount of a long-term debt instrument which can be exchanged for a specified amount of another security.", "label": "Repayments of Convertible Debt, Principal", "terseLabel": "Convertible Debt, Principal" } } }, "auth_ref": [] }, "us-
gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit",
"presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Lines of
Credit", "negatedLabel": "Repayments of lines of credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r99", "r881" ] }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayment of Long-Term Debt, Long-Term
Lease Obligation, and Capital Security", "negatedLabel": "Repayments of finance leases", "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation." } } }, "auth_ref": [ "r98", "r99" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Notes Payable",
"negatedLabel": "Repayments of notes payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [
"r99" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": {
"label": "Repayments of Related Party Debt", "terseLabel": "Repayments of related party debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r99" ] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails",
"http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r177", "r178", "r220", "r221", "r357", "r386", "r536", "r547", "r556", "r699", "r700" ] }, "srt_RestatementAdjustmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": [
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "label": "Impact of Reverse Stock Split", "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r223", "r224", "r225", "r235", "r236", "r250", "r498", "r499", "r521", "r857", "r858", "r859", "r860", "r861", "r864", "r865", "r898" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "RestatementAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r180", "r184", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r234", "r235", "r236", "r237", "r238", "r239", "r250", "r297", "r298", "r475", "r476", "r477", "r478", "r480", "r481", "r497", "r498", "r499", "r500", "r519", "r521", "r530", "r531", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r606", "r898" ] },
"ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r775", "r785", "r795", "r827" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement
Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r776", "r786", "r796", "r828" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r783", "r793", "r803", "r835" ] }, "srt_RestatementDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation":
"Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r180", "r184", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r234", "r235", "r236", "r237", "r238", "r239", "r250", "r297", "r298", "r475", "r476", "r477", "r478", "r480", "r481", "r497", "r498", "r499", "r500", "r519", "r521", "r530", "r531", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r606", "r898" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r874", "r880", "r994", "r997" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails" ],
"lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r27" ] },
"nutx_RestrictedStockUnitsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "RestrictedStockUnitsIssued", "crdr":
"credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The value of restricted stock units issued in noncash financing activities.", "label": "Restricted Stock Units Issued", "terseLabel": "Issuance of restricted stock units" } } }, "auth_ref": [] },
"us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember",
"presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings (accumulated deficit)", "terseLabel":
"Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r83", "r119", "r563", "r599", "r604", "r609", "r630", "r751" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember",
"presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r183", "r223", "r224", "r225", "r227", "r233", "r236", "r238", "r296", "r299", "r325", "r466", "r467", "r474", "r475", "r476", "r478", "r480", "r481", "r490", "r492", "r493", "r495", "r498", "r520", "r522", "r595", "r597", "r616", "r1031" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue" } } }, "auth_ref": [] }, "us-
gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenue" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r154", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r408" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails",
"http://nutexhealth.com/role/DisclosureRevenueDisaggregateRevenueDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total revenue", "terseLabel": "Total revenue", "verboseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r138", "r139", "r206", "r218", "r251", "r258", "r259", "r280", "r286", "r290", "r292", "r293", "r295", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r509", "r554", "r709", "r938" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenuesAbstract", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": {
"label": "Revenue:" } } }, "auth_ref": [] }, "nutx_ReversalOfShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630",
"localname": "ReversalOfShareBasedCompensationExpense", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails" ],
"lang": { "en-us": { "role": { "documentation": "Amount of reversal of share based compensation expense during the period", "label": "Reversal Of Share Based Compensation Expense", "terseLabel": "Accrued stock based compensation" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r844" ] }, "ecd_Rule10b51ArrTrmntdFlag":
{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r844" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label":
"Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net cash proceeds, received", "verboseLabel": "Gross proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label":
"Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] },
"srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember",
"presentation": [ "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "label": "As Previously Reported", "documentation":
"Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r184", "r223", "r225", "r226", "r227", "r228", "r229", "r238", "r250", "r475", "r477", "r478", "r480", "r481", "r497", "r498", "r499", "r519", "r521", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r606", "r861", "r862", "r863", "r864", "r888", "r898", "r901", "r902", "r974", "r983", "r984" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScenarioUnspecifiedDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails",
```

```
"http://nutexhealth.com/role/DisclosureEarningsPerShareDetails", "http://nutexhealth.com/role/DisclosureEquityDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]",
"documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } },
"auth_ref": [ "r180", "r239", "r417", "r855", "r889" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of accrued expenses and other
current liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically
been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities.
Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An
alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from
Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future
that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of supplemental cash flows information",
"terseLabel": "Schedule of supplemental cash flows information", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } }
}, "auth_ref": [] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesTables" ], "lang": { "en-us": { "role": {
"label": "Schedule of consolidated balance sheets", "terseLabel": "Schedule of consolidated balance sheets", "documentation": "Tabular disclosure of condensed balance sheet,
including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r866", "r884" ] }, "us-
gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock",
"presentation": [ "http://nutexhealth.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of debt", "terseLabel": "Schedule of debt",
"documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms,
features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareTables" ], "lang": { "en-us": {
"role": { "label": "Schedule of earnings (loss) per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a
reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r891" ] }, "us-
gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails",
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails"
], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset.
Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r313", "r320", "r322", "r323", "r324", "r550", "r693", "r717" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel":
"Schedule of carrying amount of goodwill, by operating segment", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a
rollforward schedule." } } }, "auth_ref": [ "r716", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914" ] }, "us-
gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfImpairedIntangibleAssetsTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label":
"Schedule of Impaired Intangible Assets [Table Text Block]", "terseLabel": "Schedule of assets", "documentation": "Tabular disclosure of impaired intangible assets excluding
goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the
impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and
the segment in which the impaired intangible assets are reported." } } }, "auth_ref": [ "r926" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillTables" ], "lang": { "en-us": { "role": { "label": "Schedule of intangible assets", "documentation": "Tabular
disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r903", "r915" ] },
"nutx_ScheduleOfOutstandingWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"ScheduleOfOutstandingWarrantsTableTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityTables" ], "lang": { "en-us": { "role": { "documentation":
"Tabular disclosure of warrants outstanding.", "label": "Schedule of outstanding warrants", "terseLabel": "Schedule of outstanding warrants" } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails",
"http://nutexhealth.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation":
"Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets,
depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8", "r529" ] }, "us-
gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": {
"label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block]", "terseLabel": "Schedule of lease of property and equipment",
"documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease." } } }, "auth_ref": [ "r142", "r927",
"r982" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": {
"role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } },
"auth_ref": [ "r54", "r55", "r654", "r655", "r658" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [
"http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails" ], "lang": { "en-us":
{ "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by
reportable segment." } } }, "auth_ref": [ "r31", "r32", "r33" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table
Text Block]", "terseLabel": "Schedule of segment information", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An
entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating
decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref":
[ "r31", "r32", "r33" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationTables" ],
"lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Schedule of stock-based awards activity",
"documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end
of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r13", "r14", "r122" ] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails", "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-
Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } },
"auth_ref": [ "r419", "r420", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440",
"r441", "r442", "r443", "r444", "r445", "r446", "r447" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement,
Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of changes in restricted stock units", "documentation": "Tabular disclosure of the number and
weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that
were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r121" ] }, "us-
gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation":
[ "http://nutexhealth.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price
Range [Table Text Block]", "terseLabel": "Schedule of stock options outstanding", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges,
including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } },
"auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityTables" ], "lang": { "en-us": {
"role": { "label": "Schedule of Warrants, Activity", "terseLabel": "Schedule of common stock warrants", "documentation": "Tabular disclosure of warrants or rights issued.
Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a
certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is
that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often
measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the
aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or
right is exercisable." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfSubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfSubsequentEventsTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSubsequentEventsTables" ], "lang": { "en-us": {
"role": { "label": "Schedule of Subsequent Events [Table Text Block]", "terseLabel": "Schedule of reverse stock split retroactively adjusted", "documentation": "Tabular
disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial
statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood,
losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of
inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments,
```

```
and substantial dividends not in the ordinary course of business." } } }, "auth_ref": { "r987" } }, "nutx_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://nutexhealth.com/20240630", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ],
"lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the securities purchase agreement.", "label": "Securities Purchase Agreement
[Member]", "terseLabel": "Securities purchase agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Title of
12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r769" ] }, "dei_SecurityExchangeName": { "xbrltype":
"edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://nutexhealth.com/role/DocumentCover"
], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r771" ] },
"us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails",
"http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails",
"http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of
an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } },
"auth_ref": [ "r138", "r139", "r140", "r141", "r251", "r254", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r270", "r271", "r272",
"r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r293", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r324", "r332", "r333", "r575",
"r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r706", "r709", "r710", "r716", "r755", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005",
"r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024",
"r1025", "r1026", "r1027", "r1028" ] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": [
"http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Segment, Expenditure, Addition to Long-Lived Assets",
"terseLabel": "Total capital expenditures", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief
operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of
financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": [ "r251", "r268", "r286", "r709", "r710" ]
}, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": {
"role": { "label": "Segment Information" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSegmentInformation" ], "lang":
{ "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information", "documentation": "The entire disclosure for reporting
segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to
external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute
amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a
loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." }
} }, "auth_ref": [ "r141", "r251", "r253", "r254", "r255", "r256", "r257", "r269", "r271", "r272", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r293", "r704", "r707",
"r708", "r709", "r711", "r713", "r714" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SegmentReportingInformationLineItems", "presentation": [ "http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails",
"http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]",
"terseLabel": "Segment Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [
"http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment reporting", "documentation":
"Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r289", "r292", "r705", "r706", "r712" ] },
"nutx_SelfsPayMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "SelfsPayMember", "presentation": [
"http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to self
pay.", "label": "Selfs Pay [Member]", "terseLabel": "Self pay" } } }, "auth_ref": [] }, "nutx_September2023PrivateOfferingAsAmendedMember": { "xbrltype": "domainItemType",
"nsuri": "http://nutexhealth.com/20240630", "localname": "September2023PrivateOfferingAsAmendedMember", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Information related to the amendment to
September 2023 Private Offering.", "label": "September 2023 Private Offering As Amended [Member]", "terseLabel": "September 2023 Private Offering As Amended" } } },
"auth_ref": [] }, "nutx_September2023PrivateOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"September2023PrivateOfferingMember", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": {
"documentation": "September 2023 Private Offering [Member].", "label": "September 2023 Private Offering [Member]", "terseLabel": "September 2023 Private Offering" } } },
"auth_ref": [] }, "nutx_September302029ExpirationWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"September302029ExpirationWarrantMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails" ], "lang": { "en-us": {
"role": { "documentation": "Warrants that expire September 30, 2029", "label": "September 30, 2029 Expiration Warrant [Member]", "terseLabel": "September 30, 2029" } } },
"auth_ref": [] }, "nutx_September92031ExpirationOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"September92031ExpirationOptionMember", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-
us": { "role": { "documentation": "Options that expire September 9, 2031.", "label": "September 9, 2031 Expiration Option [Member]", "terseLabel": "September 9, 2031" } } },
"auth_ref": [] }, "nutx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfAnniversaries": { "xbrltype": "integerItemType", "nsuri":
"http://nutexhealth.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfAnniversaries", "presentation":
[ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of anniversaries of
vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Award Vesting, Number of
Anniversaries", "terseLabel": "Award Vesting, Number of Anniversaries" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Share-based award vesting period", "documentation": "Period over which grantee's right
to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service
condition." } } }, "auth_ref": [ "r738" ] },
"nutx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanMarketGrantPricePercentage": { "xbrltype": "percentItemType",
"nsuri": "http://nutexhealth.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEmployeeStockPurchasePlanMarketGrantPricePercentage", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of the
market value at which employee stock purchase plan participants are entitled to purchase stock under the plan.", "label": "Share Based Compensation Arrangement By Share
Based Payment Award Employee Stock Purchase Plan Market Grant Price Percentage", "terseLabel": "Percentage of the market value at which employee stock purchase plan
participants are entitled to purchase stock under the plan" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "documentation": "The
number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan,
performance target plan)." } } }, "auth_ref": [ "r436" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel":
"Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option
plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r436" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance",
"periodStartLabel": "Beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist
and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r433", "r434" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-Based Payment
Arrangement Rollforward", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending
balance", "periodStartLabel": "Beginning balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment
arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r433", "r434" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
"terseLabel": "Weighted Average Grant-Date Fair Value Per Share" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
```

```
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "verboseLabel": "Vested",
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r437" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel":
"Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the
grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in
accordance with the terms of the arrangement." } } }, "auth_ref": [ "r437" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"presentation": [ "http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Payment Arrangement", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
} } }, "auth_ref": [ "r419", "r420", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439",
"r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Maximum aggregate number of shares that may be issued", "verboseLabel":
"Shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r739" ] },
"nutx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantMaximumAnnualPercentageIncreaseOfIssuedAndOutstandingSha
{ "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantMaximumAnnualPercentageIncreaseOfIssuedAndOutstandingShares",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum annual percentage
increase on the issued and outstanding shares to shares available for grant under the share based arrangement.", "label": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Number of Shares Available for Grant, Maximum Annual Percentage Increase Of Issued And Outstanding Shares", "terseLabel": "Shares issued and
outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement
by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number Exercisable", "documentation": "The number of shares into which fully or partially
vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r427" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationStockBasedAwardsActivityDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options,
Outstanding, Ending Balance", "periodStartLabel": "Options, Outstanding, Beginning Balance", "terseLabel": "Number Outstanding", "documentation": "Number of options
outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r425", "r426" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationStockBasedAwardsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-Based Compensation Arrangement Roll-Forward", "documentation":
"A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationStockBasedAwardsActivityDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number..", "periodEndLabel": "Weighted
Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance", "terseLabel": "Exercise Price", "documentation":
"Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r425", "r426" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationStockBasedAwardsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } },
"auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityScheduleOfOutstandingWarrantsDetails", "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationOptionsOutstandingDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref":
[ "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443",
"r444", "r445", "r446", "r447" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment
Arrangement, Tranche One [Member]", "terseLabel": "Vested on April 1, 2023", "documentation": "First portion of award under share-based payment arrangement
differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationAwardTrancheThreeMember", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment
Arrangement, Tranche Three [Member]", "terseLabel": "Vest on March 1, 2025", "documentation": "Third portion of award under share-based payment arrangement
differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationAwardTrancheTwoMember", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment
Arrangement, Tranche Two [Member]", "terseLabel": "Vested on March 1, 2024", "documentation": "Second portion of award under share-based payment arrangement
differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] },
"nutx_ShareBasedPaymentArrangementTrancheFifthMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"ShareBasedPaymentArrangementTrancheFifthMember", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "documentation": "Fifth portion
of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-
Based Payment Arrangement, Tranche Fifth [Member]", "terseLabel": "Vest on March 1 2027" } } }, "auth_ref": [] },
"nutx_ShareBasedPaymentArrangementTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"ShareBasedPaymentArrangementTrancheFourMember", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "documentation": "Fourth
portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label":
"Share-Based Payment Arrangement, Tranche Four [Member]", "terseLabel": "Vest on March 1 2026" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Share price", "documentation":
"Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails", "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ],
"lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting
Rights, Percentage", "verboseLabel": "Share-based payment award vesting rights (as a percent)", "documentation": "Percentage of vesting of award under share-based
payment arrangement." } } }, "auth_ref": [ "r947" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationStockBasedAwardsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining
Contractual Life (Years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example,
'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r123" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [
```

```
"http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Offering price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "End balance, shares", "periodStartLabel": "Beginning balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "nutx_SignageMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "SignageMember", "presentation": [ "http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to signage.", "label": "Signage [Member]", "terseLabel": "Signage" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r103", "r215" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillDetails", "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillOperatingSegmentDetails",
"http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails", "http://nutexhealth.com/role/DisclosureSegmentInformationAssetsDetails",
"http://nutexhealth.com/role/DisclosureSegmentInformationOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r138", "r139", "r140", "r141", "r185", "r251", "r254", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r270", "r271", "r272", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r293", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r324", "r326", "r332", "r333", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r706", "r709", "r710", "r716", "r755", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails",
"http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r81", "r84", "r85", "r183", "r203", "r204", "r205", "r223", "r224", "r225", "r227", "r233", "r236", "r238", "r252", "r296", "r299", "r325", "r398", "r466", "r467", "r474", "r475", "r476", "r478", "r480", "r481", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r510", "r511", "r512", "r513", "r514", "r515", "r520", "r522", "r531", "r572", "r595", "r596", "r597", "r616", "r673" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails", "http://nutexhealth.com/role/DisclosureRevenueDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails", "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
"http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r223", "r224", "r225", "r252", "r522", "r549", "r607", "r618", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r632", "r633", "r634", "r635", "r636", "r639", "r640", "r641", "r642", "r644", "r645", "r646", "r647", "r648", "r650", "r652", "r653", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r673", "r761" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEarningsPerShareDetails",
"http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r180", "r239", "r417", "r855", "r856", "r889" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails",
"http://nutexhealth.com/role/DisclosureRevenueDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails",
"http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r223", "r224", "r225", "r252", "r294", "r522", "r549", "r607", "r618", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r632", "r633", "r634", "r635", "r636", "r639", "r640", "r641", "r642", "r644", "r645", "r646", "r647", "r648", "r650", "r652", "r653", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r673", "r761" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r778", "r788", "r798", "r830" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued", "terseLabel": "Common stock issued for Employee Stock Purchase Plan", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r24", "r25", "r26" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Reverse acquisition with Clinigence , shares", "terseLabel": "Common stock issued for acquisition (in shares)", "verboseLabel": "Common stock issued for acquisition (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r80", "r81", "r119" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Debt conversion to common stock (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r12", "r37", "r81", "r84", "r119", "r370" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued for Employee Stock Purchase Plan (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r12", "r80", "r81", "r119" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common stock issuance (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r12", "r80", "r81", "r119", "r608", "r673", "r685" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Restricted common stock awards issued (in shares)", "verboseLabel": "Vesting of Restricted Stock Units (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r12", "r119" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Reverse stock split adjustment (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r12" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Restricted stock awards issued for compensation (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r12", "r80", "r81", "r119" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common stock issued for acquisition", "verboseLabel": "Payment for acquisition in common stock", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r12", "r81", "r84", "r85", "r119" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Debt conversion to common stock", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r12", "r81", "r84", "r85", "r119" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued for Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r12", "r80", "r81", "r119" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails",
```

```
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "positiveLabel": "Allocation of proceeds related to common stock issuance", "terseLabel": "Issuance of common stock to Apollo Medical Holdings, Inc.", "verboseLabel": "Common stock issuance", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r12", "r80", "r81", "r119", "r616", "r673", "r685", "r767" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails", "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of Restricted Stock Units", "verboseLabel": "Restricted common stock awards issued", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r12", "r80", "r81", "r119" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Restricted stock awards issued for compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r42", "r80", "r81", "r119" ] }, "nutx_StockReceivedInSaleOfBusinessDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "StockReceivedInSaleOfBusinessDuringPeriodShares", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares received during the period in sale of business.", "label": "Stock Received in Sale of Business During Period, Shares", "terseLabel": "Common stock received in sale of business (in shares)" } } }, "auth_ref": [] }, "nutx_StockReceivedInSaleOfBusinessDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "StockReceivedInSaleOfBusinessDuringPeriodValue", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails", "http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of shares received during the period in sale of business.", "label": "Stock Received In Sale Of Business During Period, Value", "negatedLabel": "Common stock received in sale of business", "terseLabel": "Common stock received in sale of business", "verboseLabel": "Remitted Company stock" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Nutex Health Inc. equity", "verboseLabel": "Equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r81", "r84", "r85", "r106", "r631", "r649", "r674", "r675", "r751", "r768", "r882", "r900", "r978", "r1031" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets",
"http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Total equity", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total equity", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r47", "r48", "r51", "r183", "r184", "r204", "r223", "r224", "r225", "r227", "r233", "r236", "r296", "r299", "r325", "r390", "r466", "r467", "r474", "r475", "r476", "r478", "r480", "r481", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r510", "r511", "r515", "r521", "r531", "r596", "r597", "r614", "r631", "r649", "r674", "r675", "r686", "r767", "r882", "r900", "r978", "r1031" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [
"http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity," } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r116", "r217", "r384", "r385", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r496", "r676", "r678", "r687" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails",
"http://nutexhealth.com/role/DisclosureStockBasedCompensationDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": {
"label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Conversion ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r120" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://nutexhealth.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r516", "r540" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://nutexhealth.com/role/DisclosureDivestituresDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r516", "r540" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [
"http://nutexhealth.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r516", "r540" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureDivestituresDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r516", "r540" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://nutexhealth.com/role/DisclosureDivestituresDetails", "http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r516", "r540" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r539", "r541" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails",
"http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "label": "Supplemental Cash Flows Information" } } }, "auth_ref": [] },
"nutx_SupplierExpensesLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "SupplierExpensesLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of supplier expenses liabilities, due within one year of the normal operating cycle, if longer.", "label": "Supplier Expenses Liabilities, Current", "terseLabel": "Accrued supplier expenses" } } }, "auth_ref": [] }, "us-gaap_SuppliesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SuppliesExpense", "crdr": "debit", "presentation": [ "http://nutexhealth.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Medical supplies", "terseLabel": "Medical supplies", "documentation": "Amount of expense associated with supplies that were used during the current accounting period." } } }, "auth_ref": [ "r135" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r824" ] }, "us-gaap_TargetedOrTrackingStockDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TargetedOrTrackingStockDescriptionTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureRevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of allocation of the estimated transaction price", "documentation": "Tabular disclosure of quantitative and qualitative information related to target or tracking stock issued, including, but not limited to, pricing of transactions and cost allocation method used." } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Taxes Payable, Current", "terseLabel": "Accrued taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r71", "r72" ] }, "nutx_TermLoan1Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "TermLoan1Member", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to term loans secured by property and equipment.", "label": "Term Loan 1 [Member]", "terseLabel": "Term loans secured by property and equipment" } } }, "auth_ref": [] },
"nutx_TermLoan3Member": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "TermLoan3Member", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to term loans of consolidated Real Estate Entities.", "label": "Term Loan 3 [Member]", "terseLabel": "Term loans of consolidated Real Estate Entities" } } }, "auth_ref": [] },
"nutx_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "TermLoanMember", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to term loans secured by assets.", "label": "Term Loan [Member]", "terseLabel": "Term loans secured by all assets" } } }, "auth_ref": [] }, "nutx_TermLoanSecuredByDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "TermLoanSecuredByDepositsMember", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to term loan secured by deposits.", "label": "Term loan secured by deposits" } } }, "auth_ref": [] },
"nutx_ThresholdTradingDaysConsideredInCalculatingVolumeWeightedAveragePricesForCalculatingExercisePriceOfWarrants": { "xbrltype": "integerItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "ThresholdTradingDaysConsideredInCalculatingVolumeWeightedAveragePricesForCalculatingExercisePriceOfWarrants", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of trading days considered in calculating volume weighted average prices for calculating exercise price of warrants.", "label": "Threshold Trading Days Considered In Calculating Volume Weighted Average Prices For Calculating Exercise Price Of Warrants", "terseLabel": "Trading days" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r816" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [
```

```
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r823" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Trademarks [Member]", "terseLabel": "Trademarks", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r45", "r717", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r843" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r845" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://nutexhealth.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Transaction [Domain]", "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r700" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransactionTypeAxis", "presentation": [
"http://nutexhealth.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r700" ] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureIntangibleAssetsAndGoodwillComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "terseLabel": "Derecognized intangible assets", "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition." } } }, "auth_ref": [ "r16" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r846" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r847" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r847" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r845" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r845" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r848" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r846" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails",
"http://nutexhealth.com/role/DisclosureOrganizationAndOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r482" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r842" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r28", "r29", "r30", "r145", "r146", "r148", "r149" ] }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": [ "http://nutexhealth.com/role/DisclosureVariableInterestEntities" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "Variable Interest Entities", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": [ "r124" ] }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityOwnershipPercentage", "presentation": [ "http://nutexhealth.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "Percentage of control", "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)." } } }, "auth_ref": [ "r50" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://nutexhealth.com/role/DisclosureVariableInterestEntitiesBalanceSheetAmountsDetails" ], "lang": { "en-us": { "role": { "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Primary Beneficiary", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r49", "r484", "r485", "r488", "r489" ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [
"http://nutexhealth.com/role/DisclosurePropertyAndEquipmentCategoriesDetails" ], "lang": { "en-us": { "role": { "label": "Vehicles [Member]", "terseLabel": "Vehicles", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://nutexhealth.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsIssuedAndVestedDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r812" ] }, "nutx_WarrantLiabilityRelatedToCommonStockIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantLiabilityRelatedToCommonStockIssuance", "crdr": "credit", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails",
"http://nutexhealth.com/role/DisclosureSupplementalCashFlowsInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of Warrant liability related to common stock issuance arising under non-cash transaction.", "label": "Warrant Liability Related To Common Stock Issuance", "terseLabel": "Warrant liability related to common stock issuance" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r758", "r759", "r762", "r763", "r764", "r765" ] }, "nutx_WarrantsAmended": { "xbrltype": "sharesItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantsAmended", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails",
"http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants amended during the period.", "label": "Warrants Amended", "terseLabel": "Warrants amended" } } }, "auth_ref": [] }, "nutx_WarrantsAmendedWeightedAverageIssuedPrice": { "xbrltype": "perShareItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantsAmendedWeightedAverageIssuedPrice", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of warrant amended when converting their warrants into shares.", "label": "Warrants Amended, Weighted Average Issued Price", "terseLabel": "Warrants amended (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails",
"http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Fair value of the warrant", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r975", "r976", "r977" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails", "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails",
"http://nutexhealth.com/role/DisclosureEquityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants Weighted Average Remaining Contractual Life (years)", "verboseLabel": "Warrant duration", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r975", "r976", "r977" ] }, "nutx_WarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantsExercised", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the period.", "label": "Warrants Exercised", "negatedLabel": "Warrants exercised" } } }, "auth_ref": [] }, "nutx_WarrantsExercisedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantsExercisedWeightedAverageExercisePrice", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which holders acquired shares when converting their warrants into shares.", "label": "Warrants Exercised, Weighted Average Exercise Price", "terseLabel": "Warrants exercised (in dollars per share)" } } }, "auth_ref": [] }, "nutx_WarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantsExpired", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails", "http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants expired.", "label": "Warrants Expired", "negatedLabel": "Warrants expired" } } }, "auth_ref": [] }, "nutx_WarrantsExpiredWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
```

```
"WarrantsExpiredWeightedAverageExercisePrice", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of warrants expired.",
"label": "Warrants Expired Weighted Average Exercise Price", "terseLabel": "Warrants expired (in dollars per share)" } } }, "auth_ref": [] },
"nutx_WarrantsHoldersProhibitedFromExercisingWarrantsThresholdBeneficialInterest": { "xbrltype": "percentItemType", "nsuri": "http://nutexhealth.com/20240630",
"localname": "WarrantsHoldersProhibitedFromExercisingWarrantsThresholdBeneficialInterest", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityDetails" ],
"lang": { "en-us": { "role": { "documentation": "Represents the threshold of common stock beneficially owned by such holder and its affiliates exceeding specified percentage
resulting in prohibition of exercising warrants.", "label": "Warrants Holders Prohibited From Exercising Warrants, Threshold Beneficial Interest", "terseLabel": "Percentage of
beneficially owned by such holder" } } }, "auth_ref": [] }, "nutx_WarrantsIssuedWeightedAverageIssuedPrice": { "xbrltype": "perShareItemType", "nsuri":
"http://nutexhealth.com/20240630", "localname": "WarrantsIssuedWeightedAverageIssuedPrice", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of warrant issued when
converting their warrants into shares.", "label": "Warrants Issued, Weighted Average Issued Price", "terseLabel": "Warrant issued (in dollar per share)" } } }, "auth_ref": [] },
"nutx_WarrantsNumberRollforwardAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"WarrantsNumberRollforwardAbstract", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": {
"documentation": "No definition available.", "label": "Warrants , Number Rollforward [Abstract]", "terseLabel": "Warrants Outstanding" } } }, "auth_ref": [] },
"nutx_WarrantsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nutexhealth.com/20240630", "localname":
"WarrantsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average of number of warrants or rights
outstanding.", "label": "Warrants Outstanding Weighted Average Exercise Price", "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
"periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)" } } }, "auth_ref": [] }, "nutx_WarrantsWeightedAverageExercisePriceAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantsWeightedAverageExercisePriceAbstract", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityCommonStockWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Warrants
Weighted Average Exercise Price [Abstract]", "terseLabel": "Warrants Weighted Average Exercise Price" } } }, "auth_ref": [] }, "nutx_WarrantyLiabilityNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "WarrantyLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://nutexhealth.com/role/DisclosureEquityDetails", "http://nutexhealth.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"documentation": "Present value of warranty liability, classified as noncurrent.", "label": "Warranty, Liability, Noncurrent", "terseLabel": "Warrant liability" } } }, "auth_ref": [] },
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://nutexhealth.com/role/DisclosureEarningsPerShareComputationOfEpsDetails",
"http://nutexhealth.com/role/DisclosureSubsequentEventsEquityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average shares used to compute basic EPS",
"terseLabel": "Weighted average shares used to compute basic EPS", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or
units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period." } } }, "auth_ref": [ "r241", "r246" ] }, "us-gaap_WorkersCompensationInsuranceMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "WorkersCompensationInsuranceMember", "presentation": [
"http://nutexhealth.com/role/DisclosureRevenueInsuranceCoverageDetails" ], "lang": { "en-us": { "role": { "label": "Workers' Compensation Insurance [Member]", "terseLabel":
"Workers compensation", "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death." } } }, "auth_ref": [] },
"nutx_YorkvilleMember": { "xbrltype": "domainItemType", "nsuri": "http://nutexhealth.com/20240630", "localname": "YorkvilleMember", "presentation": [
"http://nutexhealth.com/role/DisclosureDebtPrePaidAdvanceAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to
Yorkville.", "label": "Yorkville [Member]", "terseLabel": "Yorkville" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and
Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r810" ] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10",
"Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r6":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic":
"10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-
1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic":
"505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r19": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r24":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph":
"5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r29": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r31":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-25" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50",
"Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r36":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r39": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph":
"(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r45": { "role":
```

"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4M", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4M" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/230/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482309/360-10-15-4" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",

"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-4" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

```
"Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-21" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r257": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r261": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r265": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-25" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r269": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" },
"r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r274": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-29" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r278": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-30" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r282": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r285": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-32" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r291": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r294": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-
65-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r298": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4",
"Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r299": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r300": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r302":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-
20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r305": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-
50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r309": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-
50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r313": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r315":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r316": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r317": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r318": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
```

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r381": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-6A" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name":"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-
45-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r514": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r517": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r519":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r520": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-
20-35-12A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-
45-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-
50-7A" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r532": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/850/tableOfContent" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r537": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" },
"r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/855/tableOfContent" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r541": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-
20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r545": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r546": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-
50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r550": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" },
"r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r553": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r554": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r555": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r593": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-
65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r597": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r598": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r599": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r600": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r601": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r602": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r603": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r604": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r605": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r606": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r610": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-
20-50-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r615": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r618": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-
50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role":
```

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":

```
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "f", "Paragraph": "a" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
```

"Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r855": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r856": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r976": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-13" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 97 0001479681-24-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001479681-24-000007-xbrl.zip M4$L#!!0 ((#V "%G.#X5_T1@ +HB 0 1 ;G5T>"TR,#(T,#8S,"YX MN3L'69+MJFI7=/6$_*KRA&UI+7=USVD" (B$)T13) M!D@_YMQG&QREGD\Q2G'@/9%T-M[3W$28(B[Q932L+0.Z,D6&'/&X\./QV.#L?>8/"+$'&&&&>)(T_(.CHIE72WO&1+8B)\9L%GYJ_Q!GECI\.CZ,Z8HSCL;#WVIOYH+N(" ?|.!R2Z.\5^?CT]'0H4B5I-M@_)Y04,1^G@(R0NN;BF9IY(6>A*Q%$5^C3Y(2X8J\8=AGE@C)4K2CSDID;0! MWJ%CV#!.M0C+P' U&QX/C,6^.(88&=Q73S05>HBSD!? LS0Z%H!P=>BN@*IW=H@UF":%P* MCK(4/Z\Q"M/UH1\O1#%&'X]'9;6QP+Y9!#BAV(<6JD7P=CC_^WE!6=6YAX MJB3T,TIYWWM1.R13;_5)\5(K^^.0IV!,=4O3^_VFTJPS-

*E@AE#01+1)[^6>M-MNF5;W5B:4+5>D%)O5,374!*_1HBC;'.D:O5'HR%^3G'$R"+$ R##%*5\@&.# MH\.R ?AQ%[545]MY8EU9-@"(%8U=!M3((T1\II8NDNK$.#6U+$Y2*8FFV\F4 M'>$KFZ9;D)75^^ROU<6'E%H&*$TI6? .5^ND653IIML!0U.'95)-\C,CYEXZ MV!T[>=[_MAX(BG8]P M]HX?$>MOS TW=^,$NX8!E"RTQ).8,O_S%\\3,A:(H M3D5[A4_R8Y*0;!GG7_@WF%X^0WT]<+@]^/"K_;569X'O!6%^&+.,XCFOK0#1 M8!(%YQE+X\WDF;"\+>(-(5*#'#*CS"=>S&(@LGBQ?@)8F(4(3/GJ.1-_"V OD? M4J;'A7JY5 _$>KE<3PK$<>cb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{C=S^- -/OFL# AJR.WK73V/-TD<@;W6 MW;.Y#5[5!O3F=&CNLVEAWEOF+N#:P!H8Q0U0-JCV-4],N\=M47-WC_:PV6& M:\;G.42"2? ([JD)7Y+CEBG1@L,,7Z/3%?!QP0.0[!6BO5)V#Z0I(BOV_Q#1 MT3#CX(B)HNM*:W$!OC&"]>8$#A8B.#LJL@>M7U0FR;"G5@;'#O@]&{SWPOLP_5=>,G;-6(8A6/([3\1!IP:009ZY M19QT:!';C',J3V3MY7F+952>>]],?E0S>76[L&\(*U[?$'K8]X#]<8A:B;I.[48]Y-7SLT !D=@7\,D,/:->C6$TV@*;;Y M<@$]!C88\$:]B2/1A']#E"*]G\E(;T:JX2TLD! (^)"ZV4Z$!<{*75N(W+YAE#GFSR\O\];RZ;M3MX-.Ub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rO@V/7P;>N&R"55";@%$MSQ0'6'A^3A8KIYB9& M$?@3>.[P?- PYQ0%INU'9R-,.=RIW/"M%W2X@!\K%].T5_(V,>)++S\OP\F6'?!Kj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`M+;C<--ZE%,$3=YH47!2- ,E;$92BK7["5Q.S#9%'&5*!0&GG@W7+P#I+_JS+E M.W,Z:N'?9F%*DO"%#R\)3$ECRN>&R@UCT^7TB6/9C2^1RD2K1#L^1))6EWT MQ%I4M7D$V"<;%/Z':T=L\E/-M[CD+Q& M*7_&$:ZM =G%@U=\[*D^HEOUEMC1OY>EHAA'&[<^3Z!_YN%)9Rl;$JXS?!)7 M,U[NDC!^P?F[T:.,^FM.(:X+0/0/G'Z%##B[6(UL;HNJF^+=F^_9FRAX-CYL, MR=; <4!G(BF0'AP]XPOV:-?:.Y8]EY(E\#D: YK$47XC/T0W+A+R5X&L>G$Y\.M3F)8UX&/?8]P$2G/1: G6[UHQ]%/JRY@NLX#&"Q'X&=VP\4 0A11?B4KF6MYK5BG1MR++=2[B}.\#_- \NE5.G;.V)"O*ZKSR_->&9)MN>I=.[Z"CP!XF3*+% M&*U5M$'GI&[W$@(FEC\2&E"%=U!NWB4HK*AH1_YNUL*MZNA:=#>Y=U:,'VHZ: M7TP!;M.=0 5K#M<<67LOX<0_W_E33K80.ZBC=.CD#7",YU_U'FTS2QNNK/UY@ML(EU'X-LR MK6\.7$ZN=DP:B%%)F.&LN_H]YG=0"^6Z,1(%Q6/]4K?"?H5K(K7U8,ONNC%3 MW2V6"A1NLNO{Y "P8W:R,52+#AT8-B4(@VL9"P6F4!0&6GQ<^Q@&[HNO+FCN 2 M(3%[:_;;]Y+DXH;\$B.N(2O>(HOUU4=:_%(C)PO#DMY!3>%6DE.IRX1.E YJ]S6.@R# (%=VCP7]10P!()K]Y3J%:S.)O$#G M@]VP8T?N(&1R]5(T+H5E7Z;XYKG<*6 G=X4%CYO^"MF!8+$-~^]W,?QINUR M)!VA:QU.OL PQWV6<7#V G!G?'(S? W^7BN/5AM0>N@AK,0^>+O">)}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

*@%'_Z\VVRC9(72. M8L+0PKW);G!Y+&*WH0#9%N$VB7TO70NFA?DP $X;6G+LCQ"D%D5N.O-U@LQ MB\@2NE?"U5W4&_OQ$A@(AQ3F[A?DR3X'$81T8,+H@<'"F|(LBS=(H. %9X M?8.GP)G2OQ*IC%FCH-YL"%\3=D;;L|(?C97|@*P!S",)$1 <"36P:6[0P-Q M/#&2"@<'0#D4"4\@]T1W^CKNP2UK;Y/=/??BM1 !G*C!_6ET1 MBADK7\I5G6P*Z/T@.Z4 D=.:T-.%!!A&;JX,"Z#E;)ACM;W#3(-)9) F7 MPMC#.\@"> KRBH9XDBAC6PAH(3=Z$7[3JB7@SS&9.R 9H^D7(+W6_/*1+=8/3 MV]IUWN,*E$,[^-8#@T!"OI'$H!?.WURYN MW%VLO7B%TNNX*(#_HL%9Z;6[= VNW5U\G-_^>04PN[Z=??V_WXZ?_2%Z?8= MF-%P75\X,%KB%(1*/I V WHBD,!O?&MIHQ0C8)ΝR*5B:@Q M@=0#00;6&(,+@IPG.=#%)9R+L 2!#1EH@D^[.D^K% Z9(%;)Q\A15IHV[[: MR1V]QT 8WM_?.=;@ !8J77T8!S +/$LS+P[$21"<=@!6-$VI=6F' M(P"^BEPB'R-RBJ=Q1_+G^@N51FN==!P "Z"F@]L#TQ32XC1<8|\ M5+RT7CRO=9ZGA/PTOPWUM$D!O;$!U[8A58*$8B/[3U' M.YX\O]X0PTM^LQ^,91PN^_QY/=I @(OO4(!>X]OT_EXL@1U$8$7(-.X MBR1^1IB&$1? +XL]9^1357FWL,2TUQCR>S,*!0.%K0:&W(ZN![]#'D]06#697W%#XT4(X{^?& LR-TD~ M9P6E.X%@59VL"G\%YVI(ZQ@%*&I43>]X=M%':2*GJ/8E644SC(O-#@R):? MNG,=`U)W'O*G- Q"#^_*C#]"D[X 9Y3GI#>@58E/D/&DAQ*.\#^%,:.$F[%% M:Z;13$FZ*Q1E2GXL4BT%]C#>\%858Y#+;#S,<-0$;*V+MX/<7D:U+L\T'IX M*7.!5UVL,C1 MO\'Z_KLW9V_.9B|GAY')7^]#S[PXF!V& MG_U''^8' ?'&ZL$!D)3)' ;I4\$R&\'77D@#P>BR%_ ^O$$K+[]*"<|WG NIW!9' M*SW!NEW9_=7B*5*$'%R2:Y$^3^W5)S4KR^1_8:XM<'^>T< M7O\4R7J?N\>GV.FR]TC&7BSG- NW>.90R6_AFHX"X[*Z5/T:7F!3?!,8ID\(KQ">KS!B7Q5; M)D%# #?3>RK;WH()D%E_9GGQ.2;GAW6X%3QEW?K=OHE2N5JX;UBWJ';'5>&3 MU9T6.LV(4!4Z)'UZOI+WA(2(ZCE31V:!HG@FQL7'MTP+GT?R:ADL$L,D>&2(WSI+E\PT*3).0 3@|TCV0/*55,&OU@&"[% MHJDDU.(TQ;UHTB1G%) MYK(B>SK!44K>M62- W1^[5!HDXIX=YS&=;'YRW\ZMX< M=,,3>X* S;?Q$V+')-T(NMGYW/.7D3Y.;]YLN5Y%553(B)2,* M6X(O*BJEWI9NT[*!]2X-_="+TSL/9S'" M+9|\F6>W>TN'"VCVU@Z(;>N;#@*\#VA\.':G60L"Z M-<7E7<#7!-6# 5A"\SQ;$|K^)7QG3MKC:.IY2E' $4_[9M<^,>P.89]@|%;H M?$<,>W$ XHG+: (3C]'A'#'A@Z7H>_%=SW::U"]JF*1':TR/R^XMON?<>7H2\5VV]_B1<:M:WXV*SZVNGZXK>5VV)\K?&4VS\%'WD5_'A"5H+[!S+Z+U41_6"&7D1'HH M9W^ F){OR%^V2>I%O^(DWZ;[U]UIFX0&"7)4JZ(H<|Y;^|K=>=N@\"+RTI3% M410W]}6]P/C\+2M-W6@HF>348$NHDU[8T.@'X^*&IF9K2@S$10Z^ A94DW]9 MGN_H&\;2^QUF0P'X]]&MIRU!&]'T*M/I#93$CMOZ.)CHC,/EP!.O75LH?7IO MO8W\',)H XK25@M2L MES0&X-P?B_L2E) NZ|I/Y76!#]_A*GNZ%7^2Z%7^Z%7|$M^*GMQ4=SZ[U0] - M@#P&!WRV>_IQE7DO(IE)#I+F=89!^1>=0Y/1< !V>HZUM#_OX$3B;D+OJ;KO MI.#00)%"G_L,!2"9QK$[]>3=UI@.I1'2/?!0^H^ ZIM#OO@.(JQ=IY#YAW48C0= M-4 ^BB-MZ,4N,/9DGJ8H2S^B*/B08$KW;9+1>@0MC;[(L20+S700)DSCFV M*<=.N5'&^3|>E!(5\ 6:Z#ZIU ML?;P2GA36M080-T.":*8PQDX@C;86U[*F1>O0G)6+E:8X:?([H@ 2HD\H_T&?-* <,E;X9;CT2HN M"QUE/Y<:3O[!6ZTP6A'N5?]DF@O]73<7NARJ^.?]!V:X_&?PV=$UJME^M,0C M2VF6=[%K*X]_(77?,.~1.@AR;/K3QBWAU,9K*.P.JS5A^B4Z.O0Z8T]FTR M {Q@N*GNFDIUPN2LJBI?02=@<4L3B#"%12P Q<'.5VQ_B1:FOR(-+MGG$*&O7 M6U$S7[\O@<[> "HXW2]L>69;E6B@;]:L^P 742M;.1D 3N^.\Q)OTAZA\'! MS+$^\CH <+N!OX[)7^B!YR)Y)]>+59_M^UOQ|GT__*P;_[1Y[T.^HI+4'4Z" MW,\6N*P6)BC3Q6]V=)MP,13K);Q*,M)Y"%2%VHI3%O'1MW9?UDFE0B^<\!-!-L MT?:F0[P3ZS1Q7+=+]0W|O56'\BG22E"T3.^\G9A_[1:,.VSILZ]-N-,_Z!\) M_@OAE+!D3]9;&4:0Z:Y)1X=Y6|HB,<$S2=7P(*3W>,1ZWF[A,/W)3,._;A)\. M6]>#UN@9JLO# {6"}>IOD&!;OR^QKMO=2H-D+AB?A1)SJ*&3]U 2VZ#O0.9 M|UYEU4_/2I^>_,9W"'+Y[''"9T6)5P\/MNDDWUA9D7!/|-\@/A\\<[:JA^.IKFO92ISLt,295 MS0FMGC 2;@Q454MZ8&I2G.=A1',Q"7'5'Z\W6YP\LS6%_\R(85\ ^3H&.EH7 MGR9 MY>OR<(FE5*] 8]8T]1U%&XY30Y+@FBU-%>_)4\;IN2P 7L0V9+84S 8\7 MRR4Y/"_(<^^Q#LLP^ M2V.T&IT W"'N(P0-9&[?P4'KT(\$[^)&@&XB-S3|K>13))%$ZYHJK0D\;.9 M _ 5W3Z*W4+A)[($,38G\@GW<'!FD[$1-='V4-P#"H_JH&N%2;0M|? {E>0D2_I6B91S0+RE30]9Z0_6=2F6NA M@U/*04CNKUA M!_--@K/RAJ80F$#"XPT/V:,GU87Q6 !':X1$WB*1)LB[0'8A]HOI#!.@)(T> MJ1F=*Y2"U(Q3- L8I&^.4C7"QO@6LS&%$K=ULI>QYN!H80&4UPGKP(DKX(@M@%}$?IH3N B-T< X0]9-0ZP D MF(#2'D?R%'B;)?15A:MI8&B):=]0\7'BAVZF[^-%/+L^)++[%Q1?8MF M?.|_=TQGC ^4_>BF>,2AR4]J4X9Z +N354+/^>Z3]X\$LS>7)><-HQ$ GCMT M15]?VD:8G1IC";4'.I4/1I]/ N-DTD.Y-;7,1SU)!A]=H.Y1414O78=;?M^_MJC& 0T=/5:SE| G13<'X?>E!LO/*L. <+\HI5C0'L.@4J?!D^) M)5\E26IM-K 2$'14K>&%)HH3F]^"OC*4XC3 MLYX3>C'E'#^2ESM/X85O*[Q0;<-D-]5;;0!,M:%;;W WT2O"KC=;+\0HJ#E! MBW]BR?1]$6GT/^+X@ %*>* (%=;0=V9T/T3UH8T278W1-#HBE%XO61P[^D:<9 MV9QU+H>]0N>TV$\,3Y\R=G0_%BG2)BSAX3*A'DH+CR0 L.H;WJ$GG4Y('C>OO[>OLIC=@IOW\FS=_+LG3QP)\:> M&\_>U^>+ZN7I,_FB3KXHP+ZHK^3$-I'ORM:)35&&Y$-$/A-XYX22X'KK20N/ M=-L>H1-*@>AT4CVNUV7MD_+7Z5>\|_/)NG/-3N9:,/>|3N#,NT5.V MR+.4(*")JO2OQFZ,G[KE>>@X-#7I,'+Q3^#|%Y3*:_.*EJ]R)[>E[4I8=1(D M;@A>0S"^!PG+F^6NNA@7:)NDH:S>E+(+@$.1,8^% M8%P_7_N,<$9)#Q21O,04ORV TY")Z1"(F*)~@1$Y9 7SX-F+?ARQR'\>H.X3 178_7[0SN#&A>63$[,$&()147'L8[&@AFM_*U M1-?N N|T;B"P-A9(8EHB3(YL14$%=)&DL@HQPM;@' (*X0A@P)$+I3^MO#\7 M.:%6.&WX3<&Y#Z02X6.)(XD7E$G!X6DD :O)3CW@5P8/ @P97&;Q+ZV.J- MP7D>M"521^$PHGV'T=W!^3):881ZE>/XJ9N@7T:VR1=>TD_,RF_,1A!YQ;@G M)84XS[%N+^N&/? Q^*B'QKMM^;B_WN#+@'#YA,&7?MI$"U82#V\]G.THQ#*@ M_;_9,<4/^ CLAQ+0MD|KS8J;@,X+_14R_HQ0AON*0'&*"YQ M2H#Y&A-@X.9M&", 3)VW<;R91(8),%- G$AEL4A]RIS0,0@_OBNNB#UGB_R4K MJ"}N;]^H:H46Q553Q%#*1D6C(XS=H5+K&G+2@#*7!IO ! M;3,V0\E/[^YP^.QEY-M+1#-JO)M!G5X -H'Z.K;?]^D@LRR&>3K?L-AA/WET MN@/P)8\LF Y$M^Y^^M3O8OD'.W!D"WP?KM8RYX2DO?W%1BMU0KC82*# $XET ME9'V@+&*/5,*9D)UY6[[-$)EJWI!FEI%M:?ERM(6RX$X!514.9]E9+]$$ MS+](- ILD9N95S7+1)8P KA0FS)4BF<*=%GE_X_%;4,;3DL[P]@-1>$U;+P5@__M-. ^K&#[X*/9PF B<8X)V]I=9K7PXKJ-, ;$^R\O/_Q:G6^2'RQ %PM"NI*U[MAY14=_9<%R.8Q%,?)O@QN4?/"*>(&;2\22XI[_5F[& ;3:DL-;/[^ B@/+6. MTSV]J>1B>8'L:OD"]Z*UM=D"U%OI^1+@[_3-&\GF6KU+#3T1"%I2I:FM>~M4_YX42M QHB@T;&K+UMB>A&WU*1V5P"[(5UQ:&,"_JSBDK.4+8C=(+L@C0V5.5M++AD>?)9-3CNF$U M&"YP?;CZ0I.&,$5D#^6C_8|[~LJ,M$]UG%=Z.H)$H|$O[H,X<.OA%F_$2Y\ M.$=$QV_;)+YZICE(B^4E6GIYU+ZDUV< FU(2/'*NNSLR1 9UNDEV1;R&-@4D M>/>_U%OW)V/UI2I71=AUW=VS!VS]G!AF1)4.DZB0+2+B7+=!8^HT?LL4K" MWHIY[TAAW? *O>DS=CSKBAR 'HP6V2$4JYRUN.(:Q*L[\GIA\X (C?]|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|->>9& N1AS? LLL]\F+!PRG\)O9+Z8AJ/XXMTH86JX'9K5.Q M)$5.S:[=*$8!.YYR\;@\I8.6=XDF+ZYAN-,F6DS1X2[\]>=M#W@% >3]^0AS> M\I #.)7N4MD;44G3*>S-J>#7]>#7]>#7Z- PFAUH35LN:,ZZ_;Q|RT;&0]#W+P@Q MTT<^(-EDMMK8M_H"K_*0N\P6;+?9)+WA'5#$@=9F=9I/P=CR,E,YW]&@,,]JZ8Y'E<;.M!F"\% <5ZN4YWBK:OXL9\K/,\6R>8WD\)>6^_$WP%0070BA1R?5U.'),8B^=D+ M(SJ[5/B2878(IWP:;QW'N18?PY'7L8T2&6BR+ZZ'$SM_<+D&0"*+TZ MKA[#9?74T^!3'F7A-MJ13W|P?- *+4'WA17X>E9'>Q>>8G ?O<'+O91ZC2I9% M/-*8 (K$3]![@_P")\A^] \F6S[+!@!*P$ZXI]4@ =@ $]_3B3SG@P!IA^THA\Q-D6HYS;):AZ_PW7Y>|HQ42$!\V$ ME(Z=4">,6 %,& |KZ_+L7Y6@D8Z$;"QN]NV0L6/Z3.[J39ZD:)O0:BM.*&=2/AR5GYP5OOB*,WP:. , +CR+TZR+!\!3Z/85^W8=^ M:!5O,_;BW,.[MV?DI^_)>KBC$M;5 G$>CU>T;B]J,\.V[-[V%.Y,- E0<*3W MUI7XWO44WSL7XNL;^YEJ+L<0^!AEC]D8,:%M_(G\]).Y;91V.X;@ MQ)BV4?>FUVY$W.T80@0C M[T;$S)AH=7OWQE!PRCY'X8P?:X&3LV+:%>[=6:\53MP-PJ- VMIOK,B/SUV3%)FQF>#G_UH M)C^]?A#>S[,B/SUVP[XWG6X,G6X,.56I;M9#<4U@;+T3?^<8 BUV;QN)>04L M76L N*LO^/MA2N?;I K'^^=+0N=<8 T L8 P!UB%-6H2N6B\/RVE)PH12,)EMAXFD_H("YX#!=*'1!6W?#*##EEAHRL:-]6W22[&1Z.ZR:Y MLT+5T50VW#!CL^+CV]C(]15#Q.BXX,K:M,OX\@'T>L+"Z,O0!Q]5[!-*_ M'QY(/X7-3V'S4]C\%#8_AUROMS,AOX9R_1S[-+0[S[Q_#$CV)U;"LZ5_1#1$E:/8^3NK, MF=7^_#$;Z"-0\3:[OP4-/[EKOR4--W;M?@4:ON=ZZ_88F^V77H8^>"$N(C<0 M=N1F5![S?'&]93? C]&FJU%D#>'Y*R>!/N8,V@SI-J95676VV4;)#Z 'AY|"?![M1<#8 MD3XFF1?5?][(TNPVR?X79??(3U;QY"WZ"\'(":5\FA/.A#R#HXB]6&F6C,4RX> MER>L+2,TEZ2IY%U!K6X 8@J*JNA:,$Y%KTY%KTY%KTY%KT[7"4[7"> K M6G5*9;^F\SQ;D]LV | P7>..=8[C4-5"NPCBGAWO"3A_[*&0MFL2KJ0A>H M@^\?< QS N=5+QX"\M/S2V84DTB(S; @B7]TKS:%",P41#76 MUQO^Z\/?@L3, *XTD]D-+VH-Q2O<166-*BC&Z M-<,'JB[<,&D-?12SZ?4R.MH:'2$X:O6]LF-#3AJP)GGLU2>&.@M16IGD^0HC MM@<+7(GI5=@+@+R=;7L-J;K4I@3B?-1>2EZ6+YAT??Z6R!6=:,"Q,!)VH/Q>0\U M$Z%|8D>.FM-*89E\ IDZM?3)A"7 YE=O^LL;Y;Q_'CR"\A#WKW0UZ M1I'$#.IVMF\4!8[&H491%S ,D=;T+ ^V2*[6:AF/ ,*1FNLR5]QY<&.)E-B5E MN/BY7%H] %C57@K+%1\X"G!2V4L!6[WOL;RE,-URN$ZY7"Y#'J6JE)$>NBT M36)]4F71!7D?^S9)<"MK<(1!CM/M%>4F2=+!F: MC'V8E@(V!+DIR:AUB1X\ M5=+!-%;<=@"\Y55)<;?\\N^4J9KCG!;Q3HN;#.$LN!8NX\4R!6D5OFS1FI9J MYGU'>P#(X!Q#ZE*,<)*8;F3>>7B!V]0Y- G<(.JYU!E"P8W(!U^#"D6Z5]7J_M8L)ZU7[5+\+ZORG=_>)H$(M1VZ58I&=1[%9M17]$>&0'S[;E:E.*%;2XUT:FM<45 >VN|PL@Z?0H+1 P%[M]05AGQSTXE75[}$,E]Y)VV(3Z8=>=!UGB/QCQK/)8XYN5>83>+]&9\C4JM'] MYD<4!64\F%H>+_,1?I7A^LB,A[JY*G<9,.HX5CLVN68U+SU%:Z*#'=FOVM"G$" MKU@/R(FK>1Z=T^O9|NO5?E.Z /3A M'MN4=_]2T+)7ZT=+OPC>TBY6)3FA MQTN.$HX 95O\|]V)'N>A[A4!6!3RA(!L,M;7E=+=":*B3/,>X2!L1K9[)YE9S M,]:R,4D1PIE^^WSY>2"//.YHQ@B/+)]K(IOO0A>2 N;4,^!0J6JO+-_5^3V)-M\@UJ/;.#O%MIM:4F)^4$7WB13\$32U">F8M6\L/HQ!^TJA83^^1L\&AJG=K[M2\A1BZX3E|ZN1N1U7*-1]NWAEG|O%5]F\H?9I5C<%8EMF5=%S[(G_Y-LE] MERLNZ,M/F..ALUB,\/4CXV&L*LT$_K7^R.$(GQN=$RAM%9(3:4#/L:RJP80^ MMY|P:055YIM&M3I>9&3?Q*)OO;@'\5 Y+2'(]<+#2HZK@6T%5P9>S0OSRG9S] M" "K#?(GC:RVH*P# --Y+(6V3&H*GEYT|HACU?FL,BZ03@#DU/P'1! 3\|P'5OR M=VNBF>GC*=7[:%.]WTXJ=TB)W=+!/O> ^&2J+G$77_77W(;W:'L"P?*30,I' ?#5W'# M4) G8>Z#'>$ZX93QV,,KP/6-4_(|#MA9+,ZTBQ9SFK?.J(@[>A/S<3A\8; MWW+51/9E^9LEK39@0KVC"[51&+$)VOV%_5[P#BCB@+Y"29)(D[\[-\FG8,2? MN;IN](QU+_ 3[,,ND< 6O'8[MLE@I)8&61RXUNP(((@I<{OMVF;)D\A M@@L_2ZH/?V\@0+U^ "*H5N2GOPWKXGO;5WYO70BP[W%OTPOP[802_(>.[\A IMW=L?&R&`&,Q S8X 3CQ6)*C)C@DD^-]YM&.*8R@[C4X 2HY;D9P&*R:0VB>O M-$,B/:D)3]P%01=2*S-2D!_?&PA.MR> DJ!6Q*?+CXEW+"8B MU.'I.H.ZG]?V*5?'=)L_]I[:F1P#E.JT(4),=4Y_9322HV1%"J4W[AW:K(OOQ M+V9;W>|-):C7#T(M33L;3RVMPC[X8MC0"2B9^E, MM19+'YSNWKAS5HZG,*/>SYDH-\?#,5F%TJJ O'$BSG><$@GEF+,MPC,VZC%E MW,SC+ S"*_"9W00W-47^|J#HE(WU9I\8VJS6+89])=V.|Y'+.?>#*/Y?,8%C:EZC>2@*? GH]A5=+F'*M"%U-R 10-:/,6>C)4<--H3<*$\ MPX(1(7VQ6M(>0.;0KNKR'G'C((*5QB"V5!KR/_PFE8*B#*K]3?1^I*% Y?A6:%B/,0K(V7Z*G[-]+)5Z24N(:M7U8ISFIR(G\ ]R(C\Y4_V_C0]Y#WX*/;(*8RS(96TL[^-%+DO)]M&2M#;EU;Y M^= _B=(O\ZV($4]3D+MXHND>T>&]MG*HX4]CJX7"; MI:4LA\K7"B #SG:\UD5XQMO>&>1OK$YQ(_WC6-7CR_H- Q#W?)/DG7YJB'I<^?WASUO8UEV//:H.3?RW&/R:O M.YSU.B|&E.$B/S "OZ /3A&QNR M6=A>"M=MCE%!BOPZ9K,-#">JEMXUI-!$,<%,^V.2,1/,BRI#YS 5N3&E+0$X M,+D*L=]1BPB?XMR2;-GC'TG\D:U!G[S8*T*Y:O[]!P6PQ9!S7!_*!#*X)Y^\ M2NE,4_-?-TWCR=-T_GS2,[;RHB[_1AUB0* R9QM@44 M)$J(&@+,E.BU>,HP I'"*,!U"W-1]-H1'"T.I>I5,# !- X;Q>[]*06.OX MYN9"\F0\MYEC#X6Q%AU|],[;42VZR#&FY3OCX#:)_>(O M L%H|000)^LC+BUL<(18%EU-/R3X!GED$5U=)*DP3B9L#2 FUD=80CQ3UPFO M[M!<(G^? =H*'0P9BY>OA[1OT^P((=)E(Q1"=+1E=B.G8R>0C!P?@6;+>LI$C M@V/<*EM\CWP4/E-S?(M4:U*K+8#GQX:L0BTT\$337"-]@L@GA8;;XL 23H@ M4\D$;X/UD< $;62*1>1J@_*Q? !N/DDV:9'3>\B"X"T?HAX0'O/JO7*(0$%2 M_6VY*6R>H6D%3>%TD'6!\'97OSDB0^4HU^AW#X?49K($;)1FU6[PW(N\V$?K13]WTH^ISL^!|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|]GS';?%R5HQ^ M!/X+NXD,^H^2I-4W10>"=@LX/@EA.@.7;@A<_H ?DY9O&BJR]^E)/%!0.!2/8)VSQC M:9;+Y96'XS!>]7<(LTW+^8X_@,1A/>D7'X?B=A N,%3X U^GA7VZW6 XT'U, M&;6>C/7*V6!A7VVV4;)+Q9%OP8BO^N,E!0'XY'55MRX@"2*GDOG#P]A31$=:M;0 X'_I(CH7BE:,YM:9YCN_R6>09V9K%"[TX79]/HPN &-9ABB% =(I] L7 MY>(*E.UF$-QOH(H28?#_>KI<'^Z\|+@.K[PV*M HAV;J/71I(0*$< 1R2W*.MKF_.V:',)!6M):TV1Y,1VJ(;#M/_0.%JG:%@_HRPMT)5_GS'B+]E9F M8QQ-7JDA+CA"[9S$), (3M#V.'%0!_7"%<4GW_,+ FI U@.H|_02R1P!') ,= M&T6-]FF\?M?8 (H,;&XLQL$+1SDJ*X("2CB*4Z_@/]99..RYSMVA2?D&U_RS MAX/"(U)?&(H50W0I'O\[$,H5:.|ZPQP? _56I0:PMR|0S^A/TS1'0Y!87S1EZ;+9>2PT-)[2K;&#*TC9S;K4ASF"E%BE?C'L_'1:0GW MR21.(Z[\|N7B%5%NCZ/;$*0X6^2YZ3>$55GT\MCTPV7= MDO25E.8 5N74RTG3!Y5EZ|1?1AK=K4]HEX?&'%./9-R_O2[8&:];YJG___U!+ M P04 "_]@ A9[MRG8VR* #$(PD %0 &YU='@M,C R-# V,S!?;&%B M+GAM;.Rl;7/D-K(F^GTC[G_ ^MZ(:4>4;'?WO- E[SMFHEM2V|]I5.I)L[US' MQ@F(1%5AAD6629:Z;W!]Q0O?BR!!% DDN^>#W9(*R,PG*_/!._!O__/3+D O M)$YH%/][5Z^_^>XK1$(O\FFX^?>O#NGZX]!? _<__^+_^V[_]]XN+__WNX1;Y MD7?8D3!%7DQP2GSTD:9;]!3M|SA$'T@$+&B8I#CWR55Z+2VFK]_K[[[__5GR:%STI^>DY M#G(=;[_-S6'%$_I#(M3=1AY.A>-[JR%E"?];15I@O_IXO6.B|>OO_F4^ 4, M5L9/"S55_7_Z5G]XU7_\-X3^+8X"D#62"#(]3WNR;|_E=#=/N!VB[M8[)N-MMS>(XVIY_6]#LN%^)K? E>V[+ZS|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|KK2X//8Q[D- 8#6%$8>&969S$7^_^+2 MT2]TOˆ<V-X,\,,.64;E&]VH?#.O]*PS;50^?8PFU1^4E^W*5/T4?PSXOU$K. M)"\)/T;7&8OM8L4'?E%=]*L34^:.R5G$)WM-MJHX5FU(Z8N(MC;Y MB;9!$T.U%($;6BH\>O+X<96DHK34-+2$'1&KU^\^KY:Y3+GSZ^GF+,.W__M'G?/41O2YN=P(ZL521Y6M0]AQE2[B<8!):4A*3UU_\K,,8J)8*584@QM5 M7;B:G%4M S/&.BTU#;5<*,JE6ETIOCS$,0E3N=F&YP\/VQX2Y1A&61QN".K@ MK_\LV\O"#$DMB\\<7&;242$>2?GV=C.DA)\.H"_D"J^CT@?-4M CLA7524;"H@CD M^&LW= (3MA#*Y=H*ML<=#WAX2&)%&WUD?B#6OT?XRCXC^CG,MKM<:AE.%5IZ,'?B;(>A*U%(@=CM\%G!F4N M'$G!*!-OC0JW)-CZ@K)1"'HLME%]\&"E!.3(|7S7!;D,FV'&5.WX_ML(^\? MCUO,'+4ZI/S^_CY)I!Z5=5>"'H8ZF!L#YXX:D,-4R^YS!|%"!O)*%DBJ014] MUB*9#8IB'-R$/OGT_Q(U9YZ6 Q^O[<@:(5HO#HJ%;:>&XA2+!)R$1,\?>0M M=R3T^?F^]P%NH|OFYW CK15)'F&U#V%&5KN)IA%52$-!8?62]HRCXGK/_M(V';,N M"3<4>]USZ\WBL$,Q#YCSSZ]7@U$(=IV%,I[!/3BL%YV+I'8@K_|%BL%YQ"- M;>.%8_9[1ZC1.0;)\|"YR&YV&*/9 %"_&)C3)_U+&>#-)&W2)+0 MHPQO)*]Y4-S!-K_IS.@UP<:*+>+%M9+UQ%V!U=W5|]WA]A=A/CZO;FZOE M$_OEW?)V>7=XC1Y-NKY^>G01\\LD(6G2$]TGA6#'<3NF:L362\"-386=QN,@ M(,&C_] 2D5.FB'/XU?")_$(\R.YX#< MD;1!GYYF%=@9KH.WUC9UE(>,SUI6&_>9.N$H+J0]R5;'(*VF)V.E5,HE<8DU MT<[3OKK52%@M#[1E;F=%^"FL9_Z(88XNV"^\>&EBC^.4DF:[9#>[X>&WDO@W MX0O#%\5'1E;AH481V&G;K=7/X29EJ96FL9<+E)U)B'Q<|33V1X5 MV*5S9KB(HSV)T^_]0Y R9N2S>7N^IJGN3?=&@QIH9INNUC^S;BJW2.&0OCJP.5@+<96$.RO 96$|LTWCWM".8B]Y(EI? M'!+BT-CH<)_,Y1];:KQ8*P&;M5K0U&8HRH_A;D<:C M<;&RZ73\B@F.Q07:SC4G|"FBS@|HB3%2$,GI<'>KKN!Q:"^SCH3$W=&U6XJ? M;4#YULAEZ(M[D;91X+.>&5_"2(\]]HD&5(=-#4/4"4/W;IPZ64P M-PKR@2 MBW=2O./ USNXV5EA-L&M<81377H6 3S58^O?T>'_G6=KWS(B>% M80=J-\:V$R'UDG #M,?>L\|\| [*5YQG#:O9!Q4$6:6#\:K.,8?=Q2;\O^_M_A)1CQ78XA>"F(>HAX/@B)X)";/#3L3_6O2GLE1!.81>2.A'<2+D;*+(EQVN MA,0O0E9>C[F&4X1C@@X)^XV&K!@BXI+*/R3H.;OF_!OT_^4B65Y%1 0^%9#R-M_:JB09(HS)%6,7"MC2-8Z)7!/,1HENFC#]#=^0W=7&T\D]<1!C%,S8NBHH= M%=[18[H0ZLUIGM>8#6":4$YTGQ#KL\T5 MF,:LVC306 /V VMW62MUP9R[8PU4%U8[E,*:L2=FRQ5Y[F.4U1+ "46-KL8G MI\4 TTF'L>=%9DLWBO=R9*SZ3)T;EOF\\.J0SP2(+P=B=;"A/Y*

Scanned with CamScanner

[.W;S4&\E-MV)2DAUF|H[|9 RY1:=I]_B[W@,NOCO86S=0&L,D?$G[KF_XU4[NG"NS$UL&K MVO<_GZ36LOKWJ6K-M36M-
N\^83N.2NZ[\J,3D\'J_G,'J#7+.#K$EETBKJ<5[Z+0TYY9K!4&SBF=&%7SBV5)P-S2;,_QK%MM-MPLGE:3AG_,8+/(KCF,Q':2C+//!-(#J6GW"!7L+;,M
+GS(UJCCYFRHE4XLB%E@),$KJFXT06%A7;I&QJF=$,N>X%N2|BE?/M,%RR-M+;]A0//YO1T G7!HP&6LPZK 361=PTUC.I>/I +$-'*#;.F3?.6J9K0%/&6+7DVNE^OZ)1?#I MV8)&,2WA3'5=+&5PW3]XW+3S6J2697N9K7=&5PW3]XW+U-W11Y M\|Z]W-&S3-.8/A]2?M;H*>*#*&8S-8G,3,F^2L]>@-&5P.;$:7c9:I9%O M-K38K!S186KV6A6R\"-5Z6EY[0748@2 M+G&!_I_OOOGNN]?\F=<0/L?Z/L_?;?X[COQ'TJV...;MP[I-HKI/XG_/|"? M__S=XB]_?+/X\YL_BN;FSZSXFS=O%W_]8U&<)@G? ^R6V?!W2)&4_\"E>>2C[M?QU"@MY^MT L'M^*.E?$([MG$J.WK\5?WRP0D[(G7DI?2&#WT"U4K_]Q\?U? M_[SXTU_^*CSVQ\6?7K]>O/[^^\$>_V.KQ]],[W&-
M4_\FO.1F&L.^OCJTK#M@=E[?]8[]PPR:?/8./ML85.'9.EYQUV!W'-P1S4V^JOAI:%6$GJ3[V:K[%UX: MN@-I-PWO7 4BF0fT"[=:D"_5?.TDI2W 7YYBA3'=H#WR
Y^V:FS=0W>X.=-EA MJVD<5D7^(;O;$E4\?P"I7L\V2ZXOL6%"2#?'5+R"?U$<)\N^>+D-^(OFDN M*-+HN4^ T-T5I1]HR$9=?%I(3O4H,+
*<4@\TE*EQ5)FF6@O#\9<_X/+ER/C.VOPQ M76=E3V(:^=>A/ZR[XL07UW*2-KNA='%G@J=SRF.*XW0&;GE'-C0,[7C&H.\. M+6U O%>A\)Y&-=CMC2[N(>]2P&TCM"T?;6M<\93\1'?
K#MCWYQRQ[37_>QRO M8M8HI,07RVWW}'D]XG]JW,=-6&G\P#TBLT"JFIPDWJ(\6U[>:^X M5(2$)L14(:'+]6K^U#[(%OB+E7W'22ZP) M,RD72 J'D9'C I792-OPNW-U?*)_?
+XQ/Y<WWI(A6[!]_OIA^73# M"KA9],Q /_'Y<>4D>Z,0I%MQU1?3*R6@!N8"CO--V)EXM!O0N#_&2WBDCBM M1!OF(K8PTHLM_W<>1?_#25?PHW|E;?]+-@\$=Q6!&6Q\N'F^J.O
BKM=2\]O__MA% QK9)1;]QR:.#3RP@9.\\7D4[3)L7(?;5!1^&:H2-6#P"#H@.\P=-2]E M;).X5-R1^E.4B,,45_2%)C0*/XA#70V@W25A!fT&NN)2U/9BP.1#[3'=-.QN
MPC5_P54|>94_X)E&XFG7;.81^9E*NS>?3@0X%XMRN>@W*;F99=,.OJU S+\X MRX-MJU_?>-QX'^WYT10F4^Z2_X!#O!&=TWZV%_7,'\.]4#'J+H5@7/L8!@3 ML.Z^L
%MY6&-76&%(R:VY1992?^0C]=:,$(=!"Y8'58H.)>S2W]&0\JE/_LQ]3E2_EHP6Y*!J&NK8=U5X'90 M=0TWCF8I7^Y^JFE0+=5;6DP#AlO-PI3W=Q9*4BZUR @IN8:E///]
fG=#/(M^,#D8K.G6D|SFF?R^N*6$5=WR9GDVBFZUFPKB\T@WUJ,/3_CY+X*](IWY+VV MFW.6\5FZZ%V^%IF1'NN:%YM:%]IK@$[370UB]!5Q;'FY Z1!\Q\R9DYWVQ
M!0]}FTU=KE&>,[^(:/4M>Q>.'S:'F'.FK4MP)U%*),/BH4C(KS>XDS)!ON7?6L MU<1P&<[L&RV_4&=GG*H*CL\W5-6O95@,M0PS"?'HI0UX/8*-.T^ZX .JLI' M-UG7-E,Q;N^]/W>M
G\E^_%?*S9\6'RR3(5>Q;C _/H$&AX8WFRP$#7).[*. M8H=+/%)_'QY&N,H\FF(XZ.X ;'|*7EE'VQ*C;"9PX*W3Y^?ED0=7,ZR =[\ MC"#93?95Q*)L;2]+43/PL2<#861N"_QH<^/.JZ)[?
L+&R\LT MC>GS(>7O_?%9$9O-J<[U:"/ZPOT"R-P ;,#DR)!<[3)BNLO.6S4GGJ)!XS@3 M.; IU=@S5>8=+ 0N09M#&8W'09.V??_')>/-'+
6[SNI>A;K=UM+;Z)#3O#BGYE+^MQ#1/L@JET9J(CUMLW6_"91IV MK. ^9\#-NVRCP&;&C(JBL%,S#V?M=*^B+-P&N==B MX].ZF6"T)[$\I>OF".Y4^.HS@GNQ5U'F)5?
CY+6%)M9W.*&>IE_RLO/*Q1K" MKD04!>>3A75SST[!^SP%D1 ,(A"@3@9'IU3[=,A6C1Z/$UZX>N\R&===<1R+ MS\0?G^URM'RL#H^O?#S0]]@Q-
=.O"UA!'FA|!++>K(ES^&F:^\65_ MJ[NKZ|O'ZBG5[;IXS07]7Z\3A>S79/F)C[PK*@SD\CO0MP:\6T59A#IG68;M|=*"*]E MHM^XW.9ST'9ZE76
5]$.4]7K+*]RL&.V$V&M/IE6$&Z,=IL[5FRBWZ1@\)%Y M*3I H]WY0';/)%:XHJT<[*!4{JO?OM\H!#<8U:::W_DK.K]")/I-"FT&H9WQ
MS+38G%R4Y_LT%:_YW6/JWX27>$]3"3F6%\=V/FFA;AV>UY7!;AYJ&>V\957 MA73$Q5]02!V24. V0UVA=I&[#R1ES3'Q_F(SJ15%H:=K=T8JVG:7A)N?O;8 M:QJBN5A43
4ZS<>)4"XI[[IR(.Q5+3/;B9J66U\0Z3]HUO;K/4:6(WJSKSN?)D=4B4%(>^^IJ3MG*P4U.)K#8'URP$ M-PG5IAK?3RXD+E!%YA3)MG#WJ$E*C+97*\\H-M8[N9|#OGH8\?BOR
V'C^>N&+_2@ZS 5#P*-M=^%39<[P)DD.Q'\?O=>?2.S1A*S6V:TRK3?+;]>$20D&Z(M+H?2[.\\@:B"(-M,Z>0Q=9T1(4B\389R53Q$_ N&++\+AE !]B_WQV^$R8G-]D;-'=.47_V1%?W
MQ$"ZDY4_"])K0!DEZ.5P8(X,.(4W>MP@-A%*CTUSL'P$3H3EEC-84@!]{!ZA M+\2_"1]QP%^^RYYJN3K$K.M[+\;5O^#@T+QLSTP"8*8T\T;!E<.J V=+0S"F MJ2"D\'C/N#+.-"-?]!
(7C,H9'OZ<4,*LX87S1X7L4]=EU\C=;D^-FQ&"'--.MK5&N$TFE2&I=(*'7Q9VDECU3X\B8EKBPWX[\B5YHN]]) "FO+E5[X_ M$(='Z14';;92)ILE"'-EZ28.\^D3-CHFT
4W!1?F>HZYL<_.4IRMOF? 1 MY-[1'?DH/AG(1"=U9\D|[1{0[>T4%?*0KS)^S-,&6RP#2[^]*$\E=V3;LO MX[EB&8@4SG;FL.//(1\/JH]@>4T"X9L!(5'HR!ZYR2:R?]2P.U\LIQ'S%_I
M?.KA /T4!7RO9;)P>2&C';^<-",M4>"^WVK8.)Q6GF7KH//"|'=B=TONV#ROXI MNYC3MA#G]26/'=%GE/66RM\T^BW B(I2= €
MLY2^T%Q5U?:7=X/C^B&HIKR@Z2*ZHR'$/9\EX/6T'N7N67 :.?IT,A8=)U MW,Y(T"P92L,WNKVG=BFS8R(=.+>=+,[HI^@:B,]>"&WH'A_Y?A:TY-N,-^(^
MP07":],+0>^C>$UH>G!T5[\#=SV0)(VIQ^?S)+_@C5CV:SOWO8H^0)0CO^@Q M.*=TBQ)1\<[VGVASX1VM,",Q#MY1V?6Q#.IPP8R#^2.S]+[_4 3<1N9R112
MH_HL^4,I!]VN3;7N[)A%C6#"Z9ZJ/DBL,;XS5/L4<^D$UF!Q?!?D;4<#-M^_.M"GHRRYP:6^O/DAO5GM#N@^/P(;7"1YINT24K0S>$+T1->??2 M>3TJV^0X]0'C?SY"E2W)
(K//<'4OO0\\FRU\NMW M<>LTFF'S\(3>K5]%;/<:^P'XD6;4 8]#GVG4<^/H2FQX M?A3"+H1'J'-]HC|=3AB(4DL^??:KF\KVU06;'8]RT.Z@W&E(+@,=1Z<'8?I
ME7DN65JH7R!A *2^Z<2N^H5)YNX1E_PU7/(SXV=@Z]T3>Z/B@MKR;FT2%! # MRX[Z2!3<+VR6'"SI(^U|_^?#PKIXIMQR,AL>GMI96M0#?O:@N@=)
M@M]%AS"5GG]M<&9O)=B,]X>Y_DI;5PVX#*IIM_GL6'7CG5"P0%)%OI^,'G,; M%'4^72R)+MD'-$6X&(H#[&8)55,$7"(P!3)M M'TKFD2PK%4/L.HWNG&X"
<=TC:+^Y_R8L;^Y_/#PGU*1]Y=OI=1ZD?9P\BY!8!>[++BL$%NNESX?VC8! M6:&>#S2,8HZH[;D0FI3&/47M;N+GY)F#%.X=43QL6AK;CU62&DLV7,H:'>'H
M!-9X\'=]$5_BHWJ),+/+T8M 8-Q:4^9FN,9\Q;MZJ_4E3K;0@^ACLGQF1F$O M5791.ZO IB,=0/51E[IH\7-K0LMJX.5[=75W?/5Y?(?;3X^KVYFKYQ'YY?&+_ M?:+B^>WI$]_?H%
<*'L!^<[M^/@.H]"C 6$>8KW^.;$=NHX3]?9S*%68C9A:1AZ!4WI6O^L6"$W#ST?$2ON(6(AE^CPDA46HE^R^V.I\'S"3^5_ZS)P@8%/5>D3VSEXHMBNSG@&2[(Y>[*$IU/O._V16
MA4V-0_!7J4ZG'ESJ&F2]^=T;I1(^9,_4B&W#546.J,2Z#P1PK 9^OI,R5R0N M]V6OUC]&D?^'1!DWD/45A)JH.ON(I&$4YX$^^]%EM&GQ/6X+\JFR^26&32;?[M<,M4$&MR^9-
FN607KY?9 5GY#NT_,^;.HJ4^T9K$,>|\U\C[E$_YT_8D?XR#O M2C8+E6R[*\%DV`HJYW@CJK0.[_Z!EN'LY2?C[B8A10[@*]RI2XV@AJ#7O*
M0#]+H4XFE3PO%GVZ#))]J'1'E;#':>]G#5)F(:9>!FHM)2X\%X+C!/.#& M)2XRQ 4VTHK-2E[]B&G(YUE6X1.)=S3$LBMP2[ROW]]P,XW';S5W.LJ#SD*'HS7Y26%SP1QO(+8J!*6"\0;^?
, 3K;"WO9V MKJ,8S+SKPU4.]EO.[H=UE\QAZ9"S&O+*,L.QCLCN[MX7+Q_+0]=']SG, ^^4 M.]GVG.^PS+I96!PF R3WFOJCV /1KP^T/&& PS85B-_*K7-G7
M_"*V<@$R4^A'-Z5A#NBLE:8)"1-Q#!"0/$$#<2ZXA*L+;*.%'`^I MFZS7QG&FV*^5*YKNHL-B.A!M$0^5(V?]6(0;/W%&C;-/T[K$8DV M.JP?F3-
R3:A4Y6A@8=<4+!=Q8!1=,GC_(9P[O<=SQYHJ1H/ES0+MOAC)"7^4Y44(?A+$?7 M-46'.=.:*@KAK&A.Y!"^(Y+?A=!)^@Y1BH,NT|& &/(:L29CW.C2+6B6#*'A&PVFZ)-R
M.\;0P3+6C2XTU^7Z6H'L[2C^+!/?A103T:U@KF&9G1[O&=R4/\'$/MKS<@]/-M#I<".V<,O5)-F(S$BX&:+*1#C^>M,'[^+([.8]<9SG0LDM'[DNV;Y8D>S_+;=-M4WTIDF\>W&>:A#.
(PAEG'%S(673#T^1/(7QB .RK6\)#0D)^_@#*H(DPF&-M8R^..VC5 GX 8ABx<<X]$)W)Z)"*;C5.DHA?PL&&>G^)96[Y1-L@.V_"]*$Z:? M|_US9H'=TQ-VG%+P7[{!Z2E"%H#2*D1<%;|\
(5?FXO$.UX0':9\0I*U!,UO M'DY?Z8'@X#KA5VH..B%JU6!RX%#<_=V?LL[<^CLMEH_?P>%*D-0'C %=A^D,)A7.'F>"IX#AOC";/(!+"P881HF;)LK@#3-`M.
(4+ZM.,&AYPR0CO:8A#,X1!QFY!LV0(#=]H,$6'E-DQA@Z6L;89U[DNY],._M<>01XB?\"85;WH%?K2|CXBOOZ.H]#SL/>1'6>LF]PG"CNM|D\XVK4K(,W8#+ MYMU!3TAWM.P.
ZWU%+V+4I+O.1>P3*/X?!*T#;K1:/$Z\A%ZW8 M56IGOOP H%;2\H'LIS'Y;]W3>3H'TMIZKL/-)SU :E']I"=`%5*)4!N3@@3 M5MLI9A1M^=2" GW,9^MDU0(_$,\1=
<[@#1^K/(]&U49R=$:)E M9MHNN#K$]2TJOXL[Z]#J.:";[!D.OITCOT\KLV?<@RF&3;DUAPD*D1-81-Z^ MYV;1MS+.R-\O9EV9.:+>+0O'4NL;X1\4/-EMH(U>-F%LKP>4%?
=/'&5KF.D17 M76A!0HWSX?0TX'^_^2:6?.8'P'R>C>_8D]|KPD4CFBF4]P#FO[$RB=%A?,6& MO0]D1\R'^[=H3Z0UO=)6#R4F]R(K==VV%@&^VZS39>"FH*@WML$_XLX$[]%^|
URP'GR-;D34YHE9H'AS1;K+Q6Q55 M:9(CTL@1XR++Q.*;E)=[)F=$MT?D-\|#B]P^&$6W:) F.QC[@NS_2]PQU$& M&$;:*=>YW0723KDI7%#?*:?A 2N,P-'S__BYIQ<U:#
M_N)T6.G[A, ^8F0V_C)%X>:.#^3Y253;UP3L]W@43_MV(%OO4_M-Q#)(IQS&G^LUR@L1[GI2-@N:E.M1Z7Y4_#_7C#T==BY%#F[[ZB5\|$%(OQD7I%#?*:?A 2N,P-'S__BYIQ<U:#
4QRG7X13G\F&AB$/Y2[7GC%ONHHW.*3_%%#XM&L#G6O7M-PWB|\%ML=79U>D15#?(^=E5C8:6'6S7GLGK_^!U. M:+):WS/WYB&0WUEP11(OIOO,1[G]|(O.
[EEECY+DB7Q*WP7[*1]3ZX3)$58] M7NVT3JH0;B_5#NPQ:(!U3ZOV+9"PD#?-51L7Q64F]&*FH)#24)1;BG[CMB)A M["2/2_9NE)F/_P'0\"G4GH/1G15@$V_UBI[J4O#I1X-
FTWC|O&PV^'XR,GA MD6Y"NJ8>#M,V\G 1QA63AG<+M"O#*N|A/JB&NEY-N&Z$,%"[C%,B.>_?,*'YK)-%9,D%GU3C(SM@K65D<:;Z,M"V2+%!# MA_O6&X #W?+4
WDA#"4_^2$V:S/N_96FV\M#DD8[$O>TV/[U8;/.0" 43WI] M587+(4,!F'|A%'I# !GE?HSN@^]S#O+,1U;T[VT ?C],S17+O:.Y*7MV=*W/? M\MGVAJ-3RNWO#?0T.SKU8&>Z-
O+&*>7N2G!S6]_T,TZPEB|*]}[78-5.,6AIOSM1S M0 SXE;W'/$'CU'D?Z1!P!#?A"E#0Y\# MLA0/W)? >UK!H3)@LX211ZHT,4@ 7)XP@V&:$;4*)'6(U,AM)L9?>WG8"&?
M06YTM'#),P\.\9K,')UBM.(##OK6,fMKP*8$ M#;2-AXU4Q>$FNX[1IO&;OQ=^77TO7?Y=)N[T/);+C.#*T;Q+=`('@X'S);.;4WOLK"P,$+4B+]\SI>Z#L?77D++T
MG,*Q>X]/>I&Y\.2(&TJ87% #ORF!ND@<2EUW]#O!#L1&O'5,VO>@FX:.6P MTS3(;DUOY%8X&BSD M.TB-SJ'8. DS3X[QVH?.[#1/D)TC*O3CA*D>"2#3UB*WMD#"?A]UY?\Y8K'
M+8X)M]^_SQ[NT3C\>)90V+0RCL^:1R/-)<*EG9%P&1\TYH^R7 C9J*H>=**] MJ[I'XPSEF5(_DU3K|H1KK6+_ R2K0>8<;9QV1="._JDHV4<|_MQ=R"6"9TI_M"!
=\1VIZ,&G'3H)LLVC%5<[}> FXJ^.PT#3PISLFI.CSDMU'@LR45O#7.M4/'I$/JPPI.P9ZH7;"C6QEN2_^>*K,+U\Y& M/QB*W1*)Q&"M+7>[RL-.T%ZDM:&-JC#<
MU.PWV;C+DTE&3#02LMTGI06T^ORMDZ'>8;\/Q$P/#O@3#N^^#Z..U_$/?>H%F M5=C9.@1_;6RG40]N#@^RWOS"T%*)?-^&]TG03;F;R-4C6]R0JGEEB]L[=S^@ M.NS(':^]'YL-
4.G7A9L!@!&>]B\,U+5 M(2K*W+=RUKP!E!,>R8;,]$#V49 M>,,^"NU ":E+!$!@<VH'V/X_3X%,,PX4^%]]^P&U -=F+KX]I?!=I=!VY* M.UMN?MNE4("$!E15 2FH]=NN81+F&>];;=F
ZO-+@"F879T+H!HY&"X'}1D M,O2K+!.MUN]IB$,/AN"1_45K?G(LV; I950;/KWC.$0P?'H:%YYI-OZ"8\HO M/^%7KQ&F-4778>KL@'I'4A]V5@WV1+5SM"O#S8I&$;.@"-H
M!MJY.UP|L'AX3LCO!T9YUR].*X+*XK#3O0]G?>6OO2S<9.ZUV'PV/Q>,I&0(M,=H[%]I1?EY1VCWOJ2H\GS@=<|FI$:CNFQ2+8%UDY3OYZG;C0=*C_']?BFI7 MAIVOPWQ035Z]FG
S>:#]H'`+G^X?E\9L(UW59+H@M%=R-A/)Y@-1< ,Z7{A M4=RW-+_^\&N83-$8WS97NY(O[\\N]X4BM(YB1*5-;)T;A9+'"KN7-=GV3]8/ M%0I1J5$^3'U$OV7 ,KW=R95CVD+"1?
]7O!09EL.IL]=>K"#L]'FAN M\'RM"#>8AYE_U@9/<2I0_ZG&B: &EW7'D#X_0$!%+I+_/:;.Q+S&XD \$\ZX3 M,`:&C$2'U(=- H,]424"[%=]4N-W.CC=US0T)?MR[L
ML!_D@:Y]HS,+]V'FG[MS,L[5N'F-ED;Q/1OD1/X#\0*<)'1-/;F6[__]D(B+ M^ZY(XL5TWS*8/T,,[-_W]4OJ9=A.N FA#$2\XU6=2U.&H [\K$R"1M'(?O1 MTY_#/$,,[-PP]4LU-
X,*@\L.QDC.R W>,%0G.6M.'5WUB#>,F&RR.5\/Y{6$ M!_+$=V-H7.BH51=V4@SR0.-RQOZ*<,-_F/G&?25O2_Q#("_$_%(C89TGH$-2XJ_BIQA[_V"}*"ZX]C2#?9$_3 +L^#?
P1C4+!E2'FPLF(,;("R(M".[OG8=!GZ?-9MSQNKO@S1 MJ@@[,?2QU\<.?;7@IL$ V\>(_GVF;H'V7*&8/B6Y2B=SQ8X1(\Y726WA|G <'_G4:]|QO21#^ITVF
M<(&>CX@WB%C,C21REMUM6=?ZP|!TP>[!S:.+1B+G0@SE_FIGCN'RYD M9Z ; .M9=29O?E.]F^^1^+-=R]|\SUP^^9[Z2K^VO# !&NM,I<$4N-M3Y#3\G-(@ ZK
M1YEH/'VBVG8K:A^AY<3,A\|/A^>_.$R]BE;Q\@73@&-_^\6KO!T7SZ_]ZQ^Q MV+DD^'E^:RY+*@W;X(XY]-NS)M$+'D'?'79'E(MU%,
M_TG\GWDC(Q8E5V(]DK=+R;OC]2<2>S0A]WR!\($'P+D<-8KB>?/9>+X?PGWG M:YTO3XZ(?3).E98L4&X$$E8@8<9<>!,"GYND(S:11RN9=Y<;^C5(<0Z4,5\6=04Z&2461]A6(
MFS2_WJEUOU;7RI;6FRBA_H9]MQ.=49 M\F9#?V:>4A#=,&&SH#1#2&,D6;ZEI",7;.30&5ZTVT5A1C$?,Y7C72]4@ER5 M_;T<66<7RJ'Z3'(P]4-QI=`!NL'0$4KD3-
PAP#$_AE"Y4BB/\.KPP^ZE M039]4$WT"F!5GD_+>]#16^Y+-1_=Y/>|>;F] M%S5(U!SZ4&; QL@FDC_K^HHQ;_*U>-TUE^U1RIQ\8_L4S6Z/;4S\YMF(;=G M-"3,A6"TO:$X+=-7?
0Y$H@]BC 3)M:%2G=RME,";=+7K&0B'A9K7%%6>8'QW MS#X<,& M@YA#&&=)(7]ICO5(GJ5.E'"E=B<A_([IG$#3!=Y6 &3R^R8O=&6R'@VS0Z339-
MHZ<8#//UP10%&9],2",DU"&1#$&%=O=C3 *\"0G{)@4[>(O)"CXG]HWRV:MU M90=R2P>GKRQ,05TN^ECAO8"Y4HFZ.%=LB)T0[A7_5,4*/, "5)M57?S>LK#C%=MI$6'KZLP
M\%Z?END3=OU*_2@W8&%_"7Y2+{1 %_@=]@5MXVW]2B>;Q:BL;'P6FXI8GU0Q M0=91%"8YZ>#++)SA4Y> UF5K6F]\!5?;!YY(M3ZRU@5/.L746GE=8ML^\J4O.
M)S1'ZL(I@G/*/9"S"M96HRAN>E9TS*J?P22<5@1Y"U=|_+-.!.57/^~@1 M)ZHDI1X.T >"^44L.J^3G^S1 M0'Q#R"=ZB=|\^*ZE1"V;2#41=63'HJP)^Y4 ;P @K"'*0Q[\CVF;ZT+I0B*),
M(_ ,=T2 ,@K,'H=`V^L(DSODKO!"K@256E"NQL6[@D7?H+0$P/G_Q64.2W/*- M_!%^C3HC-@*@6^$WI[E)\)[

*M=9]*TZDW1ZX;\5!69Yj[/Y=FQ0>_$KK9\GUS2T9!_*1\[:0:#9&[PVI-EA.G`MF*X_\2O.6.3;@,,-#^T1[\!1*;T*M"5]'\-,/ M#@U8584/7XS_.DUH0;#HP]XWF,$@A!2Y-G(%E MJNT_U7-X5<7.A&3^:>*'ZOQNR;3.Z(Z^-M,::8D4<&L20BLQBR3OVKW5(G. M=,";"Q@#.\%'4!/X"G&8;+FQV@87AQZ% <%1DA1=[*\&F&CW,M20;\>98QQFlOCJPDU@+*

*M<>TD:E<%N"FL9[;Q>=-,F,-C>>SSEW7!C;+P ZV5D358*L5@!ML[68;+PIDTK)%$2?]D&D0NTYCX ME8E2^2=QNW!_1NG4GT>V;7NB+1-[*\//4GT(VV=PKJN^0%&]0[=C9[C^?7-V M_%'%3DOL 9-M1(S&:*1PS]RZ929F,R@TW"S]OQ^225#3V)0]5W71<E<;:A4Y+1IG]8=M>%7!<C;:A4Y+1IG]8=M>%7!<C;:*

MH]QMTF2R&9)IYD&MO43@:S,>3AZL24^$)_U6G!,27)YB./.]U?;"\-.P&Z, MC;=16DK"3< ->>|^8DN-BT4>\(?*\X3,)R9JZVO?@&.4YC_<>]ON DOCZTYZ$*

*M"4EN*7ZF@;@+O#W5]&O!S+F!J,NW?WNK .^!#P!PQ@:=@QS\)IDR1#)M*"C5 M+9! (.@C3;% MI_=:K@+E.M!MU5>9&@?/$%L(F(SA3L)ES&MO?>KAX"9,#C%FK' 98+K38SG]*

MJH"l;B#^R@6Y6O6 Di!V0%,=$]^FHO"9,;-=#53K2<%H.IZ.HRUOCl>5?)).J%N M.G%*>'GBI5RVBRQ,;>Z/>]LE_:5A9UL/RFK&*8K"S:H^@TU#4\AUWPY.#3//*

MP(C+=SC16(&V#/TFVNX)H-ZZL+-SD =;9B6[|+-W&'FGQO@%9EB3N\DOR==) MZRC%@<84Yl0^>.)F\$U5PA/%W!!W@\A[Y$DVJ8Z67'#!%7E.66_<C<7HLNNY MP?:.2L/;|*

*UTUJUN*PLK'WO1.)=XAK0]4J\\!UE%WG#AL M+3BG*%6=+3PM-9<8'>4482,8'1XFK(/K?5ROH_B.M 4<_3UCX%/O2N;G?JF_)2WV0'3FZ"$L.XE MZW<^'|/[NQ.I8_L -$9X?(*

MSXHJFM;ZX8I]S!?CTJ,8IH+?#W3/C7?#'6-YI"2/UP#H8U14FM^?BS[R+0W) M:GW)[*)IYRM8K05ATD_MFJ/^+04W+YPAZW&!V7X4QC1&DFA;E_$FA">)^%9 M:L/?]K?

A;X$G41>>]5;!+83$T6I#)=9J<9A$@74%%<3'P@.T'7"KW5" MUV$@1@5#)"=-.C:.5LQM\",,9'1.7_%8[/^C2N-X=K\@^2FC7ZJ7!56; .4K-M3QA(47XFC-16_0@G$:OT)-

*J8;Y!3M6WT,S/<4-%4WGC]@NKD(>@H?&$M!;\N MDD]&=C\#K2@+,Y>U$:;>@&XK"+//T^"\>#B9K]"(KG^9M*02\ MK>\T>>0&OC[^V$O-*

"$O5EI_FG0)V)A1E4ET^S6L!GONU\]N>]WC5I6$2C29 M]<+Y+?R'=OL,'FU_QZWCQW0M 76?A3.RG/* MT3X?J%-657,N&=QK_VC[8')-B*M"4E=VUR* !)_,#S78"7J%$]Z/\GB?;D.<*

*MO!U;!YZ_924/=FKYZJ3*G%*l':\ZP>OEYY+6"JO-[!VK;@J>\L;SONW]D\(4 MN_;=I.2;Q#'QY8M1Y#)*NMY@5)>&GHB=*.LYV%H4,YHD!WE4G(N=_M[%%C29S&I"W)$E^0(*

*Q&57S^>(_:X#K&AQ:>)U_+:HJVI(M:l*M. 8.(M#T"*R9l/G/(_]?8*NNI 9R,-Q,U^@:(\"9&;2.7NT;K[X0Z9OT?Y JKW^_<2X M:3E?$4;\5T97NWU 12KS:T_$]#Q*2/Q"!9XS@]\A-.*

M+4;+RZ70[/3:N(T+O@>SS-T\V,1%OLC1Q MMKZ%OQ^25#3V)6UJ>5H]$+]*P=8;-(IV;U0K'=;2)CXRWD.=P;,AFF]4C@>L<0 M1.'U|P?68fI-/#47*$L"IH1N= 4SM!<#3A

*]1D_.$YE^) U M[>7=@EC(ORG ML!P2B#V.K[[*_OB5R4*W>H_]?;DWKN@S_4K3K4;G8U!MP"0TW O57:Z.58&3 ME0&0R0F,V71Q7]U\6I@E)X0==80LNDK;V[WUX)SAXOU@,?*

#A+67XT"@YP M!\]&.0=OAZN6R9)%OT]\,](ZK3Y3]E+X08O&&G5GS&9V\-X'U.??LGO+8,%T:P(ID5ZC&-FAMTNYO3^*#6@0D6>SR/>-7@9[791

M";9^M.VJS#@=.W%<#2ILB3PI.RW>*T](1RE(B)6C?L.!U^*3F;A@@+;=[=!0&3CI.1D_(_MS,N%63YCE*Ol.4SVQ*-K2GSEF:*NLH##KP]A$8*]@D##L-?<\!T-Q]"F, M>R8V?HH>RO0>HD.T.,^4+R-HE<#9N0-0%O9CH5"H?1<_X*3LIW +^0RQM MR(9)":?"]B;327UQGP/-%&0#":%BQ%0M+F=;K=^SOI&\+^)!%/.]6D@K[+X:*

MD%-5"VV9JIW%H.:>]GO'&EX=M2>5F/SXWSM>PUTP1PD(38ODK+C:RO?=[6MSW M)YBYDNSF%X%9Z'&PR=LV[M;O>CQFN@EI2G'0V+LNU/&-Z]?9(_-MKM"O"IBK

*M!N(O2&NS'G#%&TH[)C44>_XOVB>L=[*MSBX +)--HE,UMNR/2(\SRU2^G#7 M%1?DVNQSFVTW:$6"BVT +^7S5,O3%^G.R.I]0B.?]8[%24%M7&-.C~7*CN*

*MZBZ&OCKP!OR#+3>-\V+=A=\T*56@BHX%XEJZ@N MHS"-L9<>&!7@5GY37L=L&@.+!P@QAIBGWS^5U2\D'1&K!ERMJZ'>IFZ3]#,.^%D;S@2LG.M&0GFE##$@BGMQ3 M=7=*

*8MC)H3^F,?T'X6M/1@_)*68XU4_R_+R/PNL7O@ZV6F>7>K=-BPP5),7 MS7U1S'D.J@U\YM,,RWGSG]F,33$_6,.G\M>'T$^RZYC%YG QX4^X;DZ#OE1N*

*M=RK4KE]ZWO/B*Y4R1V2:,4 ,6K7*08^5AD=W@>><\T:C$?DL]Z;J'U2>Y19Y0[%YL<)GO'<9">HY7:,TUX&\ M4@E*I1:6CI>$3YKSGS)NJ;=%"=.CA-00!)^?2(.T9I^8KTH^5?*

*>O=H7:&1O MZMEI5\]QFT^XNV+/ 146+9"P28X^&<,7WTS%+I09AKAEKGMCCOU:]=Q@9TW; MJMQ%*7- Z[O+AB+FW3:T^6,(_5?KSY_A6]&)4&PK1?.'@F: -RX&P*

*MA8^]TBB8W#Rj@_3I5ZI\\8:U\$]?H0I^6*ME/.WIHCF>'UYXW03:\,(0;LZKS MI\4FD!$V;G.VVTNQ&2>*36]1>,*!#9H$1XEC.4>7#5&F$"0-CN6,7KA6)O?N MX\@CQ$ _>,\:HP.5^4,S*

*=-> R80#T%;G_3J*PVT U#'/;&:E,.3=6LU>\5*O MD]7:*>'>$9Z;4OY4_9*K[\7R[1(/RF=5I"9<_I8%1V.1NE9I3%4MH_4K1*= MAOP->Y?=A:%OGKX GBE8H$R%ZS!V(CK)*

[]J7ZS[Q;Z?0IR+&'^D_@Y;JUU MF?9Z,'EJ,'+URF!+),C|!'W31TOFBI(BL9UT&BQA=YG(MY$\OM#1DV\4@9V> M,7BJF5C]'&[2M5IH&F-WMWV./)+=>XAC%*2+/)957ET16P5<!*(N-*

<+\F2U,7&4U6=.&0T__M#"+K.Z,;:*)8&*"6+8UIT"884Q7V,>ON6G1B@>]K"BF$FJK6A\^-@SRAGG/HJ R,'8=!F&;)L50WW;&K@9,14S]C E=NE]R3 M6/:4;!R[XJ?+W(2?;-*

*EJKW7T58>9Y:9^7A#AP=5)W5JLB>DC.G$GGT^CU,U=B MVP4-D<>4\7^Q;!MI81>4HU;C^Z3GH-5]YAFN$LH"R[0.N5%'QBN=4O}!0\]2I;+><>C1/0Z6H<_?H3KPH;6T*3LVVW)H*

M1!PYLZ'589Y1$*N>D%E1ZT!(95%'R91\T"75BIL!L51<\FYV|[^Q7W<+GD-_MN__%GX(KY["G[@-_CW]+M1+VA=@O3#[AW9X/8O]P__IO?_KP^NW5'U!X+>HY @?M$>]V/)^VB,-

TF"V%)NJ6L G%D3N7?&[S>ZDR^GWM MB\DTESR?Z;9_;Z.[%{$FPB/R"*;8G%X>X(G*ZQ&K 2VO<&V+/ZFV3E.OY.Y] M<(^/^#D@-*

*Z'VQ2Z;4N;#^0.\HF)\#1'SXOLA@,;9R5>P^E[JX7R>$WR^T0[& M)]J*- M^:R>5]A0,#'[<"BP[<%G>OJCAV''. F TN32@XF?THK$#U M8T"/F=^$*6Y?*

9G'ANTM%E$TU[\"%F] %^!3=9U?U5A[<785/48H#+>(>(F@F M=#W8-ZTDK2UE1M0\'-,XO)* >%N[6KKV'#?{<9?7.P*P_]6O%0KAG57KIF-M/PCM$-AV+G'D8J^3;&&$)_BE0-

0G\O&'!^(1^D)\YAZ&(<%>2|:RH!)S&=Y M!+KO:9 N'N?S& 8WZV<=U+LMJ[L&; ,00%M-^([B=#$_F^,Z9EO%GO#L.+'3%M\U6;]6 FXF#DQ12V3B7@,]:#*

MOQSKY:8!X@,Z3](/HK-3KR1J=U9?++-B?T-HX!?O\'WZC4WEAG'=^(QV1@E>^+1-66_5X2%$5,:HT0^8GBT,_-MQ=/=9%C9@F=_3ML* M?GW$4[&DQ]7'

^O/E37[+C>4GG,+#K%Y<>M;%/IY CZ_$?D+HM"QW=Q/I>XO M4K;]$!A7>>;>'Z-E)%;'H+"]D}$PVU?'02V%(.[^.IZNIS34)GQ&A;O!G@<U M[N\1J9YONUZOB<=?WRDW#"A\,U0&*

L0T\HCZ3I$> 7 3V@S&- =#%ZC06=GL M#N"&D:G=,MP+9XOXEU+F5M'_Y4^O.J"5I:FVGDEO#9BI(@!M,8H+@Y\]Y]I MO/&)BW+D4%&4KT BG*8Q?3ZD8BMO&F7CD^I*K-*

T!QO3>"T@GAOFU%9=7;<_MA+)F;CKS33.%%T>XIBEQ3+T[Q@9R%]Z^G?=-6'2F0'ZMF%&1S6XO90AQI_= M"-^W'B&S.P"9$NBR>8K>)/6'OB-*

7WFC+T;51F'Y5F%EJ@K__^AZ/>#=D$H MC'>D'G;/)9YHI0(=[}/)*9YHI0(=[}/)*9YHI0(=[}/)*

^AA5PB2MHF'_%"BH,Y:TT>AR$'TFECR1&V3%,1.'($-U8*@0@ M)@%Q$>&""/>0I5-ZN1JN1ST$/OOJWQZ@#[IK%V5'J\!DL3EX^_L&^O)PXPDC
MK<\@,+Y0,;CZ004$VBGPAKAH$1\8XMT0L9^WQ.3\$%M[?]L,E3"X9.4>LI4<+!M$=2/16)2A1CO$U$.=?AO4:(B$BHCKN$&MEFSM-M-%$@XBF9UR'.YM#?HV*A
H7AF1+%W=%\D+_O,.9WM,+,.5Q-+O$[$9@>_LR-MF\@N/*\%N'ZY$,=29^/BA,NT*XG$JJ12)(9-FN%9\LH\+O(LCM|+6ZD+$RG-M-D*HR+*{JNMRDVK[S+(;YA*=0Q.
>1?'*TZ+KZ)^3N+NYN]#SRLGW0+E$A.1[-MY53Z$CAG*%$U51.-4,]/F=H$VC06T/\MH[EYH,U]+:L7VXESSZYEP10MKQ9W MQ9*QA7(=&57TTWM39:'737TMXH(WJ;"HHF7I^Z;O3NZ8:!Y^6Q8 J:SC:#ASTN=? W/I<:47+Y#TSX0FN_I M:8J\0'>8_+/S_,29!$O[MIFJS"HZF_HULT$!\!W.4IXO?9>S_8C91*=[B'$6 M$WD.GRL/LL,9:+]X=+5'7-
N*-AQB2 M=W_4947_TO;7\=)PNZH!2M6P?5(49@*7Q*GJH\OA/ M]'!($WFQ\%__Z+0B<>]?/_^-?]{V]?/_%!+ P04 " ! @ A9FDW#YLAF M "9P@< %0 &YU='@M,C R-# V,S!?
<')E+GAM:,V167C,+8N^QXBGW_0 MK?O2^R&K,'E{JZ-[GY'G2[_KM'QL9!37I>U)!4Y#$+HI4JG__G?_]?_^,?_>G3_[E^>1S-?3M> R\:V0&P(C ???>BU>C-WVPL M,.05!
(!CNJ/KP)DOP6AT>O+SYYI/?CX=??KTWTD3UU8d[_C>*&EK_/-L H>; MK#?7^_OHZI?/OXO/QN>CT]._GYS_?QRI/PU+,_<5]FSAT JZCO?GW]%_WN'W M1E!"+_5/C]#YYT^K*-K_9=?
OG__O/WLY_]8 GKGYS^\G^^/K[;*[""V/CE> M&%F>#7[*;Z%6FNJ=3B:37Y*_YD5K)7^\!V[^G;-?\N[LH9_=0CE"ST)G;^' M2?<>?=N*$[*HGQEA2Z!_?@?@>^"%[8
M)>+]/=INP#]_"IWUQD6=27ZW"L#BGS]Y=MV%%<"/%;#<:/6S[:]_07__I5(GT0Z3'G]IV=G7'%(N_;(W!QYD M)OPA]%UGC]AX;;E(_:\K **0412N%K44]-D*8+D5B!S;%Q7L_AK.
M%K,~))!)@=?-,ZBGZSLKPE"!-\N__$3K25+G^M?2V58<6B>]?_+A_^0LO]M"7]KA+;KAW$ 9L'2\H_$@),O3DWSYE;4B'8;[Q>6\%VMGAUEA[<'=B6%TUM
MVX^]".YBGB$4M@/XI61M5H7(MX"'"_G@C_R"U;NK*+[+^ #>#'[OFNGHL M/P<^)]TA8Q'\]<&C6IN"9H;42'.@P>WETOGW073.(1+,^S1K[X__P[W\]Q2 M$=M2(1PO5U$S-
L$/@S?HA0*E2727ZM@(/LCA\!L'K"A[W M^#5?:T#-IG(#RZ.A:;F{C?N#M_"#M>"8H#.H1$RP1%U}5A#$VIHVE2XZ<3U;_M<'OU%EAPTK%CC?XAE2(]9L5P$V%B_98 &[8HSNX2
CM7/_-J2(]R'X3PR)M<@_>{UC^!%51M0-%$W=G4+5GT>Q0[H:X)3+82K5U.=@)2D-]2K-#G]"$#"U[M?>_3%)N[?56'/[TYBE75'00"_U^NK,^Z5<.(%A:,U[\-?>5Z<(%A:,U!\->2V5#
M(RHS9^NJ+-]J$Q6QL0^%)#?[*6BX#L+2BW:\$16-H4:&@#Q[\!W(^25R+K&5; M,?'M]42S)70]16@Z+M] #BW]H,6TPMBJ+@++/%%.I< 33 #K(^!Y:M$6EY6M<
M,_&SU=Q;9EO/#I2 _81fJNA =*6B,AN&1 7G_X JT],LCI#+,G(=1_\4WBX1 MFE)F50/!^M&W/*3^1(<#R)LO '.GE9#T1E6)^PQ7%\N93^]L(7-MYFA9'W.E\#&.W)H^ NY_, UN!?-
P:D?.AQ-MY0I, 8H^ M"IEM$A-#;;;5]0I"_ HHX04>$(3RUX=_>4X4/H0A7'/A>T/-_A',Y6J MYYK.QJZE[O6BHB#O8B+\%Z5^?X\!>P1+/-KB5Y_J1_1MU-D*BDE=K]!$",EIE,
M_;L5!%;+@RF]075BHJ#&<>>R"V:(P!A,Z7%RB^2&.TJ5U M<;<1AY"U71V$EB6DXHL4\L6J^!4*8[MZW-BFMAA86GMZ2%D^\M IC9U\K$5 MOX2@M*?3C7PQDGFZ1K>4PG*+?
$(G5WH(%2[C3NEM:X$ M1 V&L,6DM1#0/R_]CU^ /4^R?] ?$ND3R1 ^\T)F# $XB:",,Z1?O0911X?1>V MUEPB+:D%?@$WD-QH34:3V2/\6R85^@Y\Y95D&
4%@1\!\.9@OONM$Z'6O,L+ MV(63R7 MD\ED?]V[UL1X1EO0[J<5V'G3\,<2ZG4(LA*_;)+<&)_LE>/N,%X$_AJGI.R# M/F,__0"2^Y_G?XTBD/8'3|QS:$D"TH^W_'<(4'@;M] 1L_]*.4'*($+"
(MD*QKJ!95J (#SQU0WV#XG'4X4B"HY?@ GY 3>/O"$9RK'G]]Y\UNX?2.@ M62I75,1G.&,-3T^UQY(N0(;DF9)QE>R9G=1X2AE8U:)#1(-)A@R0\X$-K60K MO+UW7/
4K]_WBW\!RFJ1(4'(U/<,NHM>QU+.LQ>P=%#/O>)C)6C=-.4W%A@< M0_\S$"X5@(#LK@$^',\)LL1:PX.(7YP.L<|*$'NS?CS, MHJ /E!OXX"]H\[QX-DGW)LBRG4):+80!"$2&'HU^3
M0:F'R?(W"YX#_-)<^$2,:D4'RPP+'+DZ-1-"+VA\^R'0>T^2\N@ M9.A2Y+CT:O! 0WD- N#1/"/0]H(]M=^YMNNG_2ZUC?)PN"\]K#V4)#![KFT493!{NKU[>5KV

M,VC4CUHR]DVTF'O$N??D1U`!C7L6D2;*JAI/QA?ZI\\59Q!5\MP|>#)PEL"? MUDY<78\X;Q\6-TA"Y[30PVS<->N/R'/@V //P'JWD@<'LX,AU#"#):*'YLS0-MPX,,-&&@](7(/) [=GM#GB$H%,P-7E#/"VY#7-LH^.99:Q\2_B\PSW7!=*)I MJ&<&2=]DFW/%$(-M\6T"#"V*19!D\!'B%S M-G3],D>O"T6Z'PJA(-*

*G,"#FLYIL,#N=AXG@QQUW3\#5B&GM;RYZ3RB#S*5$C MJ1>',)FRZ@=&(Y+4.8%DNKAILWDMG-;V"DJLA20&,=4WCT+B8N<<&I =M7A3 MA9S$'KP;*UPQ'W^)UHN M1*7/O#?T##P3CY@>,11!{>3>6.(B;B0E BYX3A0N 32%V #WH?7VW9K,?3 MIU8P?VLXXDMO7Y?1A40]6E6V7)>5.MO9>4:WGHO4C"$X?%(KKAWBUY3 M-%/UH!BOQQ<-R(=V@1:H:CPY!H$Z?,D36LVC[X*;)N<#P)CU""7\ SO$"J7^ M3TXFXXL++0 A.+>RE^,73{6HGG@1?;\F08H]S6C\BE$TK'-[8T2TA]-4T@- M/J@J$'}=V"/]fG&E N;RMPN(*;&Z,)S 0^T^.+FX,HHH^KG:%MOE=,5"WZ M< 0JE=$%:E5G(+HRM'N_EL<$(ZS#O5Z\,=/YJXM/Z49..ED:#"]lZ67(KWB^ M@# *'#L"\V2:,ERTB&5U8TIOJ-<)QZX?/<^G,J_$MF]8.T+VO*¥V MI,$.GH0;"&5W;^DE#GW3.%KY 7:L9N%BLR^>_#[MSX'_8D56(BPIEXB4-@^3U9UH398/D!X.?ON'RTB{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|C>Z=,$'Z>1MA'Y2O4D\]\ M7@.Z]+0*BE%DD5W@O#HP3NI?6K$*8]7'JEKV9,OY^<-EODH%2SJOZO;8:=-UKH KXT5[5\:CXZ* M/]M%[W/L,!T?U<^2[8'NS7%1QO9@B(Z+ZNG2+,1F-!*\=%N4PZVA4!\[ZKDQ-XY+L\j/6V(PU]YU.IA?GFR?<^_MDA/^R_ZQZ-Z-,$V=T&X4=,/*/DTY$&H^IBW@5&@WZ0OXOU,&H"_S/.(2./ MR4J&%P&-XTO#/!%381A#_\WR.\RQO02')>G=$=XV]7'U]C \55)O93L#6[A MI')O.4'J[..#-8.GE\8L@QJ:.UKC<-Q8RM:XQH/2F)'8XP#1MO 7@%P8=C@V;-I[26*#E\\R/+++?X=.;L_^=&_ M0/0"\;'_I.7\\G 6KL^\9,_)X;5']:O2XFNV[5[/8^'1S<"I[56KXQ,%RO',E M=A"_K9K6]W1UO9/4]8{6R! JS4:L6A)W7,*_==A$[T6;'239$&<\-?E*BV&? MWF/,%E//3'MP0-4/ON.O'1R=5>@S(_2E40_5[#9WZ*_/<6"O8 D4+B,0 MTWW)$=,=?S>+Z,Z_/$*?/D9VBP3\?CY&=C-$V%R=GDS.SLZ"-GJN;?(IVR MAAPBE.K*J2>]9\'**COAU544H,/[@K$ M7,+I-\EW^;,"*U$_>B0-:03K6H.JL[.HHFQL#@?,X;DZBG4X)6)5Q)C"GM779P3.Y'7X8Y&\&2NV,5 MP|=*.3T^I]<=J2_M>_.;3\QU[GPDWJD!:.OE M>DYI;-OQ.DZN%!,O930> K"'"0\+Y |>1!(\^F%(NH+E:4*7B8"@__H@;BT@ M=KO?\S(0OX?:W+\&"[:N5V :2USSP-Y[8\KJ@*

*V@AHE;2_9!F!7V\]$+!MD" MO8\5PJ$ 12#GI*96+.MJ#'6EV,,,"]0&4HA)K)}_178<#<2.2#,]QW390"2*

MG0_A"3E:)>W@%H.K>D86$EO/6U2,.>'&M<)PMQC=0IOB:!8D[KR$Q00);7C=6 M=+!8\,FNW45J6U805PE"#=V8P0L!MO @<&5? M /CD'/S$_Q58Z*2-UK<';Q-'E/=N<,5U(T$'TSZ7Z)(LBDIF_29!B9, ^OH)N MM.#"D(T">]LXTDF07. ,\YL,1Y;A.M"6^)-L+4=PC48%HUVDL]^$5DE\@=>KO[/4\81#]2K=1+2B=_7]L*2P5=:--1AA,"T4(>FZ0,E,LY.U,(#"N@*(^O!7&|I1 MJ07N:!!():V+(]]9.T&0&#A/E-4<&,-0H:^=I,KXZTX,GPM 2Z,(HOJV+57_A M NI9(^AX9-94O#^D", "U*:/!U4%8B[A]#-3=1L1H!A3+FP]IBH!,8>\N,_X MG] JAHXG/]Y(P:,*E-JF.+D3H\F*;6WY)*2V4,*0B)/'(T%A6-T;PPU>G +N@ M0YX<"F9[XGZ_5DXWR-GA:KB28A).SSV\?"^V1TH@&&\SNC&E@^5"BDHR?GT>*

*M++*PX@Q(HM0HZRBT9310?9<-7G_KX$'%DX43KTY-G.\;84KG.6&LYD#8984M4BR_FD5<34Z M@\|B^(PL,PY"X\,ZB$3L*66,GY>,:QOWGFMY/!:4'2Z,0OH5W#J=>MGC+R M3;0@GYR$5V&ZF\WSOY",7=CRAG-*3/[<1'IB!EGR00+W\>DH*6PDWD"PQG"&-M5NU]".DAIQ!FF<>RV7+K'7/@:]RWAVHP'NHV:L?(+"=$(]9%WN#C84K6#8] MZ=B.Y3YXD.0@K.;=D-RZX53K0ULY({6VUM=E^0+<>>9MA69OR[/!;G?0;*_G M,**LJTN(S,0X9LE024X?4XSV^Y0%-S[4+10N>_7#!E#1\YE7R&& VU/QM&$X MS^3J)">;+A9\LKYZ%CO29!9]ES,FU^X \N"%/%M9*0^!.?DZ"(GC1Y/W'6: M2E#PV]=>(*0R52E0-A$+<* M1\|4ZF78%))3G/M+.G9U)N=PL[N@.:- M Z1SPK:HJ;CAM! 2/Z>*

(5;M74SL=/IO.(P0_;&'?:8ZAG-&7>YZZ8>%FY<-M^.$N]_UL.86K(?SA-]^-U^!W@"9,,,]^F1CTP_R\">;W?G!CN3;2,YQ+,]-9 M6HIL.^KT@X9S49$"$?O(+L:'4)T[K'SQ\"

*MR56K,Z>\!19\.9;.57KID8;@/?E1(;8;JA9%62.C(F+,*68?P-M,6;57D_'D MTB2F2E5+5CA#C/^-/B;8$9@[EN!ID)]36@7!/GFYR G9U*3"6>YT^79<>VFBZ M$)^*&,X$9I%$@"7EN.G_Q96&Y+4"CI",,8^P?!JE[8^2#XSR+QP?9^EP02]MQ8*04&;W1)E1.GA%4YQ!VMHMT-^'] %L20.O0A%4YQ!VMHMT-R+Y/J:XDK I;()XY-S\(EJ&K7U2$E+0ZXT"$*TGO#)XG:0\4'FN2N- M$49WQ77?A!^@926''*[=?>8;IR AFA2I"3L^ 0*>V4,GG@!VR;+D8SF(#:,0R=' M*Z$E9;Y)-*

*XQW7N<30,6=HW2AR7+@9*FO"SODGSV%11]"MLG==G1/>9*\))8P M-J$+4>1@C.%,&UUH>!RED">-5JH(6DA=06(-K>Y\T$5("4.;7K+CD1A%)4/ M@B-B6ACDV5-T!6)JX"#*

*((IX)2>EH>R),@!PI:7AS4Y-R7K*Y/QWP4D;EGI'UK34E:P7U-3EH"]*?Q M1T]>BO8-:\?.GB\]I*@:BOT.&+==SOOW5(O!7^>9D&*TRK>!R[%$2.W9XI(## M5.?*

*@6'"*N%:V"50S+QWL(S).O+!-TB8PX@W\O!L[2EWGH)S.G. SI-Q?QF_0#\ MGLYG)Z=53^>TN5'2GO[.S#OA|S)@/)L9:OQQT?:?DXKI$D, ^[M%<:(*:%EW289"G+UR:(K':CV2NN(=C>^ M%SE>#,\BLTWV5B]N^6)OP% 2,8O:E1V@PX@;*_"@7.$S")(U&ZWH<=KB;'&W MX5]DSNN+3/Z-$53>*/E*FM<^_Q"\KKE[?M5_.:DJBR&L!EM#RK59O$9T](-I M% 7..U0G/#>^^4\(B\)Y)#&I,PT7 V4&7\.&7^F//:% LC^Z]NUH)H$0SR! M:/\:!V:^+I71!35), -2G;+]TDE;PCM- W@+/7SM>F^',V80NU! 9T#)$Q:[6 M/0<|EP_=^=;)'\QJ!<>IQT;_^2¥VM %=VE UB>%]OK0RA@O?>?R/CW?K"V M*,=G6C5=E,0Y@|02#VOP5(LH:79H+*L+=]W H&/.ZPA72X%Q9C59C5|+:.7I M@=").WP3^'T"[_3ZBW/U4[HH!W)Z<57!+J9>Y.P1-

9TA/L+_0N/MANS%$[AZ. MC\+)IB(6\X+&\!\#YP+Y6^B\"SS/6ABR*^BM53*[,:Y 5(>CNZ^]!M/>^!> MG?!]ZJ<\IE.SA="]Z<,#OBG!2DJ*QH,.K+OUQOGW('US?9;TO-&UG%I^&%RB M(-FP1>>2=_"G-5)T06,90W&GRSAX,^H7 #>CC@W/FPFWOWE,%+Z\?B-"3ZQC M*!7X95:=MZ.]@Z'O?8 @2HAERYJXG)R=J0GYXH.J C&7_!?P@>:59+%[W;@. M(=247+3,K3+FPJ5SC"%@YT"-ARQGQD(+?JMY7>@9=]V,YT[<<> M]H8&ZMNZ<,A3.DEG+T&'O3C&@=!=U^AIO-FZR!{'<&RM]6FQ1OE_XBI#L^L]7N=\YZ\"#10!@]6\|\ M">!#ADJERF/@\'1L?*':Q8D'F>*M?, ^&/SYX'Y#?<"&;>O-[QI,\&_V_ G]2Y8\Y;+!MPI8QJ1-5:.)#>6-M*B. MNQ\;N+H[$>PUW G O1+D_741F.?00.ITP5AB'R1 M&YE!]7

*(Y!!1B5:Y2##L.+KS3%\?;B(&OO0A?DW<[?+#<&3^:[\A=LXD"6N(@?&]/:Z&<+#O;_MA@G4 M).E]9Z,Z925=3.!*P)G73]HNOA0.CDBP-Y6P2MD!/4C9Y8(GV_BK<7\ 23<\% M3Y1I& (*(^_?98/;2]HVR42;//A-81=RB/M<4"&]MJ3HI;OME;@<V5,\%[3.9]EN4]&1 MRO*M#H8X^_K:T444U#H_,(76RAVU??!>81+!T""]H\'\0$P3LR<&3\7_>_L42 M 1-?*

*+4EHLXEQ_PUCS'S%R(FCI:^R\)Z=P.%RJ3RBI4=C7RZQ)F^ =&NW4PBO M;+:S.V.UTP[R5"4X'3+DUSV.'DXM6'|8T'2^AJI/?FD8%XL"L;4.$N96@JD_0 M?5G3A@@LEV!Z6M,H.=-

NB@[ZR;$0DTRON:!V"$O?"'''/K2<>771L"GS<$5U MX0 G4C2(139- [B:SHP/WC+?3A(S)6)*ZPTYT_PN(]'J/9]%6=]8Z936=*GO!6 (1^.54O7,;U/690G+T8"41U8:>>T8."]%4!IX^DCK_ MLW94$ 6LCCU1Q,&O&+\&?A@^|_{"P7GV%DH8<#)-R@[6 I41.MDRN,]%-)W/ MD[^1__1]Y:/*:; >"W*T8+!K&FK!:FMS%B(,83=MIT42V\?72/|_I7\$\,B*

*M0@V#6<,K=5>/.'1WIYX%\S];0;1]"RPOM&RQ,_?/l;".K.U1TOBHV+K^M^TX MO=!OW>DU5=V^XWIVO2W]A>G^G;.M\D@93]Y.U,P/7!B1;N+;RM[EO2S5R!BC MP_4&=1];X,U,=>+Z0*C?#RJ]D=&V17""->V,+!7<%;<+@.0W&|5NXTU'C/7 MU05P+E#*6+;3M=,;^>?5-G3@UL)[?+OIMOSBBNF$2SL%5R|O&/655?93'I<|\ MN'AK)8Q%DLF056;,3% ?*

*G6@NG*D2^^.T?)?5T;CRIQ@K$0\TL]>:MK M87?Q!C]#<%IL**D+$;K<0/&*K]TEO1@9B+Z-M7*Z$8$5+"+,(OLH9<%[5M8 MX%CN*P@^'!N$N_F0L'C3:VF,+,>\+B:FZEV9[K[IZMG0Y83/KPA)FX$!9I4X M.YN,)VK35O'#A;U2(0BHW\0OUP]>_QRI&%0F=PZQ!C^A8V:Y1XI##.V:=ASH*

*M<%H7TH6>3YGS>&9&*Q D5\?U!W$;R^A&"2'8ZNC3930LO-RVD34D?+\.V:(S< MH">?O&CJS5%VQ_0?PU#24(Z*2]L]M28+%#C9.=WI 7KYR?&6-WZ(]<+!*

ME:4%#S2:N59@]DVYDDWBL]H@=G;BR2L=0VC0GO9M7H%B4,&[QX6Q(2/5, M)@2WW%II621MHY$F=4;K)OZYW\:R91V=3\[&YI'F!K'C1OL,U-'&DVNO:3@C M&*

*(0UZYDAH7 .8V GBB?!$:.*.7T;(E[]J-0B6P+.W+[Z_#M,@Q^8W,)UL]%$-: M5&*S'OMY 9OLJ%2VWJ%G:K C'U_%,(XBRSKH1XR2[KSRO_."ARTW"61L"",*

*M(G/2M>6B5_9>5P!D#Q?7Q.^!?U1WU\|^-\N^-\@_"/V;?'(7HHR,K .K^#ORS M8&EY6:Q&*1YYZLV?'PCM'O"VW-VE&(.7OZ3F>W^Z<-_11Q"&;RO+ ^WWEN^YV M]MT#\|?*

*X/73FCA5LGY.AC7X9A"MGL^/A8@%L- IO8,4E".'NG!0NT-GWRH/^ M LX,:N8Y^82H3W[]*E%I;,+>)I#//|04..6BNO!"#79[[G#K2#/8&3+?5 OK M*

CVWZNFH$034),5CXWYE^QPX;TCM:^"!!?+K#[;$|"9\C>B.-P&T^APO072M MO#5"@\"\|#]^F0,GI0_|8<\;^(_'L'2DT=JQ^<@<:.2$9(4D-6_U1M5LQ&7#*IGA@[CO\;*

*M%G*LXJCV#L& -OWR_/\Q:-5_'M9KDLIHUW@P,%'E&'PD5Q?+|R/%[.33;^[" M-]7[(W7*OR82-,?42Z?BV4.@7-DS!LNK*D*DK0A*5]?]NS[&/@;$,_3JFLE*

*MOIYW_XF=#;)DXMU82%6./*KSB%M?JK=,|$B5.E48M23)<5?E M;J<@*75A:BQ[H ^1/FP+DR&NO@6YZ10Z$H=('!)=6KL!*UNG7B/?_A/]%(H1*

*MHEU_+8($7[*LD,!0(6<'SQ=&+77B5*QL:H$'1F8:T:H=246^'*N!T6GN1<}ST>G0N':SZ;X'Q 3Z14*ZS"Q!N$R2-Z!,U?GCCCJEP,& MQ7)XSZB$0MA[1AT(K/ID]9Z1]O[>O&?*

*4ZI^J32'U6H120[E5V$T^OU>L&R M0JZ4G[ZY9CI.L53?'HGG5Z"DW2#7U!9B.EJ5$=U"5K.2.-U8X0KG?/_-'BT MJ<*H'L9Z>Q8.&^%N(25=YZ]T9Q7NKNEN .8@39-*

*)TCVL)H9*WCN0 0-+D)F MF]*OCI482*GRZ/=LV$LR#6.S\I?=4&/#D$#7-V/M]X @P, MY9]NR'(./B2Y[EGYY$<@^>WKQG6B&]_[@'^"4KT@_$Z9/:?)S6C.%S+H33X*

M$L0W!,87Z]!+U7!"NH_G;:FKUIJ9H8:AM&%5](.5ID^D^O+6U#8KI"\&P M<===Y_R6CGAWQ^ EE]!=/X+2FS:7:GRC*TX]<+" ,A MZA'>#[8Q'D8U!T5>(ZW#)\! MD!P6KK?-*

*#1"NI#O\HB[$$]H7J-*/>>Q]LM;DNW%:-=UXU#OGO=*"'3XW0H"B^)T42I35L/I MY&P\,0%VNHS#OX22%$*H ->A"^P&L21=-BF9W&LF[UDK)NM]0*&* MMK"3$62X"J*

*)V4ER6SWNB7ZSW'C_TEFYF(D$P LF:8,7!O3I?.ZD(CQ;SOS! MN[$V3H3D:3X[-)*OM_LBS]8VN>O\;@7S MU)1;?,W391YG Y/]'6.8VH]F)"69W0!{U3F4-8B.W)6)T.F1O 35Y.;#$RGT*

*MO?/F1H&W$$]8;A:I%0SAFY"@N0\:7O)(:.,Q*2O MS00+<_)734'-A08+ 8.9AM+Q-:&X"I"&Z<@(9?4L0TI/"V=]@=&^\Q*78>*

*M6**,Q0_G!4,">IY]|\$('=OXML)#H!1L,:U**B_/SBVI*BJS14=;J MJ-(L:RH*)/(_?DF)FOWNQ_]_4$L#!!0 ($" "%G9ZW(.+_P" "(-)P 5 M ;G5T>"TR,#*

*(T,#8S,'@Q,'$N;'1M[*UIDZ+*UN!W^ROJ!AOWGO-&O'0# M(FCO??8-19QGP.D+@9 "_LJ@XJ^_X%1JJ35IF59(D[O4I,DUUK/&G/Z^__ - M3>-I"EQ/LZW__O[B?*

[K"5B4+6N6\|I_9SBZ5/K7__OG?_W]OQ'D2>MEV!4G MV98"$UC^D*?0RTTSSU=]/G.TXHO54 ZZK&<93UM5D!:P?P="U$_T) ;$ M(:NNL}(7/6E;OS>,.PWBO[&$T_-

VG/+U<-5;>B M;KBAXG?4&_HSE<83/[$D09"'S5G@3C4))?7MX5,I]_L)3Q)# D632$H>4@@1 M/8,,DR*!B"1!@22>PDEY/3C5CW@5\HHBB\Y\?]N\[OW_]&HG>]*?M*

*M*K_6/RP'_6/=V- L?=MR-IO]G]=8!D:1!'$K_CG8<203?.YI^VUGB4V,,%? MO5J5E51@BHAF>,YH2<]/17W*_O;!W5+#8GI)L4E94X"F=" MPJ]5^BG293J9B#.1H#4CHM -*

(F8O"9JO^LAX0F,DD$(^%6)I"UZ^*QM]8LJC MK)3K:,)+8R#] =+-*/QKLW-;]HV3B:I'#LO5I+TAY0)WB5+/-_".3|9N)1N.'=#0X5S1*E@SF%1"N MAL5) IILRYFP/V^AA2%*#E-*

*E8=RE6@(N8#_^02.=(Z@TF<+^_K4WP*N.EPY< M-QIL7O,D?=@#T64L.1?YV>V0%YR:,;;Z-10-&XEL:.0474MN"8EXR B"X9'A M_\QYM9QOQO.*

\|$WWG:XO83=GM7;.H$OD)+7]9&YE,U12#BX<-ON-U8F]$+ M;'E_M!-EBG6P;G:B%T:+#"Y[%%/G6T(R'FT+/S'6UY314T47>$)N0K-PET4G/ZRFE0>:#&B@#23-%*

(W(6I7K^F$+:%NO:DLXNW]T(_-AAQ-'BGD8F MV6$5&4WXAAZZG3*7=0(P8V<__B&2&!.YI@V]&P*O1O#K9O0R|#83LW;",NIS MO9)DN$;1:V!30XGH3:DB)J4QYH=:Q,#L1NI7-

{1,! MA)#>{GCI-T62_J1;I@?SF.CK^F'=IL& MXZA^9Q7H?,I?C%V!XWS,ZXV\KELSU=JS'!J3#'KNNBV79#4.C-*U3KRWE'GAZI^A+TL;Y$ 7K0EN,G&IFKGG+3S7-TLS MK %S"%R!G5,>4\0YBJ|D\1 L2E@G755VN85=E%L(O3E&*6VPS*39195$M6H8 MX1(Y21AY)-45A]I"F911QF0;U+#.>^ZTV+H>LK Q7PCZ3)_E)W+>K6<- M9$+HR@I9B;_4,@S=4;/-*

ARIB\Z/9C&=TW)Z[A6(?H-ID=CUN9%"]ARRFF1Z# M./AH(C;,Z42ZA MJJCK4X29<%;S6TME\89S19N2KO?3>%9N$7S7KO%2>CCJ=)BE!<;^,$[40\20 M9FU#1?%BANXX?

]I6,^.^F!.D@%$!0?;FPVN>.:TTI0*Y1HOVIHXH#GTUATVO MR"NOPE>RH'[01@MM,\126#I'=5!?[HG>]&3]0QG,:D5Y7K3&-I3+,,,)Z 2WN%HP'+0}.BPM9F59VL9'!=;*

*MUT..D2!ZHKQ(8@R)8%77KTL0 6N&)A&XTT-#E6G3+KK;Y2>8& MT2\4R$A7A\YC!GA/.CXG?1X5$RHXZ|&!B2\:'2;W8G($*P^J=>.F60M69TZ MRA^J)4&==CN\1/.3L*

62Z(A0^>0M^Y?=,%[CJC)&7D.3Y\C@$=N1S792G&7W23<^';-HC$&9,AHQ[^[T_NA67?&UH@.7PPOC+2!":!%8E MRCVVCW(+/3-MJ8+.CLMJCN%0?=.0-C$T-PI;JF':;<-*

*#IA@Z&FR)KHA*OH1 M-Y9>@.>8#"QQ_268LFZ:K344 ;c2^NK>4-?WIB8EX]5#+\ C2S)(N/<)Y.5$ M2%>,Y;R<,&AKBNKOEXRO>)I-._*G5'(V'D>G; L1POC1;92C(Q0D^Q_L"1[*

MMUK7;GN#ZGB0LO6"+^%\N,B38/'5]OAX_7T#HNK),=G9=K>8R/Q@HUQI3>>CX];F@ZPO.78 M=K0W&SXW::ZT:CFTY3^=:#@1U%;8B]1,BGX5%;#'ZQR7E_72E"_J)!.(88?'

*MLKU@R>Ms]+^O='\1=Y_=W^:#8>>)CL:E#!X)Z84X.=*G-'?%] %,4T5SK#$< M/_&;N)XT*QVB?Y-B16(W1U]_R,WT9LKO-!]P"W@P[(RG>+XXNYXB+C+M,16]*

*MN*Y7$]JJY^URS!2^.D@<6J!8->5@<$D3 9L:R\TN#WMZ99*7)MM^/F%S.. M[G7911J8W4Z_(1V?LH+IH^$V=-'A0Ff[<8@+.W'WQ\-Q^GBZF70-N8P^ @LL%%*

*M&E%SX5>7S^ZD:"0ATW8C..K-T4(J[%4&%M5.S[]^^N(NBD;6HB0JB1Z),HB6 MF_3*75^:EUI?7C3Z!AK:)/Q\99;A-92VZ^-Y;-8BP^UAD*22N-*

*JJ0;,_5#OE5&4JRNV4BQ:R*C/$!BVQ;?ZQA:Y>VQXYA5:MA3;2 M?K;9]\N98NX3A:Z/KE[+1!FLO%R^9HCK94UUT74%9&)P')D %>U$=^[:^/=<$(N,"2@/?/W_$RY-*

>+EQLOOU.7]I[@A&Q6.O^<>W\DO/709+CYX=N,M/R\?@O]=<65*P M7O FX =&(R!];D'"*KJ2&53 %QIX-V;8I64[@>\L&B8/R7@V(M7H3!F(/+5B\,T6*

*L0PT+&-2&P11U)=VB98HPL/Z*HV1!U]>$PN3!4<*R M@>XLUYMN/FER_'D4#?QIR5AP=#$_7:KL+S<]7:KL+S<]7:KC3&O+2'2KCW+TLGF$7DE_MV\PG68M^7>X0V2+ _:7S\\<^+]B\9^?*

*>OHV]IQV!.2>#YJ6\2PQ";1\AHCUOY)BX8VLFU+$]<=">"7[*&N7!>IF?9$+3=]1F M/80/T1&YOT^O[<<_R[KZF_CV<1C'(IAC^..U[^7X)0$<@=3UXP7B6PBC6W8_*

*M_J85I;S3E$02Z/,K5K]\-NV1AR9WW37Y@;+P&I%&;5X8LC6FRA?ZV1)=L:E)-MSX<.D1NCM4?9LRT[2MHU14\B&/EFT3\WO8#H"6%OZNYYYBZ*_OR5'DK $]-^ M=Z?4--OE[#:*

*((Z^=6.S :|\'-@VG;E>+EIW70YNS2:$]S]62T,$<F-'>;(V-M)^<9\WDO# 5<$PA*O-%2'32]%EP_CAI:LO2-MF8\UIGBI2=0;-C5F>P>XA M^.> #\N5#Q_N(RE>G7]7 K<9<32C+(A5?*

2>EQ&L.%<#]H7 Z?JBK;DCD 3%<E>L\#D M22:54F #YP.D'TQ(/V_^:$/THG1GO."GX2Z75CSWLK-:[/VY]+VLSI.TUB3 M8RP=)!8+@F1)<"@@^BM[>=),.W?? U)0W]YTWRIQ/K^L^%ZG6/A.NH5OT9D-/,T"GI>1)H'F:&[M8_M_C>&-/5S$Z\&M"VEH=1["9P.V)_^[+?&G 5X!{]@U5% MZYQF>P@?D/.T;F1XOI)IP:H/)QB\T88S'+Z*

*0IP357,&^C@%GW_S4;&N:3XJ MU:N!'OI\A>_5]7CA&MI&J"UOYZ>,1W##L$!I-@8];A9G(ZOX3[@^%Q(:?F4 M'C8TE2T5]YE6"EKX[!*XGV\B+RF(7XK&KXZT/@8&H+>4.GD4]D)BE*

E07&M M#:V'FBX [^\OH745Q;H!SA'(7CBC9S;,7H9SGW1@$C<\>_2B1UU0C M"D?6E/9;7HM,)PX,@\&);H5WRZ[$APR18F+/%LJ?OP3?IPCX\K3P-3;IX&I MFXCT+4O:*

[T"DNV3\42(]L083/OMV.\Z];[<>?)PCD/APQC=Q;K?I99+6=ZR" MAI%S&/IFSF&7K;2]_2@]&/F&IM ,M^>F%[%RESQV[PXO1", ^C=DT:*C M^:*Q6?|!JK:2SEHYW2RI&*

*<#C^I6[UVES)\'],K \SOY#EBG93A\QD.}$7 MW.9.S?1%F;Y^&O8+-'+=B>4O ;>5!UG*3^@+063#T4;K.CC^34A-Y=Z5^3:6 M&P99G[?A7TCRWT=:7>SQ4QC-&U[NAEH0T_6*

M.JFZ!D/MY7K&$[US"<1& _2ABK9G$M_-\H4U@U7Y-J4T3]QZ+?JG?2FONM[FQ M@\;Z+C$K)V=5UN_S="8=VBT:F[#I>Q?S#1P7+,(^[GT_*A0)&MUC6FH,B7Q

*MC^9TU'N7|BT\UX7%ORMV|F+_8=E^E@G!1-MTSVOM>N]9MG-HO0.[Q9P^)WR6 PAT\SF06^YKY)07M=P+=](P MZ@M.URN|KBQ/Z\EVJ_&PW/6^*

MCK0GOB)YTP7E\PAHE6>L62W(UU\7<5/BM_DE?AF_!?E&OHTV>TU&TW.LVO)8 M30P?IQO$S#=]^-!0+"-P5\UG%E\")=3O9F9:-S-F#$B8;I>R]B_D&C@L689_W

M7$VUJ1=GQ,+!%/+Y84AZ88\Q'I[KYN+^Z'J$EWN<;O;[(L<2Z/FO(M2.,V$ MUS/WKL]OWY[[+=8=O)1]%\R(SB*'EE"$:6+5,)?((_Q#]Q4KVK*

M8MX176TC7EL,+9+7!IC9TE@:33NO8IWA5*%(M<[)M.DC9 I9XK2AGK?^0TH.73+%GQ5:O:%,0. M+&ZT?LZ?)ZN\H3N('G&9'EDMISQH0Q<)W-16'SN_Z!Q;OQOV;,^_/"*2IXH*

MR#V!"8OE4FTV3;*9>@,X:O .\V9!^K>ZI7?"QTN2TN2%%0I=,+J:6G1<(1T M'3J:]5VE>'BLW?)\T9W.YJ637!!OJ+H"PRRT=W \Y%N/@#O(MIRZ_HWK_ZHMU(.GX2[&G<32!.7-*

*65&]X<3_KO5 ;:&NV^;;7;W;\HK^@#!=-M8PA=GK6=L-J_!F;=Q+U:)NSZ\ ZIUL00PZ)&U F!%C5#01)6EM#QNECD\NE) M,%%:A-6S'!/H*A=](EN7*

*NDSLL2ZO5E!R@Y4M.!)"D,@B#Q'[TJ6KU#XS629-MO",3A)X0Y@0?I>IV,3-D*H JHAV&K XT:,O@IX1YCL3O)$W1"D0WQ%-G7*?(-M"6(*^/94#\16K6/7+),C[DL[7Z?R>\H43YV0J8?*

TC7FM,>XR-)WRZ[+B%VW[M7F5ZBLIO%/JC.'UY+XBS'&\CYJ8.#+:)5"@+.'15@K?(J R5WU:F)R.C"DK, M$N)\,D4:,J67:DX9G>GH?(;RC2.ZY.G9$HL^,9(#8412F;[*0TM)1?=*

*MYGT%2*I3^,?(=''/P,B:3'.VQV-HPZK[?K&GE,*+ R/4^!PR +4,54>U+' M3!L>1J=N4_QBP3=UNCO(U?\VTDU#X,N]PQ>-+&O%@V9Q-+&O%@V9Q-:+&O%@V9Q-:+&O%@V9Q-:

{A%&6M1:KTTY M9H^(@^M3V M1]"Y8AB7U-P,B-<_]>IC4%<*HI7FH2!BD.B; *I{\U[#]MR Y$FH3 M19M? M,,I\W-,+68\(W0DZU>*

fGO5A6O8W@22O@L//(:GDV5K7X'H+E#5|/=FJX%Z; MAC:S^)X2W;WMB=R\|8F\Y(K@_2SE^?P+SWTGROS?('SW:B5IJE M[%^Dj(HNR$;,EN.-,)&DEC2LWN**5H0/3G4!V-0E %O+F=R\|#?LYKC3[,;9 M7@$ZG-W:8AVD6<\'=YP1TN??NB/=G2LDWR/>2VJ8]_(,7+,SZM7B)'/K[C$ MY6O'U!$.A4I+*F>|ZJC,(+FK6#=LKLIAC&O=BZ% M7_,[;P?NNAMKF" 6M.SB/-+*RKM?0^>B^3$K=]6KY[*MX_(#T5T:,& G] MIGA/\T-/ MI :6S*#*7L!2!;HM]9K%%'0*\<@%WA,R;81[-45,=&-G8.F#T4\G474 M:.^-)(5PL)CH95"2(54S.?^1EM^U*GY!]O)0QDLI8\/.]&*>Z4A)=-3 >#!! M#>MJ61N,LP^O>, ^]N!7N'Z2(, 28$D]#+6Y8[:%XP4=2K0Y4G\-[8.1=0?I/ M#/3@"-4Z=++66H'R'3_<'Z.>CA*].J:28[!@_DSH C MNVKG3'$.WD,$N0?T]@X^3"ZL^@F*]JO78YK1OZHW1&,O7^7Y5)$&7_5X%?5 M M[GIY^O!'I-G1#O"4EZNX-9G^,Z*?"YCIMQYQ=("$RT4>Q"X25BN:,-OR;$.3E^U*/C#W M#RM>WENRIIDQ-%,SQ)W=$]M88U.*R :>9@'!8U=;,^EGS80#<:+V^6TJ>;M M[%7MZJ-$LFE5&5+(SD*4L56^#IV]B LNQUGUC*N5NA*7'B0EEB*;>#HK< G^,>65N1#M M5^=."6&ZB:17;@>+]CSZ']7R6Y97X(#"D?H*,<:<]#!!EIE"O5=2^Z2H-K7[-MUO@OJZ]-)-37"RQL?SHL**5 YQO!5'-K:L7BF/N.TVY:8(%(^"<*T4S:&AJ??*H!RE9.Q]9]TW M+:,% <3/AO/")YNXDN9H4?QF3;%MAL.'R^@L(7-0O(C!C9/$O91&Y-3]I1?:W. MZV2B,)*$:K4ZR$$;N9TE=?!>-/6'I&;(S_>1N65:E,77OZS-OZX M(--J (EHF4YCF>AUH/HD=6Y%B5+6DMP_P"X**9>DW[TL:)MR))=K=(]#Q]U-M8_(O-AAZFJR)I%=U*$#&J,.Z\;[ZF+6[5;"706XVWY^FPRWWO5I?9;E)\!4. M\'BBA(0* UVP&C'^]P'CUT fQOF3J'H3G$^)].4+#V3VN=<>TZ(3TO[XB]8[MPX_!9#N%< 0G5U)4?-]!0U)$KMM6W+=K&T8\#QYOV ?>1F'RU5H:8^93@.): MGW3R5@?D9/CC^/-I_SF*OW^:]J&"\EF<@.',#_B*54"UD<4O* TSP1@ZPWHG M.+GOXO)9G'1R1")?D$-)#SO!A&_C?"<0),*?K30?!8G=&5;4#-R MNLQ4RJ-I1>!CS,6+UZHQDRXLZM.3- @=) M^?,9@RS444#"Z!HFDM6'|HY[M,'OFTP\3]HWS,B>B8ZV MDBFP]$+G#UZ1]3Y-#UEO9'UHVX6Y4IDAU6?,3T3M=H2\|O' UQLHG,+]8?:O9G\|K_/OIR7K 0M0]O> <&F6]QN=,=H=5H2>@!%L ;Z3F^0[[M!+F$?Z^TF42FEBTW>3/@\|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} 7M(^1S=?X+3*9;/F..@4\Z^41(44'@5'!D[]30SXDA8W5%AA*7'B0EEB*;>#HK< G^,>65N1#M AY!=%;$*?<&B:EF=]VEN>@O+!OM'OFTP\3]HWS,B>B8ZV MDBFP]$+G#UZ1]3Y-#UEO9'UHVX6Y4IDAU6?,3T3M=H2\|O' UQLHG,+]8?:O9G\|K_/OIR7K 0M0]O> <&F6]QN=,=H=5H2>@!%L ;Z3F^0[[M!+F$?Z^TF42FEBTW>3/@\|KW> MI-_T.G=DW"'P[W=W]R!?Q/]>9/U%_OWN9'UHV]VRIU&^13?U+C_R*\W,])^5 M'_X=0FF_\P:6=_CW!4\HY7P"""@[:*23^,(N(/<4T,/AW^_K;IX#_XZC:*56 M&)HIO6 ,VZ!0F8\4_M[.P-?Y]_N2]8%_=_A^.?#12<"PKCSD+,)@:L-[D_77 M^??[DO6A;3=*G) <=R:T.RAKXH"FTG-$"N3=A?VMK0P/$K0X6VFY798:L.(#&B/5M2=\U_(Z_?" FHNEJTVC8C=$H&J^E MK'NR1VVD2TRP/M^HX.E94\G((1>Z>&#C]5\R:N_X])>

*@M3-'I%G#^:]E<5\]J??_=OS]`M@Q,N$)A5<|1S8PR.>2T#7R504&PG<#7.O=:|+EXEK"9_I%ZIXP;/LM;PX4L# M/!H\%K/!TAUXR (R!@J/K=J:H5KPN@/K,,'!WK8%GH?!|&FC?S+IA/Y+?1E< M\,(=@OVINA*!,?R\A\T;Z9:UVVGL+[!_@9\KK-SX 2_2WP_8H^Z]<%1>^RQH MP"6]. +"!$*A3<0;\UGA6/ M?-%^?9IONL7#-+?/E!T%+QL/"%[Q^1#,A[$X!KD!/X2>_BY\(!TX^_&^P!;6 M 6=]HI_MB]X6]GS2=_R^KAE =?V!>>#P S0C7O+MQ_IX8]M9Q/_^R)731T)S M@A#?(,*W$;Q@9>X'\ 8(O,?&JF2F-]XPFR *#=(O=]7EZ)&]_?C%X@3'XCPL M8?:2"K^P<\+EvAH81NS\:_P/9V<&>&:KW--+]0UO;EN5H=#!UB9=[<) M]!.WST^LA?@MP^_O*@E^50=^%7&X;V6GMLU4(%(#?58:&Q5!X@\LVKV MMHJ6(#Q0S"ZD].>3G-!0@H)VJMCSC\|N]@_V:"6)!YI]W:1U]^&?=&EER >> MO;CY-S@,:>)V^K3N]![$E=SE;VX ,7=?Z Z'74X!4\PK#:JS2TW1:$?F>T*<% MC:-ZN^+(UZG]?:2^]77]D+]NRPB;7V)AL\FG^):0 :Y$K) OG]ZO&4\4)=@2 M(5DI-Z5RL_'Z4/_]-WMX%HC87@G;?3Y{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}Y7^\"!H: M,K0'*>#T+&.X%3%8,7X::|&!TAWZ;R??,9@ L=26XXRC;+RC;+YS5]O6A MH(5]+&R, .`]7N'-9U?NMW%|X,\0Z|[2SPPR.E^A(7JA2\+]KD4;/Y1^.B MCI#EI3C"6)V/"OG6]]#KTZJH#%XU1&86B64H0>HRLD3X@\|+0P8C7K9B?NM MDFJ70MQ3+H-JO-[!$PM(0ULD!=M_7G[SO7W(Y+J=RX!W_/O:;M_?\[_^135=4!Q^L*P>]JPC#Z0!%TG51Z T(C]3Y+",Q+7&MJ2KY.H+6"0^2E M9$5D9*2[F'36%4HC7(S6/M7];5)N1,MUF]E8JQP>\,%3HPY%^(ST;"4*N M)R>|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|>)D4ZW!QF$'0Q6_M'-_,5NK0G,D)[C-TI\,&%@SE#K E:8T8E,%9R:@F_=)(R4R(+AAZA%UJ"5Y/ M=|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|;<4^I#!0.AH]!(Z7BI=MJZY%9R$1#2[6&3]Z1&<_!=_]Z9DQ4R_OO#^('M%J9)_/>'L?)_VO-)W_&WQ_Z!V>H$T&+NQ8;J.OT)A3%N]^'_I&=)C/M)U75A ME8N6:LWU'Y@'MD@/9MZ&%Q743EYJ-$S%S'#-^GP\7_4Y&P;OTC]^,00N$#PN M\NQ__OV2%C=]8?UM10;)/)+YWY%YDH"#H-!XK"3HKD'YY4%2:N1G_JI9&)9R MJ=I7"_U;'4NYC/LX,QOBLK>>CJ]PRD8X#H>=^_*(HG"# `Y8[(?01OTR_4E3B M8?4AF).OZ8!*/4M'E^M(7C#>!Z+7K3HC?'.( O1<2MW8B53]2:.+*NK\U8!T!`MG%Q2=!+M$#Q<=M>$I76H%UKK$>UB@_3]H"B_&26HQB<)LBS*PH1,G(+P-7_\8G*6YW%2$)'1\D]DOMHZS&?%7QZ*#?4V#A>DN8=-;89)HI[M7ET"P>>@X),LA1,<<#>&CYP-2UTZ[CE5E&^HC]P5"-TYXEQ*T]B)TAK RQ%< M&4FD/!_1Y,:3"]X1TPSME)C,30;31VFV$4==1ZGWU'$:DFV"S#26>'8A#18!Z#PON4APNB[< %1E2$-I$@6PD(;,Y8 M4?I\N$DOLO%O3)I.C(H.:7 9 M7>P,*EX(U^[_-GDO|(I:%2K39AXKEZI$NUVO9PMBHM:N0O+Q +EAR1I7.) MG*&1V0<).!+P:&HA[TFXDK:*":)5$$PJIA6Z9GWL)V)+(.% W9)7&.$G"'H MNS(8!48BV(@'=KN&7=YG[QO\!^^GZ?\9!WS^HJH +%2%R,.6?2KA$YA#J@K/X23#X31UVV:4G WV:&C MU.E0'3FO*^D;*B#?}. Q77[,]?WF/(_D_IO(_05SHWY+ M\/-=,;-N9KBUW'ZDJ9HP)I=M*>@P#H-N@=*3%,{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|O>(8^=6 M.NRYOWH#P]*.6P^ELPJ$E^_%6W:2FL;LP!>)4&20#87K[NN1WM"VU1R:279]:Y29Q.3\STB0FUMI(SY7%MK08% M'7IB"%P@!)RG3B5FWT18!X[G%H04[%NR'!>*8|E)K0=:-2%Z7;@&LO\4UZVLZM'N[2.=9O@UBEU*5RU7)O3<1HP\RH=:]5F0$0"\K.D;@H"K!J-[*/((%'-A|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`X^/]-!Y*D](S,"#":'6%TG=N/AC_AJ#M>P?Q7THI MVLESSM:SIW=6Z14P6:O91T:UV*0N4HFTQ7(%@<..2 M4,'?7!H08B##$N*YF]'G(6%&ECC..\653IZ0^;P\3Y&(=A' !(VQQDF%QGCWE M^KU)\U&8]H/2?;[P$AA=D?^:/(`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`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|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{]D2M5C7;;BSV":8^PMX9CA:A1O6"VYP;B>V\V*F-B6#33C"ALD>;ZF=T5@TU8&#9[]TBRVI+ET8D3, 6)01]BP2:9)RU9')9F;ZOHK5B_7QL4E"I K5R<M3D^`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{J;03QU5IX2'PCQ_GBJ8:P^R5&?3.'"%/F;?+40?!+&%VWGX]W&YH-Z2 MBW?72CT0U/A)"LQ".A.XAK>MK^4& 7'#F;F!ON&CIFK80#%PPEUR ^&W^(& M]BZ9G3ZWSG2-A/"ZOM#MN?IS(A 7C0SW:US5O[S4_L,LE(\<07 M531Z#?#?8]VG(:_/^M$C!3H8D'0<\PE'BB70N8 X_XLXG]HK4OS>Q>=]Q2^S MCA>T-L;Z!ERE8Y_MA/N>O]EUJQ.=I\&3%U_(A6OFI.:N"N>!B^RME)R^IK;B4]$E/=Y7X9+1L9O7) M6)X,VF-1WI!%4_B#9IN!&<({]4EXGX{9E\O6++.@:XDJ405".I?ENJZ7VIIG]/JE6FHA3C\\Y*-NCR8ZF;[M3% MWO("4MW1,K(Y:/L):>TLG>I*L\:$#"LE<#}^L23.D20N$/2%RNRAL_IVI?]= M8.*]$6KR?=$=U7Y@QKMY*126]E4^;@LES57%%`:6AE8\E9G2OMQX=(1\|H[_ME%)0],4'OT@*G-4T@<U/,1;K!HK/ZU]?Z9!SNO8GU.@:5Y41BNU1ZL?P3K?I $@0NB^$Z7YQMT MCKXR&U2=Z=P*]A .A7Y30J0LA]$SEM]07Z(K>YHB3*DH6SR>.M13T.2'KI2=!?(7!SU5ET75NMR:I F\RDP]12]"40N-^28\1BQ(SD26RAR33E.M6\UF36&#IFDXP_.X+5SDLG0U?T7DA RA$4*CJUAJ/HQ&CN?D&ZMZQY#41G-5 MUA;CS=",.!!J-_*9#)];DVC0V/:J?GIB4-H\#-(+MTG":I'#N8AT2D&Z$T.@< M<081)E24+4P?5XT>W5ASZ%HSN2*UBLN&*;RI)?OO[*Q M]'0Q@'5THX9NU2WBKJ0DU\O"FUI@*V-PFJ4!)C%>G-Y5=P2X6 ME,C?]"JE\GHDN6Z=JR*I1<}I>O214J/Q1'[<2X[UU" MR_*R[I9=KT\)=R%5.%937UL=':PS&U>'CG>L@(L4M@S/L*24'-0<{4EVW(DN5:YKR>FVQT2ZZRH9PMAT<677F)=T[Q*Q?(\UFT]7 M1^,&$2-;&U[/<6:U M$9H#MP07P<&76%>B2Y;KFE(6Z!#80DI4IEL8%_M1UMX0;CA5!J;00T)&2,CT3>>20H@?PS2#:0;*!S \E&I"LR1(T0Z-A HA'!D@WG MI$347PANN){O8>]C.FKJ6Y[NG>^8G5?NJ0CU15O-^OK!>|%M0_NZYH3VAYAEV/I(">Z'W_ZY_6O@V_]#*PR7W3(75(.(HGV7=:-9(.)%H WH M!$ \'JVR >@ 0 = E(7CNMGW7W^9B51JN;IY'H0 M H' (7!!8[>8+Z)NG;"#]N!3\BZ)Z\[_#>#\-'2B:R4[{T6}$:CTEKXZJI-MINW6 `R(/WZQ+,X0)$Z1(M)'$)Y$'D\BY].]I_C@#P/*DIG&RLFN-)?U.4M4 MFK%FTO*A/@*CA5D"YT0>]T _><*+NSGYE]DF"<71F!>FLY_/UO,M|"@$&\C"%E2ADIOFHW+L4YGV51IE6ZR,51(M MIP1)PE6)RB+G+C0@Z@2*P:X43$<.*BEIC?Q@FFEDCUTZ,,)\^K[5ZZFS-U M?UF#,,%!G. 9'A?XN^R)@&ADK!P[-")>$*P_#8[3)5]E^O7&@FYP#8?LU[& MFF;40'L081M]7* 8G.,Y1#X@G/BV\2/W9#CY;- H-\T*^O.,M%PIHDE.AR ME8I#H CRK@5* MG+FH8>=]W!B)'?? 9880I]*0&G.M2>E3%Q K[+L)\Z/4B0/>=A-|<)N.K_M- D:^ZILSG^S+5]SNQ_>DZPC\Y!/I M#*HQ!595QA"2]YR%5ZO >R!IA0&9VD*%T[:EV .;$X4%PEN9*P5GQ-FJ7R\&,\0 MTZ9,Y,[^8-6YV:08G*^:H8 G19RXI*$ G:\W+K5'Q1[]+?!VHBRKJ,_]N\=%C0:! MI& ^-E$=;,B]R-8WQ ^W9%H?4FG0?:0M&K-)!MT"<$3F Q/5\,K=<8&.R=R\)RSU[>\,Y"4$$RI[P>-LSHH?;#6(%)%;D@K6DIN MBU#W9%QY#SIZTT2AINCS%:%YG/-U5E;,@(]!#8FY' 1W,H8^H*)MT@106#R MX!)5;,4/5E\WD,3A2Y9Z,*1] @4F- MS&54OU0GYK+2KDR,M-_-!-H!M*>0!'Z0/,[1%RS^^NTD .'"'5-)=,ER3W:1 M#P!#&GTRF]70&$H-2FX1D4W4J,,ZU -0A,(P2!%QBNYCVT:B0C*S-9>\]D(1P M6,S2!WJ;ENAI]T7#G?W=*($\,$@VD&R@8P*)PHW4A$"G!!*-*\ BBE4. M_H02M^9TSKB.YV%3UQD8/K(?WZF=*/*U3I 'Z@L]TX'(5P,)/]:P<-A=C/BE MKA$OO^!0I4:*F<[B"LD%+5 IG.5(G+],\PE9G2/)^PA-;AQ-+NK//HTFL]FP M;A6S&B&M8XMX998P34&H030)FFQP#(>+%&JR@; C*MB!G.!?YP0_#1W"<)KN MU<:L,,Y[UF1#9)/#-S6$T""^^$53.$*.$,@!S<'DRB#"?*HP4$0"[RX.R(#U1\D.T?.$&3Q17V!Y U+LH%D _G, MD2@@GSDZ);.) "":0:R&=`^9)YF#/#N%-H-!T*

*M7$8F6V25NE__!?;7+>>Q2LIY;QU/;';^L (JJ8U1]JK)Z T)_>$N>S8FNJ- M -H!.OSW1^P(I,FQ46=8V/04>9:2$SUA8-<&_25X;YCU"C->F<,,U[^1#1NA MQ7=!BWM*6?T-X#A(3I.;[<1,BN6)NLVUXJU8-XD5@IZ. @2003H*=ZYH$?&>ZI#%H90_"WX2P.;P:,'[AI ?M4*UIJRK%8@7.,AYKI>$C_$@2&F=HG(&= &G4X1P!"@*42/B%T:D;G?V],2&Y M@=B)6S9T?/C0'5<\AJIV!"%!399VJKWNBGIO" I=$1VZ"$]N"4\B'U82N!GX MB9?WI]'C|)>&92%'!I)=(C]H9" @04189BNK9<=.JM[H69"'+CG=,'_ 3Z5*_ MJK*>5>6J6D<9E%^@=#5'@)T4>IT54%AQA *&\]^7ET3F(>#U2#0[H!+__MUC'8TLV,E&D9$;ZC?'$"[Z8:*,)'OX=&]5:@^A)"X MW8^_)\MR_+,_DBEWV'|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|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|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`-0%KK45T0V2FW,-*1=&Z;AE&[%M2# M,=^O&(3]'2R5",6HC_<#N M^*UQY%K6P=^T>T(R.G]1C19ZI*OW8KB]KM+6P?*5R11-A^9F?]:AFN,X[L7V M&C\2+=.1B1J<734W_;;58>1:W-)@'4=BNA$K.XYE92K_]&YI)Y[&,VM)L$K",G*=/(^4$VKD_8RZDC]XUR0)ZPTDXN2N=G'V[XJMU2IH2-UK7AFJ]: M]&Z57C,W^]5%I;7&-+$/"\;',(8P#+)K'+1'Y,]-T MTI'YMV_KV"0;KB!/=D<1WC4%X?#&BLS^5<:!A/37OE=@=]*9G.UW$F22 KI-MR-PKX?TCW@\/]3G?;VDM=.G"X\TX'9EH5I_/%.;+C& U7>=F.\6;6INR<S MK]3!FF*W@E4=\I7P%:HLQD;+29\S_TIA79V._9D>VJA*F/5.TV8\SDP@{O]. ME(II4TSA EY<\1_[^(^L>C5,A^9>BJF/UFYM.FK!8K6IUT-A6T%H-AV:>ZO5 MOKJQZF.L#Q\HMK7>V]%X&&57S;W6GIQ4FGL"D_F^:"M':);$@[>))D.T/RS\HZ M-W>_#_L!WV8J8VVM8>O6(!N:6Z?5,9HZ /VA78<=6UA!A(WYV="<2BV@3E?$ MIWPHK>N01ZXVK(8Y9-,>4A5IY@K#]*#"7/(I3&_$M=!QL;Y3_4Z]2H3M M>&UOZ-U^AMHF%P7S0LA,;UW#=*V M6ILO3^%Y5ZAME93ZTC"XL8(\8]L-C8GL?5F)02HC_&P MB,B#(=(5B2UR&IL3F3'TAY.1IVA+(F[Q/:HI'}MA,A8[LX6PP3@8DVV#]@A M@"*G#4'#;&C^<3L+)):Q>#V"N1!!S#8VM0A9R,;F'M),[-NUH>)BMUK"Z M"V0S&YM_!'%NCY%^NP7KC06WY/[*(]>215BS%4)CLTU,%E4'C@9B7372W-FQS&&17S6G9?C"N#W?(V(/)N@@;?5UCTG5 M_QNV&/@&G'86Y*T#L=0U-K'L?"7TAJKK#H;S&&/:';5_'MM MN\NQ/H(E76I/9^)RV;/M2C49>V;S1%R\NE>/,F1/INJ"V"#1:E\1TJ&Y]{X Mf=7Kf;.!3(IF35RSB???9].AN??BVM.*P&YV&_UETA_UI>-23.[:MYZ(?<6 M?5#&%3CBC?$X7S2G(K0>F:C;?8A8K(:=521W5FE9JZC(UEG I-K=C1)'0. M38-U>32P$F]IF[%U"A[@CPJTMO];#^0!Z)=%W=#=+8+BSG1]&ON,BJ?R_L\1G5/9 MQ 3,'643Z)^?/WSO ;8QD*>H3AH<4$!\A1_C+=\=`3Q%6^!%X\7-\\/EI*+WTYU.*DID\LM0T5-(-M,+OQ\U!E$7AI[/AIHD;P/S#QS?',!XJRWKM2/3IZ]\>HKV:#@CF3'KSLDZN MXN@OSPN=Q5)O-B_YR4BCK$0R$Z&ON$%ZVO8Y^Y3\M?[?O=S*ZZ+ZGDS]7LF0Y&/+1?6<](?_]Q/^Z4]QFOX'/[]X M?:FQ)B? R3OD*66O8>/2GIWZ'M_RC7UYC[W^GIB!AZJOV5J7^)#;[PB^NK-"^V MU- _7FKD/PCUWB*\|$)BDZ=+MRG%*0T42X,L%RRG6RTGY &6DZI&ZR@U;32P MCFX'2Q1RY^NHY[DIK]'W"'=Y2K"4;KC#O;O(+KR41EZH.#^N(,"B?# 7Y;7U M<4KIS7^]$.B,^__ME]7TLO_Z2,N\4S965@(`Z^D;Z^E%|_;1UE-5-RS5 OCT+OCT@B/{2.NIF?ZY M'H27,Y_ BGJ[/_M(*XK?1HF3]U%=WNSOR N$3Q[) 7YO*?VQ5_R.I4]_1\V* M)K<;^,,WM[AN):0[7UNGY#L@MWLPN.Y1*6\DI3M?76"GO+/U!]3T 5,7*04) MR.UNUAN0T@=87;Z7*0<@F%4?0]8=0;==SJC262BN1=8LMY7_!U[J WEK_,)*V,] M*KW>/4H,%5=3?.VY=U1URXFC2++F-CDEX.TTF)K-.?MCIR@VD/M&6IL7RUI'MH?)3GZ? T8J1$XW.YC3 MA#@6YC[1VOJ0*[+9JI%AW]2)_]2/PB!]NT3\9QI.P92C48U%&Y'TWXWAJ-M31)*ZJ.CG[{@90S#RS1*YGI,7425;M,@\K554SC5NH6O?]59.1E=HNE>9G8%;H? G!ZDZ:I. ME,[!P/-3 ,!AZ%N+*"L5//)^),<_\P?.0$YGKA]6>"/";!02M6"Q&70P.>US M09P@)]^[\B*;]+.9#/"F&%*Z"> \E,WR3H#5+2DOSX=.P(=@R@B.EU$& M 1 $(.C*$)0/UA? P17_5=?>3.6BHAXKEZMIS*IJ'IS.$'I.;]E5<2D$ MHJ4+\"A MHDKI1CCT_'$[5<TZ*:0>8U_B,6;7 M8AJW^ E1]>9-1'.,E=N#T<\8-*?6 MT<@>5?B%I{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fU,XH&EO=/54C2=X6T-$_$*_JZL4UP$$B$-(`H4D#I@)@*A1/ M2A]OUP&K D@)L$O!J@"Z<_N@7|%U!B';S>O'I)TOY4"$*-%8&F6XA^>RID& M092V>CL39/%YF/.9ZMZ VPZY(D5U)@LP*|.GRL,T+R(L0"T!>-U<2O=!/[WG M".Y%$4[% !8 * /HB4 &@ A^$OIB32+&+W[QCW+)KN9Z?-5Y? XI0Y+C5.+IC,Q!8MU_!!N&G5^PML,W#EB[2/%RDP6Q43*!$;5$3S? MJ!:40P:P]$$HI3>'I'%0T%ILIEA"_2;6/"CO MM*>')<<+ .7TOU^';L_%M(-U\S] M"? %%RNJ'UQPOP74@*Z!W8H]M \PHOQ1,5 MWTU+W#U%UN8H-HCWV^&OY5$I(M,<&+55&*0.4D0:H=M=2?)',#%#M#D\-?@_; M9LV5$;+^(H:C7[2%QXH\0%9LAFW9"0!%X67R3&4A@&T V^Y)BB]RG0&VO=?1-MP^\!DH%UW8:V6B[@=]=KM=%H6WIGM3\86E19M95"DS%#YCF?7.$:XR9G!Z0X5 MQ4EIX"4E+'457UW^U[\0$OXWA1/'}+1 03HQR2_7;[<,QO(?>,"Q5>K0R@8 M*@>73&Z+K 6+U@=.7_B+^L[9]_2C,$A?SDK]N1PNK%TTVLR%^19NQZ$\DU:J M*(G* M'?XF>< 8Y}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`Z'$SN^:-,+F=J0V537$K/?$!ASL*1V8"4 M"FXX73\V?%%8>OW4:=ARQE$/CU4>]@@=UV(>C$*-6F2?+MCDD(7J^VA&!61K T?$Y@98++*UTN[M_[^_6TF0"(?+QWBYN!S]5[@?X(S8:YK0E.Y$GZ]N@Y/)=K]SQLG(M;&-+1#,)P,A=Z2WVYG"P8=AQY>-5,,HE/R (JA98PF M 10!*+IE9+M04 2Z0@ 5^%!=(8 * !6XN4'ZX.SW7QBD"YL1A^K!1&RRCZD- MWI%P$2V.$=E@]!UMHSUQ;9)2_6X+F3]:D1F1*0?^9$7BV&N)%0=]*#F!3&WD]=0\$B>++(OB>#*\'FUQ+]H7N[MDGQ+\Q^%R@=#^VT+ fV=>*$N@:]YW&G&O1 M/$<@?-/ #$D);6$I]B5T$G "$_E C^4B"0]<+YX/C8B D0(>_>3SNEN< OPU3 M+4R*,<@(Y_P!TOQ_V^80)!12F'(2F +L>$#*;*4'LJB^M""!K\-6%-V$-LC M).S!_9G;7XT%_ ^CT,KN*_O0%Q9DRB8.D'@!;A982X,F#50&D\'CR8%4 W0$\ M^8]RI/'[H4;,KVU,]C'CE5T-[2]K"G1 9>,_-]_M&F01/":;[L)]C@'6 XG<%XT=$%@ @07L 4 %@ H)B]0 -:""Y;)6^0CLE>+ M@X^K.%;K:P%/HRCK31$I7%U|>-6L ,?NF]OJX$>LWWUF*T""S-4OS#4_G@ M((C2[H#G\OH(=;QE-*8AM0D.6TPIP;1WK(P064%P$?*!-&#E!J 0H!,_0"1 MQXM"QXZDN?!|[M6DI:KE57V^LAF,S0PZJ-^!€>?E45>MX I2<"2OD-.SX5# ME^#D"@CI@U!VP=$X.!HOGI0^WJX#5@60$J S@E4!=.?VL=ABZ4Y.2,6N[_^. M\=FNY7!^UK3M=),J_BV\D-PX*7.,8U3Z['-_N&^J](@I5F/6Q+D$CAN?& M4[@=R.$W')Y0B/!-%'H$]FE/#TN.%P#BZ05=.\|/UAQT&OP9V>Q+(@>=86NE? MJA8K[!QBN\F8@]> E9:+:A2/KN1847<5F>4,K4J&_-/7<6![QE6 MV$E M[SMRC7!W4:C.ISM4%"?EAI>4L-2*7/V__H60\+\QN'SZD$X8X#^_,Q/M1_# M$O0#0O&CAZ$5 C_3HC_<4TJ>9$ECO:?,KO!]>KPX=M)6Y(+08VI[4$,9BCMV[LBT>,?,%-=PWUZI1D'Q2>;,2&L^O2 M9@I?=`))%XF4+*, 1 #(*9[$'LQE>*N)"QT-'?H=@+)VUKG=BL;=V#;2N* MN4 >6#6W^J#=6Q>#537-M#K8AE7AM=2PN%H V4HG3G$L.Z6CD#*#H&7T MC/L(..(R=X?R5Y(;"FR) INCKUZ*K?O#GO30[>G5*L_7[=O#60[%-MZH<>%JH;U8;&&#$A.K4%NP MGN;)FQ[56$L*/YZ)4.!VMV3Q@ <936=2;3Z>2Z(H(OY&F!ZPR0EXTM06F"ZC MB1^(4+_L#_L_V9VO VJGC[]Z2>6FVAW^)E"?SBM>AD=TG&G[]+??$Z]=$M] M^LNOY\WH[T. (DHE-A@U%9P@-D0V53#QI L9D>@&GGC-`)2&JP2*)K,G__Z/-M\OP7B.'-?O4(WL-F?5U430,OSS2&@X'T<^1 JL=6GHCZSYB(<;-MB6JK.U\ZKEMUL M]],C71GW7ZJ]0Q9:*&*;4GHH+G<*.2QFPW%?A[*6\I^N+$<&-[66LN>W6NA MC5XVE/QY*.M9D^H\;%=ML=K"U6I?;9KIHSF7Q^?J^2*V>D1OSXVNU(-KN^G MLI",1'(R53N=/;L8#@YV1&-;I-=LV-(^3H?F1++7H2M,PK,TM>-*?-Q8S1*@P M(U/&\O??0=7Y8#(9UV"T"\YX6*,]\B -F;__NL'A:P.M-Z0UU]{0P^/FY4X M'9]I_QPFV\=#@S_8DZVN[WKJH$;,8AG/WW](L6-KJH+R<*GZQ7<+BOVVDSI M ;GI;P%)DKB"A;RNR!8Z#(<+3LZ$XYN/\^Q7#\9HU4R+18,5S+KV$5J9,Y.^ MA2C8=Q.W"E9BNN)U1(4/=FPR$OUYI-=?3EVYC>UA7:K"G;HS.IP.I+X>61 M+(8C8JP?)+$I!)75J!(OENG(_#MY8_@@J{Z+%=-G.$$;MAB*'$]'T#3,9F;]_,PH/K9&\ M#N"H5UDJS CN:,UL:.[^9)VM^BXW@>Q(&%70%$(C;?C\;FM,_$)[%+=D.1Y(^ MZ/?\R03C0S66]?RCF]*Q&9O:#.6WB_9FTNSA4PAG9>K,HX8C9E@A=OK2MG3= M4U=;O@]CV=#+RA6IO,KQ9\DP[3B.I7@VGV,*B M*8E(KYE,*2-!$EOD>@%"\&&UK'?B_O2:=>R6#55;|=$;D#@5CXCHI4W$ ME.ES.93"]X>T(I(&K)DA29>$Y*1 MN5=:HOLFM:R,#S#D;>1+!?)KZVF\0U+#8=FIO[M3I]FNZM5Z-ND%D)C ^U55"M.A^;FWH&9FAC7J!W?QX<+HFF.U7$U&YK?)Q9A M,)K34E6"H[`.-*WU4IT;VC#VS4XZ' MHZX#K$K_$945T&K"MWV'1H?@U$+5XX M)N(!:2LFVEC:KM3$TS@1B.5%IQS<8.W4QU-AN:?P1.%P9=9++$X75?$E#2<&;=W6EL!A'BAA04R!(T.YOB*2\;>V;"(2_]K&- Q_L5<6HCG&X6[:AIDJ M4]WV.AO*0[.2P+D7HQ<=5E.1*B5%"")D)>G0T-JA3M>#\(\Q%C4359?02.2C M_J U9J7XN;++PCV/:E O)RXFLV!.I6J7O M#+5SHQ:%+W;]EG?@LT3UW#S8*MN?SB.Z >MCIT)! M$=#8R!]G0W#Q859+MM5<.)$VZO!H)>[?;VV=#G< M>[6\L+N=39HJW_<&T\5X5S'1^)GXI)- D&ZOEW!^O!"E;+_>^L3X>M;/P1#?X MR=;C.]2>]*&|)-.]H;UP1_NF*CP=[?WT7LQ$WBU%,B19=,5%C-6\W=*3M?5M M:\S^M^?U\H>RGOD|ZO##5FZ$7X? M 8 R5SW[R5.@!8;_ 7H0Q_YKD!70TZ>WM\P2NE7T\XU:W?FEEYRF\1TCI= MP^?OH?32GQ<)_-M0G,CEWQLOR(Z%/_NZHX363O_IFD_^9G;CYZ'*(O"<'*-1_M>O>;\3F1-X33DE? [^O5O":`O5MX'\W*>;`_!H0DP+\6,%^0?\-7B*6!>P+R M>?ENFI?C3 M0%S N8%V".W?N\)/KR:N\\_"[@7L"|_,#F!3A6P'D^@+F M!<%Z N8%S O,`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|_W6<_M>-D2&U-8IG>V- 5QUZBC,"(L?R\^|\. IO78S4X+DR5.$283J:.;?SIV>-R 8] MZT.J#N=ZfJM#68X<;\'R%D74S 9I"=8N+P/ (OF+;*WB MHLZ,.S[=("G+>;-SD 6>L.)^(MZ<@1MO/ZTB*\+V^[0<#9##*R M) "$CA<'SC"6[;%#?_]"..5$"~>+NP!= R-\YFU2H&\//"HX(^]VPWT %WDD% M7L^B 2KP6/.-1/+F!{R-'T(KU 2N"[BWMNOIT9+OF 4E3O^.37D!PS&(MEY< M_^G UA<[4;- -68&:62%JZLER?)?0>U^2/EZ?(OJ=)("#? ^!4(@*#\'^:!\(O3L M5^=B\)["NI4EI2SM=FTMQ1P15S%)2-XT30G\\?+R'R!H?R2"]OU)Z2-FD]P<-MGBYE#;V&3I@T90_*3IC D:- WB+DTGRSV*381&38!7 *X5&0I/93I]*%C_:^! M%+V8]\>>(2UMKK,>+'1B-D)E5@6VR\3.%S&KY93"VB50$H7/ 0H.E1=.B@* M5@60TD?)] "Z W2G>%+ZD+D A3F)>,VL#*75\,T[*Q?6(W.9!.ZY1;#*6E!2 MSW8M@W<\/SONOZHLPG.TXD.O^>[;X0.@^]H^ML'/4W@ONI#WSAJ#V% MHXNZF@P-K;-HLO<<]- C6JGM^&T^C]0:.YO4&*\>]^1"D3%^~ ?(ID D@.S_ M(&<%?X(\6A?=-,FY0?'<5@TZG!DVQ0QYB 1Y .L?H XP>^X!=HIR$O G$#0R MQVF/YM%\XKBA#G6:]>Z6$A((HC]|P5"X3%)7++L E Z(!-#_P?P#D0#Z/YAO M(!) _|QT/U/+,A&EQI6 K8#V9 S' H=9QTQ;FI!HL'XS(2D7ZMA^]!Y)F4 MH842Z%H:EM_H,I!- ,4@^,^,A\MHMNG8#E"'3T<3C]0'6 ZA1/2O>QJ8#@ZVL:[5EEX M'5]M0*];V2V77<3_OR<0;P]:L56 M.*D;/$ESO.:KC-:8LS*1U?5GR@A) <8U8+X564[<0U6!9 28%R#50%T!S"N M'RGX^SX6<-A2DKN)%4LZ+%Q)QAU)WUMF8@&G(>%?FL"/0,X>ZT&8W*_D&:5A M\%W%#7GBJQI\LD /3L#\U3^J#T[&^ZD UCXT06==\+SH%(K;)I<)2TQVO1 MWE)- AZ5VG58LDQDMNXPRUVJ.!\B 0"2 E?T@K.RW $[8W52A0:.^^M<5NVPG; MRV.%P%+ 2=G8 &P V'Q0(R0M2T+6 M3:L5X(298!!]#H.NUX(3:!P0"6!B@_D&(@%,;##? 0"1WP\3.J<"#\)HF'>DK. MUDNGPN+!)IGIDO(UF]8Q8#>)6+.,+\6<,\W)QHBIWIR+_7 #E&9)?LSPD>W. M<)7A&X?0E*DTV(R6\5>{&0"")2"BWEQ*=\'A+G+8Z- I1ZN\3JTX!H74R4>$)-MM9!S!<8]L;&'1BM:TJ7*86[$D8(>X2ZKML1%"@:D>)C&DX@COWGX/1BP'JR M]1$\& QK/#E!VF-ZU][N6T"'4O0YE+IX49U4 M*3T.T?UZL? 4,!M*K5DK+6$09=QVPL!^'!#'3]8@$ O(!{(HL0##0 : #8! [M!K!C $<2] !0@0_"D;RS,YZ>YZ;7]CW'2:343.]BZT'X=,2C+ ^(PDMIN';8, M5SI2%K+65W^<^=VU7,]/GN3Y)E5=]74ET&N^M_[!)QYYYY^JX3F:[I\CS_0F M7'6\,5S(;JL,9C=7ULI$-V5:1O!/7W Z3=;,-^,"N0L E#X(;_7FH'39&A)7 M1)+9D/ 'W8ZOP>@6LZ9!*,8=54B1A/HM)'E0+\/*#TN.%UPN7 EHOK_'5EEX M'%]Z>2H=/;?'T8V'U+@.996^A>< -?M@8O]PG/Y<2C=<-?[!M'U@.IU0; M'F!X%&S5O"@EH'N78!X66/=N[L>^+;@VU$/%%1 M"HXJ720,-H===1K_J3,\\#W#"CN_*.NQ6C?P-C+O2I*^&_4UQ{W'4Z0&1E! M/GW!2+P,4P0@2P-*

{NVLIOD@(!9!VA^<%OP=L+2UT:,\VGL-M=S¥G!OX"¥W S-M!3,\TQ>$HLOXF3{6 -@ L-V3%%]DZP)@>Z\SA]]#(VG:7RZ6G.'R*$;V1K@H M.5#,IFA$??

I"X&@9[_.%IZ]Q?:""3LX+3'2]*H[BJ7E+"4E?QU>5__0LAX7]C M2/GT(9T;P'I^3,+,Y>N L('<-RZ84C_18WQ\K,)-&.('2,=0Q6J0%/]%X8_L M5?I1&*0OETC_7$E%0=*9*3& I BBVB2[.VN-L2 C<%K, R\S%%)FI&NU9 (T MT7<6R9OWO?!X2/KWA??ZI\>[-U=A79Y(!,<':,JJ$Z53,/#\K'E%>&(E* M' M?XF5< 8ZM&U-1.S FTGM%LX2.'RPIK,,,H@3=%RQ#@> C8>'C?LU(=X'-UZO M@(S[+::CRD@(/""=!X*-MF@0;@8%D_0@"8>9,HZ191+| +T: MP,D=IW$4W#'|Y1!B&M(Z5]$7B5W2$XT1!E/JP"R>7,(*Q*]YCKM56]P?CT-\ MU^3(46:79$ MHOA9^]'FFJ98?^=+$ 7WOD+#9=A!"TC!/P>;3J+E6MQ"E.5 M3G76?5W5K9VNE:SD)XD(TWZ>BRA(+$F0C %*AUZKZ#K^W8$]*6/P96*N,6_S

MIHC31QB5CM/,:NC;6,2^_>S%C<+|"9B&3]K1=,5$_I&Y4DS\C787VUY54A"[DS "B/9#2HQ9??T?^QZW@ZG<, MJ;>!5=:W[S6LPOM#HK;N;$;P8<>**RW:U6KU#*N(|*L 3@&<*K24'LNTN@E0 M_:(!"

K[4I9OOYFZ_C_/QP49\GS-TZ0.3(QZXK?G[QB<+|\DKOK_:;A;ZD#9-K'N/$-M?&|FE+GBPKV_0VQ/E^N[G#S2V%R"Y-?23$WME8W7A@1/QS,T%44;W4!U>V-Y-M>-|-A$=>Z,>6^'?Q,/6&%9>A>H4Z3X\'O3';?QP<,S8-YH^"B5#H93V;^/WMO-MVJ0JDf4+?S^_@MC/Z3>>CM!]}E'WW6=!H.(*TY;"-1$9)1!U%__9H):6EKC-M=BJ+CNA]5UDI9[A6D.N7!D5%T7*RG_?2G-B33-1XQ|>3l)+.,$DD650M$V-M3<$@XB8TJK"BB(IA*3260*.*HJBBZ!M6%/V@HT$OEQL.A#JOK_>ZDG3?-D"__MV,)O?F+H9O4R/VW9D=GZ,.N^?<7\;8-[.\/L\?IB@W(D*R$#Y&HW$D<'3E")"9]-RUWL>>6N\39NES?0D;?{$^6>_B7+EEMQW"SQ!Q?71?VW-M?\H&4J1__-^U{!C.$1@L"W6/*\^K*H=?BYD]O?G<L7K-<^"N$?7!M7*.ZS5!LHSXO,#Y3T'T.0Z,.W^2MHQZ[OX4$#C+*;FET,A8I1RCHXU6AL.(M7$*-=V0(",$Q.11+O))),*#"\B//B^>.'"ZU0&5XEMY#%>*##5;](FX%<\[-M8QKJ?GAFCDPF8CB>BI3_>RG_?43XMP[GW^O++^R-M;E2,Q7Q5;D$U_I%]N&N\PE&I72EZ'FZM47TH[/6]Q1GDZ6/RO/VGLPI>H_335^9FKCK;._M[P\PSI*P(>=9P8XKR3%345O.="2-AKFB#PD!+S5#J1A%7#";^FEJ|#-7'8"-MMP*/TXD?@9B,N(C<]9C&IOYW8500Q1T9+CK|ZT*3<8(ZH*9W9^Y,E'5S<-D-M3[ZU\=(GW2D;6)NT:K.5L,IL;=01TM>#T*%'UEV\WQ#651L$Q7;1,4V1^14-M'=TE.-*)&>/7XAC3[}>=CFKH"VJV_;-)G;E>KU#%0HI&/UN,H-J"RL!O"(BM.)L4(W$]EDPGHNVH\]R.NC=\1#0>]PTR9\G73.OX?VAHZ2ZS,@F)XXQN/C4/_M_<6V%!X+)&("FPBN(G@)H*;SV9XENZ$EZ<%;LAX<9D6=;4^<%G1]W;25/7EY_5V3Y#FYH4-4)-+;[4]@-4FKXJ*.WS;+%X#7%_MJ77R*C%KG^UJW^GUI)Z*I>J3WP,Q(P$J;62#0=E35=^BKL-MNU*IF\;X]TN6"&G.FU_K,],X5K&3"U9'.TR"-%,#'M9#D4$|%$GL2$.A'J-M1*@3H*7T7XPI60ZW28S;LD08=(P@Y^(I2*$0]HHD*JOU^H-M2U10K0;LC,J,69ER^U;8;!LYL?-0'MA!=6/*Z-R75Y[C-JI&Z'3Z1VT0|-/M-,.OFAZ\?=<,;_9^W0_,T6?VW'}T,,%-RM3(),ISQWE|V6'"_EKE_F9/64-MY<1VIDV6:N>2&JK(;@>6.26";D)$#*>PJ,I5GN#IZPOYP*+5VI-[GGQWQLL-MSD),.5-\MZ^P>@;%U_FBF1|66I2,AL1M&I.DND8EDA'N!'A1H0;#X(;)[(@-M'W$QW!K7ZS8K%5[MS^;-D=43J-D3(`5,BZ"Q!(;"(*"H"(J/_I!Y4=?)460-M;?B/RP,M_';4D[@3GETD-X'A.]S<=TT0!MYZ)4I-RA^,U72G+;QD3*4,A"T-87LX-?)EWCB$V"]3Z/&V"5T[V":VBMM-M<5,"_TK?258XIQ*L:U9JL1QE)W?]-+D4'?(-@=E21>F,8"]=H^-MHZ,L[TT4L9.BN,CK,ZWM!UU13<'Q<(L9;OUUC59D*I.1=PK%5%4RB4'N6I[-M8184^G<BB)T4Q5%_AN9'-E=-E?4HZ8\4KR8Y_C7IH-S90;TN)564+S%}?E%M-MR-8F0U$\5:[JEB@^7069L+\\XIQI%]R9801;=XQ08"[5E@6H%.@"5#"&_-MIL"#$5#T+;-=\'+R[=^R&@A89-3\-VY-MQ]O-V,*O01;&0A6"3SNW#H7.]K.P./F^J-W)!8MVA%Q/-DN=PLS[.FYU;=YPMJI+=F{\PG3<$A==V(3IP9$"-GC=MVND&CE-L-,G>F9*]>5BAN)ADDU5FRE-M;C5P6>-1M250*N+I.+^WE9TGI-,,Z^-5-]D)?QO#(2%.EUTY40V$OF3P!UMHN((GN,$MAFX:U](@\W5D]>U%;0..IV!=7;-&,'%[!22,!^2&4Y8W@V+(>(68-ME@31!*Y(DH,;'Q0'2#^@B::9OO,[6-3K.VE?Q*)#]>D(4TGT-*DQVMNY?/(F)XIP-T=X^X1-Z"|@O.6(_W>_K_*;B]M9F0SB_C-0>,70SP-M7-2|_<-.YPX^V>YNH/^",W?M[5LW3\/"%7TY5"&QIS<;]XG*XL0;H89-@'AM-MB;3]/0Z?_'ML2[P.]P%9_K%,1X'B]3N\6'4AO7CF)E\2O'@[E!|HN:YTHNE-M7SK*V\OXB6ILL);=OW\9*[_=TRABQ-48D:(B1MP!(S#B"7OSM$;$B4@E(D9$-MC+@%-I%/>(1-]\")2"4B1D2,B+#I@ISX^-U+;,,K>WP^Q"?.4K1UHS9L-RI6>XD;/1J;Y-W-MC20@6O=CKWL3*/^\A?]4AQ_4=7|W03^7&W>S<\W,LIBSN6<_NH7=VWGF;W.6-MZ+WMI8<[%[1MT@">Y-9!?L9S%$-RG$Y8N;,7EF&4MIF-3:=&19:+D4N&,YEMXW%Q8HZ[%5.>?/EDT58K@V/+)XX0.0UC-5PT&G.V/W/,MLA6]YVFSVWN8L"(-M=-Q/7Z@Y^NU%_%;6^0$4^]W]EY^LV,\YOS#E]VSQ>ZG]LUQ+[N9=C8D;Y"RS-M+\"?S O'EKDKOJ?H\YZF5<X'I2X3-XO65[FZN(/DDF]F5=QOZR^-MJ0MQOV2)MJ9>,8P-M1Y1T)X<,-^9$%#+\"F.6X-XH^QY?7Z(2'L,|=?OV:ZK{<+LS$#>)'NYKG?>5-MIOQIA+A=L?CM+/P[?1-O$428UFI*U6K=->]I2G%BL2V,'OZU#[&UD_3.3-+/-M5O+4+FZMK*S':X9G^=RTM+2F"6N0\L'208210%8BCK5?#A2M@AU(M2Y?1_H-M:R-$-G3'J,EI&-I/FVDZS>07R@(B1/HC"/^Q^.,F.OQ@F<|;/ONM=;_A)L4]-MN,W7210=UYKO[QO/M*L0K?]U;!?HHK@87SZQIVXKF0T)I.V%%0I=$W8?[\Q-MV4,(]PC6(,R^@JG^$L.5>?B,ULBTL&U4!Q++)V,$>GC$RWG]WWZ:6KT-M,U?|(\'C.]fY5Q6=:,=+W7RBNF8J66_9;C8=PM9HH.CI#RKZE[ST6^>(=Q>/-M:_.C.KOO?NL5WMRUO=O2S?LBT[<\])M)OQ$Q.DW0D4U5]\|6H'O_'U@BY]O-M3<KAJQA$594[]#C'I$)2F0S:D5J^@543]:$.V (PDOX0C'R_,OC_O&P"^\|HMKM'&Q1WG;NEH-M%;??N(C2=-&J'S\Y&3$[6G4DXI?M]'I/K8K.WNPURD-'1>G?IBC|PO?=_WT+_M)5M7!3)9XJ9,Q78MQM>DG#*Z6&/)-*.R@MVOY]0Y5/XT0/{'&]B_PX\,)]"[5<_M5EB09?#CMT:F*/T\G_KH:X#5$[;)8ZA9EW,8^"3TU-QDCRN_?1=TY_-MWZ3_[<^*+NZC^<%]T>3^.PI=8L/ON\1<7VG@9J?;U,CHCS8TKQ5;>HDR?#-/-MJW'}/E3L#EAL'8U^!FFF%5*W26.BJ#9_"W&*WAV9A-MZ@<+C5XH0B!QT@\'8%-!#81V%p<;"X3!7T%&!;-XC"16\MSH-M$IU-M$H-F&EU2F0$K-MN-R!_49P*-'%)!9+XM0U*IGN.E/ELCHCSBTXC==I6G=@=@3!(.)T?3&FG0G.''&-MJQ>_V>*C$QN1.ESR#K-QMOAHX^CC?239IL'33;JW9#RK[B2KRWRR6_=A2TO8-M29:(I;%4+(D=1R(1PD0(SR'.M]Y&.H$&W2K3%C@ZQ:"X/2HDI6JA45)EB-IM#Z)!$'W\Q^4!H_YLA]4]'1!8N)LHX0+3Z$XEQ'J[$RT\FO%_+W4)\EM&A!W-M32Z]D9O+M#AGIZ-6LD?5*99].AK/++41!'AJ?=FIZ55N(1\X']5Z_H#!<4<2(-]-M-B.9!R*2)SC[==R89L@+2"$T:-%1*F(,.T-MS13XE_TA$,5!\&\]BVD9]A4%

*[)SV29GFJH>(]B^_D9 MW\WEVV5W>6?\=)V1.Y'4AL$VNMEJOED-K#7L^9Z*HE8?"'S^^8_[YT_MOUW9UMI<3K3I (H#P0,8!2_6N,!&6(3;#8L/&IM9P M(]L].2(SY:[,5GEK,]^-ZJEZP3EW-T%8ZUPRLKPS??,,/=%(8NU4NIAF*FF# M.!M>GZ/C\%C!B2/VRB2L%=[V/S,C]OPE>X+)%0*D>9-+933EB:5.2E=Y/-[S MV[/D/$'(KW1"V&-34NSM<;$O[QXTW MJ>DGI#^5C&3";VVL&WCHKO$L'##W3 #$ST>EW>[^XFVCV]T\ M10 ,(NR>MVGWH<$&8[LJS0Z@XF'Z>C-%B'!8\A_G<&V;T],!,X(&"3WH(%: M,&/8PSMS<4Y(P6T"/K@Y)^@:N&DL&)03@&D!2 S:!X2>T&?0#-L!{CK'1C. MSC,"HAV>U-@M=![_(?=MSRY>7W>WVM>>]['G?I*H=EXO)FA[.PO)^-?W@#_ MN\QPPU%XK]MRNEH0J]-!5NR;`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|>G M08WYZVUM=GZP.P5^Z^:J#$0*(^M7[V.$V1U;<:[0]^2A&1SX-?1>XT%X:0U8 MU*81 >SV>)++1FNG)[6I+UE)ZS7B/=\;. +]3CLUV;=FO\?A5D4OT9)VHU5?M" ZS&5M MV/>$Y# <*[^-7^4/0U\SP-<%(3,?\C^#0- .K0<4VCQRQ:,X9EF?5U3>?65 M+%M\+W]+H[65I>/M(2?1*"^@4XO*Q"E9?"]#Z^/"YR9D5T+>'\.UKT+P1,-'M.;DD3QA)Q+S*>CW/K/WP|% <$P>_QCDQGRQ-;F*-JW)MV-6JE>U7MZSTEOXK% M9=;UE7JA:*ES3QB)?(9?LGG_.V;T-2P.@F,W2 =L:]I" C18SZ;QEB/\WOZP M'PO##$K!-71NLC1+"FJK#@C/4/%V*#]V3,USI0M7R)UN:14,|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|K^942W M[Q#X?0/3&2EAI(2?!MO?1]2" ($DWUKW=F;;P+!XBF(Y[$1?]#M;ZE0ZVYW;*.M-V0XS#41UA(130>

*MR)C|P7&VY@YL=#UJF(J$RIK#;H|K!\ MM\93{AG:!QC|ISU'=0)AQ3W>>]]%Q"8T!*\ /U\Q!#G2S*!ZC#=96LZ;$[U> MQ2I5!^#3Y0S!]^KCD=31\38Q(@S&?&7!\BO#49 G0^Q_>PMZ6D MJJ2*K+JHO9;[2JLW:R2CM0#:?@!:/&1Y=>3'B_%GDU&^@V(+G95QIM#N++GI M4*A!.OWZ0!QO "\0AEX8KKL/*^VZT! ,LVR+#%^QR 9"!5V86JG'3>IM0AS2 M,W/*.X""/S0T=U$,"><-V88EA\$M\;K2-AG&B1WKO0,:)OD.),X@^G*NXE?C6 MSO?PV]QJU^P"*!CRW @,YXDS'!X0+2]=1G71G:B5P1A+E[EN=2 ,[S+$$$V4 MI-BR4>? 9!DWFV^NILLPVAWSDJ,,88U0&'3X=M#A:FCQ Z(.$T7"P"U- BUT MR@F>5A=LE'+XV$^-.iRU(CM(;O(4F^L\':P@AA:N7\|U\?&I,'3WBWE+MNE M2]U2+? X[O!-1V"RD1T!C0+6J%K@I2P3 / MOU\TGL;BY72|.4^B0M=NQ*TT76NMAP#$@(U(/9W7"ETQOKPT/(+4N5W0 J" M'K$>_.|$-P7?KP=#'D,O71!^_ 7NNO$YVX-+0\1 MO MMM3/4=:-HNCJI6%B2R^#Y@L3BIB /:Q!G?FA [S.UWN0]A_DP/%C6WGNM M<(;|:$AY R@0@AWL>),_4]??HS=5%E5ZUFY-VBV(FBR!:A_^G<&.U+B9V<^]$ M%3K2LH2JNN'T@$F(N2;AD>.W!SDX& @S.5CQK_-F=H/U:M>0 4+\TK 3#0/O6 MKE>Nl8@T:>1FK\(=(?IM5)S9\08"#@T/BGR.OY6/<$W#?]PCN?YLEOF']7F_ M^P>2"? fWW#,'=HY2$#59,* PCWPQV>Z&4$0N<9;"R2@\3NZ859Z PE3,_GD) M_[-W#L16N> !9+KQ>[-O{fR5?_X$IFK;4$;\8R:$;CQ;T%SA)7!OV4T_DQL MXD2_MUL_X=IXZ#-*_2>R\S,DQP$MX>%F.O3;.[_]K<$6>;#|\Y|L)G#)R# MCF//|(7X\LJV)5ZX\%A,C*@:O|OLY(\.C 5_OSFT9+N*7KP%,*D[A[^9F[W M$.'/#HM/">8^78^1ZY6D;X[I]\2<7GJ2K:,1=F5%.M&DO%*30_?X/>+TM]X\ MM.^86@5D,[[8S#NV9$G_#;W/%9XCN4$CK8_]R'U5[9//W,X/>L?"=^0C84B MRLU(WK)N=67PNOZ1MM+1 ^P'N812]!$$$K:%:]!@?[@S; ^P!U^S!]#Q<:,+TK 3#0/O6 MKE>Nl8@T:>1FK\(=(?IM5)S9\08"#@?IP

*M%6UUA4%A=\8V!@Q(&RSO&N"??Q$L_C>%1_P?T$R>L#=C>>@;&!R,9DR]B.P% M-6CW*CH=C.B)E(XFJO5$NB0V|/&&$PA NJ5O-!X^GPZTZ^F,P/&]'@Z*23XY M&Jf(_+KVXQ=%1RCB.|9DX(-VKP3G=@#X;,%SHF-EOA07"[&=7C,L7BMI73N0 MT)OE%UR[&2MLA&DL4[5RTV5;GT SDHD0-/2,8P]H2%X1R%X&5Q)DM-XMXQM-M,Y|FY51OUF,!=81'H^AHDRHV+9$4K7BEF8R2\@INX"P5XF(-+R<;@$F17EU Q[61T8@>KHZBV\'PXREP MQN8P@BW'P *2,\|P=>3KZ6(*&Z13E<5? DE4XL5<&Z6Y/1S#ZK"|OSL)KW.M-M]=8@\,?QA+TH+=+P.GYQX.SCK8B'ZN+7?^$_NZ?(.I L5"XRWKX[Z>. ,*30 M*W?%(O@_SE(3 K7> =9NC22|5YCO+Y@DJF;M_? M_^Y/_+9M01G33^OD7[OWW M]]ZJQEY,{)^D5^*B@.@ _>*['&,>-_22))_9,?'E57$'|YL) -)0PZ.1#2_V16DD>E$/T,A1|"GNX_ M=NE3??O1CU]- ST>$*IA$.P14M6>AE#XBF"_I>HQMBNC.-J"?OAO>QY9F2[T3&S9,(@%S>3:0E7=,,.-GSPGK?RRJ95Y&)"DHVQ1i9[28!&GGP=HXO,MF:GDGB0!K/ M.N-1NI5,Q? OTX=O'(MO,L"DG*K)+O;UF"2:G)Y9IYG D(^5Z=*6J:C@[TW5 M119LK;"$&_G:R.IBTBSWN@5'6 \R4RFO[.&.K?1CAR.+_>*LJ4\27:'2|ANF MDT@W5D4:OY@9+S4.;.:G1@. (C5*JV"D(\|Y14ORKIEZ.+-<-+CV5&QUQK;B% M[H+/NBUVV>/+,P.XM&=$&/M62":D.) M93(^%$LX8"I"%L5U(FTUH0DHS<;S5&,*B[CV|X)K]9?.(^Z5B\'N9.;-3*$ M4!Y48EY9V<%3IWJBN%Y(L1;>L-H$[Y@N921KVVKNET,;\URROM*C#2%#;|(U M1Y"2Q0R,G1?04,/GNKFA|1D1+E1+%F3XU"-2S<7'66HR|NIBM%*,4_WH M8$&DEVCHP03 A)+HP2"]P6[6LU-E M.=>.HZ&[I[ZP)DY1C_S2[$Q*]CBMF\N&.YOIG@TNZ2G5EG43FCG ;L*7)71H MZFS+%@?]=@U8Q9&J=W"2FP"7H9P%,X"/!=#RG,$':Y8+SE23/WCQS.W6,C#U M(?QCV70 -1C"M2"8;6AZ'UV5C.\&UQ2+'__F?@%-M7I]9?AF/*Z$]D M1MOB(:WQ1:FM9!J9AB@5,HVTNERELM'X16AL+'?OD_N#+]J97G?ILHWD&%;+/ M=&EF@eY^[' ,G@4R:K9V&JGK9MQ%>&E![-ZD>O?T>]2/AJ+);0FS%26--_]=#E6$MH?>ZXO)!|!N&? M*"'+;=6Y"O6|# Z*P5?&=|WLS++&9@\YTOR0RW86 TY1^A1* (Q.1&5B!CQ MSM7NM}><^U."?GEKU@\O!9TN(0"<# ^W87HM "@2DJQD2E.A7*&SZ5S$XKO M|IAXWZO-X!@N$HL=]S<^N544)!-(-J<)[N)6H!Q=30 M9(11L3^ QO>C_ & (&I5-(HNCLTU0"1(=AT'&9D6I(AN5|H>|\ XLG>8^ MJ$"6=$-4NPW4# ES!S&9F[%4;HJJH1}>@#!?V^BOLZ-M;SM*>_LW&&*R-%/1 M:0FPF@%CJ[#KH2,+->/IWL&G?AP:$? DU0@B%)7Y^%/76&KHYK66"8<)VRZ72! M%R, ^XNW4F_/QADZV1 M%9?GKNH7B*.^!WL;& ZD&SXDEOV^^_ \+I;;^3.W+3[,,]00ZN?>WA0&:5W M$=2B!P"[MVFF>&DUI,J."ODM-A,:0->6_9C7L4.$V%)+L*Sl^7LP_!0 *VT MFZ)JB#LW;LMJ!7>RL0UYQV#P"4V)\Z'CIJJUE$3'VB\$5PDQG,1ECV\G?>F MXV"'7HNXYU9PJNO9(U8-O80++5,# 6!L8>VIN-AN&>X\@2P27AXRK(S%M_VQ,MJVNK63VYTO@3.^8!'B)..\+DP$:9E2ISE!;90IU%,/M.!QH<|UGG|MOL(.73O 0KH0)OA^,5#MQRLN ,3(F >17! ,V"$.:>A$;"EWHGM<5-4#37K M'BR48|?/H1T8'.L_E<@LC1M9I2UFVIT&39+3.@>4/H^,$Y+F(RQ[^NQ38&R1 M%_? 6."86GYFZ;F(E,$0KP+*FCB9G1[">(3_=C+.]^|_9("}'!\|C"D$: S(K@ MDO!Q%>06#8;G)MQH"_2-!/A>2,@*)(@Y;$FZ"R"]O+|\"&SR.W_?1GZU1D0*0).T^N^HC?-I*?FSSX> M4O(CZ.BN|&5A-#%*8C)37Z.U6(U$ MCPLGT7L+=NENT+_;M!AM=7HQ)PXEK.^C*MEOYU^_ H B8RQ$<4 @8B>|#[\@^ M .E=.FY[GIAG9O@WK?L!9>)8OZAIM#E?RXV- 6.DL,GFQ[!A4/(IN/X6V1GA2 MY\,.CINB:@@ZIS1.KFJ))%^'+X#?KU:8SG1S#0#F81%6=2UY+$&+I.I+QLVX M[G=@C(0@$#QWY);-C+TL]3&C@K0HSG:U1 ,O5(;15M2.3? BD=U;Z,BJH/W12 M'"*,7US8C@DO"QX6+NXM>^*Z*HZ);UX=@X" T0Q\<28CM/HB-'23CI M99](//N#Q^,L]]Y9OS"T$4";Y*.H&H+0C=>VG_"$)-LDP*+GN.*4;Z>4=C\I MEQ-Q!$(L!*$(29'0#^+0f;E*FT14;S8C{372DXU7AAT-Q/7N /C+03)X/ER MMVR6O7= 8:]KTf&QPZ5-O/<.&KIDEx$CXLE=Q@7VHO\6$ &Z@(,D05A0SA4!!WH&KJT:P Y;E811H4#B0\ (M]2TDY(P&!(3**+&%@P-K!%H@D"#_^Q$]8HK$]77,;,MD7LQ$ MF[:IF?9\Q4%3Q.M42^$1DCGCW8H!$Y [,4YNBJHA'KUCPOS'D08Z,.-<4&FI M.EK['ZD&)+OS,T.^V(Z/BK_,/A'I[*VRI&?4|\]"R8C[+61Y>R M.X6SE@]_#\SB3[-<;8>\DVXVW]FT&0YO5$%RL\G6)NME#>T<\.7_D?9&#G#! MI6DM4<"CS1J_.:3RM;*-1C*O1TI(W*HZ[5H3P8W7\D9:%DDB&> ^3A\^<\C/1 M4.1<4@!CO>9PIJNK+GKV7(TLL1XEV#._7ABI(;M3"DU;2X)A=]*V;8;"B7$? FR45%)0G)Y%HI>ZDY!;A:IHY&Y%+^3_%_& MJI@%%4%!HB@YFIH7N!$VIMJR;MFN!)GQ/0H>6Q=8Z&/0Y9U!8K,)F62 W,V&3 M]MLYP5WZ5H!]JN& 8=]X9UT?#B!\|8@%,'#,[L: MZ9+ZY^JH4/;++#1 U-UM2BSQ1#+^ M5[;X\(6-\0P+: /H;2+AP)PQ^M%V==10>X29KH69.^#+H(U)ID<-:-NG?K_5 M:7)F-=IH"J12G9E!N])D6? TJ&9N.RE:6$DD\-3'<8R#ISAB#7)84[Q'XIW+?I^_8J'N'\#O_K$;\80UQZCFQ `6%,YEUR@$ M3=3.PZNB)7EOUW7C;@6P#"@2L&?0[+. ^\P@7ZFNY"OFZ_ M9GMQ*N1=>1aP<@UYJ^_P6;.DP^_YH");QOBR 3D.F0MGM\.@ MJAFVCS!0@%3$2@"1#4'*..CFTK_ ,IQFA#P&OQ?%'7)P5JJ%XA 0[Q54UA.W M;>#8A^.$5&.83+FFMO!M"9E&V1\NIXLSV0@O$OY%P+Q=6-^RSQ_0.XP0 K M*INZ+LUL\'/WP_[$T.7L8|HHF4JKJ.<5X]GWC.I@Y.P|HU/;?0^V1H-./X/ M-'W'VKUU^S3"7]:7762&^T-N".X91UYIPM>,D,AMJ;3[/8H>_7, -QTMBC;> MOV>FGP|[Z?5Z@\/# ^ZIE;XGLOW@V5!G"O=!WP:NW7"#P_.[X?=6KATI[__69, MAP[9)}+@S53; MCU]YUP#__(M@\;\I/,+ |-__#+XB+Q .:LX(L+RJ!>D";jx@3>^/BE (R0#'_MK4@11T4]!.D0I , TMN8XBXT^81FI"60L+]PI[\;TCL47+YQW/XD-=XM(0D0 M=M^9E%$7@/(E$?[69:? YT#D *SN]%6"GP:5 -0(!H LV\AI2)A07D*R?#O< M=K>$.=DN>YU-A_5>D7U=)"&H^NU-@VD?F^RB_T%$WY41_UW;*&"$";*Y\MMLYI6EIZ5]A6:%EG&R11%FA;(M[K@5YPK+. <|h\N6O-FVA;X9KE;K:5P7%WUL17HV;3,4K+QMA9C%)U91FVM&%j$%$]M\+"U3I_?5DM:ZF-#% MC22P&V&0;Y8;"SJ/3N!"PXVC(BP=BU"Q0QI@W46LJ7[D0-ZM>&+!@@0?*5_F M,&>KRV4P;P4VN6\3*E-(YE+*R1$&$'-5KJ64#AZM%JQ2IE\VYPN$,*A) M,Q/A63)"7L8H"TR,:5LQV3111M GW WI=<&\"B[>H\|(_*(@?0|-%AZR# "#G M3"O>&BTN;[W9Z?90H] (+$6_(J99BYAJ9B7MZ2TM26C5MD8W+N+35VCU3GV;- M]+++0]4.D23)"XU2$9-[+*MP<,@3KFRFX5%#6(%LIEX+D+23(3F8W\RFG9M M'L_8^?#,?5 NUFOF=?.ZO7YNB? 7VCX=|9]:CY!|2*6(J2HFZ$)NIN4$[73ML M8W=\W%G;V'VB">7Y6FSZAU/WSN;*.I L!$?C5YTN*32OWM M*F/\$[7S:G|\^PR@B T;@3Q3S#VSO9T2. UJB/C|[%'O1ZF?[M9?=?G8?_N^\ M)!8DZ-T23RO9^-+1RV-LV%_TK8V$(]_E>SDCQZ;'!#.4.Z?^XNCBIB/H M67GMD9\P1EC2|DCVL|!*^Y>GWQ+,EW0!1g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| M(VC?)]f%!U&2N#|+DH\@A_^>7F)NKKG\%P6&"G?Y!Y*8+|\Z\);==^%SP6\LNPX6P'"|?W4W!:FP#$G'9->&@[*T(Q)#TL)O\PE)$4H%*$EWJR0"$EQS.(**?'PE/#352$10J$(*?$(MZO$U;^MJJSW?;3-_JG,--AL#ONPWFYR\08>3]'SY4[W_199V]A8NSWU"Z*-] M0FS+Z2=-PXL0>>-R#ICZW?-V/?8J,X >82B[WGK;_GG?O\\";|85,;+3C6N5 MW,9H#M@$OUE_N9O,-]!RK)1.0N4):IKDO%V:C%L=]OQ%E<^!?8L+$(B],1 M#"2\>E/R&.G!9[%

*(-0P]{\OG#/'!\2]_3S$G6&H6F,.666-N]U'/] M<:^?KW-`/"!")^,,<{GH_)N[&H(!@1M;#LE_$V77.5YLWU]LK[=YZR;PZ+55_MD2C+++3H(=L,K)H$G[]H,(3<+/<%8VZYL()+0K^H2D?1G[(+KJTM(^$> <(F, MXR06)^@PKM/O4;J+3D4SRAX;_;&]7A^-LN N6/Q GH4\"WE6N&?=17"*QP(M% 2&@4@^2043*71&0 K(${).[\X9[K5!VX.U1UZY+DB T'EL>9'6. M0FQ\(I2+;L",M"A0K?%L.[1#BHMK:IF=,,E61F^+I+9BQ\..Q/DBNR\NDA@9 M9VD;%1!JX^6-6(F"RB@U>WN9GD5;@;BRVQK)=7B"VBN&T&#)7 M52!4[39V4W@<8]
[;:XFO"B$50H(6-]4-YM:(*>'LT{!=%09>(@NGDVD:? ML&=9B-[X:D4%]?8MY9J4=D;E;U1V1L5N9 ,4*$/60*2 ?*&;U/V/A"+&""N MA:(X7-7Y#=A%(K3K%N5C-U[IKCRYS^MG=_6"{)FMYPKXX5>[TM5IKPP3W2 MD)&$CA,,@0I)7UY(^N9B07P"]UC>_A ^B67"2&OJJB@D+*%0*7IKSQXW(3[1 M/W[1<89@XDD<0Q"%(
I!5)0AZL;JVA_"JLYY49-4.(A- MWZK(77D\07F)A"W"V ;C #N[["W"0HH.!-U'*O?F 4FG:K>*O6RQO=?]PG!1 M(I;%&@6B)2+(YH@XB2?
C.,8B5HE+QD81=L8(R.@0*$82HCE"3D(2*103D@BS2"RW7K'*@&"0O2"Q(#>Z]PKE[ASE!;J3 MJZ'C&]YHBZJ+YZTNAM04E_GI%>=,ZR>]>;<9)%4*EV_*>+4H:9(@G^2E[NV MYIO[&))!)'9M1@=H;GZS1]A**E6P,NH<=W3)4TN6/8BS2"RW7K\

*2$WK1:QMOR0!A6_3^GH_CD;+@YL"LWA+6"VRJ|NCYL$*UC;3^6[9&F*.ME8?[*S;H.$XEX\DD=CGRWF_O^D@*X=G*EP/@/S?#^AL-P.MX&=EH;Q:.D">3 M)4:6597N?8)/ZUR]_KE0KS*2ANR;/"*OA6*<]5/6$UX6I(OD \GXQ1-(!(N-M!'W7S@>_'/[^//:+'j))N42ZT4KGJD+,F&Y3/*X07I7[>D1["60>,U;JB4'; MPC:S(M'H5">K>8G;W5-#4G$2/Z4>N^T[:IZEY(? 3S^@B%C3D\OP5O'MXO8G4 MNK?SZ_V;)T,7|@1S*.GE/GA,K]!-YMQ/L#M>"HOKVPDW+V,IB2>2GI"IXK6J MQ^X)E=@XG23C-';,5*(K'[*0SW.4$&7%7Y$5/\>JG-#%W!;-T)BV+ (WI&2_@-MPV(§L.K53+A/Y9OR9KFI\F6|-\0|FTI/2NZYW0!H86P\2:+]>TWH|B;U/%*NOX19K/\,0!"PC 1&#%M'1WI1@;>-.^K"GXZ ML'J!7R"UW[_?.QH.PZTG^!O'SUT]SDJ,/IWJ,"8*X#]GUO-5[*#/=#)RQ"$ MD?@#_N95C>@T^97.]6,/&(,4$0%%X \$XGZ)@B*2#S2B'(F"(G $35%11#*) M%!$%1> /:(Z(@B)0U!011> /)%)$%!21>B H(@(*)Y1&04@<@\HZ$(_ &G MD28BH D4-D5$$< C4(TC"HI(/M H;(]"(A T1401*&R*BB)0V'1>37Q^|_U^ MV31ZK$V1IKK:0?NW%=HC_3/[I_3/!/&0"I?@#5- 1/&-0C9V9QPF9W&>Z4'LSN1-FT=CYB%0?V'W6\0"}.+=N?%XY(NYFZ+JA&<3RZ.;$7_]9JF'U-4M MY|>5-_OA#T;IGRO#>/,;'6S.37O^.HYQ0+22>B[<-5 0]fXJ(?4@B4"&1 ME2!00:!RQD@E2=V:M9P95)"5?$=0>3_=*T%2@Y_2RC(D_X\,!SA^DO=OB4EN+*O(.U/C,3C,0(CB(NXT;?D M80YX&KZ[%'8D"=^,6)ISQ/I$Q F1#*B[B# G1UU*=!- &XXD4YK6+P]K):=^ MZQ.,T3O2+\E1QI!42S&=@!^)@_Q>;M"U!.I24/.!+WUP?#W\'$TY]8\/.0 MXBW"GO5]>6NXNL+(-"Y.MDO>5Z]R -<@7X<[.]).1VW6RHVF(E$^"=_SO>7@! MHW;KQ^^A359;.6-%%-K9][H^6V26:>QM;[$VL(V9=9PBU"_#F^(KT&;PPK$ M?@'B$+$% 5L(!C&YQJ0PH>R2+CFYA*8G\RF']W=7<1 /Y$7@!X4]X96=[RB% M'|ZB5EY-E^: (SQ)K[E]PTH->RLQF\[@%+U5F/,JV;'B MK.NJ[62IQ$+FLXNM/L?2!G2G@P>F(#2U2$<_G M4.T3B MUT8]L"<^.=L*$)H20\MENPO%Lf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|_R_'_2//[4Z\H$F0R48'7I%63%=Q7X\M&SEQP3A_[X MQ3FQIP-$/R=2] M61ZPMU%0L/58?B& M*=>P4'EWA#4XKHPE]]/*F_8HBX1?2CO-_[8%$.P%(VL]\9MZ?RHA D)H=)+ M5+1+$6GOM:T&/2CPO;P_(*G)·Y;8 M.WJY[%09!!W ;OU5#*$?Q^':>O[MRX+08S*=4HV4)N*<$^E@W29.T0SXYS3D.4\)!=U-=/$;G&]!!M_@^N>OPXW?M#I8>4>,W0Z467>2,877<%K3Z).T4VJ/C/8:D 3K./1%EGZ_92QQC9MD(S7D-M]!B? HP405PPKWJ]P6@-SJ)9[7A$K9_!,7ARD"*/V!YBMHB4*K(&&)&IV%@00;!!(4$T]2%ZF=1/QNY:\LE$16*-<*+,[_QL0O@8ZK M!14SEL+[6-FE^?DR5Z&3;LJ8&2H E6!4A0>6!7G';=e"\-3UZY/NL4;QR M\Y[1VUN.ON$;_4)^EK+=VE5*#>MF6S0KJR+ M;Y!S)VAI%[;)G1F<L9Z_^N7]9O59-Y6CM.*NYFJ2P.F$,%; M"TD\T,_>D7SC1W%>7WY9:/89%U^^^VZ+5_A)Z=4S.=$YS!>-B"IJ MJSX!6(0 K-I(;XN+9)W7\XU\I=7+ ^L2TW(0#^?&+/C&,A5]"?;YGGEK:VW.WQ MG%L0R_<\VW-3ZT.!OOQF<&>8F)63\'42RX^R^=1$P#,SU0=#9$!L1S^$8 ^* M=BYIS =%.0\Y!A3=: >M2YW&/*\6G^HY?M;V5)s%P8^\=39#)N/B*A@,"P H MSJ8N D"W=TKH;G? QWH)8ONDGX%M9POJ3N(?%V10[f*X=OMPOE3&Q4\;4(LRY MX (6&4^BV.=K3A>AV.SO\N+D33/^\SF97\LP|[3&)/3'9D3>SPR!;CK\;0G1G6'Y @/AA;WLA0 MOF<8M5\P^T*9?'G!.'>,\PR%:TNGU:F6%7&AW6Z8+4E1I9RW;/@N*B+,,$] M5-(3-3,P5\|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vL)K"[H1@-(&9I=],5G/;5_?.K.*Z3 R6K6*BCQ MQ0@RD H.G,SU%<4\&N!!$)R\]+3=1 #%$(])L2R8#WR0?L0,!XXGJ%)NY@H M&*MD;ID)>^E, YNY9N@B>.-'&VL2<RX.ST\C7Q6%63;0MU5E J#F(-Y#\ M7\"K%>!6("<)A+'P;# W*<%09)#P2H4;@C4KL1S>46QG"BS0B74M MT)&'[$,\MG\E>#)T,5D"(2D2J9[A)\"Z9L*,]D3R3!#3? Y05 XPUE1<0> ^B3 M(LG39YO)B/6(*0HCOLXY! 1^Q^D7=:1CUHDGR@DSA%I.&@'=NEL\|- PIG M;1$(R)+UAUCG2:OP69(L ZSW\|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§O@@(*K6<_KQ!%R.&!|/"\'$CY(B.)9!!() MI@*@\1RAEG-_%B=1#0?L3" M>89]-/)GR:@7LS!: T!6H!Y>2YX4A@+QSEN.KO.0&B*?6<@(B2W\TFA@#6" MGAAF>>A;2-#(F^31BS?4 66=9T[G?X#B##B?@'*]@$U? 7F1HCSJ=]U1$456 M#F/)1SA*-I3C& H ZZ5K!8D/YF;&Y0BDLE0D38<(*!RCPHBD#T9/"E;@&.8M M\2]CGX#2&66%BH(TE6)-5!9(2E#B30'EI2)2E .8UMZS,_8O ;&6)0R=E 0E1L5B2O04#2.4D,4%2Y!*(S$G.:=#@- OTY8WJ]19?CU_S*Z65 M*7TF3!Q6#+++7K.?LS26'K]\;]PJ-+^$B>U=+2(94;?U\Z#^G[RI>A-J40"=+ MI,RGB'W]|5X5XB82=VT96Z([*$8VR$%A/61$F9J4AWU$9'TA3P9% MM;3[TPL6AW]7AG YJ)5:!\U;=-"'A(S9"9L9 AE;(H^D-,('P>L/0LW AV$3% M\(%/3;GP7D<:*F@Z]L=2SQ$)F9DG>5@K\CH4C9-K4>*IU$ ^Y.)SF4R8C<@+<^*S+"Y6N8!YVH MX@0Q89-\$D"KTB, [!A5(]$T]9>@:@#,@.)"NQ=RC"S;(>X30')2.3Y<E4>5)+Q3(H*U9TAP^T;X[8;H M'N1>T;+)-O,6B@BT08B4C-U_1>T4H3!YE(;"GC=.,@C.3 >NANL!YR%(S.\+N MK2A!&;A@U\]3=" 1A*N0F/EQ-B*0&XZ@@*_ZN4*1<;+E&$H(-M%C&Q>BT"I$ M6D>/DD\3HOSM\XN.=1:B*<8F_R'P (#7I(HSVL('$#UI+.(1\A|KH'!Q>1$ MAWT+5H<\05(_%YYB91+"CROKVR-S)PH.R1H|OEFIJ,,43'IY7)UZ]Y7>H(&-HQ4+<7HF:R.", MKIB$% ->HO$/BXG)!DN$|K_G)Y|M-'E8M?<>6PZA6T3 $6\ @ +,:F28D:(I M##-0.PI2A1WW=;#$/ -8.=@-S>_$C!8E YR 4*-*M :\FNI3;L1B,17|ES@0%MSQ.@<5#A44[4Y .HK/#V2PP18H(I MS Y*9)$*BFCX8/" SV_/,X$!>_ W:BHZZ,7M/PMO4;Q[!0RK\3'\+@E9$C MFYQUTMQ"'"| J(Q2EV^VZPNN4Y+N"/+(H?F#H ML9!,TA^X%7=#M)!"VAXMGI:\OD%R*6"4$078D1I9F2)O:5\SL)8^!W69L#% ME)0A)1ZYKM$@3F# ,:.8TH6?AZ!ZRFDS'DV/Y-F(,;2X'JJH=0<;&.6)S_0P M&8A7\L6"F0FPR61&^@(3N:OXL=J22B#1.;3ZS'2[8QO;'AC M /-4!#.X\9) Y]%|LV?\<1HD4 M@KN#SF'X\0!6KECIX/>Z^I'5S0U1ZF=V4[G/YUG*N?4;_#++K'=4!+JAZ7Y9 M#'0W _D=.OZ,GCW^G(57=\2>K[^?H@7L>.VD'JEG6M-9J#/=:>.ZTF#[C8:0/6, MW$[_V5.EVW5[=^39-YMNCXM3HUM02K"5]7^? %6<0\ 5;V^XTG21WPS^B(+MP%_?K@E<^^$22U1S, M\R6/IP5YX5'DXI%/X/W->.\;L? V<\PAI-U_>S M> Y>CCW9&3PQ53;*'O[$U 'SW1OJK88Q9./4?;Z8 MWT3X-HB/-^E8#|W?/P9(K3AXSM@?ON"#VO=Z4T4XMZ61+TZ,W'U>++5Y#;,> M)SZ4.Y&RTQX76<. +226(8!#(H G]^XWB/T; [#\!TH?#LWQ# #L"+BPZ;\AMX4'?C!MVN<>H|O%/OR&B M8>=TF-331;=ODR2/H1U#.T;R&.HQU'-'ZB$|[CNZ2/0!5O-GD>7A|/K.5Z/B M9W4+M!0IRD1NRV7EVF74M8NG&5Y;32_C;;G:FU..%P?KMPCG"5Y7+BZE+B\L MMQ#Y%N)+>7F!!)PF481GD($5H43P=.P M#W%/N\"7VIIJ:PCQOO%I>(5 D==+LSGPFMQ:\/(N9O!!'P* 0N1S"2]$IS*Z#8UG+&4SZYIJ?57=/5;>&S%SS&RZ5AYU%(-MUPWCX/P"WLY*(/M)AI=E:[=TK^)U/F.Y#2TQ'OM(Q8#8+[_+L0KU/$OQ%[^-MM: +PN&Y!"")3CU#NJ0T+Y#$[^0@:(=!|YDLI+.[?Q-P5!F&+.ON $S/^K",4=,K2^ [SP_N9&1'3G M?8C; /FY#@\DPO+$Z]P(\!%.\/7&;S(A9A@/E$L0G_.4[PH_EJQA))%(U)(MQ $4 ?,%)'STI9 P8FD.7%P7+R_/:[@[

*,KK4ACT,BCWL)R1YFH*WG2K<.0PQA M-(,PVN"/WBHW'-?N#GM&;ACR."3RN)?_0H'^0FVXGRK?-U6TPVWBV#3,W<&]0?B=F M_@S",'73XR))@F48121VMVM S\VRK8UW^NL$G3,>VM[87-1M:,70RN.:.T9\ M- 1C)/:B(]&XH@YAV=&*_LRL)[.FOHGCWG*(NI0P()Y&(=9CAW3+KE*BS-Q MG;L0=W:, CZHMC<8[E7IY*N/>B[(".[QJUF:,;0S"XT, [;'_:$IB49PB$;Y'XP?_ZOXP)#N!72&SZ HHVE(8L[AN1%+U^YVQW90\ Q< M_(8VFD$;S\6C[,;M\0!]%;Y!$D,LAEAN]5AT7=L=WN=F\]>-@V$B89SSE&?Y MOOL_'(+ (.SB2;64Q1|_NGMVWlNW+#LTZ[_DIMN)\CU[U//L;F_4,N@:##=% M';L&4GOCD3T:|PSTV%U;)&U9&G*KSM*BO#D@8 MWV(CNPG4W"R+VCBIMYW$UE9"H+D-NG9W/##=A R%'!*%F-HE0Q)/K4AV^R2V M"HV^/0"A 6;_$1J&0@Z)0@ZC8@G&_$ Y;R_#V$_F_)6)UYALV.=?8[&[^!N/ M[7[7W;? P;]#6#9D8,ME#EV+/]KNCMI&)H8H&4D7C2REVIHH1KVI,QGMOWMV@ MK1LR,62RUYPWD"-C]UE$HLIRH|%"Y,.A>66]C)(L>V5-^#1)N96S]_UU@# > MQ@9X4$3,<3Y(OC('XB_VI_=UZ2'&UIV)%[Y@S>^.\W+M;G_OEI81'@U$ ^-!OYOP M&/8=V!MI@X=FG8RA%4,K]H'*,.STI,%HO"X]FAZGVFQ-@?VDXE76RPF/^33, M7[7%S= ((FFZN^\"X)/\[8X\NH]?=||WFT*:AAV&9%0),KO;6?;0'6#?AO6N>}.HH MXM.QZ,]#@A#D'0QE(?A)&1!PT^%OAIC<88<[!4,;7GL3]M#*I'E0>62%>O9?6_PFVR%4&_8- +'F2AC#,+SRZY+(@-')++%V='ZN,ZC6HDM M1>H#ZRKFV5VG;[N>N9G#;+[%*+ ^S7[!GNX.!W>OMO?_*(9@U#0*PZ26VO<&W MW1L,[6'/,] WFVX? RN\>XG%L9S2R>|Z&1.SVURK]RK/LV(17[1:.+Y7D:3HJ< M32)NY8D5)_!SG*=)%,'BX&'1\MM4-.U]VRT*BSZOJ[O!)W4_V\@;@MXXW'?' MY>?C 3*T9FCM*R3Y<#2TO? &&C/C6T9QWVN)/M:013J,&U\W@=) 4>;#,0^YN"CEIW$YW,D^Z,%/TU+,FT+'M@2+SQO4;)],=]V- MH#<<_(VX;\!MVX>V^AWJ"M&|0WJ+-^YJM8>N /,= M:!>ZGT|IO3!{/BOHD]- JPTX>'HS#F1S..YP,#=;]]G2<+ M&F5E3_U#/R2^G$4B]:X7YZ[_=5L#\:!N.3O=Q&#W?70/6^*L@P=':# =>/9X MW+//WKAE9&"PWGG]OX+[#VR\^+#7A-QAA5L%0QFVQ*S^)\- BWN+T.Z#^B-&ZT)B4R1K&I\'}97BI^/PQR6X<,*WB?QT3]/3CY:/XUQ0>WZ_:L-\E\P5)X *"\|VO>$Q|"H\"S>XFB M%7 _!1(0I_U-M].S8$D14*1M):G%Q#! G//3=V@M@,2R&0#'MJ;P M1'EF+7D*3Z4,)4WBV>6,KFV9H"\,'#*+WE<<"LH<(7>]Z 2 M.#;YCG1@@GB)V"+CQ^K#ZSV14;E%M6\4GZ.9W3.HAKWE%^]^/$7@8|+D)8\SBW$D3RSL<\5DB|VL0*D=4>=[K>.]RG^ M?4?B9!DH)Y+Q+D,@P*V$=(9?9GD"U#- G.0A/.Y9D"V3]F5H/C'"%6:,$I,8 *.MN^ X)C_WK<6,)T5&9(>T.LU9RE.ON11A/_%:9.%CW$+\,8T ,*-X33U.6@A M%3&L"6Q#&H=$&]P: M5=9M!'#H"M"]<7 /9:6" RI&CMOI*BU$Z#'?|/1OY/B"@>W6>6:G_@48(Y; MSG8CQ K"S\"RG'3"HV1)XS+0T:9A')9XL&XYK6RW VHSMX"LYYG4;9"9*N*@<MSH=E\'SE;"'"< IL(' M\,GX'/MTJEVY/:W\|\BBU|-63?_^E[[XZH10&4C28Q7I]+"(+Y,;>,%QRB/@)<<1Z^-6^HAKM,9/!!E4C)=D',^KEN.]Y'(KD;G5&_2(46 M5 LDQR1&=A#^B&;J8M7W$%MY D/" |\;AIU!*9]TY1[%6= 1?KS!:K91?R_E M 9K_"BYX#)@0(GK%07:\DJXU[,] \#,D29+RM?{UM_>_O1<14RZ\,4 M)H.34!M1[]]6XW7<;RW"07$B]Z.3;8$FCC/6[*E\QG+A]$";2+@FWG*? SR<< MS]Y&*#E&!.?D842"B4"NDO4K3,!9LA0F95S0D0&PZR:T;BT+W,_VZ>5YB..\ M@W4K%H(R0 HV9(Z^8*IUB:-%$]2X69?H>:IF53Y_;|>IWF$W|>&Y.K M-0ZO39G -%. LSHE]3>EOQT+D;V$<{E55);_LPE9=9P"&'T,9*0LSH#1S(_I M$U+MRZY[!#^]>F!QNMF[3@_>(8VK4H&^,AKGD<{Q9!#2_"OKP#* ,(\X?$ X M_<[,9!H "0,21A &$ 8WO2 D- C]3IQ;=-R,#8'GF.DIF$*;]UTF;_5ORJ6B M#?>H1OE8\\P>/P@S M/8P]FR?;]QU2Z&OS-+.>59I3!G_,OIM#-P;S]|(O[]MC4P\\EZU'*#]@;5K<# M<*W=9'O$6LQZEQDKJZ:8;4D@F-,6,76)N,O*U@>@DO2"Q2K7 MCO<:&<4K G-HHJT;*KFIWQ[_>G,(.OM3.P3X*IU@<XM?TN'(\W(#Q1[@O, OI0&1_C--;#1-+|-]&C%7 ZY!&T0G$, M^25"<#WD[FC5"93K: @T %693:11$&%3_)L$8)*(>% MJ5PBNT(H"8Y:'5I'UO)RL3;%M&D&/P$H_4W,,,^0>)#5R7/+4EH(7F+\Z%N"N<"H_"_<*"|TK7K=!+P]>,)?"8A/RT MK$ZF>7&]6>,+5A^IV)<(=:L=DB^3S82+I!#&0E&;\#JE WBVG_H?G%B$GPM3 ML3+\E\(QH8 [+0><3CBKM1US=KZL\+K^]2_U@YFPRF^^-%!:TN>R[9"6:>[MH11.0.6V1:L@%]0,,'CA,Y^>70YIV=Q$B47UL;P"I \PGF!%"<.A/ 0]9<4M& _U>!OAP#UZ0%8 XXH(S.9ZNMNH3;HO;@19(&2_C5:F5O M@: [I+6!Z"SQ>,X$;=Q6T53HAB'Z1<$OR$EJ?%C<0;$IL]&,:^/BST+&5*H'= M7^0#;R+@2Q<<^85PA'6L$VG|"X_"JF=R.[O >127D"\0%U^PZS1\[7HZS3AI M%*KQH/A99U&E7QP'S_+$_W(T(4T&.3/824)U53;3DPG;=4'7*"7UUDZHFO&! MG8+*_J?/76_YNH,[13G!LUSAG]!@5K\5OM[^>]CAUL#0NFNPUQD)_>;NCN$0 MYUU9F7!;,^&DA7$!I0$C"$%$4Q^#5RY\.0X]FI4%!5FS8T@F_3)Z,7*&IJ7 M4_!_@X_ ^5N&Q@5)0(@G_[,T[GU%K3^P]*IOPXW_XG=4 !4Z;P:B765%(L.L M%TBZ]6>]K=X)L#44#L445%7J8#:O7$\;IBDM+C $.0.[3#@E$8$D(A*V(/), MHX(KEY{_8_%%97D!><"*&& 13G] O(S$L-0<0;SE4@$R/3HDT*R?H+8=_MT)$D^)O ;U3%T!&A<@TKGH0G=9NL9P M(E(@?!;YA5!;,HZ]\RCV3CX+TE7H1?*95=Y,-'"FBR;,E5Q$6&LXB.=TH+ MRD#+H13)D66Z9>,TS[=;]FZ-Y'N=02W!=F?2 MW#6]UG1O- _A8Z]Z^O?GG_]" '"LMNBD_?9M/TW?|KGW7=V8?*UW7!;6NJZ MJ[ANJ#%=UP\>W9YEU_4F^(GNTQZ9]HN0_,>U-O:!"PG?'|FE.[@\3&H0 T?-M_NZ;YM36K]*1- UV\#B>D>W=I]FZ;KNR:XF);KAFA,MVS38)D>:UCJ[-T^@>M09_S+Z;0S<&\TW+==-_N7&;,(\X:UF+ZI%C\N\/!M\T&4@Z &@\|;\7G0M]U>S[1<_Y]6ZP]>$4+IE/,DTW*B'Z? I^OVR'UN<\|C@ MGNNNUH3@CCW7;T;(7=NNEQW5V]9!W?.TWM'WH--=^Z<[GI:=?9<&ZMX8.,A3 M-5#?D+QM&];?M2A@+PW3=Y8;A-6@;XQOZ)? N]$<#,I=B2'=JF+ZEFWFM8?KJ M-0B88&#:I9MVZ7=G8:9=>JN :=]EFW:IEUZRXG8MS$W|=)-N_1';)=^-Q/+ M'6@M6SE>+L7?HKV>{ZJ^EZ)MKV<;I6]KE/!H? 9^;T_3MF99O#TWYMBG?;DJY MMFD2_N1-PL>,:*+A)?M_4(GRTVR4ES>D.;KJ"MZ4K>%_KJ+,,>IJ>X"U#$-,3 M_,%Z@AOT>_VP+<'!?'1-2_#]V6!WK-UM+FHS*PQ^>'$^GG;fGM\? G0>#X>2|-MQ_K^^83UO?-N?\"G;-0=#OON"Z&V/|)>;JHT^C4$;1B@7$3<><.$# _Z3]W.2(\34_H0GBPJ'9\@KJ*2OJ2 M\XO,+_P^]O5C3,]#B? PF@ZX4!$]/'$M@6D:IEFN*YTR$ZCSE,;HO1U6C[/6 M,WFN\CB/39_W@^NK_0;)B/2?RH?#4 .3@2S*KAI4Z5,JR[5LE@NFWTKSY5Q3 MLI!D|C%Q0|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|2@5+<375,J)"RK M-&>0R:&L8"EQ8EFNU,]\]Y')>S=Y{\W)>] <;D)35Q$(50!853H$FRW*99($9 MJ44LI#ME;A&; (T)$YTE"\TX_X+,)65A5G4# 'E C&6"#PC#4A;UPC H=32& M=AA*P9WR4O5;9E&C7W80*KOAU*1<|^TW"V=U1?4TYW/KU";> [79?5]<"GU4% MBC2]HZG^1RS\

*!X$* TLYPR_14Q21*Q$Q58)%LPI6&E%83BHV6;^"R4=.YJIBY MP^W&JGVW5/MX14;_O#EL>P<|52]VC!EH,"**,#P;Z8T(E3,_82A/ D# M M68R! ?*

%OI^#QWA;NJ!FF+!%#V>^Q\R0V,GS$H"^,GAY#\I+L+*^UB1 MWU4=%DEE1F%ZUN+C"3X'PY<(@D*B@FJQ8LVLJ5 :VO%4!>92 4Q4EKYD^YXA M$2 -O,$MZ)OQ2*J9J>^PJ,N*!5\[EJN8JD5@13]BD,E"XV"-/$KG-X!*,TQ3,,_!*Q0L> +,0'IEZ%EDQ#-&KS&6V#3!1!,3X)A3 MG*K(?A(JRN35EHIK? -8.!B"Q=P+X+*M B&*

P@>VG8@*$@FJDB!>F#:LQF M2M>[ICCBGW(/7OL'@$.5* D\FPK8/CKV MC$[*$SY9^AF6YHF8,^B=Q<(Z%[" D#%L0]Y^_5U!>ZU'1DV"7]8E* 1SUL M$+R.K>\ +QG-

A<>'+;REQ.M04Q.4R_D ;2.;;@4@2FBO6K7[4=P"^I53 M*$!0S>KE)^YD]>836VKWF+BPA/^P6GF*@0,"?WD=D_(P3%@Y8L\YZ+RM"ZF< MNA+8=[D>\MX_FUH>I_ZF+[06:?<02+"

LRZG&X,D6&:L[[#=Z]P40:X.'RO# MW7W'.WP5XI.%]$5>2K#C=-Y_9P'>W=@S"G#K^..\^U?1L^OL'[SME>ZAE+'G M8' QIU'D3,X@IAZ(W]TY6/N(QR]ME/R#35U/^426V;;;

[7=ZJT82PA0&7'!08[MZ^W4-0<%U4O0W^N-S/O?OZOO\[$Z-;S;SWCA9GP:7$^D*+(0SSF$[%:U2^VM MZ]6.DL'V+8;K;F?E?>^R:>5U![)NODN=TPIJ^9/2Z2(-9)=.!0]+=!WL.[O+

M4LNVM"TR,#(T,#8S,'AE>#,Q9#(N:'1M[5K]<]H\$OY7=.GT;3(#-@[YH)!F MA@"Y<-.27DKF[GZ4,1EK8EM^)1G",?6W*QDPA#1)T[QS29N9 -;G:O?1L[N2

M3_Y6KP^RF&8!"\G%^,MG$HJ@2%FF22 9U5 ZXSHF8Y'G-"-?F)0\2(UG"/'VS\T&O7ZZ0F.U2L[B;Q-6NZQN_8/R">UVXTVOL-\O4+V.T>\[_9. MX_YE,_R?KP.!Z\?

KL_#'MFIN^Z_FCW7[8_[MN+ :7AD+&FFN.8BHXGK#D8[M9"?6.F^[!FPVOQ>;T%+337"3L]<1??MJTOPOGI2%;7(F\W&[GN M0$\7JC?:W-

9G/-1QVVLTWG=R&H8\F!03%NFVYSG'1ZLRR2?OJE#8Q;4E2ZCF M4X:C5\8-$D9EVQ>4>- M3A/D."%14'W^ERPS@'W 9&6=/W=MO<'5>'@^[*7'P\L1N3PGO8OAX)R<#T?=

M46_8 0Q%4#NX>D-+_GH]>VZ.QJ3\26YNOX\L';UFMVZ=[#;W:./W5& 6GG8 MMY4OJP;OXW?58!#>>@F$@]W"%P/R:=*[OAJ.AX-O9/#OWD5WI//[;RG=-.AC?Q#9*3GD#/P$;I& B8U

MC^9$QU2W3UP<[S6NR\+TOD_/L=]#*$M,I(Y)-.9N!A]0Q5^3/@DK 63*\'EQ(M#7Z3G N9@F.M_Y.(B(P* "6Y8#31L4.&6>!TW]JB]DM%G5%E @B2SLE-)F8)

M@U"C9O55:BD4,%4F($#'2C/",WFI,BT+!C(!N R 0RHCY(4GB2G"8EH $62 MB)1KHH5M=Z=!Q@*F%)5S,)+2&P;S5L944!:",#!E@MK";!!P"5$3= .XB@% MDH1,DEG,@YBH

C]6_6=,LG(07$#*%3AW# ELG"69REE@!,1Q1;"A*$9)\#M(BA#&!/M5 M%%D#VW/EV<=K.OKC76O?.^ZH MTK"ES\ -(Z*(PZ/1W!\0R8R=0,_<3QC]DS AY]P%6-S;)8"62!AX'/(59 (

M54_]!IFNP7 I(AJ!8D5VP3\C X-8(@UO('C+(>[JP0Z^*A*E%^$+KWN$N MVS/]OC5\/'#]J^AJPAHH1[?!3G;9V# (*-W RJ"UDL.PD@/?@"Q*)#PT2; M&'!Y#!L"8T%_%KY9AGH

;Y6L&T2P+WI_PIF'MWS\= #N$!YB(BB2F04B9(J M0",&+@@S*L,%R0&$G/H\X7J.GFO:M+@!##J.X2UVUY!6 A_#0[?E@O)"Y + M9OM @9&@%,"#1A&3C0!/ -2Q'0&,3",\LQF

#\!S(\%=%65"B;#"E26'V M/9J 11%$*'P*RE-;(HVE%WT$C]G'[<&' 15T! Y2-L3Q1;'OE^ Q3$N7K1G& M;]'#D2_Q%$AV2?,;@+DZ>#@OR@NP@7[6)7?-1TF265$86JVXN,)G((N2P1!

M(=% %5^Q9=14* WE>*H"8ZD !BI37[)[3Y<(D 9LL-&Z%!R":F;R.TS]LF(I MUYZ5*J9]Z5B11PPR66@(UNBC)+\)Y9'$W+,"F3O8WVM6>KZ$VC\?!9T;HY"PD7 M2*VM-C3R2Q4MJ[V-

]GZ"+[T3.BU%HQ ^,2'5TGV9 A@R3;G6C'V'/7T!#A+K M0P[RF4%Y 5- 5@K)$+XQB%ML!/9GP4%\ _HB"TQ.N/>K1^)=2*PQ3.$!\Q0 M..$). /[E:YG&1'/&+U!7V+#!.-

-3(!C3G$62?.34%$&KS95W,(!-(2.BBTI MX%X$E6$1= $80/12LPY-@3=310K:[!.8Q934N_4XXJ^A!^_C_R.:%J%R%WQ2 M)&$#UL VS' &6->L[K-

5B"2A.:*M1< JJL!23OE0O">$14)9EJ .!\65K%^"8DGE2A,GEO ?+F:> MH@^!&*"\F4EY&":L[''HM)KOJY=5Y="+BZN7NC!;OQ[!<;-L0*&\9/%UB)M MMZ $4S=+-

NT8%LXRL_%:^XWF6OKCZO"Q*FNVG.9OG3U19T[K^(5)H ;>^[N M/YNW?W#MAY[S\?!HJS I9H|!YG)G#R1=PWS]ZK5XRIW6]RCJY.UOV9HO#4N?@-PZL6<1>1\&5Y>VM3X M-

I) ^(^N9R-HMC\?Q=88EO*HG+ZOZRIEZV6!O.P!=DP=QLOFE5U<=C MC6Y$M9^Q7*8P-+B92%ATB&F,D.U%Y%)YOW*]HA1P?T/@1:RS]F9G6;3V8N?F

M2ZJY9*YU7S)Z4Z<1D)QM.A4\+.%W?.0<'"\#+5O6,.^9VI=1S=NML\#4$L# M!!0 ($" "%F-<-6Z 8 *<@ 8 ;G5T>"TR,#(T,#8S,'AE>#.R

M9##$N:'1M[5GY4]LX%/Y7WJ;3!6;B*Q>)$Y@)P0S9:0DEIMO^J-A*K*EBN;)" MR/fU^^0C##$^E9)S#@63AC (XMMDRG5K3M UCOX>Z!H60B%UH6[M6

MS:XUP\%%G@G^F16I.6]87(B4F[$* M*_L!W8*;TE(3(#(R]JOG'U1)XI=4*U]0V _*9'N1*BH>]W$;9))*3<5L3*F9.[XRMT: M$,XFDFU5MXXIOZ"*!02?4P362*EDTZUN-CQE?

U'T"R/D+.*9&$'-'S5]fJ^BE M,E#+++'8#) B5W1P4M\!#R]]VF=SFL()7<*9F),8S68MVGONN0 7(U!B[K91 MW05+V81QIE9NQ.*0QFC@!S?

MFEWO]BRM'.%/GB34;*;*2)U&H@##A7;^K<.> MW"_F;/0RMSD1/$15WF6$0:O?WS@MNUNOF4[/FCQ/G/-,._NWKF=$1//'$W M./IX$S?

PSOSAT7#0!X>C$Q@=/>6\/668QT/O"+Q/WN#<'WIT,%",V3M[!=&> MGI^S_LG/O@C<-IP;HI-@0EC;Y!-LE-OVM ?0]P=.!IA[YNAB3L[YCMQ H M\(^]5XK3N'IVT#_QQC#ZI.

[[#/V!K^,MV7;MT0-^C-W]F4'>Q]F QX)3OH*I MD* B"LE"8N; 0F(*@9@G?(4Y29IH?6-Z;F8<)RF04"0ZJ4.Q=$'0"R4@i8%_M/$#3&[5HK6,B)R2FJ3&ZY'0%)%"Z1Q.A"L-J-

F01AU2F2%#4-H@8G8)W28.% MSEQ@-)VR@$HM<[) *L,Q)1P[&L:!"=M:6D]#S>X.T&,2K[)?3G>G"A&5=+(" M%%9LNJK"A*19"@KS%7R)Q9)33%:U-T1E7GQ8$(fK

P$YHXF02@\]$G*,Z;SQ MH8RFL++&[&LN!!4#",&/14R+<]]NY@\ZU:U>-<3377OH)TP5'DQG>#+'/X-.< M)?VZ8)+J]#N;D7$!K5/?)CMK"G]7F,3&F'[WSAJP7.?14)E9C.]AI_Y4A?-

J]P'#G&"7>@O9HL4=59!+ M(1W)U4I(MZSK&K.#19&V+4O#)3(Y BI$(O(4Z;57:5;*,1=Z^0>$%R?@'">- MTT)ITS;KS;>.;I4IAOJQ=-.JJM#5L"=4ZY6)8,*\;2TD2=X*U[A=CB9C\9P6W

MfB>35'#!=X-9=;/VPJ1ZO*7Z70?G3P&H89O. ZS5?!KI MT7<(@X@PB7+EM<&\(#+\M; ?94$WID, IEE[YI3_85=T97\|D2P.6$(XT#4+ M1<[*G=O)9F47'V?1^;RW/'>=

[XTJ.5K7QA,2?)E)L8A#?6\CI%LFWAMOE:]V M%]6KCEL7]D(BU?71=.5U]G77Y4G9$:-_,. 3!65+KD0+"S8MMLR&[OK.B%O ML[../W\%G[W3W_\;4$L#!!0 ($" "%E+.%ZRN04 !HA 8

;G5T M>"TR,#(T,#8S,'AE>#,R9#(N:'1M[5IM3]M($/XK-6-UUUO"+E??[-^@4 YM<<<5*!5(&&=?9N9Y9G8\8]/|S3"& M24R2@(9PYGT\AU $JR5-% 22$H6C:Z9B\$2;D@0^4BD9YW

B6;B@ (YM'IA. M8]^T#:/715F#P;^4A+WNDBH"04QD1M5Q[=(;&6UU]L]BK2_"3:\;LBO(U(;3X]]2R 5+#"52MVFGJH,[+9R^M^;;6+-0Q:YC MV[!W4A*&+%D8G$;*=1SS\.!V3+)%?

#LH"G"ND)PH=D6U!"VY .=$NKY0<>>^ MBH=VIM6^2"3*B,B2\8V[,R"<^9+MU"?.*+^BB@4$KS,DULBH9-%,)U^>L;\! MVH4(.4NH$=/"4+/1{BAZK0R4LDC< .$RDY\BEORH?<_]-

IC2YK!A*YA)I8D M0;7YB%9?:"[)181*+-TVBKMB&?,99VKCQBP.;8(*WK]K-QFIVMIX4A_^BQ0 M@B'DX^T717ES.YI?]B0?>%)PV7)ISPT[VWHSZ%_.KWP MAJ>PO,I<4T3]D7V

1(%W-OQ%>9KW9R?]R7 .TS_/AW]!?^!IO W;?OKT]139 MZH7O/$^3@.>"4[Z!2$A0,85T);%RP$TB@D L4[!F]O#]&XC/3/S&"<9D%"D MN[C#;=F*H!5*0$#*77B .#F^4HJ7.B?1)0C-

C>LWI!DB@](P.A#],Z_F251)2 MF6& HK1!S&@$(Y9@\RPE"&,THX6C1. A-V]6[MAH;=&:#% M)-GDWYS.7AUB*JF_ =RL6+2I@T^RO 2%Y08^)V+.*1:KV@"B)"E[KU.X86TBL[

M(5IQ5)GSS9#!G&ZJ6MO*R:1+KISC\Q+.IWF+MF](9<&*XFU'FX<7F.1FV#Y MW2\8=HZ:+2!)6 !D"5]])+F$.,.$,$TV2W(I)=Z(.(T^E333NMZFF!9C]LP M8M

7.)&B%5GAM>C&1R@PS O.7!^N6O'"9I%2F>O.IO%GOM9#\TOF@5-TL O!MU6*5HZV$9S@%.6 M0'2SHD,08^QN.Z21W.V$],A67Z.5RTIK14L!7X75^)4^IP'AY2UOB5[BM)2R

MGS=66_U)I.[J5;:ZJRWQ D5&7*PKCU??C;4DJ>MC;_O96","W^S8;N:)GPF. MV:RC&\=]1*9T*ZM/])M?X6ZZ;]<-G-J]1T#17I9_5?C=R!VS???3*H?\$AZJ0 M\OV=Z".]U33;K5?

NK,GY(4>-?W(%/Q&TK;"2S+!=.*XU:M]UP@[-@U>=AAYZ)EH%T'_DHM4PF\UXG\(YNG^7TK]. MVVSN_W]NWL+FJ1+S6VSJRV.GMS![",?&6:[J6088"E&V.WC,U'$VM[#P6;E

MSU][XOQE>XM'=!/QS0,;GP2?%U*LDE_*A+2K M/U!+ 0(4 Q0 (#V_"%G.#X5_T1@ -+HB 0-1 " 0 M !N=71X+3(P,C0P-C,P+GAS9%!+ 0(4 Q0 (#V_"%DF9,PZ& | $W8 M 5 " 0 9

!N=71X+3(P,C0P-C,P7V-A;"YX;6Q02P$" M% ,4 "]@ A9M.0F*79* 2" 4 %0 @ %+* ;G5T M>"TR,#(T,#8S,%]D968N>&UL4$L! A0#% @ /8 (6>[*"TR,#(T,#8S,'AE>#,R9##$N:'1M4$L!

A0#% @ 0((64LX7K*Y M!0 &B$!@ (!%GD$ &YU='@M,C R-# V,S!X97@S,F0R .+FAT;5!+!08 "@ * *8" %?P0 ! end XML 98 nutx-20240630x10q_htm.xml IDEA: XBRL DOCUMENT

0001479681 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2024-01-22 0001479681 nutx:AhpHealthManagementServicesInc.Member nutx:AssociatedHispanicPhysiciansOfSo.CaliforniaMember 2024-01-01 2024-06-30 0001479681 us-gaap:RestrictedStockMember 2024-06-16 2024-06-16 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:RestrictedStockMember 2023-04-01 2023-04-01 0001479681 us-gaap:RestrictedStockMember 2023-04-01 2023-04-01 0001479681 nutx:PriorToReverseStockSplitMember nutx:SecuritiesPurchaseAgreementMember 2024-01-22 2024-01-22 0001479681 nutx:SecuritiesPurchaseAgreementMember 2024-01-22 2024-01-22 0001479681 nutx:PriorToReverseStockSplitMember nutx:CommonStockWarrantsMember nutx:SecuritiesPurchaseAgreementMember 2024-01-01 2024-06-30 0001479681 nutx:CommonStockWarrantsMember nutx:SecuritiesPurchaseAgreementMember 2024-01-01 2024-06-30 0001479681 nutx:ClinigenceHoldingsInc.Member us-gaap:CommonStockMember nutx:MergerAgreementMember 2022-04-01 2022-04-01 0001479681 nutx:EmployeeStockPurchasePlan2023Member 2024-04-01 2024-06-30 0001479681 nutx:EmployeeStockPurchasePlan2023Member 2024-01-01 2024-06-30 0001479681 2024-07-23 2024-07-23 0001479681 us-gaap:SubsequentEventMember 2024-07-02 2024-07-02 0001479681 2024-07-02 2024-07-02 0001479681 srt:MinimumMember 2024-06-17 2024-06-17 0001479681 srt:MaximumMember 2024-06-17 2024-06-17 0001479681 2024-06-17 2024-06-17 0001479681 2024-04-24 2024-04-24 0001479681 2024-04-10 2024-04-10 0001479681 2024-04-09 2024-04-09 0001479681 srt:MinimumMember 2023-06-29 2023-06-29 0001479681 srt:MaximumMember 2023-06-29 2023-06-29 0001479681 us-gaap:RetainedEarningsMember 2024-06-30 0001479681 us-gaap:NoncontrollingInterestMember 2024-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001479681 us-gaap:RetainedEarningsMember 2024-03-31 0001479681 us-gaap:NoncontrollingInterestMember 2024-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001479681 2024-03-31 0001479681 us-gaap:RetainedEarningsMember 2023-12-31 0001479681 us-gaap:NoncontrollingInterestMember 2023-12-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001479681 us-gaap:RetainedEarningsMember 2023-06-30 0001479681 us-gaap:NoncontrollingInterestMember 2023-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001479681 us-gaap:RetainedEarningsMember 2023-03-31 0001479681 us-gaap:NoncontrollingInterestMember 2023-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001479681 2023-03-31 0001479681 us-gaap:RetainedEarningsMember 2022-12-31 0001479681 us-gaap:NoncontrollingInterestMember 2022-12-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001479681 us-gaap:CommonStockMember 2024-06-30 0001479681 us-gaap:CommonStockMember 2024-03-31 0001479681 us-gaap:CommonStockMember 2023-12-31 0001479681 us-gaap:CommonStockMember 2023-06-30 0001479681 us-gaap:CommonStockMember 2023-03-31 0001479681 us-gaap:CommonStockMember 2022-12-31 0001479681 nutx:PriorToReverseStockSplitMember nutx:CommonStockWarrantsMember nutx:SecuritiesPurchaseAgreementMember 2024-06-30 0001479681 nutx:CommonStockWarrantsMember nutx:SecuritiesPurchaseAgreementMember 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember nutx:EquityIncentive2022PlanMember 2024-06-30 0001479681 nutx:PostReverseStockSplitMember nutx:EquityIncentive2022PlanMember 2024-06-30 0001479681 nutx:EquityIncentive2022PlanMember 2024-06-30 0001479681 2022-01-01 2022-12-31 0001479681 nutx:September92031ExpirationOptionMember 2024-06-30 0001479681 nutx:May112027ExpirationOptionMember 2024-06-30 0001479681 nutx:June92027ExpirationOptionMember 2024-06-30 0001479681 nutx:June302030ExpirationOptionMember 2024-06-30 0001479681 nutx:January282031ExpirationOptionMember 2024-06-30 0001479681 nutx:January282028ExpirationOptionMember 2024-06-30 0001479681 nutx:January272030ExpirationOptionMember 2024-06-30 0001479681 nutx:January272027ExpirationOptionMember 2024-06-30 0001479681 nutx:January212025ExpirationOptionMember 2024-06-30 0001479681 nutx:January212025ExpirationOption3Member 2024-06-30 0001479681 nutx:January212025ExpirationOption2Member 2024-06-30 0001479681 nutx:February282031ExpirationOptionMember 2024-06-30 0001479681 nutx:December172031ExpirationOptionMember 2024-06-30 0001479681 nutx:August42029ExpirationOptionMember 2024-06-30 0001479681 nutx:EmployeeStockPurchasePlan2023Member 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember nutx:EmployeeStockPurchasePlan2023Member 2023-12-31 0001479681 nutx:EmployeeStockPurchasePlan2023Member 2023-12-31 0001479681 nutx:PriorToReverseStockSplitMember nutx:EmployeeStockPurchasePlan2023Member 2023-05-31 0001479681 nutx:EmployeeStockPurchasePlan2023Member 2023-05-31 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-06-16 2024-06-16 0001479681 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-06-16 2024-06-16 0001479681 us-gaap:RestrictedStockUnitsRSUMember nutx:ShareBasedPaymentArrangementTrancheFourMember 2024-06-16 2024-06-16 0001479681 us-gaap:RestrictedStockUnitsRSUMember nutx:ShareBasedPaymentArrangementTrancheFifthMember 2024-06-16 2024-06-16 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-04-01 2023-04-01 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-04-01 2023-04-01 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-04-01 2023-04-01 0001479681 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-04-01 2023-04-01 0001479681 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-04-01 2023-04-01 0001479681 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-04-01 2023-04-01 0001479681 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001479681 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001479681 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001479681 us-gaap:IntersegmentEliminationMember nutx:RealEstateDivisionMember 2024-04-01 2024-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2024-04-01 2024-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2024-04-01 2024-06-30 0001479681 nutx:HospitalDivisionMember 2024-04-01 2024-06-30 0001479681 nutx:HospitalDivisionMember 2024-04-01 2024-06-30 0001479681 us-gaap:IntersegmentEliminationMember nutx:RealEstateDivisionMember 2024-01-01 2024-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2024-01-01 2024-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2024-01-01 2024-06-30 0001479681 nutx:HospitalDivisionMember 2024-01-01 2024-06-30 0001479681 us-gaap:IntersegmentEliminationMember nutx:RealEstateDivisionMember 2023-04-01 2023-06-30 0001479681 nutx:HospitalDivisionMember nutx:ManagerialServicesAgreementsMember 2023-04-01 2023-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2023-04-01 2023-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2023-04-01 2023-06-30 0001479681 nutx:HospitalDivisionMember 2023-04-01 2023-06-30 0001479681 nutx:HospitalDivisionMember 2023-04-01 2023-06-30 0001479681 us-gaap:IntersegmentEliminationMember nutx:RealEstateDivisionMember 2023-01-01 2023-06-30 0001479681 nutx:HospitalDivisionMember nutx:ManagerialServicesAgreementsMember 2023-01-01 2023-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2023-01-01 2023-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2023-01-01 2023-06-30 0001479681 nutx:HospitalDivisionMember 2023-01-01 2023-06-30 0001479681 nutx:EREntitiesMember nutx:ManagerialServicesAgreementsMember 2023-04-01 2023-06-30 0001479681 nutx:EREntitiesMember nutx:ManagerialServicesAgreementsMember 2023-01-01 2023-06-30 0001479681 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2024-06-30 0001479681 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2024-06-30 0001479681 us-gaap:VehiclesMember 2024-06-30 0001479681 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001479681 us-gaap:LandMember 2024-06-30 0001479681 us-gaap:ConstructionInProgressMember 2024-06-30 0001479681 us-gaap:BuildingAndBuildingImprovementsMember 2024-06-30 0001479681 nutx:SignageMember 2024-06-30 0001479681 nutx:OfficeFurnitureAndEquipmentMember 2024-06-30 0001479681 nutx:MedicalEquipmentMember 2024-06-30 0001479681 nutx:ComputerHardwareAndSoftwareMember 2024-06-30 0001479681 us-gaap:VehiclesMember 2023-12-31 0001479681 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001479681 us-gaap:LandMember 2023-12-31 0001479681 us-gaap:ConstructionInProgressMember 2023-12-31 0001479681 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0001479681

nutx:SignageMember 2023-12-31 0001479681 nutx:OfficeFurnitureAndEquipmentMember 2023-12-31 0001479681 nutx:MedicalEquipmentMember 2023-12-31 0001479681 nutx:ComputerHardwareAndSoftwareMember 2023-12-31 0001479681 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001479681 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001479681 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001479681 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001479681 nutx:HospitalDivisionMember 2024-04-01 2024-06-30 0001479681 nutx:HospitalDivisionMember 2024-01-01 2024-06-30 0001479681 nutx:HospitalDivisionMember 2023-04-01 2023-06-30 0001479681 nutx:HospitalDivisionMember 2023-01-01 2023-06-30 0001479681 nutx:PhysicianLlcAndRealEstateEntitiesMember 2024-06-30 0001479681 nutx:NutexHealthHoldcoLLCMember nutx:NutexSubsidiariesMember nutx:MergerAgreementMember nutx:NutexHealthIncMember 2022-04-01 0001479681 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001479681 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001479681 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001479681 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001479681 us-gaap:WorkersCompensationInsuranceMember 2024-04-01 2024-06-30 0001479681 nutx:SelfsPayMember 2024-04-01 2024-06-30 0001479681 nutx:MedicareMember 2024-04-01 2024-06-30 0001479681 nutx:InsuranceMember 2024-04-01 2024-06-30 0001479681 us-gaap:WorkersCompensationInsuranceMember 2024-01-01 2024-06-30 0001479681 nutx:SelfsPayMember 2024-01-01 2024-06-30 0001479681 nutx:MedicareMember 2024-01-01 2024-06-30 0001479681 nutx:InsuranceMember 2024-01-01 2024-06-30 0001479681 us-gaap:WorkersCompensationInsuranceMember 2023-04-01 2023-06-30 0001479681 nutx:SelfsPayMember 2023-04-01 2023-06-30 0001479681 nutx:MedicareMember 2023-04-01 2023-06-30 0001479681 nutx:InsuranceMember 2023-04-01 2023-06-30 0001479681 us-gaap:WorkersCompensationInsuranceMember 2023-01-01 2023-06-30 0001479681 nutx:SelfsPayMember 2023-01-01 2023-06-30 0001479681 nutx:MedicareMember 2023-01-01 2023-06-30 0001479681 nutx:InsuranceMember 2023-01-01 2023-06-30 0001479681 us-gaap:ConvertibleDebtMember nutx:September2023PrivateOfferingMember 2024-06-30 0001479681 us-gaap:ConvertibleDebtMember nutx:September2023PrivateOfferingAsAmendedMember 2024-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2023-07-01 2023-09-30 0001479681 srt:MinimumMember us-gaap:TrademarksMember 2024-06-30 0001479681 srt:MinimumMember us-gaap:TrademarksMember 2023-12-31 0001479681 srt:MaximumMember us-gaap:TrademarksMember 2023-12-31 0001479681 us-gaap:TrademarksMember 2024-06-30 0001479681 nutx:MemberRelationshipsMember 2024-06-30 0001479681 us-gaap:TrademarksMember 2023-12-31 0001479681 us-gaap:CustomerContractsMember 2023-12-31 0001479681 nutx:PHPTechnologyMember 2023-12-31 0001479681 nutx:MemberRelationshipsMember 2023-12-31 0001479681 nutx:ManagementContractsMember 2023-12-31 0001479681 2024-06-30 2024-06-30 0001479681 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001479681 srt:ScenarioPreviouslyReportedMember 2023-04-01 2023-06-30 0001479681 srt:RestatementAdjustmentMember 2023-04-01 2023-06-30 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ProcareHealthIncMember 2024-04-01 2024-06-30 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ClinigenceHealthIncMember 2024-04-01 2024-06-30 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ProcareHealthIncMember 2024-01-01 2024-06-30 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ClinigenceHealthIncMember 2024-01-01 2024-06-30 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ProcareHealthIncMember 2024-07-31 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ProcareHealthIncMember 2024-06-30 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ProcareHealthIncMember 2024-05-30 0001479681 us-gaap:OperatingSegmentsMember nutx:RealEstateDivisionMember 2024-04-01 2024-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:PopulationHealthManagementDivisionMember 2024-04-01 2024-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:HospitalDivisionMember 2024-04-01 2024-06-30 0001479681 us-gaap:PropertyPlantAndEquipmentMember 2024-04-01 2024-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:RealEstateDivisionMember 2024-01-01 2024-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:PopulationHealthManagementDivisionMember 2024-01-01 2024-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:HospitalDivisionMember 2024-01-01 2024-06-30 0001479681 us-gaap:PropertyPlantAndEquipmentMember 2024-01-01 2024-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:RealEstateDivisionMember 2023-04-01 2023-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:PopulationHealthManagementDivisionMember 2023-04-01 2023-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:HospitalDivisionMember 2023-04-01 2023-06-30 0001479681 us-gaap:PropertyPlantAndEquipmentMember 2023-04-01 2023-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:RealEstateDivisionMember 2023-01-01 2023-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:PopulationHealthManagementDivisionMember 2023-01-01 2023-06-30 0001479681 us-gaap:OperatingSegmentsMember nutx:HospitalDivisionMember 2023-01-01 2023-06-30 0001479681 us-gaap:PropertyPlantAndEquipmentMember 2023-01-01 2023-06-30 0001479681 srt:MinimumMember us-gaap:LineOfCreditMember 2024-01-01 2024-06-30 0001479681 srt:MinimumMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001479681 srt:MinimumMember nutx:TermLoanMember 2024-01-01 2024-06-30 0001479681 srt:MinimumMember nutx:TermLoan3Member 2024-01-01 2024-06-30 0001479681 srt:MinimumMember nutx:TermLoan1Member 2024-01-01 2024-06-30 0001479681 srt:MaximumMember us-gaap:LineOfCreditMember 2024-01-01 2024-06-30 0001479681 srt:MaximumMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001479681 srt:MaximumMember nutx:TermLoanMember 2024-01-01 2024-06-30 0001479681 srt:MaximumMember nutx:TermLoan3Member 2024-01-01 2024-06-30 0001479681 srt:MaximumMember nutx:TermLoan1Member 2024-01-01 2024-06-30 0001479681 nutx:TermLoanSecuredByDepositsMember 2024-01-01 2024-06-30 0001479681 nutx:PrepaidAdvanceMember 2024-01-01 2024-06-30 0001479681 srt:MinimumMember us-gaap:LineOfCreditMember 2023-01-01 2023-12-31 0001479681 srt:MinimumMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001479681 srt:MinimumMember nutx:TermLoanMember 2023-01-01 2023-12-31 0001479681 srt:MinimumMember nutx:TermLoan3Member 2023-01-01 2023-12-31 0001479681 srt:MinimumMember nutx:TermLoan1Member 2023-01-01 2023-12-31 0001479681 srt:MaximumMember us-gaap:LineOfCreditMember 2023-01-01 2023-12-31 0001479681 srt:MaximumMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001479681 srt:MaximumMember nutx:TermLoanMember 2023-01-01 2023-12-31 0001479681 srt:MaximumMember nutx:TermLoan3Member 2023-01-01 2023-12-31 0001479681 srt:MaximumMember nutx:TermLoan1Member 2023-01-01 2023-12-31 0001479681 nutx:TermLoanSecuredByDepositsMember 2023-01-01 2023-12-31 0001479681 nutx:PrepaidAdvanceMember 2023-01-01 2023-12-31 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:ConvertibleDebtMember 2024-06-30 0001479681 nutx:September2023PrivateOfferingMember 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:ConvertibleDebtMember 2024-03-26 0001479681 us-gaap:ConvertibleDebtMember 2024-03-26 0001479681 us-gaap:LineOfCreditMember 2024-06-30 0001479681 us-gaap:ConvertibleDebtMember 2024-06-30 0001479681 nutx:TermLoanSecuredByDepositsMember 2024-06-30 0001479681 nutx:TermLoanMember 2024-06-30 0001479681 nutx:TermLoan3Member 2024-06-30 0001479681 nutx:TermLoan1Member 2024-06-30 0001479681 us-gaap:LineOfCreditMember 2023-12-31 0001479681 us-gaap:ConvertibleDebtMember 2023-12-31 0001479681 nutx:TermLoanMember 2023-12-31 0001479681 nutx:TermLoan3Member 2023-12-31 0001479681 nutx:TermLoan1Member 2023-12-31 0001479681 nutx:PrepaidAdvanceMember 2023-12-31 0001479681 nutx:YorkvilleMember nutx:PriorToReverseStockSplitMember nutx:PrepaidAdvanceMember nutx:PrePaidAdvanceAgreementWithYorkvilleMember 2023-04-11 2023-04-11 0001479681 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001479681 nutx:PriorToReverseStockSplitMember nutx:PlacementAgentWarrantsMember 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember nutx:PlacementAgentWarrantsMember 2024-03-26 0001479681 nutx:PriorToReverseStockSplitMember nutx:CommonStockWarrantsMember 2024-03-26 0001479681 nutx:PlacementAgentWarrantsMember 2024-03-26 0001479681 2024-07-23 0001479681 2024-07-22 0001479681 nutx:PriorToReverseStockSplitMember nutx:AccreditedInvestorsWarrantsMember 2024-06-30 0001479681 nutx:AccreditedInvestorsWarrantsMember 2024-06-30 0001479681 2024-04-26 0001479681 2024-04-25 0001479681 nutx:CommonStockWarrantsMember 2024-03-26 0001479681 nutx:PriorToReverseStockSplitMember nutx:SecuritiesPurchaseAgreementMember 2024-01-22 0001479681 nutx:RealEstateEntitiesMember 2023-03-31 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ClinigenceHealthIncMember us-gaap:SubsequentEventMember 2024-09-30 0001479681 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nutx:RealEstateEntitiesMember 2024-06-30 0001479681 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nutx:PhysicianLLCsMember 2024-06-30 0001479681 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nutx:AHPIPAMember 2024-06-30 0001479681 nutx:RealEstateDivisionMember 2024-06-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2024-06-30 0001479681 nutx:HospitalDivisionMember 2024-06-30 0001479681 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nutx:RealEstateEntitiesMember 2023-12-31 0001479681 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nutx:PhysicianLLCsMember 2023-12-31 0001479681 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nutx:AHPIPAMember 2023-12-31 0001479681 nutx:RealEstateDivisionMember 2023-12-31 0001479681 nutx:PopulationHealthManagementDivisionMember 2023-12-31 0001479681 nutx:HospitalDivisionMember 2023-12-31 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-06-30 0001479681 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001479681 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001479681 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001479681 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-06-30 0001479681 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001479681 srt:ScenarioPreviouslyReportedMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001479681 srt:RestatementAdjustmentMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001479681 srt:RestatementAdjustmentMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:WarrantMember 2023-01-01 2023-06-30 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001479681 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001479681 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001479681 2024-01-01 2024-03-31 0001479681 srt:ScenarioPreviouslyReportedMember 2023-12-31 0001479681 srt:RestatementAdjustmentMember 2023-12-31 0001479681 nutx:EREntitiesMember 2024-06-30 0001479681 nutx:EREntitiesMember 2023-12-31 0001479681 nutx:PhysicianLLCsMember 2024-06-30 0001479681 nutx:PhysicianLLCsMember 2023-12-31 0001479681 nutx:MicroHospitalHoldingLlcMember 2024-06-30 0001479681 nutx:MicroHospitalHoldingLlcMember 2023-12-31 0001479681 2024-01-25 0001479681 nutx:CommonStockWarrantsMember 2024-06-30 0001479681 nutx:CommonStockWarrantsMember 2023-12-31 0001479681 srt:ScenarioPreviouslyReportedMember 2023-06-30 0001479681 srt:RestatementAdjustmentMember 2023-06-30 0001479681 nutx:CommonStockWarrantsMember 2023-06-30 0001479681 2023-06-30 0001479681 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001479681 srt:RestatementAdjustmentMember 2022-12-31 0001479681 nutx:CommonStockWarrantsMember 2022-12-31 0001479681 2022-12-31 0001479681 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-06-30 0001479681 srt:RestatementAdjustmentMember 2023-01-01 2023-06-30 0001479681 nutx:CommonStockWarrantsMember 2023-01-01 2023-06-30 0001479681 nutx:PriorToReverseStockSplitMember nutx:CommonStockWarrantsMember 2024-03-26 2024-03-26 0001479681 nutx:CommonStockWarrantsMember 2024-03-26 2024-03-26 0001479681 nutx:CommonStockWarrantsMember 2024-01-01 2024-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001479681 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001479681 2023-06-29 2023-06-29 0001479681 nutx:EmployeeStockPurchasePlan2023Member 2023-05-01 2023-05-31 0001479681 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001479681 srt:MinimumMember 2024-06-30 0001479681 nutx:EmersonEquityLlcMember nutx:September2023PrivateOfferingMember 2024-06-30 0001479681 2024-01-22 2024-01-22 0001479681 nutx:PopulationHealthManagementDivisionMember 2023-09-30 0001479681 nutx:ManagerialServicesAgreementsMember 2023-06-30 0001479681 2023-01-01 2023-12-31 0001479681 2023-01-01 2023-03-31 0001479681 2022-04-01 2024-06-30 0001479681 2022-04-01 2022-12-31 0001479681 2022-04-01 2022-06-30 0001479681 nutx:EquityIncentive2022PlanMember 2024-01-01 2024-06-30 0001479681 nutx:ClinigenceHoldingsInc.Member 2022-04-01 2022-04-01 0001479681 nutx:YorkvilleMember nutx:PrepaidAdvanceMember nutx:PrePaidAdvanceAgreementWithYorkvilleMember 2023-04-11 0001479681 2023-04-01 2023-06-30 0001479681 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember nutx:ProcareHealthIncMember 2024-05-30 2024-05-30 0001479681 nutx:PopulationHealthManagementDivisionMember 2024-01-01 2024-06-30 0001479681 nutx:September2023PrivateOfferingMember 2024-01-01 2024-06-30 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:ConvertibleDebtMember 2024-03-26 2024-03-26 0001479681 us-gaap:ConvertibleDebtMember 2024-03-26 2024-03-26 0001479681 nutx:PriorToReverseStockSplitMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001479681 us-gaap:ConvertibleDebtMember 2024-01-01 2024-06-30 0001479681 nutx:YorkvilleMember nutx:PrepaidAdvanceMember nutx:PrePaidAdvanceAgreementWithYorkvilleMember 2023-04-11 2023-04-11 0001479681 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001479681 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001479681 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001479681 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001479681 nutx:September302029ExpirationWarrantMember 2024-06-30 0001479681 nutx:October312029ExpirationWarrantMember 2024-06-30 0001479681 nutx:October312025ExpirationWarrantMember 2024-06-30 0001479681 nutx:October312025ExpirationWarrant2Member 2024-06-30 0001479681 nutx:November302029ExpirationWarrantMember 2024-06-30 0001479681 nutx:May312027ExpirationWarrantMember 2024-06-30 0001479681 nutx:July312026ExpirationWarrantMember 2024-06-30 0001479681 nutx:January252029ExpirationWarrantMember 2024-06-30 0001479681 nutx:February262026ExpirationWarrantMember 2024-06-30 0001479681 nutx:December312029ExpirationWarrantMember 2024-06-30 0001479681 nutx:December312024ExpirationWarrantMember 2024-06-30 0001479681 nutx:SecuritiesPurchaseAgreementMember 2024-01-22 0001479681 us-gaap:ConvertibleDebtMember nutx:September2023PrivateOfferingMember 2024-04-01 2024-06-30 0001479681 us-gaap:ConvertibleDebtMember nutx:September2023PrivateOfferingAsAmendedMember 2024-01-01 2024-06-30 0001479681 2023-01-01 2023-06-30 0001479681 2023-12-31 0001479681 2024-04-01 2024-06-30 0001479681 2024-06-30 0001479681 2024-08-05 0001479681 2024-01-01 2024-06-30 nutx:state nutx:Vote iso4217:USD shares nutx:segment shares nutx:employee iso4217:USD pure nutx:D nutx:item nutx:entity nutx:individual nutx:facility 0001479681 --12-31 2024 Q2 4511199 4987268 0.067 0.067 0.5 0.063 0.067 0.067 0.1 0.1 0.5 0.063 0.1 0.067 0.1 0.1 0.067 0.1 P10D P6Y 0.1 0.3333 0.067 0.1 0.1 0.1 0.5 0.063 0.1 0.067 0.1 0.1 0.067 0.1 false 10-Q

true 2024-06-30 false 001-41346 NUTEX HEALTH INC. DE 11-3363609 6030 S. Rice Ave Suite C Houston TX 77081 713 660-0557 Common Stock, $0.001 par value NUTX NASDAQ Yes Yes Accelerated Filer true false false 5065709 40807975 22002056 60658832 58624301 4577189 4152068 2759448 3390584 5066994 2679394 113870438 90848403 78881900 81387649 11690957 11853082 187096271 176146329 16180504 20512636 13918719 17066263 764462 431135 422403251 398245497 16742370 18899196 6796475 6382197 2909296 3371676 14223944 10808721 1998512 1579987 5570604 4315979 23417191 12955296 71658392 58313052 22406516 26314733 2000714 14690566 15479639 226820535 213886213 2804492 5145754 340381215 319139391 0.001 0.001 950000000 950000000 4987268 4511199 4988 4511 472529641 470521218 -409800662 -409072539 62733967 61453190 19288069 17652916 82022036 79106106 422403251 398245497 67604878 51611803 127634247 100899967 8477383 7312651 15901801 14353904 76082261 58924454 143536048 115253871 28398075 24860702 55401219 50697375 9505222 9747873 20824676 18937204 3588464 3264202 8910306 7288084 4532804 4169160 8719006 8162907 7496465 7235594 16962432 15673655 53521030 49277531 110817639 100759225 22561231 9646923 32718409 14494646 217266 -61241 249645 -12074 2149645 3473635 3473635 3197391 3197391 10652390 9759816 19310800 16935360 17262175 10009461 25969752 19302271 5299056 -362538 6748657 -4807625 5054532 4843048 9498894 7983137 3060096 5660843 599502 123528 840694 -123927 3904122 -5082058 3751300 -12914689 893892 -815612 1283557 -1726271 3010230 -4266446 2467743 -11188418 3374278 -787399 3195866 -2562092 -364048 -3479047 -728123 -8626326 -0.07 -0.79 -0.15 -1.98 -0.07 -0.79 -0.15 -1.98 4334826 4335 459144291 -363285925 24464699 120327400 4258133 4258133 4682 5 -5 6667 7 1899993 1900000 28000 28000 1537141 1537141 -5147279 -1774693 -6921972 4346175 4347 461044279 -368433204 16922732 109538154 3774 4 -4 53571 53 3232386 3232439 1431 1 249644 249645 621550 621550 1149163 1149163 -3479047 -787399 -4266446 4404951 4405 464526305 -371912251 15607720 108226179 4511199 4511 470521218 -409072539 17652916 79106106 746 2 19024 19026 444444 444 1540499 1540943 11824 12 320676 320688 49167 49167 1298 1 -1 2426 2 -2 481293 481293 -364075 -178412 -542487 4971937 4972 472450581 -409436614 16993211 80012150 -5060 -5 -30245 -30250 2061 2 14407 14409 17640 18 156140 156158 -61241 -61241 690 1 -1 300850 300850 1380270 1380270 -364048 3374278 3010230 4987268 4988 472529641 -409800662 19288069 82022036 2467743 -11188418 8719006 8162907 5660843 3197391 3473635 453017 -12074 2149645 -2341262 -1724111 579121 953236 -58211 -208423 61734 2148508 -6921239 425121 797058 -631136 -1082509 1692907 3048993 -1617151 -7189929 414278 3453 10481831 5619907 16310869 1064332 1291492 7446902 711306 1039157 -2002798 -8486059 132167 1949919 4915000 16952905 594547 1592714 6156543 7481893 1440016 1870670 9202500 300850 649550 1861563 2686304 4497848 5920793 18805919 -1500934 22002056 34255264 40807975 32754330 Note 1 - Organization and Operations Nutex Health Inc. (“Nutex Health” or the “Company”), is a physician-led, healthcare services and operations company with 21 hospital facilities in nine states (hospital division), and a primary care-centric, risk-bearing population health management division. Our hospital division implements and operates different innovative health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (“HOPDs”). The population health management division owns and operates provider networks such as independent physician associations (“IPAs”) and offers a cloud-based proprietary technology platform to IPAs which aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers. We employ approximately 800 full time employees, contract 230 doctors at our facilities and partner with over 1,700 physicians within our networks. Our corporate headquarters is based in Houston, Texas. We were incorporated on April 13, 2000 in the state of Delaware. Merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. On April 1, 2022, the merger (the “Merger”) of Nutex Health Holdco LLC and Clinigence Holdings, Inc. (“Clinigence”) was completed pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) entered on November 23, 2021 between Clinigence, Nutex Acquisition LLC, a Delaware limited liability company and wholly-owned subsidiary of Clinigence, Nutex, Micro Hospital Holding LLC (solely for the purposes of certain sections of the Merger Agreement), Nutex Health Holdco LLC and Thomas Vo, M.D., solely in his capacity as the representative of the equity holders of Nutex Health Holdco LLC. In connection with the Merger Agreement, Nutex Health Holdco LLC entered into certain Contribution Agreements with holders of equity interests (“Nutex Owners”) of subsidiaries and affiliates (the “Nutex Subsidiaries”) pursuant to which such Nutex Owners agreed to contribute certain equity interests in the Nutex Subsidiaries to Nutex Health Holdco LLC in exchange for specified equity interests in Nutex Health Holdco LLC (collectively, the “Contribution Transaction”). Nutex owners having ownership interests representing approximately 84% of the agreed upon aggregate equity value of the Nutex Subsidiaries, agreed to contribute all or a portion of their equity interests, as applicable. Pursuant to the Merger Agreement, each unit representing an equity interest in Nutex Health Holdco LLC issued and outstanding immediately prior to the effective time of the Merger but after the Contribution Transaction (collectively, the “Nutex Membership Interests”) was converted into the right to receive 3.571428575 shares of common stock of Clinigence, or an aggregate of 592,791,712 shares of common stock of Clinigence. After completing the merger, Clinigence was renamed Nutex Health Inc. 2024 Reverse Stock Splits. 1:15 Reverse stock split. The Company’s Board of Directors determined to effect a reverse stock split of the common stock at a 1-for-15 ratio (the “1:15 Reverse Stock Split”) effective as of 11:59 pm Eastern time on April 9, 2024. The stockholders of the Company at its annual meeting on June 29, 2023 had approved a reverse stock split within a range of 1:2 and 1:15 to be effected within one year of approval at the discretion of the Board. The Company’s common stock began trading on The Nasdaq Capital Market on a post-1:15 Reverse Stock Split basis under the Company’s existing trading symbol “NUTX” at the open of the market on April 10, 2024. The 1:15 Reverse Stock Split was implemented for the purpose of regaining compliance with the minimum bid price requirement for continued listing of the Company’s common stock on The Nasdaq Capital Market. 1:10 Reverse stock split. In addition, the Company’s Board of Directors determined to effect a reverse stock split of the common stock at a 1-for-10 ratio (the “1:10 Reverse Stock Split”) effective as of 11:59 pm Eastern time on July 2, 2024. The Company’s stockholders, at the annual meeting on June 17, 2024, had approved a reverse stock split within a range of 1:2 and 1:16 to be effected within one year of approval at the discretion of the Board. This 1:10 Reverse Stock Split is in addition to the Company’s previous 1:15 Reverse Stock Split as discussed above. The Company’s common stock began trading on The Nasdaq Stock Market on a post-1:10 Reverse Stock Split basis under the Company’s existing trading symbol “NUTX” at the open of the market on July 3, 2024. The 1:10 Reverse Stock Split was also implemented for the purpose of regaining compliance with the minimum bid price requirement for continued listing of the Company’s common stock on The Nasdaq Capital Market. As a result of both the 1:15 Reverse Stock Split and 1:10 Reverse Stock Split (collectively, the “2024 Reverse Stock Splits”) the number of shares of common stock outstanding was reduced to 4,987,268 shares as of June 30, 2024, inclusive of whole shares issued for fractional shares, and the number of authorized shares of common stock remains at 950,000,000. Unless otherwise indicated, all authorized, issued, and outstanding stock and per share amounts contained in the accompanying condensed consolidated financial statements have been adjusted to reflect the 2024 Reverse Stock Splits for all prior periods presented. Proportionate adjustments for the 2024 Reverse Stock Splits were made to the exercise prices and number of shares issuable under the Company’s equity incentive plans, and the number of shares underlying outstanding equity awards, as applicable. See Note 19 for information and disclosures relating to adjustments related to the 2024 Reverse Stock Splits. On July 24, 2024, Company received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Stock Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from July 3, 2024 to July 23, 2024, the closing bid price of the Company’s common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed. 21 9 800 230 1700 0.84 0.03571428575 592791712 4987268 950000000 Note 2 - Summary of Significant Accounting Policies Basis of presentation. These financial statements present the Company’s consolidated financial condition and results of operations including those of majority-owned subsidiaries and variable interest entities (“VIEs”) for which we are the primary beneficiary. The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the “Physician LLCs”) and real estate entities (the “Real Estate Entities”). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages. The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. The Company has no direct or indirect ownership interest in the consolidated Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interests in the consolidated balance sheets and statements of operations. Many of the Physician LLCs and Real Estate Entities are owned in part and in some cases controlled by related parties including members of our executive management team. The population health management division includes our management services organizations. In addition, Associated Hispanic Physicians of So. California (“AHISP”), an IPA entity that is not owned by us, but is consolidated as a VIE of our wholly-owned subsidiary AHP Health Management Services Inc. (“AHP”) because AHP is the primary beneficiary of its operations and has 100% control of AHISP’s operations through its management services agreement with AHISP. All significant intercompany balances and transactions have been eliminated in consolidation. Interim financial statements. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly,

they do not include all disclosures required by accounting principles generally accepted in the United States of America ("GAAP"). The unaudited condensed consolidated financial statements include all material adjustments of a normal recurring nature that, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. These interim financial statements should be read together with the consolidated financial statements and notes thereto included in our audited financial statements for the years ended December 31, 2023 and 2022. Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include (i) estimates of net revenue and accounts receivable, (ii) fair value of acquired assets and liabilities in business combinations and (iii) impairment of long-lived assets and goodwill. Actual results could differ from those estimates. Cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has cash amounts, that were at times material, held in covered banking institutions in excess of the insured amounts, but does not deem the risk of loss to be likely. The Company has $4.5 million in restricted cash as of June 30, 2024. The amounts included in restricted cash represent those required to be set aside either by note payable agreement or compensating balance requirements. Fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows: Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value. There were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented. Segment reporting. A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments - the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities. Reclassifications. Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation. Recent accounting pronouncements. In November 2023, the FASB issued Accounting Standards Update 2023-07, "Improvements to Reportable Segment Disclosures" ("ASU 2023-07"), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required only on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for our 2024 annual Consolidated Financial Statements and interim periods beginning in 2025. In December 2023, the FASB issued Accounting Standards Update 2023-09, "Improvements to Income Tax Disclosures" ("ASU 2023-09"), which provides for additional income tax rate reconciliation and income taxes paid disclosures. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are evaluating the impacts ASUs 2023-07 and 2023-09 will have on disclosures in our financial statements. Basis of presentation. These financial statements present the Company's consolidated financial condition and results of operations including those of majority-owned subsidiaries and variable interest entities ("VIEs") for which we are the primary beneficiary. The hospital division includes our healthcare billing and collections organization and hospital entities. In addition, we have financial and operating relationships with multiple professional entities (the "Physician LLCs") and real estate entities (the "Real Estate Entities"). The Physician LLCs employ the doctors who work in our hospitals. These entities are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to the Physician LLCs in the event of cash shortages. The Real Estate Entities own the land and hospital buildings which are leased to our hospital entities. The Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We consolidate the Real Estate Entities as VIEs in instances where our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. The Company has no direct or indirect ownership interest in the consolidated Physician LLCs or Real Estate Entities, so 100% of the equity for these entities is shown as noncontrolling interests in the consolidated balance sheets and statements of operations. Many of the Physician LLCs and Real Estate Entities are owned in part and in some cases controlled by related parties including members of our executive management team. The population health management division includes our management services organizations. In addition, Associated Hispanic Physicians of So. California ("AHISP"), an IPA entity that is not owned by us, but is consolidated as a VIE of our wholly-owned subsidiary AHP Health Management Services Inc. ("AHP") because AHP is the primary beneficiary of its operations and has 100% control of AHISP's operations through its management services agreement with AHISP. All significant intercompany balances and transactions have been eliminated in consolidation. 18 1 1 Interim financial statements. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Accordingly, they do not include all disclosures required by accounting principles generally accepted in the United States of America ("GAAP"). The unaudited condensed consolidated financial statements include all material adjustments of a normal recurring nature that, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. These interim financial statements should be read together with the consolidated financial statements and notes thereto included in our audited financial statements for the years ended December 31, 2023 and 2022. Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include (i) estimates of net revenue and accounts receivable, (ii) fair value of acquired assets and liabilities in business combinations and (iii) impairment of long-lived assets and goodwill. Actual results could differ from those estimates. Cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. The Company has cash amounts, that were at times material, held in covered banking institutions in excess of the insured amounts, but does not deem the risk of loss to be likely. The Company has $4.5 million in restricted cash as of June 30, 2024. The amounts included in restricted cash represent those required to be set aside either by note payable agreement or compensating balance requirements. 4500000 Fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. We classify fair value balances based on the classification of the inputs used to calculate the fair value of a transaction. The three levels related to fair value measurements are as follows: Level 1 — Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The estimated fair value of accounts receivable, accounts payable, accrued expenses and notes payable approximate the carrying amount due to the relatively short maturity or time to maturity of these instruments. Accounts receivable and payable with related parties may not be arms-length transactions and therefore, may not reflect fair value. There were no assets or liabilities that were re-measured at fair value on a non-recurring basis during the periods presented. Segment reporting. A public company is required to report descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet established criteria. The Company operates three reportable segments - the hospital division, the population health management division and the real estate division. The real estate division is comprised of the Real Estate Entities. 3 Reclassifications. Financial statements presented for prior periods include reclassifications that were made to conform to the current year presentation. Recent accounting pronouncements. In November 2023, the FASB issued Accounting Standards Update 2023-07, "Improvements to Reportable Segment Disclosures" ("ASU 2023-07"), which requires disclosures of significant expenses by segment and interim disclosure of items that were previously required only on an annual basis. ASU 2023-07 is to be applied on a retrospective basis and is effective for our 2024 annual Consolidated Financial Statements and interim periods beginning in 2025. In December 2023, the FASB issued Accounting Standards Update 2023-09, "Improvements to Income Tax Disclosures" ("ASU 2023-09"), which provides for additional income tax rate reconciliation and income taxes paid disclosures. ASU 2023-09 may be adopted on a prospective or retrospective basis and is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. We are evaluating the impacts ASUs 2023-07 and 2023-09 will have on disclosures in our financial statements.

 Note 3 – Divestitures Sale of Procare Health, Inc. On May 30, 2024, the Company completed the sale of Procare Health, Inc. ("Procare"), a wholly-owned subsidiary of Nutex, to an individual buyer. As consideration for the transaction, the buyer will pay the Company $0.6 million ($0.1 million paid in June 2024 and $0.1 million paid in July 2024), has assumed liabilities of $0.2 million and remitted Company stock of $0.1 million. During the second quarter of 2024, the Company recognized an intangible impairment of $2.1 million and a $3.2 million goodwill impairment loss. Upon completion of the sale, the Company recognized an insignificant loss on sale of business. The calculation of the loss on sale of business includes the derecognition of goodwill of $0.5 million, which is offset by consideration and other assets transferred. Total revenue for Procare for the three and six months ended June 30, 2024 is $0.1 million and $0.4 million, respectively. Net loss for Procare for the three and six months ended June 30, 2024 is $0.3 million and $0.6 million, respectively. The Company does not deem this transaction to be significant. Clinigence Health, Inc. and Letter of Intent. The Company signed a non-binding letter of intent ("LOI") with a third-party limited liability company to commence the negotiations for the sale of Clinigence Health, Inc. ("Clinigence Health"), a wholly-owned subsidiary of Nutex. The sale is expected to be completed in the third quarter of 2024. The Company recognized an impairment on definite-lived intangible assets of $1.4 million. The Company reclassified all assets of Clinigence Health to assets held-for-sale, within "Prepaid expenses and other current assets" in the condensed consolidated balance sheets. The value of the assets held-for-sale of $1.5 million are based on the LOI. Upon the reclassification of assets to held-for-sale, the Company recognized an insignificant loss. Total revenue for Clinigence Health for the three and six months ended June 30, 2024 is $0.3 million and $0.7 million, respectively. Net loss for Clinigence Health for the three and six months ended June 30, 2024 is $0.4 million and $0.7 million, respectively. The Company does not deem this transaction to be significant. 600000 100000 100000 200000 100000 2100000 3200000 500000 100000 400000 300000 -600000 1400000 1500000 300000 700000 400000 700000 Note 4 – Revenue We disaggregate revenue from contracts with customers into types of services or products, consistent with our reportable segments, as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:26.33%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:27.36%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"> Hospital division revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"> 67,604,878 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"> 51,611,803 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"> 127,634,247 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"> 100,899,967 </td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"> Population health management division revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,477,383 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

 7,312,651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,901,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,353,904 </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,082,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 58,924,454 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,536,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,253,871 </td></tr></table> . Hospital division revenue. We receive payment for facility services rendered by us from federal agencies, private insurance carriers, and patients. The Physician LLCs receive payment for doctor services from these same sources. On average, greater than 90% of our net patient service revenue is paid by insurers, federal agencies, and other non-patient third parties. The remaining revenue is paid by our patients in the form of copays, deductibles, and self-payment. We generally operate as an out-of-network provider and, as such, do not have negotiated reimbursement rates with insurance companies. For three and six months ended June 30, 2024, the Company recorded approximately $1.3 million and $2.1 million, respectively, of net revenue for cash collections for services that were previously reserved as uncollectible. The following tables present the allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:26.66%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:26.69%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.97%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#cceeff;margin:0pt;padding:0pt;"> Insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"> 93% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 93% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 92% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 93% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;margin:0pt;padding:0pt;"> Self pay </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"> 4% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> 4% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> 5% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> 4% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;margin:0pt;padding:0pt;"> Workers compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;margin:0pt;padding:0pt;"> Medicare/Medicaid </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:26.33%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:27.36%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"> Hospital division revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"> 67,604,878 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"> 51,611,803 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"> 127,634,247 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;margin:0pt;padding:0pt;"> 100,899,967 </td></tr><tr><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"> Population health management division revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,477,383 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,312,651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,901,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,353,904 </td></tr><tr><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">

76,082,261 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">58,924,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 143,536,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,253,871 </td></tr></table> 67604878 51611803 127634247 100899967 8477383 7312651 15901801 14353904 76082261 58924454 143536048 115253871 0.90 1300000 2100000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:26.66%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:26.69%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#cceeff;margin:0pt;padding:0pt;"> Insurance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"> 93% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 93% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 92% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 93% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;margin:0pt;padding:0pt;"> Self pay </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"> 4% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> 4% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> 5% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;margin:0pt;padding:0pt;"> 4% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#cceeff;margin:0pt;padding:0pt;"> Workers compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;margin:0pt;padding:0pt;"> 2% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;margin:0pt;padding:0pt;"> Medicare/Medicaid </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.56%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 100% </td></tr></table> 0.93 0.93 0.92 0.93 0.04 0.04 0.05 0.04 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 1 1 1 1 Note 5 - Property and Equipment The principal categories of property and equipment, net are summarized as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:15.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:top;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:14.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:49.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:11.69%;background:#ffffff;margin:0pt;padding:0pt;"> Useful </td><td style="vertical-align:top;white-space:nowrap;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.4%;background:#ffffff;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#ffffff;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:top;width:49.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:11.69%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Life (years) </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:17.4%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:16.1%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:49.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.55%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.13%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:15.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:14.23%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Buildings and improvements </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,611,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 18,947,818 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Land </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 4,410,747 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 4,401,888 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 10-39 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"> 27,931,959 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 27,606,383 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 2,951,145 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 3,776,138 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Medical equipment </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"> 33,844,363 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 33,519,026 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Office furniture and equipment </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 3,590,926 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 3,698,874 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Computer hardware and software </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"> 6,227,105 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 6,066,520 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Vehicles </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 94,726 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 135,590 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Signage </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,111,244 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,576,475 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Total cost </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;width:9.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 100,773,469 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 99,728,712 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Less: accumulated depreciation </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,891,569) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (18,341,063) </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Total property and equipment, net </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,881,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 81,387,649 </td></tr></table> . . . . . We consolidate two Real Estate Entities in the Company. Refer to Note 17. . Depreciation and amortization of property and equipment for the three months ended June 30, 2024 and 2023 totaled $1.6 million and $1.1 million, respectively, and for the six months ended June 30, 2024 and 2023 totaled $3.2 million and $2.4 million, respectively. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:2.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:9.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:15.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"> <div

style="position:absolute;top:0pt;width:100%;"> </td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:14.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:49.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:11.69%;background:#ffffff;margin:0pt;padding:0pt;"> Useful </td><td style="vertical-align:top;white-space:nowrap;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.4%;background:#ffffff;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#ffffff;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:top;width:49.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:11.69%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Life (years) </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:17.4%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:top;width:16.1%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;width:49.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.55%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.13%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:15.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:14.23%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Buildings and improvements </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 39 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,611,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 18,947,818 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Land </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 4,410,747 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 4,401,888 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 10-39 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"> 27,931,959 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 27,606,383 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 2,951,145 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 3,776,138 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Medical equipment </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"> 33,844,363 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 33,519,026 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Office furniture and equipment </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"> 7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 3,590,926 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 3,698,874 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Computer hardware and software </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"> 6,227,105 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;margin:0pt;padding:0pt;"> 6,066,520 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Vehicles </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"> 5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 94,726 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 135,590 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Signage </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,111,244 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,576,475 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Total cost </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:9.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> 100,773,469 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;margin:0pt;padding:0pt;"> 99,728,712 </td></tr><tr><td style="vertical-align:bottom;width:49.07%;background:#cceeff;margin:0pt;padding:0pt;"> Less: accumulated depreciation </td><td style="vertical-align:bottom;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (21,891,569) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (18,341,063) </td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"> Total property and equipment, net </td><td style="vertical-align:bottom;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,881,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 81,387,649 </td></tr></table> P39Y 19611254 18947818 4410747 4401888 P10Y P39Y 27931959 27606383 2951145 3776138 P10Y 33844363 33519026 P7Y 3590926 3698874 P5Y 6227105 6066520 P5Y 94726 135590 P10Y 2111244 1576475 100773469 99728712 21891569 18341063 78881900 81387649 2 1600000 1100000 3200000 2400000 Note 6 – Intangible Assets and Goodwill Intangible Assets. The following tables provide detail of the Company's intangible assets: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:33.49%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#ffffff;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#ffffff;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#ffffff;margin:0pt;padding:0pt;"> Net Carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> June 30, 2024 </td><td style="vertical-align:middle;width:2.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:12.95%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Carrying Amount </td><td style="vertical-align:top;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:13.83%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:top;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:13.83%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:top;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:16.91%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Useful Life (in years) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Amortizing intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> Member relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,491,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 2,632,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,858,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 474,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 321,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,965,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,784,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,180,504 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Amortizing intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> Member relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,491,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 2,015,772 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 16,475,228 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 15 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Management contracts </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> 2,021,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 221,047 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 1,799,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 16 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> Customer contracts </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> 914,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 106,633 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 807,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 15 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Trademarks </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> 1,426,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 262,557 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 1,164,238 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 7-12 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> PHP technology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 409,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 143,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 265,850 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 5 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,261,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,749,159 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,512,636 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Amortization of intangible assets for the three months ended June 30, 2024 and 2023 totaled $0.4 million each, and for the six months ended June 30, 2024 and 2023 totaled $0.8 million each. Certain intangible assets were impaired upon the sale of Procare and pending sale of Clinigence Health, recognized in the second quarter of 2024, totaling $3.5 million. See Note 3 for discussion over the sale of Procare and pending sale of Clinigence. Goodwill. The carrying amount of goodwill, by operating segment is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;white-space:nowrap;width:41.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:2.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:16.04%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Hospital Division </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:17.14%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Population Health Management Division </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:17.14%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,139,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> 415,201,301 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> 416,340,598 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated impairment losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,139,297) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (398,135,038) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (399,274,335) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,066,263 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Purchase accounting adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 502,864 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 502,864 </td></tr><tr><td style="vertical-align:bottom;width:41.4%;margin:0pt;padding:0pt;"> Impairment of goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> (3,197,391) </td></tr><tr><td style="vertical-align:bottom;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Derecognition of goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (453,017) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (453,017) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> Balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 1,139,297 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 415,251,148 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 416,390,445 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> Accumulated impairment losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,139,297) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (401,332,429) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (402,471,726) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,918,719 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,918,719 </td></tr></table> The purchase accounting adjustments of $0.5 million to the carrying amount of goodwill in the Population Health Management Division relates to the acquisition of two Florida based IPAs in the third quarter of 2023 for which the allocation of goodwill is subject to revision based on final allocation of the purchase price to the identifiable assets and liabilities acquired. The impairment of goodwill of $3.2 million and the derecognition of goodwill of $0.5 million, both for the Population Health Management Division, relate to the sale of Procare Health, Inc., a wholly-owned subsidiary of Nutex. Procare was considered part of the Population Health Management Division. Prior to the sale of Procare, the Company recognized a goodwill impairment amount of $3.2 million. On the sale of Procare, the Company recognized the derecognition of goodwill of $0.5 million based on the remaining carrying amount of goodwill for the Procare business after impairment. See Note 3 for Procare sale. Due to the sale of Procare, the Company tested for impairment the remaining goodwill in the Population Health Management Division of $13.9 million. On June 30, 2024, we determined that the estimated fair value of our Population Health Management Division was greater than its carrying value. Therefore, no goodwill impairment was recognized for the quarter ended and year ended June 30, 2024. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:33.49%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.95%;background:#ffffff;margin:0pt;padding:0pt;"> Gross </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#ffffff;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;background:#ffffff;margin:0pt;padding:0pt;"> Net Carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.91%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> June 30, 2024 </td><td style="vertical-align:middle;width:2.07%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:12.95%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Carrying Amount </td><td style="vertical-align:top;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:13.83%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Amortization </td><td style="vertical-align:top;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:13.83%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:top;width:2.29%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:16.91%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Useful Life (in years) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Amortizing intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> Member relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,491,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 2,632,136 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,858,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Trademarks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 474,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 152,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 321,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,965,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,784,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-

align:bottom;white-space:nowrap;width:11.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,180,504 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Amortizing intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> Member relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,491,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 2,015,772 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 16,475,228 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 15 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Management contracts </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> 2,021,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 221,047 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 1,799,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 16 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> Customer contracts </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"> 914,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 106,633 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"> 807,367 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 15 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Trademarks </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;margin:0pt;padding:0pt;"> 1,426,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 262,557 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;margin:0pt;padding:0pt;"> 1,164,238 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> 7-12 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;margin:0pt;padding:0pt;"> PHP technology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 409,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 143,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 265,850 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 5 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.49%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,261,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,749,159 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,512,636 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 18491000 2632136 15858864 P15Y 474000 152360 321640 P7Y P7Y 18965000 2784496 16180504 18491000 2015772 16475228 P15Y 2021000 221047 1799953 P16Y 914000 106633 807367 P15Y 1426795 262557 1164238 P7Y P12Y 409000 143150 265850 P5Y 23261795 2749159 20512636 400000 400000 800000 800000 3500000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:2.53%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:16.04%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Hospital Division </td><td style="vertical-align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:17.14%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Population Health Management Division </td><td style="vertical-

align:top;width:2.86%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:17.14%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,139,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> 415,201,301 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 416,340,598 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated impairment losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,139,297) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (398,135,038) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (399,274,335) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,066,263 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 17,066,263 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Purchase accounting adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 502,864 </td></tr><tr><td style="vertical-align:bottom;width:41.4%;margin:0pt;padding:0pt;"> Impairment of goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> (3,197,391) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> (3,197,391) </td></tr><tr><td style="vertical-align:bottom;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Derecognition of goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (453,017) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt;"> (453,017) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> Balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 1,139,297 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 415,251,148 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"> 416,390,445 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;margin:0pt;padding:0pt;"> Accumulated impairment losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,139,297) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (401,332,429) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (402,471,726) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,918,719 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,918,719 </td></tr></table> 1139297 415201301 416340598 1139297 398135038 399274335 17066263 17066263 502864 502864 3197391 3197391 453017 453017 1139297 415251148 416390445 1139297 401332429 402471726 13918719 13918719 500000 2 3200000 500000 3200000 500000 13900000 0 Note 7 - Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.46%;background:#fffffc;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.46%;background:#fffffc;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:18.46%;background:#fffffc;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:18.46%;background:#fffffc;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.37%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:16.08%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#fffffc;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.37%;background:#fffffc;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;width:16.08%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued wages and benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,426,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 6,590,710 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> Accrued supplier expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 3,920,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 2,504,544 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued medical insurance claims </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 2,293,873 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 1,865,280 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> Accrued taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 4,824,866 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 405,352 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,951,623 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,589,410 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,417,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,955,296 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.46%;background:#ffffff;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.46%;background:#ffffff;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;width:18.46%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:18.46%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.37%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:16.08%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.37%;background:#ffffff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;width:16.08%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued wages and benefits </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,426,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 6,590,710 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> Accrued supplier expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 3,920,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 2,504,544 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued medical insurance claims </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 2,293,873 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;margin:0pt;padding:0pt;"> 1,865,280 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> Accrued taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 4,824,866 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 405,352 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,951,623 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,589,410 </td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"> Total accrued expenses and other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,417,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 12,955,296 </td></tr></table> . 8426753 6590710 3920076 2504544 2293873 1865280 4824866 405352 3951623 1589410 23417191 12955296 Note 8 – Debt . The Company's outstanding debt is shown in the following table: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.89%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:43.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:13.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:12.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:top;width:12.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.09%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#ffffff;margin:0pt;padding:0pt;"> Maturity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#ffffff;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;background:#ffffff;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;background:#ffffff;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:top;white-

space:nowrap;width:43.09%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:13.05%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Dates </td><td style="vertical-align:top;white-space:nowrap;width:1.72%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.98%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Rates </td><td style="vertical-align:top;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:14.21%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:14.21%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:43.09%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:13.05%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:1.72%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.98%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:12.35%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Term loans secured by all assets </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 07/2024 - 10/2027 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4.15 - 7.71% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,077,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 7,030,613 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Term loans secured by property and equipment </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> 07/2024 - 10/2028 </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> 3.59 - 10.00% </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 9,408,077 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 10,562,207 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Term loan secured by deposits </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 07/2024 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 7.36% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 2,801,354 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Line of credit secured by all assets </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> 07/2024 - 09/2024 </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> 4.00 - 9.50% </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 2,909,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 3,371,675 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Term loans of consolidated Real Estate Entities </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 05/2028 - 03/2037 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 2.84 - 5.75% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 12,361,238 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 13,005,019 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Unsecured convertible term notes </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> 10/2025 </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> 8.00 - 10.00% </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 5,384,990 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;text-align:right;margin:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 5,384,990 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Pre-paid advance (convertible debt) </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 03/2024 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 0.00% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,078,302 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:top;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 40,942,087 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 42,432,806 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Less: unamortized issuance costs and discount </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 1,402,331 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 1,937,676 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Less: short-term lines of credit </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 2,909,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 3,371,676 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Less: current portion of long-term debt </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,223,944 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,808,721 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Total long-term debt </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,406,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26,314,733 </td></tr></table> Term loans and lines of credit. We have entered into private debt arrangements with banking institutions for the purchase of equipment and to provide working capital and liquidity through cash and lines of credit. Unless otherwise delineated above, these debt arrangements are obligations of Nutex and/or its majority-owned subsidiaries. Consolidated Real Estate Entities have entered into private debt arrangements with banking institutions for purposes of purchasing land, constructing new emergency room facilities and building out leasehold improvements which are leased to our hospital entities. Nutex is a guarantor or, in limited cases, a co-borrower on the debt arrangements of the Real Estate Entities for the periods shown. Since the second quarter of 2022, we have deconsolidated 18 Real Estate Entities after the third-party lenders released our guarantees of associated mortgage loans. Certain outstanding debt arrangements require minimum debt service coverage ratios and other financial covenants. At June 30, 2024, we were not in compliance with the debt service coverage ratio for one term loan with an outstanding balance of $0.1 million. This balance has been included in current liabilities. At June 30, 2024, we had remaining availability of $2.6 million under outstanding lines of credit. Pre-Paid Advance Agreement (convertible debt). On April 11, 2023, the Company entered into a Pre-Paid Advance Agreement (the "PPA") with YA II PN, Ltd. ("Yorkville") pursuant to which the Company requested an advance of $15.0 million from Yorkville a "Pre-Paid Advance") purchased by Yorkville at 90% of the face amount. Interest accrued on the outstanding balance of the Pre-Paid Advance at an annual rate equal to 0% subject to an increase to 15% upon events of default described in the PPA. The Pre-Paid Advance has a maturity date of 12 months from the Pre-Paid Advance Date. The Company, at its option, has the right, but not the obligation, to repay early in cash a portion or all amounts outstanding under any Pre-Paid Advance, provided that the VWAP of the Common Stock is less than the Fixed Price during a period of ten consecutive trading days immediately prior to the date on which the Company delivers a notice to Yorkville of its

intent and such notice is delivered at least 10 trading days prior to the date on which the Company will make such payment (“Optional Prepayment”). If elected, the Optional Prepayment includes a 6% payment premium (“Payment Premium”). On April 11, 2023, the Company requested a $15.0 million initial Pre-Paid Advance in accordance with the PPA. The net proceeds of $13.5 million received by the Company from Yorkville reflect a 10% discount of $1.5 million in accordance with the PPA. Additionally, in connection with the PPA, the Company incurred $0.9 million in placement and legal fees, which the Company classifies as debt issuance costs. The discount and the debt issuance costs are reported as a direct deduction from the face amount of the PPA and are amortized monthly based on the effective interest rate method. The amortization of the discount and debt issuance costs are reported as interest expense in the condensed consolidated statements of operations. As a result of the Pre-Paid Advance, the Company (i) issued 0.2 million shares of common stock to Yorkville (23.1 million prior to the 2024 Reverse Stock Splits), reducing the principal of initial Pre-Paid Advance to $7.3 million, (ii) made Optional Prepayments of $8.2 million in accordance with the PPA, consisting of $7.7 million of principal and $1.0 million attributed to the Payment Premium and (iii) paid off in full the remaining outstanding balance of the PPA on January 30, 2024 and the parties terminated the Yorkville PPA on February 15, 2024. September 2023 Convertible Debt Issuance. From September 2023 to December 2023, the Company conducted a private offering of convertible notes (“Unsecured Convertible Term Notes”) and six-year warrants (“Warrants”) to accredited investors (the “Holders”) as defined in Rule 501 under the 1933 Act and issued Unsecured Convertible Term Notes convertible into an aggregate of 89,751 shares (13,462,500 prior to the 2024 Reverse Stock Splits) of common stock at a conversion price of $60.00 per share ($0.40 prior to the 2024 Reverse Stock Splits) and Warrants to purchase an aggregate of 44,875 shares of common stock (6,731,250 prior to the 2024 Reverse Stock Splits) at an exercise price of $60.00 per share ($0.40 prior to the 2024 Reverse Stock Splits). We also issued Warrants for the purchase of 26,925 shares (4,038,750 prior to the 2024 Reverse Stock Splits) to the placement agent. The Unsecured Convertible Term Notes mature on October 31, 2025 and the Warrants expire on December 31, 2029. On March 26, 2024, the Company and the Holders agreed to amend the conversion price of the Unsecured Convertible Term Notes and exercise price of the Warrants to $30.00 each ($0.20 prior to the 2024 Reverse Stock Splits), resulting in the Unsecured Convertible Term Notes being convertible into 179,500 shares of common stock (26,925,000 prior to the 2024 Reverse Stock Splits), the Warrants exercisable for 89,750 shares of common stock (13,462,500 prior to the 2024 Reverse Stock Splits) and the placement agent Warrants exercisable for 53,850 shares of common stock (8,077,500 prior to the 2024 Reverse Stock Splits). The Unsecured Convertible Term Notes bear an annual interest rate of 8% if paid in cash or an annual interest rate of 10% if paid in the form of common stock. The payment of interest in the form of common stock is at the discretion of the Company. When paid in common stock, the number of shares is equal to the quotient of the total accrued interest due divided by the last reported sale price of the Company’s common stock on the last complete trading day of such quarter. The Holders have the option, at any time, to convert all or any portion of the unpaid principal and interest outstanding in common stock at the conversion price of $30.00 per share. If the Company fails to pay the outstanding principal amount and all accrued interest within 30 days of the maturity date, the interest rate payable is adjusted to 12%. The Company appointed Emerson Equity LLC as placement agent for the September 2023 Private Offering. Per the Placement Agent Agreement, the Company agrees to pay (i) a cash commission equal to 10% of the gross proceeds and (ii) warrants to purchase a number of Common Stock equal to 20% of the total number of shares issuable upon conversion or exercise of the Unsecured Convertible Term Notes and Warrants, as applicable. The net carrying amount of the Unsecured Convertible Term Notes was $4.0 million as of June 30, 2024 and the weighted average effective interest rate on the convertible debt is 21.5%. The Unsecured Convertible Term Notes interest expense was $0.3 million for the three months ending June 30, 2024, comprising of $0.2 million in amortization expense and $0.1 million in accrued interest expense. For the six months ended June 30, 2024 interest expense was $0.6 million, comprising of $0.4 million in amortization expense and $0.2 million in accrued interest expense. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:27.94%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.89%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:43.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:13.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:12.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.09%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.05%;background:#ffffff;margin:0pt;padding:0pt;"> Maturity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#ffffff;margin:0pt;padding:0pt;"> Interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;background:#ffffff;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;background:#ffffff;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:43.09%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:13.05%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Dates </td><td style="vertical-align:top;white-space:nowrap;width:1.72%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.98%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Rates </td><td style="vertical-align:top;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:14.21%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;width:14.21%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:43.09%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-

align:center;margin:0pt;"> </td><td style="vertical-align:top;width:13.05%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:1.72%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:9.98%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:12.35%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:12.35%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Term loans secured by all assets </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 07/2024 - 10/2027 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4.15 - 7.71% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,077,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 7,030,613 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Term loans secured by property and equipment </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> 07/2024 - 10/2028 </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> 3.59 - 10.00% </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 9,408,077 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 10,562,207 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Term loan secured by deposits </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 07/2024 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 7.36% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 2,801,354 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Line of credit secured by all assets </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> 07/2024 - 09/2024 </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> 4.00 - 9.50% </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 2,909,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 3,371,675 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Term loans of consolidated Real Estate Entities </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 05/2028 - 03/2037 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 2.84 - 5.75% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 12,361,238 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 13,005,019 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Unsecured convertible term notes </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> 10/2025 </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> 8.00 - 10.00% </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 5,384,990 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 5,384,990 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Pre-paid advance (convertible debt) </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> 03/2024 </td><td style="vertical-align:top;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> 0.00% </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-

align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,078,302 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:top;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 40,942,087 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 42,432,806 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Less: unamortized issuance costs and discount </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 1,402,331 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;margin:0pt;padding:0pt;"> 1,937,676 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Less: short-term lines of credit </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 2,909,296 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;margin:0pt;padding:0pt;"> 3,371,676 </td></tr><tr><td style="vertical-align:top;width:43.09%;background:#cceeff;margin:0pt;padding:0pt;"> Less: current portion of long-term debt </td><td style="vertical-align:bottom;width:13.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,223,944 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,808,721 </td></tr><tr><td style="vertical-align:top;width:43.09%;margin:0pt;padding:0pt;"> Total long-term debt </td><td style="vertical-align:bottom;width:13.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,406,516</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 26,314,733 </td></tr></table> 0.0415 0.0415 0.0771 0.0771 8077132 7030613 0.0359 0.0359 0.1000 0.1000 9408077 10562207 0.0736 0.0736 2801354 0.0400 0.0400 0.0950 0.0950 2909296 3371675 0.0284 0.0284 0.0575 0.0575 12361238 13005019 0.0800 0.0800 0.1000 0.1000 5384990 5384990 0.0000 0.0000 3078302 40942087 42432806 1402331 1937676 2909296 3371676 14223944 10808721 22406516 26314733 18 18 18 100000 2600000 15000000.0 0.90 0 0.15 P12M 10 0.06 15000000.0 13500000 0.10 1500000 900000 200000 23100000 7300000 8200000 7700000 1000000.0 89751 13462500 60.00 0.40 44875 6731250 60.00 0.40 26925 4038750 30.00 0.20 179500 26925000 89750 13462500 53850 8077500 0.08 0.10 30.00 P30D 0.12 0.10 0.20 4000000.0 0.215 300000 200000 100000 600000 400000 200000 Note 9 – Leases We have entered into hospital property, office and equipment rental agreements with various lessors including related parties. The following tables disclose information about our leases of property and equipment: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:26.2%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:26.38%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 569,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 938,502 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,213,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,887,017 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease cost: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> Amortization of right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,453,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 2,547,035 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,679,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 5,031,310 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#cceeff;margin:0pt;padding:0pt;"> Interest on lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,116,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,826,321 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,516,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,514,841 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> Total finance lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,569,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,373,356 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,195,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,546,151 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:26.2%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30,

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:26.38%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 569,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 938,502 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,213,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,887,017 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#cceeff;margin:0pt;padding:0pt;"> Finance lease cost: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> Amortization of right-of-use assets </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,453,351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;margin:0pt;padding:0pt;"> 2,547,035 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,679,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 5,031,310 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;background:#cceeff;margin:0pt;padding:0pt;"> Interest on lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,116,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,826,321 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,516,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,514,841 </td></tr><tr><td style="vertical-align:bottom;width:42.92%;margin:0pt;padding:0pt;"> Total finance lease cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,569,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,373,356 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,195,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,546,151 </td></tr></table> 569222 938502 1213920 1887017 2453351 2547035 4679021 5031310 4116174 2826321 7516401 5514841 6569525 5373356 12195422 10546151 Note 10 – Commitments and Contingencies Litigation. From time to time, the Company, its consolidated subsidiaries or VIEs may be named in various claims and legal actions in the normal course of business. Based upon counsel and management's opinion, the outcome of such matters is not expected to have a material adverse effect on the consolidated financial statements. Note 11 – Stock-based Compensation In 2023, the stockholders of the Company approved the Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan (the "2023 Plan"), providing a total of 73,426 shares of Common Stock (11,013,943 prior to the 2024 Reverse Stock Splits) for issuance. Awards granted under the 2023 Plan may be incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units or performance shares. The awards are granted at an exercise price equal to the fair market value on the date of grant. The 2023 Plan is subject to annual increases on January 1st of each calendar year through January 1, 2033 of up to 1% of the issued and outstanding shares of the Company's Common Stock on the final day of the preceding calendar year, at the discretion of the compensation committee of our Board of Directors. During the second quarter of 2024, the number of shares to be issued under the 2023 Plan increased to 118,563 shares, most of which were issued as restricted stock units in June 2024, as discussed below. Obligations for under-construction and ramping hospitals. Under the terms of the Contribution Agreements, contributing owners of the under-construction hospitals and ramping hospitals are eligible to receive a one-time additional issuance of Company common stock. <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">With respect to ramping hospitals that were acquired before the Merger, 24 months after the opening date (the "Determination Date") of the applicable ramping hospital, such owner is eligible to receive such owner's pro rata share of a number of shares of Company Common Stock equal to (i) the trailing twelve months earnings before interest, taxes, depreciation and amortization on the respective Determination Date, multiplied by (ii) 10, (iii) minus the initial equity value received at the Closing of the Merger, and (iv) minus such owner's pro rata share of the aggregate debt of the applicable ramping hospital outstanding as of the closing of the Merger. The number of additional shares to be issued will be determined based on the greater of (a) the price of the Company's common stock at the time of determination or (b) $2.80 ($420.00 after the 2024 Reverse Stock Splits), as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to the Company's common stock.</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">With respect to under construction hospitals that were acquired before the Merger, contributing owners of under construction hospitals will be eligible to receive, on the Determination Date, such owner's pro rata share of a number of shares of Company common stock equal to (a)(i) the trailing twelve months earnings before interest, taxes, depreciation and amortization as of the Determination Date multiplied by (ii) 10, minus (iii) the aggregate amount of such owner's capital contribution to the under construction hospital, minus (iv) such owner's pro rata share of the aggregate debt of the applicable under construction hospital outstanding as of the Closing of the Merger, divided by (b) the greater of (i) the price of the Company common stock at the time of determination or (ii) $2.80 ($420.00 after the 2024 Reverse Stock Splits), as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to the Company's common stock.</td></tr></table> We recognized a credit adjustment to prior accrued stock-based compensation expense for three and six months ended June 30, 2024 of $0.1 million based on our current estimates of future obligations to the contributing owners. <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"> Options. The following table summarizes stock-based awards activity: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Remaining Contractual </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;background:#ffffff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Options outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 34,318 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 345.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 7.60 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Options cancelled </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Options outstanding at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,318 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 345.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.10</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 335.75 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 6.94 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Options cancelled </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Options outstanding at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,590 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 335.75 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#ccceff;margin:0pt;padding:0pt;"> 6.06 </td></tr></table> Options outstanding as of June 30, 2024 consisted of: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> Expiration </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Exercise </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Date </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Exercisable </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Price </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 686 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 686 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> January 21, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 241.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 21, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 412.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> January 27, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> May 11, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 1,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> June 9, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 167 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 167 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 376.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 28, 2028 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 241.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> August 4, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 68 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 68 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 834.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 27, 2030 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 1,157 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,157 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> June 30, 2030 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt

0pt;">715 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 217.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 28, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 6,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 6,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 241.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> February 28, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 1,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 1,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 300.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> September 9, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 12,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 12,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 412.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> December 17, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 501 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 501 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 525.00 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,590 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,590 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Restricted Stock Units. On April 1, 2023, the Company issued 4,035 Restricted Stock Units ("RSUs") (604,158 prior to the 2024 Reverse Stock Splits), valued at $0.6 million to certain employees. Total of 1,431 RSUs (214,720 prior to the 2024 Reverse Stock Splits) vested on April 1, 2023 and another 1,298 RSUs (194,720 prior to the 2024 Reverse Stock Splits) vested on March 1, 2024. The remaining 1,306 RSUs (194,720 prior to the 2024 Reverse Stock Splits) will vest on March 1, 2025. On June 16, 2024, the Company issued 118,538 RSUs (1,184,946 prior to the 1:10 Reverse Stock Split) valued at $0.6 million to certain employees participating in the Company's long-term incentive program. 39,514 RSUs will vest on March 1, 2025, 39,514 RSUs will vest on March 1, 2026, and 39,510 will vest on March 1, 2027. For grants of restricted stock units, we recognize compensation expense over the applicable vesting period equal to the fair value of our common stock at grant date. Grants of restricted stock units generally vest one third per year on each of the first three anniversaries of the grant date. The following table summarizes the changes in restricted stock units during the six months ended June 30, 2024 and 2023. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:23.54%;background:#ffffff;border-bottom:1.5pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Shares
(in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;border-top:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;width:17.88%;background:#ffffff;border-bottom:1.5pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted Average Grant-Date Fair Value Per Share </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested awards, December 31, 2022 </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">151.50</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">151.50</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested awards, June 30, 2023</p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"> 118 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 5.40 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested awards, June 30, 2024 </td><td style="vertical-

align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 120 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 39.98 </td></tr></table> As of June 30, 2024, we estimate $0.8 million of unrecognized compensation cost related to restricted stock units issued to our employees to be recognized over the weighted-average vesting period of 1.8 years. Employee Stock Purchase Plan. In May 2023, the Board of Directors adopted the 2023 Employee Stock Purchase Plan (“2023 ESPP”), which was subsequently approved by the Company’s stockholders and became effective in June 2023. The 2023 ESPP authorizes the initial issuance of up to 33,333 shares (5,000,000 prior to the 2024 Reverse Stock Splits) of the Company’s common stock to eligible employees, who are entitled to purchase shares of common stock equal to 85% of the closing price on the purchase date with accumulated payroll deductions. During the three and six months ended June 30, 2024, the Company issued 2,061 shares and 2,807 shares, respectively, under the ESPP. The expense incurred for the three and six months ended June 30, 2024 was $0.1 million each. 73426 11013943 0.01 118563 10 2.80 420.00 10 2.80 420.00 100000 100000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Remaining Contractual </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Life (Years) </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Options outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 34,318 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 345.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.60</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;">Options outstanding at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 345.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 7.10 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;">Options outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 27,590 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 335.75 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 6.94 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Options cancelled </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Options outstanding at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,590 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.06</p></td></tr></table> 34318 345.00 P7Y7M6D 34318 345.00 P7Y1M6D 27590 335.75 P6Y11M8D 27590 335.75 P6Y21D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</p></td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</p></td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercisable</p></td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited</p></td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:top;white-space:nowrap;width:15.36%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 21, 2025</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">686</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> January 21, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt

0pt;">300 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 241.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 21, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 1,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 412.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> January 27, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> May 11, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 1,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,401 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> June 9, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 167 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 167 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 376.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 28, 2028 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 241.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> August 4, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 68 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 68 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 834.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 27, 2030 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 1,157 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt

3pt 0pt 0pt;">1,157 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 225.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> June 30, 2030 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 715 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 217.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 28, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 6,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 6,667 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 241.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> February 28, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 1,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 1,333 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 300.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> September 9, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 12,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 12,781 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 412.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> December 17, 2031 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 501 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 501 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 525.00 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,590 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,590 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 686 686 225.00 300 300 241.50 1214 1214 412.50 300 300 225.00 1401 1401 225.00 167 167 376.50 300 300 241.50 68 68 834.00 1157 1157 225.00 715 715 217.50 6667 6667 241.50 1333 1333 300.00 12781 12781 412.50 501 501 525.00 27590 27590 4035 604158 600000 1431 214720 1298 194720 1306 194720 118538 1184946 600000 39514 39514 39510 3 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><div

*style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:23.54%;background:#ffffff;border-bottom:1.5pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Shares
(in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;border-top:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:17.88%;background:#ffffff;border-bottom:1.5pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"> Weighted Average Grant-Date Fair Value Per Share </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested awards, December 31, 2022 </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">151.50</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">151.50</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested awards, June 30, 2023</p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"> Non-vested awards, December 31, 2023 </td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">151.50</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.40</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested awards, December 31, 2024</p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"> 118 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 5.40 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;margin:0pt;padding:0pt;"> Non-vested awards, December 31, 2025 </td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">151.50</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.40</p></td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vested</p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-vested awards, December 31, 2026</p></td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;margin:0pt;padding:0pt;"> 118 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 5.40 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:50.91%;margin:0pt;padding:0pt;"> Non-vested awards, December 31, 2027 </td><td style="vertical-align:bottom;width:4.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;

space:nowrap;width:14.42%;margin:0pt;padding:0pt;"> 151.50 </td></tr><tr><td style="vertical-align:bottom;width:50.91%;background:#cceeff;margin:0pt;padding:0pt;"> Non-vested awards, June 30, 2024 </td><td style="vertical-align:bottom;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:19.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 120 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.42%;background:#cceeff;margin:0pt;padding:0pt;"> 39.98 </td></tr></table> 4000 151.50 1000 151.50 3000 151.50 3000 151.50 118000 5.40 1000 151.50 120000 39.98 800000 P1Y9M18D 33333 5000000 0.85 2061 2807 100000 100000 Note 12 – Equity We are authorized to issue up to a total of 950,000,000 shares of common stock having a par value of $0.001 per share. Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and to receive ratably in proportion to the shares of common stock held by them any dividends declared from time to time by the board of directors. Our common stock has no preferences or rights of conversion, exchange, pre-exemption or other subscription rights. Common Stock Issued. Following is a discussion of common stock issuances during the periods presented. Securities Purchase Agreement. On January 22, 2024, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with a single healthcare focused institutional investor for the sale by the Company of 444,445 shares (66,666,666 prior to 2024 Reverse Stock Splits) of the Company's common stock, par value $0.001 per share, and warrants to purchase 444,445 shares (66,666,666 prior to the 2024 Reverse Stock Splits) of the Company's common stock. The shares and the warrants were issued separately and issued on a one-to-one ratio at a public offering price of $22.50 per share and accompanying warrant ($0.15 prior to the 2024 Reverse Stock Splits). The Warrants have an exercise price of $22.50 per share ($0.15 prior to the 2024 Reverse Stock Splits), are exercisable immediately upon issuance and expire five years from the Closing Date. The Warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained therein is not available for, the issuance or resale of shares of common stock underlying the Warrants to or by the holder. The holder of a Warrant is prohibited from exercising any such warrants to the extent that such exercise would result in the number of shares of common stock beneficially owned by such holder and its affiliates exceeding 4.99% (or, upon election by the holder prior to the issuance of any Warrants, 9.99%) of the total number of shares of common stock outstanding immediately after giving effect to the exercise. In the event of certain fundamental transactions, the holder of the Warrants will have the right to receive the Black Scholes Value of its Warrants calculated pursuant to a formula set forth in the Form of Warrant, payable either in cash or in the same type or form of consideration that is being offered and being paid to the holders of common stock. The gross proceeds to the Company from the offering were $9.2 million after deducting the placement agent's fees and other offering expenses of $0.8 million. The allocation of the proceeds was $7.7 million to warrant liability and $1.5 million to additional paid-in capital. The Company used the Black-Scholes option model to compute the fair value (level 3) of the Warrants, with inputs including volatility (approximately 120%) and risk-free rate based on US Treasury yield curve rates. The Company classified the Warrants as liabilities due to certain contractual provisions and recorded $7.7 million in warrant liability on January 25, 2024. On June 30, 2024, the Company remeasured the Warrants and recognized a $3.1 million gain on warrant liability as the fair value of the Warrants was $2.0 million at June 30, 2024. For the six months ended June 30, 2024, the Company recognized $5.7 million gain on warrant liability. Under the Purchase Agreement, if the Company, at any time while the Warrants are outstanding, combines (including by way of reverse share split) outstanding shares of common stock into a smaller number, then, on the tenth trading day following, the exercise price will be reduced, and only reduced, to the lesser of (i) the then exercise price and (ii) 100% of the average of the volume weighted average prices for the ten trading day period immediately following. On April 26, 2024, as required under the terms of the Purchase Agreement in response to the 1:15 Reverse Stock Split, the exercise price was reduced from $2.25 per share to $0.68 per share based on a calculation based on the Company's trading price as set forth in the Purchase Agreement. On July 23, 2024, in response to the 1:10 Reverse Stock Split, the exercise price was reduced from $6.80 per share to $5.34 per share. Warrants. During the three and six months ended June 30, 2024, as part of the Securities Purchase Agreement, the Company issued warrants to purchase 444,445 shares (66,666,666 prior to 2024 Reverse Stock Splits) of Common Stock at a strike price of $22.50 ($0.15 prior to the 2024 Reverse Stock Splits) for a period of five years. These warrants were outstanding but not yet exercised as of June 30, 2024. Additionally, on March 26, 2024, the Company agreed to amend the conversion price of the Unsecured Convertible Term Notes and exercise price of the related warrants to $30.00 each, resulting in an increase in warrants of 71,801 shares (10,770,000 prior to the 2024 Reverse Stock Splits). Warrant activity follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Remaining Contractual </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Life (years) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 73,553 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 294.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.80</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,750.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 302.46 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 3.26 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 135,537 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.42</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrants issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 444,445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;">Warrants amended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 651,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 40.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 4.91 </td></tr></table> Warrants outstanding as of June 30, 2024 consisted of: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> Expiration </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Exercise </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Date </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Exercisable </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Price </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 3,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,000.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> October 31, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 108 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 108 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 187.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> October 31, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 10,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 10,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 232.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> February 26, 2026 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 1,922 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 1,922 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 600.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> July 31, 2026 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 16,888 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 16,888 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 232.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> May 31, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 30,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 30,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 262.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> September 30,

2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 444,445 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 444,445 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 6.80 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> October 31, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 16,501 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 16,501 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> November 30, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 57,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 57,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> December 31, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 5,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 5,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> January 25, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 64,683 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 64,683 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 651,783 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 651,783 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr></table> 950000000 0.001 1 444445 66666666 0.001 444445 66666666 1 22.50 0.15 22.50 0.15 P5Y 0.0499 0.0999 9200000 800000 7700000 1500000 120 7700000 3100000 2000000.0 5700000 1 10 2.25 0.68 6.80 5.34 444445 66666666 22.50 0.15 P5Y 30.00 71801 10770000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> <div

style="position:absolute;top:0pt;width:100%;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Remaining Contractual </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Life (years) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 73,553 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 294.16 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 3.80 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Warrants exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> (9,710) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 232.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants expired </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (20) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 3,750.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Warrants outstanding at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 63,823 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 302.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.26</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 158.16 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 4.42 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants issued </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 444,445 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 6.80 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Warrants amended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 71,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 30.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants outstanding at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 651,783 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 40.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 4.91 </td></tr></table> 73553 294.16 P3Y9M18D 9710 232.50 20 3750.00 63023 302.46 P3Y3M3D 135537 158.16 P4Y5M1D 444445 6.80 71801 30.00 651783 40.83 P4Y10M28D <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> Expiration </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.53%;background:#ffffff;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#ffffff;margin:0pt;padding:0pt;"> Number </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.24%;background:#ffffff;margin:0pt;padding:0pt;"> Exercise </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Date </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.53%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:14.08%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Exercisable </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:18.24%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Price </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:40.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.16%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:15.51%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.71%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:11.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:3.01%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 3,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 1,000.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> October 31, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 108 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 108 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 187.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> October 31, 2025 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 10,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 10,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 232.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> February 26, 2026 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 1,922 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 1,922 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 600.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> July 31, 2026 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 16,888 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 16,888 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 232.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> May 31, 2027 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 30,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 30,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 262.50 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> September 30, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 444,445 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 444,445 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 6.80 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> October 31, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 16,501 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 16,501 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> November 30, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;margin:0pt;padding:0pt;"> 57,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 57,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> December 31, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"> 5,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 5,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"> January 25, 2029 </td><td style="vertical-align:middle;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 64,683 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 64,683 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;background:#cceeff;margin:0pt;padding:0pt;"> 30.00 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 651,783 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 651,783 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.36%;margin:0pt;padding:0pt;"> </td></tr></table> 3701 3701 1000.50 108 108 187.50 10444 10444 232.50 1922 1922 600.00 16888 16888 232.50 30674 30674 262.50 444445 444445 6.80 16501 16501 30.00 57250 57250 30.00 5167 5167 30.00 64683 64683 30.00 651783 651783 Note 13 - Income Taxes Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. The income tax impact of discrete items is recognized in the period these occur. Our effective tax rate for the three and six months ended June 30, 2024 was 22.9% and 34.2%, respectively. The primary difference from the federal statutory rate of 21% is related to state taxes, income of noncontrolling interests in flow-through entities and permanent differences for non-deductible expenses. 0.229 0.342 0.21 Note 14 – Earnings per Share The following is the computation of loss per basic and diluted share: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.11%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.14%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts attributable to Nutex Health Inc.: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (364,048)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (3,479,047) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (728,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (8,626,326) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Weighted average shares used to compute basic EPS </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> 4,969,726 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,377,088 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 4,909,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,358,367 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Loss per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"> Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.07)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (0.79) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (1.98) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.07)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.79) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (1.98) </td></tr></table> Due to antidilution, the computation of diluted earnings per common share excludes the 27,590 common stock options (4,137,149 prior to the Reverse Stock Splits), 651,783 warrants (97,780,228 prior to the 2024 Reverse Stock Splits), 1,298 restricted stock units (194,720 prior to the 2024 Reverse Stock Splits) and 179,500 common stock (26,925,000 prior to the 2024 Reverse Stock Splits) issuable upon conversion of outstanding convertible debt for the three and six months ended June 30, 2024. Due to antidilution, the June 30, 2023 computation excludes the 34,318 common stock options (5,147,770 prior to the 2024 Reverse Stock Splits) and 63,823 warrants (9,573,562 prior to the 2024 Reverse Stock Splits). The dilutive effect of convertible debt was calculated using the if-converted method, whereas the dilutive effect of the assumed exercise of outstanding options and warrants was calculated using the treasury stock method. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.11%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:25.14%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#ffffff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts attributable to Nutex Health Inc.: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Net loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (364,048)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (3,479,047) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (728,123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (8,626,326) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Weighted average

shares used to compute basic EPS </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> 4,969,726 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,377,088 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> 4,909,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,358,367 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Loss per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (0.07)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (0.79) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (1.98) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.9%;margin:0pt;padding:0pt;"> Diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (0.07)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (0.79) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (1.98) </td></tr></table> -364048 -3479047 -728123 -8626326 4969726 4377088 4909481 4358367 -0.07 -0.79 -0.15 -1.98 -0.07 -0.79 -0.15 -1.98 27590 4137149 651783 97780228 1298194720 179500 26925000 34318 5147770 63823 9573562 Note 15 - Supplemental Cash Flows Information . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:33.86%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,731,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 858,773 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;margin:0pt;padding:0pt;"> Cash paid for income taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 781,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 737,000 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash investing and financing activities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Financed capital expenditures </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 517,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 4,111,435 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Acquisition of finance leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 15,628,963 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 18,798,667 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Exercise of warrants on cashless basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 1,268 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Issuance of restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 249,645 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Issuance of common stock to Apollo Medical Holdings, Inc. </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 1,900,000 </td></tr><tr><td style="vertical-

align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Deconsolidation of Real Estate Entity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 4,258,133 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Warrant liability related to common stock issuance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 7,661,557 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Reverse stock split adjustment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Common stock issued for Employee Stock Purchase Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 33,435 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt converted to common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 320,688 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 3,232,439 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Payment for acquisition in common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 156,158 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock received in sale of business </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 30,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;width:33.86%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.65%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Cash paid for interest </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,731,171</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 858,773 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;margin:0pt;padding:0pt;"> Cash paid for income taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 781,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 737,000 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash investing and financing activities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 517,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 4,111,435 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Acquisition of finance leases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 15,628,963 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 18,798,667 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Exercise of warrants on cashless basis </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 1,268 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Issuance of restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 249,645 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Issuance of common stock to Apollo Medical Holdings, Inc. </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 1,900,000 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Deconsolidation of Real Estate Entity </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4,258,133 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Warrant liability related to common stock issuance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times'

New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,661,557 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Reverse stock split adjustment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.46%;background:#ffffff;margin:0pt;padding:0pt;">Common stock issued for Employee Stock Purchase Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 33,435 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt converted to common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 320,688 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 3,232,439 </td></tr><tr><td style="vertical-align:bottom;width:64.46%;margin:0pt;padding:0pt;"> Payment for acquisition in common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> 156,158 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.46%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock received in sale of business </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> 30,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr></table> 1731171 858773 781000 737000 517941 4111435 15628963 18798667 1268 249645 1900000 4258133 7661557 3 33435 320688 3232439 156158 -30250 Note 16 - Segment Information - We report the results of our operations as three segments in our consolidated financial statements: (i) the hospital division, (ii) the population health management division and (ii) the real estate division. The determination of our reporting segments was made on the basis of our strategic priorities, which corresponds to the manner in which our Chief Executive Officer, as our chief operating decision maker, reviews and evaluates operating performance to make decisions about resources to be allocated. We evaluate the performance of our reportable segments based on, among other measures, operating income, which is defined as income before interest expense, other income (expense), and taxes. Corporate costs primarily include expenses for support functions and salaries and benefits for corporate employees and are excluded from segment operating results. - Reportable segment information, including intercompany transactions, is presented below: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.18%;background:#ffffff;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.16%;background:#ffffff;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.18%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times

New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.16%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">373,398,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"> 278,635,841 </td></tr><tr><td style="vertical-align:bottom;width:58.85%;background:#cceeff;margin:0pt;padding:0pt;"> Population health management division </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 29,339,169 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"> 83,647,378 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,665,530 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,962,278 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">422,403,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 398,245,497 </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;width:27.25%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;width:27.75%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue from external customers: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 67,604,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> 51,611,803 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 127,634,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> 100,899,967 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Population health management division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,477,383 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,312,651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,901,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,353,904 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 76,082,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 58,924,454 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 143,536,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,253,871 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Segment operating income (loss): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> $ 22,791,199 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> $ 9,105,114 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> $ 33,262,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> $ 13,883,751 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Population health management division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ (229,968) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 541,809 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (543,840) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ 610,895 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Total segment operating income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$ 22,561,231 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$ 9,646,923 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$ 32,718,409 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">$ 14,494,646 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Capital expenditures: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> $ 558,169 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> $ 3,069,919 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> $ 1,291,492 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> $ 7,446,902 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Total capital expenditures </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 558,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,069,919 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,291,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,446,902 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Revenue from inter-segment activities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (196,595)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 258,015 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">603,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 516,030 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Depreciation and amortization: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 3,670,212 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> 3,715,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> 7,434,559 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> 7,279,890 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Population health management division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 411,305 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> 411,614 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> 832,300 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> 799,661 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 451,287 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 41,678 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 83,356 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Total depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,532,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,169,160 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8,719,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,162,907 </td></tr></table> 3 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.18%;background:#ffffff;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.16%;background:#ffffff;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.18%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.16%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt

0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,398,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;margin:0pt;padding:0pt;"> 278,635,841 </td></tr><tr><td style="vertical-align:bottom;width:58.85%;background:#cceeff;margin:0pt;padding:0pt;"> Population health management division </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;margin:0pt;padding:0pt;"> 29,339,169 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;margin:0pt;padding:0pt;"> 83,647,378 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,665,530 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,962,278 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.85%;background:#cceeff;margin:0pt;padding:0pt;"> Total Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 422,403,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 398,245,497 </td></tr></table> 373398552 278635841 29339169 83647378 19665530 35962278 422403251 398245497 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:27.25%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:27.75%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Six Months Ended June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue from external customers: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">67,604,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> 51,611,803 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 127,634,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> 100,899,967 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Population health management division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,477,383 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,312,651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,901,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,353,904 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Total revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 76,082,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 58,924,454 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 143,536,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 115,253,871 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Segment operating income (loss): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> 22,791,199 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> 9,105,114 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> 33,262,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> 13,883,751 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> Population health management division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (229,968) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 541,809 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (543,840) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 610,895 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Total segment operating income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 22,561,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,646,923 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 32,718,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,494,646 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Capital expenditures </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Hospital division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> 558,169 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> 3,069,919 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> 1,291,492 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> 7,446,902 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Total capital expenditures </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 558,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,069,919 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 1,291,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,446,902 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Revenue from inter-segment activities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (196,595)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 258,015 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">603,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 516,030 </td></tr><tr><td style="vertical-align:bottom;width:41.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"> 832,300 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 799,661 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;margin:0pt;padding:0pt;"> Real estate division </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 451,287 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 41,678 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 83,356 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.66%;background:#cceeff;margin:0pt;padding:0pt;"> Total depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 4,532,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,169,160 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8,719,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,162,907 </td></tr></table> . 67604878 51611803 127634247 100899967 8477383 7312651 15901801 14353904 76082261 58924454 143536048 115253871 22791199 9105114 33262249 13883751 -229968 541809 -543840 610895 22561231 9646923 32718409 14494646 558169 3069919 1291492 7446902 558169 3069919 1291492 7446902 -196595 258015 603255 516030 3670212 3715868 7434559 7279890 411305 411614 832300 799661 451287 41678 452147 83356 4532804 4169160 8719006 8162907 Note 17 – Related Party Transactions   . Related party transactions included the following: . <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Physician LLCs employ the doctors who work in our hospitals. We have no direct ownership interest in these entities, but they are owned and, in some instances, controlled by related parties including our CEO, Dr. Thomas Vo. The Physician LLCs are consolidated by the Company as VIEs because they do not have significant equity at risk, and we have historically provided support to them in the event of cash shortages and received the benefit of their cash surpluses. </td></tr></table> . The Physician LLCs had outstanding obligations to their member owners, who are also Company stockholders. These outstanding obligations primarily represent contributions for facilities currently under construction totaling $3.3 million at June 30, 2024 and $2.9 million at December 31, 2023 reported within accounts payable – related party in our consolidated balance sheets. . <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Most of our hospital division facilities are leased from real estate entities which are owned by related parties. These leases are typically on a triple net basis, where our hospital division is responsible for all operating costs, repairs and taxes on the facilities. Our obligations under these leases are presented in Note 8. During the three and six months ended June 30, 2024, we made cash payments for these lease obligations totaling $4.9 million and $9.6 million, respectively. Cash payments for these lease obligations made in the three and six months ended June 30, 2023 totaled $3.7 million and $7.2 million, respectively.</td></tr></table> . <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">We consolidate Real Estate Entities as VIEs when they do not have sufficient equity at risk and our hospital entities are guarantors or co-borrowers under their outstanding mortgage loans. The consolidated Real Estate Entities have mortgage loans payable to third parties which are collateralized by the land and buildings. We have no direct ownership interest in these entities, but they are owned and, in some instances, controlled by related parties </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;">including our CEO. We deconsolidated 17 Real Estate Entities in the second quarter of 2022 and one Real Estate Entity in the first quarter of 2023. As of June 30, 2024, two Real Estate Entities continue to be consolidated on our financial statements.</td></tr></table> . <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Accounts receivable – related party included $4.6 million at June 30, 2024 and $4.1 million at December 31, 2023 due from noncontrolling interest owners of consolidated ER Entities. </td></tr></table> . <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Micro Hospital Holding LLC, an affiliate controlled by our CEO, and 2GT PLLC, an affiliate controlled by a physician partner, made advances to one of our hospital facilities, SE Texas ER. These advances totaled $1.4 million for Micro Hospital Holding LLC and $1.2 million for 2GT PLLC at June 30, 2024 and at December 31, 2023, respectively, and are reported as accounts payable – related party in our consolidated balance sheets. The advances have no stated maturity and bear no interest.</td></tr></table> . <table style="border-collapse:collapse;font-family:'Times New

Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Accounts payable – related party in our consolidated balance sheets included $0.9 million at June 30, 2024 and $0.9 million at December 31, 2023 for reimbursement of expenses incurred on our behalf.</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">We provided managerial services to emergency centers owned and, in some instances, controlled by related parties including an entity controlled by our CEO during 2023. In the three and six months ended June 30, 2023, we recognized $0.2 million and $0.3 million, respectively, of revenue for these services.</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Two of our ER Entities were obligated under managerial services agreements with related parties commencing in 2022 and ending in 2023. Payments under these agreements totaled $0.1 million and $0.4 million for the three and six months ended June 30, 2023.</td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"></p> 3300000 2900000 4900000 9600000 3700000 7200000 17 1 2 4600000 4100000 1400000 1200000 900000 900000 200000 300000 2 100000 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note 18 – Variable Interest Entities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">The following tables provide the balance sheet amounts for consolidated VIEs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"> </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:58.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Real Estate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Physician </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">AHHSP</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Entities</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LLCs</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">IPA</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> 173,701 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8,637,398 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,786,496</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,130,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,303,955 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,641,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,880,494 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> Current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> 15,262 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 5,626,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 10,880,494 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Long-term liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,317,109 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> 12,332,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;">
5,626,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> 10,880,494 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
20,971,584 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
3,014,356 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> -
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Total liabilities and equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,303,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,641,066 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,880,494 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:58.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;margin:0pt;padding:0pt;"> Real Estate </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"> Physician </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"> AHISP </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Entities </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> LLCs </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> IPA </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> Current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8,074,928 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,473,486</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,277</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,089,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,452</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,227,978 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,078,596 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,575,215 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> 38,510 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 5,648,516 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8,575,215 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Long-term liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,959,171 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> 12,997,681 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> 5,648,516 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> 8,575,215 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,230,297 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,430,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-

space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Total liabilities and equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,227,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,078,596 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,575,215 </td></tr></table> The assets of each of the ER Entities may only be used to settle the liabilities of that entity or its consolidated VIEs and may not be required to be used to settle the liabilities of any of the other ER Entities, other VIEs, or corporate entity. Additionally, the assets of corporate entities cannot be used to settle the liabilities of VIEs. The Company has aggregated all of the Physician LLCs and Real Estate Entities into two categories above, because they have similar risk characteristics, and presenting distinct financial information for each VIE would not add more useful information. Real Estate Entities are consolidated by the Company as VIEs because they do not have sufficient equity at risk and our hospital entities are guarantors of their outstanding mortgage loans. We have been working with the third-party lenders to remove our guarantees of their outstanding mortgage loans. As these guarantees are released, the associated Real Estate Entity no longer qualifies as a VIE and is deconsolidated. As of June 30, 2024, two Real Estate Entities continue to be consolidated in our financial statements. The Real Estate Entity we deconsolidated in the first quarter of 2023 had $1.0 million of cash, $8.4 million of fixed assets (principally land and building), $0.2 million of other assets, $5.4 million of liabilities (principally mortgage indebtedness) and $4.3 million of equity reported as noncontrolling interests as of the date of deconsolidation. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:58.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;margin:0pt;padding:0pt;"> Real Estate </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"> Physician </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"> AHHSP </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Entities </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> LLCs </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> IPA </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-

space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> Current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,701</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,637,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,786,496</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,130,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 33,303,955 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,641,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,880,494 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> Current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> 15,262 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 5,626,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 10,880,494 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Long-term liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,317,109 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> 12,332,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> 5,626,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> 10,880,494 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,971,584 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,014,356 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Total liabilities and equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,303,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,641,066 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,880,494 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt

0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:58.51%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;margin:0pt;padding:0pt;"> Real Estate </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"> Physician </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;margin:0pt;padding:0pt;"> AHISP </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.41%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> Entities </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> LLCs </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.54%;background:#ffffff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"> IPA </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.3%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:16.1%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.5%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:15.04%;background:#ffffff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> Current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8,074,928 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8,473,486 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> 3,668 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> 65,277 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 33,089,636 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,452 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt

0pt;">Total assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,227,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,078,596 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,575,215 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> Current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> 38,510 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 5,648,516 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> 8,575,215 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Long-term liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,959,171 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,230,297 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

2,430,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.48%;margin:0pt;padding:0pt;"> Total liabilities and equity </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,227,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,078,596 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,575,215 </td></tr></table> 173701 8637398 10786496 3668 93998 33130254 33303955 8641066 10880494 15262 5626710 10880494 12317109 12332371 5626710 10880494 20971584 3014356 33303955 8641066 10880494 138342 8074928 8473486 3668 65277 33089636 36452 33227978 8078596 8575215 38510 5648516 8575215 12959171 12997681 5648516 8575215 20230297 2430080 33227978 8078596 8575215 2 1000000.0 8400000 200000 5400000 4300000 Note 19 - Subsequent Events The Company has evaluated subsequent events through the filing of this report and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements, except the following: 1:10 Reverse stock split. The Company's Board of Directors determined to effect a reverse stock split of the common stock at a 1-for-10 ratio (the "1:10 Reverse Stock Split") effective as of 11:59 pm Eastern time on July 2, 2024. The Company's stockholders, at the annual meeting on June 17, 2024, had approved a reverse stock split within a range of 1-for-10 ratio and 1:16 to be effected within one year of approval at the discretion of the Board. This 1:10 Reverse Stock Split is in addition to the Company's previous 1:15 Reverse Stock Split as discussed above. The Company's common stock began trading on The Nasdaq Stock Market on a post-1:10 Reverse Stock Split basis under the Company's existing trading symbol "NUTX" at the open of the market on July 3, 2024. The 1:10 Reverse Stock Split was also implemented for the purpose of regaining compliance with the minimum bid price requirement for continued listing of the Company's common stock on The Nasdaq Capital Market. As a result of both the 1:15 Reverse Stock Split (occurred on April 10, 2024) and 1:10 Reverse Stock Split (collectively, the "2024 Reverse Stock Splits") the number of shares of common stock outstanding was reduced to 4,987,268 shares, inclusive of whole shares issued for fractional shares, and the number of authorized shares of common stock remains 950,000,000. On July 24, 2024, Company received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Stock Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from July 3, 2024 to July 23, 2024, the closing bid price of the Company's common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed. - Unless otherwise noted, share numbers and per share amounts in these financial statements reflect the 2024 Reverse Stock Splits. - The impacts of the 2024 Reverse Stock Splits were applied retroactively for all periods presented in accordance with applicable guidance. Therefore, prior period amounts are different than those previously reported. Certain amounts within the following tables may not foot due to rounding. - The following table illustrates changes in equity, as previously reported prior to, and as adjusted subsequent to, the impact of the 2024 Reverse Stock Splits retroactively adjusted for the periods presented: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> - </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock - Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 660,742,624 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> (656,337,673) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4,404,951 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> Common Stock - Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 660,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> (656,337) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,405</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Additional Paid-in Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 463,869,968 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 464,526,305 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.72%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.17%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#ffffff;margin:0pt;padding:0pt;"> <span

style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock - Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"> 676,679,911 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"> (672,168,712) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4,511,199 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;margin:0pt;padding:0pt;"> Common Stock - Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 676,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> (672,169) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,511</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Additional Paid-in Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"> 469,849,049 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 672,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 470,521,218 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2022 </td></tr><tr><td style="vertical-align:bottom;white-

space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock - Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 650,223,840 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> (645,889,014) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4,334,826 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> Common Stock - Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 650,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> (645,889) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,335</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Additional Paid-in Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 458,498,402 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 645,889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 459,144,291 </td></tr></table> The following table illustrates changes in loss per share and weighted average shares outstanding, as previously reported prior to, and as adjusted subsequent to, the impact of the 2024 Reverse Stock Splits retroactively adjusted for the periods presented: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,479,047)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,479,047)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Weighted average shares used to compute basic and diluted EPS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656,563,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (652,186,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,377,088</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> (0.01) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(0.78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> (0.79) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six months ended June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">(8,626,326)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">(8,626,326)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;">Weighted average shares used to compute basic and diluted EPS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">653,755,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">(649,396,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,358,367</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;">Loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> (0.01) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">(1.97)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> (1.98) </td></tr></table> The following outstanding stock options and warrants exercisable or issuable into shares of common stock were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three and six months ended June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"> 5,147,770 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> (5,113,452) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 34,318 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> Common stock warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"> 9,573,562 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> (9,509,739) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> 63,823 </td></tr></table> Stock options were adjusted retroactively to give effect to the Reverse Stock Split for the six months ended June 30, 2023. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.86%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As Previously Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.05%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impact of Reverse Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.78%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#ffffff;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#ffffff;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ffffff;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.11%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#cceeff;margin:0pt;padding:0pt;"> Options outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"> 5,147,770 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;"> (5,113,452)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 342.70 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"> 34,318 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 345.00 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#cceeff;margin:0pt;padding:0pt;"> Options cancelled </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;margin:0pt;padding:0pt;"> Options outstanding at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,147,770 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;"> (5,113,452)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 342.70 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,318 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 345.00 </td></tr></table> Warrants were adjusted retroactively to give effect to the Reverse Stock Split for the six months ended June 30, 2023. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.53%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As Previously Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.59%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impact of Reverse Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.78%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"> 11,033,015 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;"> (10,959,462)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 292.20 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

*New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"> 73,553 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 294.16</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,456,453)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,446,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (9,710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232.50</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,725.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,750.00</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Warrants outstanding at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,573,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> 2.02 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (9,509,739) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 302.46 </td></tr></table> ***** 4987268 950000000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-*

space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock - Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 660,742,624 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> (656,337,673) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4,404,951 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> Common Stock - Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 660,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> (656,337) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,405</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Additional Paid-in Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 463,869,968 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 464,526,305 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.72%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89

space:nowrap;width:11.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.17%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock - Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"> 676,679,911 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> (672,168,712) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4,511,199 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;margin:0pt;padding:0pt;"> Common Stock - Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 676,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"> (672,169) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,511</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Additional Paid-in Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"> 469,849,049 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 672,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 470,521,218 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2022 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock - Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 650,223,840 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> (645,889,014) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 4,334,826 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> Common Stock - Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">650,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> (645,889) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,335</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Additional Paid-in Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 458,498,402 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">645,889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 459,144,291 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;"> (3,479,047)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;"> (3,479,047)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Weighted average shares used to compute basic and diluted EPS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656,563,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;"> (652,186,078)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,377,088</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> (0.01) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;">(0.78)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> (0.79) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six months ended June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Loss attributable to common stockholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (8,626,326)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (8,626,326)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Weighted average shares used to compute basic and diluted EPS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">653,755,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (649,396,664)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,358,367</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss per share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> (0.01) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">(1.97)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-

align:right;margin:0pt;">(1.98) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three and six months ended June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;margin:0pt;padding:0pt;"> As Previously </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#ffffff;margin:0pt;padding:0pt;"> Impact of Reverse </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;margin:0pt;padding:0pt;"> As </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"> 5,147,770 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> (5,113,452) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"> 34,318 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.9%;margin:0pt;padding:0pt;"> Common stock warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"> 9,573,562 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> (9,509,739) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"> 63,823 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman', 'Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.86%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As Previously Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.05%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impact of Reverse Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.78%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#ffffff;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#ffffff;margin:0pt;padding:0pt;"> Options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.11%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#cceeff;margin:0pt;padding:0pt;"> Options outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"> 5,147,770 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> 2.30 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="font-size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"> (5,113,452) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 342.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 345.00 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;background:#cceeff;margin:0pt;padding:0pt;"> Options cancelled </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.11%;margin:0pt;padding:0pt;"> Options outstanding at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,147,770 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (5,113,452)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 342.70 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,318 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 345.00 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.53%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As Previously Reported </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.59%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Impact of Reverse Stock Split </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.78%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Revised </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ffffff;margin:0pt;padding:0pt;"> Warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;margin:0pt;padding:0pt;"> Weighted Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ffffff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.97%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Exercise Price </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;margin:0pt;padding:0pt;"> Warrants outstanding at December 31, 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"> 11,033,015 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (10,959,462)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"> 292.20 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"> 73,553 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 294.16</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,456,453)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,446,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (9,710)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 232.50</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Warrants expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,725.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,750.00</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Warrants outstanding at June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,573,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"> 2.02 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (9,509,739) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63,823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"> 302.46 </td></tr></table> 660742624 -656337673 4404951

660742 -656337 4405 463869968 656337 464526305 676679911 -672168712 4511199 676680 -672169 4511 469849049 672169 470521218 650223840 -645889014 4334826 650224 -645889 4335 458498402 645889 459144291 -3479047 -3479047 656563166 -652186078 4377088 -0.01 -0.78 -0.79 -8626326 -8626326 653755031 -649396664 4358367 -0.01 -1.97 -1.98 5147770 -5113452 34318 9573562 -9509739 63823 5147770 2.30 -5113452 342.70 34318 345.00 5147770 2.30 -5113452 342.70 34318 345.00 11033015 1.96 -10959462 292.20 73553 294.16 -1456453 1.55 1446743 230.95 -9710 232.50 3000 25.00 -2980 3725.00 20 3750.00 9573562 2.02 -9509739 300.44 63823 302.46 false false false false